


**CUMULATIVE  
SUPPLEMENT 12  
DECEMBER 2013**



**APPROVED  
DRUG PRODUCTS**

**WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**33rd EDITION**

**Department of Health and Human Services**

**Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Generic Drugs**

2013

Prepared By  
Office of Generic Drugs  
Center for Drug Evaluation and Research  
Food and Drug Administration

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**33<sup>rd</sup> EDITION**

**Cumulative Supplement 12**

**December 2013**

**CONTENTS**

	<i>PAGE</i>
1.0 INTRODUCTION .....	iii
1.1 How to use the Cumulative Supplement .....	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition .....	vi
1.6 Report of Counts for the Prescription Drug Product List .....	vii
1.7 Cumulative Supplement Legend .....	viii
DRUG PRODUCT LISTS	
Prescription Drug Product List .....	1-1
OTC Drug Product List .....	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List .....	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution .....	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists .....	A-1
B. Patent and Exclusivity Terms .....	B-1

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**33<sup>rd</sup> EDITION**

**CUMULATIVE SUPPLEMENT 12  
December 2013**

**1.0 INTRODUCTION**

**1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT**

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 32nd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 33rd Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

## 1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
  - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at [drugproducts@fda.hhs.gov](mailto:drugproducts@fda.hhs.gov). Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff  
Office of Generic Drugs, HFD-610  
7620 Standish Place  
Rockville, MD 20855-2773

### 1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
BIONICHE PHARMA USA LLC (BIONICHE PHARMA USA)	MYLAN INSTITUTIONAL LLC (MYLAN LLC)
BOCA PHARMACAL INC (BOCA PHARMA)	BOCA PHARMACAL LLC (BOCA PHARMA LLC)

### 1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHEROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

## 1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

## 1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

### DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2012) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

### DEFINITIONS

#### Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

#### New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.



REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST  
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2012</u>	<u>MAR 2013</u>	<u>JUN 2013</u>	<u>SEPT 2013</u>	<u>DEC 2013</u>
DRUG PRODUCTS LISTED	15343	15445	15408	15472	15711
SINGLE SOURCE	2400 (15.9%)	2467 (16.0%)	2440 (15.8%)	2502 (16.2%)	2517 (16.0%)
MULTISOURCE	12825 (83.6%)	12900 (83.5%)	12890 (83.7%)	12970 (83.8%)	13194 (84.0%)
THERAPEUTICALLY EQUIVALENT	12683 (82.7%)	12758 (82.6%)	12750 (82.7%)	12827 (82.9%)	13055 (83.1%)
NOT THERAPEUTICALLY EQUIVALENT	142 (0.9%)	142 (0.9%)	140 (0.9%)	143 (0.9%)	139 (0.9%)
EXCEPTIONS <sup>1</sup>	78 (0.5%)	78 (0.5%)	78 (0.5%)	78 (0.5%)	78 (0.5%)
NEW MOLECULAR ENTITIES APPROVED	17	9	5	8	20
NUMBER OF APPLICANTS	835	844	841	832	866

<sup>1</sup>Amino acid-containing products of varying composition (see Introduction, page xx of the List).

### 1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.

CAIN Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.

CDFR Change. Dosage Form; Route of Administration.

CFTG Change. A first time generic for the innovator product. A TE Code is added.

CMFD Change. The product is moved from the Discontinued Section due to a change in marketing status.

CMS1 Change. Miscellaneous addition to list.

CMS2 Change. Miscellaneous deletion from list.

CPOT Change. Potency amount/unit.

CRLD Change. Reference Listed Drug.

CTEC Change. Therapeutic Equivalence Code.

CTNA Change. Trade Name.

DISC Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ABACAVIR SULFATE

TABLET;ORAL  
 ABACAVIR SULFATE  
 AB HETERO LABS LTD III EQ 300MG BASE A091560 001 Sep 13, 2013 Aug NEWA

ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL  
 ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE  
 AB LUPIN LTD EQ 300MG BASE;150MG;300MG A202912 001 Dec 05, 2013 Nov NEWA  
 TRIZIVIR  
 AB + VIIV HLTHCARE EQ 300MG BASE;150MG;300MG N021205 001 Nov 14, 2000 Nov CFTG

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL  
 ACAMPROSATE CALCIUM  
 AB BARR LABS DIV TEVA 333MG A200143 001 Nov 18, 2013 Nov NEWA  
 AB GLENMARK GENERICS 333MG A202229 001 Jul 16, 2013 Jul NEWA  
 CAMPRAL  
 AB + FOREST LABS 333MG N021431 001 Jul 29, 2004 Jul CFTG

ACARBOSE

TABLET;ORAL  
 ACARBOSE  
 AB VIRTUS PHARM 25MG A091343 001 Oct 17, 2013 Sep NEWA  
 AB 50MG A091343 002 Oct 17, 2013 Sep NEWA  
 AB 100MG A091343 003 Oct 17, 2013 Sep NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL  
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE  
 @ WEST WARD 500MG;50MG;40MG A040261 001 Oct 28, 1998 Jul DISC  
 ESGIC-PLUS  
 + MIKART 500MG;50MG;40MG A040085 001 Mar 28, 1996 Jul CTEC  
 TABLET;ORAL  
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE  
 @ MIRROR PHARMS LLC 500MG;50MG;40MG A040883 001 Dec 23, 2008 Feb DISC  
 @ WEST WARD 500MG;50MG;40MG A040336 001 Aug 18, 1999 Aug DISC

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL  
 ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE  
 @ MIKART 356.4MG;30MG;16MG A040109 001 Aug 26, 1997 Feb DISC  
 @ WRASER PHARMS LLC 356.4MG;30MG;16MG A040688 001 Apr 03, 2007 Jun DISC  
 TABLET;ORAL  
 ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE  
 @ MIKART 712.8MG;60MG;32MG A040316 001 Apr 28, 1999 Feb DISC

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL  
 ACETAMINOPHEN AND CODEINE PHOSPHATE  
 AA AUROLIFE PHARMA LLC 300MG;15MG A202800 001 Apr 15, 2013 Apr NEWA  
 AA 300MG;30MG A202800 002 Apr 15, 2013 Apr NEWA  
 AA 300MG;60MG A202800 003 Apr 15, 2013 Apr NEWA  
 @ MIKART 300MG;30MG A089238 001 Feb 25, 1986 Jun DISC  
 @ 650MG;30MG A089231 001 Mar 03, 1986 Feb DISC  
 @ 650MG;60MG A089363 001 Sep 09, 1991 Feb DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE;ORAL  
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN  
 @ MIKART 500MG;5MG A081067 001 Nov 30, 1989 Feb DISC  
 @ 500MG;5MG A089008 001 Feb 21, 1986 Jun DISC  
 SOLUTION;ORAL  
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN  
 AA PAI 325MG/15ML;7.5MG/15ML A040838 001 May 10, 2013 Apr NEWA  
 TABLET;ORAL  
 CO-GESIC  
 @ UCB INC 500MG;5MG A087757 001 May 03, 1982 Nov DISC

## TABLET; ORAL

## HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	CARACO	325MG; 5MG	A090118	001	Dec 23, 2008	May	CAHN
AA		325MG; 7.5MG	A090118	002	Dec 23, 2008	May	CAHN
AA		325MG; 10MG	A090118	003	Dec 23, 2008	May	CAHN
AA		500MG; 5MG	A090265	001	Dec 23, 2008	May	CAHN
AA		500MG; 7.5MG	A090265	002	Dec 23, 2008	May	CAHN
AA		500MG; 10MG	A090265	003	Dec 23, 2008	May	CAHN
AA		650MG; 7.5MG	A090380	001	Dec 23, 2008	Jun	CAHN
AA		650MG; 10MG	A090380	002	Dec 23, 2008	Jun	CAHN
AA		660MG; 10MG	A090380	003	Dec 23, 2008	Jun	CAHN
AA		750MG; 7.5MG	A090380	004	Dec 23, 2008	Jun	CAHN
+	MIKART	325MG; 2.5MG	A040846	001	Jun 09, 2010	Jul	CRLD
@		500MG; 2.5MG	A089698	001	Aug 25, 1989	Feb	DISC
@		650MG; 5MG	A040849	001	Jun 09, 2010	Feb	DISC
AA	TRIS PHARMA INC	325MG; 5MG	A202214	001	Mar 27, 2013	Mar	NEWA
AA		325MG; 7.5MG	A202214	002	Mar 27, 2013	Mar	NEWA
AA		325MG; 10MG	A202214	003	Mar 27, 2013	Mar	NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

## TABLET; ORAL

## OXYCODONE AND ACETAMINOPHEN

AA	ACTAVIS ELIZABETH	325MG; 2.5MG	A201447	001	Apr 12, 2013	Apr	NEWA	
AA		325MG; 5MG	A201447	002	Apr 12, 2013	Apr	NEWA	
AA		325MG; 7.5MG	A201447	003	Apr 12, 2013	Apr	NEWA	
AA		325MG; 10MG	A201447	004	Apr 12, 2013	Apr	NEWA	
AA	AUROLIFE PHARMA LLC	325MG; 2.5MG	A201972	001	Jul 15, 2013	Jul	NEWA	
AA		325MG; 5MG	A201972	002	Jul 15, 2013	Jul	NEWA	
AA		325MG; 7.5MG	A201972	003	Jul 15, 2013	Jul	NEWA	
AA		325MG; 10MG	A201972	004	Jul 15, 2013	Jul	NEWA	
>A>	AA	CARACO	325MG; 2.5MG	A090535	001	Dec 26, 2013	Dec	NEWA
>A>	AA		325MG; 5MG	A090535	002	Dec 26, 2013	Dec	NEWA
>A>	AA		325MG; 7.5MG	A090535	003	Dec 26, 2013	Dec	NEWA
>A>	AA		325MG; 10MG	A090535	004	Dec 26, 2013	Dec	NEWA
	@	MIKART	400MG; 2.5MG	A040679	001	May 16, 2006	Jul	DISC
AA	VINTAGE PHARMS	325MG; 2.5MG	A090733	001	Jul 11, 2013	Jul	NEWA	
AA		325MG; 7.5MG	A090734	001	Jul 11, 2013	Jul	NEWA	
AA		325MG; 10MG	A090734	002	Jul 11, 2013	Jul	NEWA	
	ROXICET 5/500							
	@	ROXANE	500MG; 5MG	A089775	001	Jan 12, 1989	Aug	DISC

ACETAZOLAMIDE

## TABLET; ORAL

## ACETAZOLAMIDE

@	WATSON LABS	250MG	A088882	001	Oct 22, 1985	Jan	DISC
---	-------------	-------	---------	-----	--------------	-----	------

ACETAZOLAMIDE SODIUM

## INJECTABLE; INJECTION

## ACETAZOLAMIDE SODIUM

AP	SAGENT AGILA	EQ 500MG BASE/VIAL	A200880	001	May 09, 2012	Jan	CAHN
----	--------------	--------------------	---------	-----	--------------	-----	------

ACETYLCYSTEINE

## INJECTABLE; INTRAVENOUS

## ACETYLCYSTEINE

>D>	AP	INNOPHARMA INC	6GM/30ML (200MG/ML)	A200644	001	Nov 07, 2012	Dec	CAHN
>A>	AP	INNOPHARMA LICENSING	6GM/30ML (200MG/ML)	A200644	001	Nov 07, 2012	Dec	CAHN

## SOLUTION; INHALATION, ORAL

## ACETYLCYSTEINE

>D>	AN	INNOPHARMA INC	20%	A203853	001	Jun 21, 2012	Dec	CAHN
>A>	AN	INNOPHARMA LICENSING	20%	A203853	001	Jun 21, 2012	Dec	CAHN

ACITRETIN

## CAPSULE; ORAL

## ACITRETIN

AB	BARR LABS INC	10MG	A091455	001	Apr 04, 2013	Mar	NEWA
AB		25MG	A091455	002	Apr 04, 2013	Mar	NEWA
AB	TEVA PHARMS USA	17.5MG	A202897	001	Apr 04, 2013	Mar	NEWA
AB		22.5MG	A202897	002	Apr 04, 2013	Mar	NEWA
	SORIATANE						
AB	STIEFEL LABS INC	10MG	N019821	001	Oct 28, 1996	Mar	CFTG
AB		17.5MG	N019821	003	Aug 06, 2009	Mar	CFTG
AB		22.5MG	N019821	004	Aug 06, 2009	Mar	CFTG

	CAPSULE;ORAL							
	SORIATANE							
AB	+	25MG	N019821	002	Oct 28, 1996	Mar	CFTG	
	<u>ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>							
	CAPSULE;ORAL							
	SEMPREX-D							
	+	ACTIENT PHARMS	8MG;60MG	N019806	001	Mar 25, 1994	May	CAHN
	<u>ACYCLOVIR</u>							
	CAPSULE;ORAL							
	ACYCLOVIR							
		@ MYLAN	200MG	A074977	001	Apr 13, 1998	Aug	DISC
		@ WATSON LABS	200MG	A075101	001	Apr 15, 1998	Sep	DISC
	CREAM;TOPICAL							
	ZOVIRAX							
	+	VALEANT BERMUDA	5%	N021478	001	Dec 30, 2002	Jul	CAHN
	OINTMENT;TOPICAL							
	ACYCLOVIR							
AB		MYLAN PHARMS INC	5%	A202459	001	Apr 03, 2013	Mar	NEWA
	ZOVIRAX							
AB	+	VALEANT BERMUDA	5%	N018604	001	Mar 29, 1982	May	CAHN
AB	+	VALEANT INTL	5%	N018604	001	Mar 29, 1982	Mar	CFTG
	SUSPENSION;ORAL							
	ZOVIRAX							
AB	+	DELCOR ASSET	200MG/5ML	N019909	001	Dec 22, 1989	Jun	CAHN
	TABLET;BUCCAL							
	SITAVIG							
		@ BIOALLIANCE PHARMA	50MG	N203791	001	Apr 12, 2013	Sep	DISC
	+		50MG	N203791	001	Apr 12, 2013	Apr	NEWA
	TABLET;ORAL							
	ACYCLOVIR							
AB		CADILA PHARMS LTD	400MG	A202168	001	Nov 15, 2013	Oct	NEWA
AB			800MG	A202168	002	Nov 15, 2013	Oct	NEWA
AB		HETERO LABS LTD V	400MG	A203834	001	Oct 29, 2013	Oct	NEWA
AB			800MG	A203834	002	Oct 29, 2013	Oct	NEWA
		@ MYLAN	400MG	A074976	001	Apr 13, 1998	Aug	DISC
		@	800MG	A074976	002	Apr 13, 1998	Aug	DISC
	<u>ACYCLOVIR SODIUM</u>							
	INJECTABLE;INJECTION							
	ACYCLOVIR SODIUM							
AP		AUROBINDO PHARMA LTD	EQ 50MG BASE/ML	A203701	001	Oct 11, 2013	Sep	NEWA
	<u>ACYCLOVIR; HYDROCORTISONE</u>							
	CREAM;TOPICAL							
	XERESE							
	+	VALEANT BERMUDA	5%;1%	N022436	001	Jul 31, 2009	Apr	CAHN
	<u>ADEFOVIR DIPIVOXIL</u>							
	TABLET;ORAL							
	ADEFOVIR DIPIVOXIL							
AB		SIGMAPHARM LABS LLC	10MG	A202051	001	Aug 29, 2013	Aug	NEWA
	HEPSERA							
AB	+	GILEAD	10MG	N021449	001	Sep 20, 2002	Aug	CFTG
	<u>ADENOSINE</u>							
	INJECTABLE;INJECTION							
	ADENOSCAN							
AP	+	ASTELLAS	3MG/ML	N020059	001	May 18, 1995	Aug	CTEC
	ADENOSINE							
		@ TEVA PHARMS USA	3MG/ML	A076564	001	Jun 16, 2004	Apr	CAHN
AP			3MG/ML	A077425	001	Aug 29, 2013	Aug	NEWA
		@	3MG/ML	A078676	001	Jul 31, 2008	Apr	CAHN
	<u>AFATINIB DIMALEATE</u>							
	TABLET;ORAL							
	GILOTRIF							
		BOEHRINGER INGELHEIM	EQ 20MG BASE	N201292	001	Jul 12, 2013	Jul	NEWA
			EQ 30MG BASE	N201292	002	Jul 12, 2013	Jul	NEWA
	+		EQ 40MG BASE	N201292	003	Jul 12, 2013	Jul	NEWA

ALBENDAZOLETABLET; ORAL  
ALBENZA

+ AMEDRA PHARMS 200MG N020666 001 Jun 11, 1996 Feb CAHN

ALBUTEROL SULFATEAEROSOL, METERED; INHALATION  
PROAIR HFA

BX + TEVA BRANDED PHARM EQ 0.09MG BASE/INH N021457 001 Oct 29, 2004 Apr CAHN

BX + GLAXO GRP LTD EQ 0.09MG BASE/INH N020983 001 Apr 19, 2001 May CAHN

SOLUTION; INHALATION  
ALBUTEROL SULFATE

@ APOTEX INC EQ 0.021% BASE A078623 001 Apr 05, 2010 Apr DISC

@ EQ 0.042% BASE A078623 002 Apr 05, 2010 Apr DISC

@ EQ 0.083% BASE A075717 001 Feb 02, 2007 Apr DISC

@ EQ 0.5% BASE A076391 001 Apr 01, 2003 Apr DISC

AN + MYLAN SPECLT EQ 0.083% BASE A072652 001 Feb 21, 1992 Jan CAHN

@ WOCKHARDT EU OPERATN EQ 0.083% BASE A075394 001 Nov 22, 1999 Mar DISC

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

AN @ APOTEX INC EQ 0.083% BASE; 0.017% A077117 001 Dec 31, 2007 Apr DISC

CIPLA LTD EQ 0.083% BASE; 0.017% A077559 001 Dec 31, 2007 Aug CAHN

ALENDRONATE SODIUM

SOLUTION; ORAL

ALENDRONATE SODIUM

AA ROXANE EQ 70MG BASE/75ML A090520 001 Feb 25, 2013 Feb NEWA

AA + MERCK EQ 70MG BASE/75ML N021575 001 Sep 17, 2003 Feb CFTG

TABLET; ORAL

ALENDRONATE SODIUM

AB CIPLA LTD EQ 5MG BASE A076768 001 Aug 04, 2008 Jul CAHN

AB EQ 10MG BASE A076768 002 Aug 04, 2008 Jul CAHN

AB EQ 35MG BASE A076768 003 Aug 04, 2008 Jul CAHN

AB EQ 40MG BASE A076768 004 Aug 04, 2008 Jul CAHN

AB EQ 70MG BASE A076768 005 Aug 04, 2008 Jul CAHN

@ MYLAN EQ 35MG BASE A078638 001 Aug 04, 2008 Aug DISC

@ EQ 70MG BASE A078638 002 Aug 04, 2008 Aug DISC

FOSAMAX

@ MERCK AND CO INC EQ 5MG BASE N020560 003 Apr 25, 1997 Nov DISC

@ EQ 10MG BASE N020560 001 Sep 29, 1995 Nov DISC

@ EQ 35MG BASE N020560 004 Oct 20, 2000 Nov DISC

@ EQ 40MG BASE N020560 002 Sep 29, 1995 Nov DISC

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

UROXATRAL

AB + COVIS PHARMA SARL 10MG N021287 001 Jun 12, 2003 Apr CAHN

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

AB ACCORD HLTHCARE 100MG A203154 001 May 06, 2013 Apr NEWA

AB 300MG A203154 002 May 06, 2013 Apr NEWA

ALOGLIPTIN BENZOATE

TABLET; ORAL

NESINA

TAKEDA PHARMS USA EQ 6.25MG BASE N022271 001 Jan 25, 2013 Jan NEWA

EQ 12.5MG BASE N022271 002 Jan 25, 2013 Jan NEWA

+ EQ 25MG BASE N022271 003 Jan 25, 2013 Jan NEWA

ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

KAZANO

+	TAKEDA PHARMS USA	EQ 12.5MG BASE;1GM	N203414	002	Jan 25, 2013	Jan NEWA
		EQ 12.5MG BASE;500MG	N203414	001	Jan 25, 2013	Jan NEWA

ALOGLIPTIN BENZOATE; PIOGLITAZONE

TABLET; ORAL

OSENI

	TAKEDA PHARMS USA	EQ 12.5MG BASE;15MG	N022426	004	Jan 25, 2013	Jan NEWA
		EQ 12.5MG BASE;30MG	N022426	005	Jan 25, 2013	Jan NEWA
		EQ 12.5MG BASE;45MG	N022426	006	Jan 25, 2013	Jan NEWA
		EQ 25MG BASE;15MG	N022426	001	Jan 25, 2013	Jan NEWA
		EQ 25MG BASE;30MG	N022426	002	Jan 25, 2013	Jan NEWA
+		EQ 25MG BASE;45MG	N022426	003	Jan 25, 2013	Jan NEWA

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

OSENI

	TAKEDA PHARMS USA	EQ 12.5MG BASE;EQ 15MG BASE	N022426	004	Jan 25, 2013	Feb CAIN
		EQ 12.5MG BASE;EQ 30MG BASE	N022426	005	Jan 25, 2013	Feb CAIN
		EQ 12.5MG BASE;EQ 45MG BASE	N022426	006	Jan 25, 2013	Feb CAIN
		EQ 25MG BASE;EQ 15MG BASE	N022426	001	Jan 25, 2013	Feb CAIN
		EQ 25MG BASE;EQ 30MG BASE	N022426	002	Jan 25, 2013	Feb CAIN
+		EQ 25MG BASE;EQ 45MG BASE	N022426	003	Jan 25, 2013	Feb CAIN

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

@	TEVA PHARMS USA	0.5MG	A077979	001	Feb 28, 2007	Jun DISC
@		1MG	A077979	002	Feb 28, 2007	Jun DISC
@		2MG	A077979	003	Feb 28, 2007	Jun DISC
@		3MG	A077979	004	Feb 28, 2007	Jun DISC

ALPROSTADIL

INJECTABLE; INJECTION

ALPROSTADIL

AP	TEVA PHARMS USA	0.5MG/ML	A075196	001	Apr 30, 1999	Apr CAHN
----	-----------------	----------	---------	-----	--------------	----------

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

>A>	AP	EMCURE PHARMS LTD	EQ 250MG BASE/ML	A204040	001	Dec 12, 2013	Dec NEWA
		@ HOSPIRA	EQ 250MG BASE/ML	A063264	001	Nov 30, 1994	Mar DISC
		@ TEVA PHARMS USA	EQ 50MG BASE/ML	A064045	001	Sep 28, 1993	Jun CAHN
AP			EQ 250MG BASE/ML	A064045	002	Sep 28, 1993	Jun CAHN

AMINO ACIDS

INJECTABLE; INJECTION

AMINOSYN-HF 8%

	HOSPIRA	8% (8GM/100ML)	A020345	001	Apr 04, 1996	Nov CMS2
--	---------	----------------	---------	-----	--------------	----------

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE

@	INTL MEDICATION	25MG/ML	A087209	001	Feb 01, 1982	Jun DISC
@	PHARMA SERVE NY	25MG/ML	A087392	001	Dec 15, 1983	Jun DISC

TABLET; ORAL

AMINOPHYLLINE

>A>	@	HIKMA PHARMS LLC	100MG	A084540	001		Dec CAHN
>A>	@		200MG	A085003	001		Dec CAHN
>D>	@	WEST WARD	100MG	A084540	001		Dec CAHN
	@		100MG	A084540	001		Jul DISC
>D>	@		200MG	A085003	001		Dec CAHN
	@		200MG	A085003	001		Jul DISC

AMIODARONE HYDROCHLORIDEINJECTABLE; INJECTION  
AMIODARONE HYDROCHLORIDE

>D>	@	AGILA SPECLTS	50MG/ML	A076394	001	Apr 25, 2003	Dec	CAHN
	@		50MG/ML	A076394	001	Apr 25, 2003	Aug	CAHN
	@	APOTEX INC	50MG/ML	A076394	001	Apr 25, 2003	Apr	DISC
AP		HOSPIRA INC	50MG/ML	A203884	001	Nov 25, 2013	Nov	NEWA
AP			50MG/ML	A203885	001	Nov 25, 2013	Nov	NEWA
>A>	@	JHP PHARMS LLC	50MG/ML	A076394	001	Apr 25, 2003	Dec	CAHN
AP	+	MYLAN INSTITUTIONAL	50MG/ML	A076217	001	Oct 15, 2002	Apr	CAHN
	@	TEVA PHARMS USA	50MG/ML	A076163	001	Sep 05, 2003	Apr	CAHN

AMLEXANOXPASTE; DENTAL  
APHTHASOL  
@ ULURU

5%

N020511 001 Dec 17, 1996 Jun DISC

AMLODIPINE BESYLATETABLET; ORAL  
AMLODIPINE BESYLATE

AB		ACCORD HLTHCARE	EQ 2.5MG BASE	A202553	001	Apr 29, 2013	Apr	NEWA
AB			EQ 5MG BASE	A202553	002	Apr 29, 2013	Apr	NEWA
AB			EQ 10MG BASE	A202553	003	Apr 29, 2013	Apr	NEWA
AB		CIPLA LTD	EQ 2.5MG BASE	A077073	001	Sep 26, 2007	Aug	CAHN
AB			EQ 5MG BASE	A077073	002	Sep 26, 2007	Aug	CAHN
AB			EQ 10MG BASE	A077073	003	Sep 26, 2007	Aug	CAHN
AB		UNICHEM LABS LTD	EQ 2.5MG BASE	A203245	001	Oct 21, 2013	Oct	NEWA
AB			EQ 5MG BASE	A203245	002	Oct 21, 2013	Oct	NEWA
AB			EQ 10MG BASE	A203245	003	Oct 21, 2013	Oct	NEWA

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUMTABLET; ORAL  
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB		MYLAN PHARMS INC	EQ 2.5MG BASE;EQ 10MG BASE	A200465	001	Nov 29, 2013	Nov	NEWA
AB			EQ 2.5MG BASE;EQ 20MG BASE	A200465	002	Nov 29, 2013	Nov	NEWA
AB			EQ 2.5MG BASE;EQ 40MG BASE	A200465	003	Nov 29, 2013	Nov	NEWA
AB			EQ 5MG BASE;EQ 10MG BASE	A200465	004	Nov 29, 2013	Nov	NEWA
AB			EQ 5MG BASE;EQ 20MG BASE	A200465	005	Nov 29, 2013	Nov	NEWA
AB			EQ 5MG BASE;EQ 40MG BASE	A200465	006	Nov 29, 2013	Nov	NEWA
AB			EQ 5MG BASE;EQ 80MG BASE	A200465	007	Nov 29, 2013	Nov	NEWA
AB			EQ 10MG BASE;EQ 10MG BASE	A200465	008	Nov 29, 2013	Nov	NEWA
AB			EQ 10MG BASE;EQ 20MG BASE	A200465	009	Nov 29, 2013	Nov	NEWA
AB			EQ 10MG BASE;EQ 40MG BASE	A200465	010	Nov 29, 2013	Nov	NEWA
AB			EQ 10MG BASE;EQ 80MG BASE	A200465	011	Nov 29, 2013	Nov	NEWA
		CADUET						
AB		PFIZER	EQ 2.5MG BASE;EQ 10MG BASE	N021540	009	Jul 29, 2004	Nov	CFTG
AB			EQ 2.5MG BASE;EQ 20MG BASE	N021540	010	Jul 29, 2004	Nov	CFTG
AB			EQ 2.5MG BASE;EQ 40MG BASE	N021540	011	Jul 29, 2004	Nov	CFTG
AB			EQ 5MG BASE;EQ 10MG BASE	N021540	001	Jan 30, 2004	Nov	CFTG
AB			EQ 5MG BASE;EQ 20MG BASE	N021540	002	Jan 30, 2004	Nov	CFTG
AB			EQ 5MG BASE;EQ 40MG BASE	N021540	003	Jan 30, 2004	Nov	CFTG
AB			EQ 5MG BASE;EQ 80MG BASE	N021540	004	Jan 30, 2004	Nov	CFTG
AB			EQ 10MG BASE;EQ 10MG BASE	N021540	005	Jan 30, 2004	Nov	CFTG
AB			EQ 10MG BASE;EQ 20MG BASE	N021540	006	Jan 30, 2004	Nov	CFTG
AB			EQ 10MG BASE;EQ 40MG BASE	N021540	007	Jan 30, 2004	Nov	CFTG
AB	+		EQ 10MG BASE;EQ 80MG BASE	N021540	008	Jan 30, 2004	Nov	CFTG

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDECAPSULE; ORAL  
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

>A>	AB	APOTEX INC	EQ 2.5MG BASE;10MG	A091431	001	Dec 30, 2013	Dec	NEWA
>A>	AB		EQ 5MG BASE;10MG	A091431	002	Dec 30, 2013	Dec	NEWA
>A>	AB		EQ 5MG BASE;20MG	A091431	003	Dec 30, 2013	Dec	NEWA
>A>	AB		EQ 5MG BASE;40MG	A091431	004	Dec 30, 2013	Dec	NEWA
>A>	AB		EQ 10MG BASE;20MG	A091431	005	Dec 30, 2013	Dec	NEWA
>A>	AB		EQ 10MG BASE;40MG	A091431	006	Dec 30, 2013	Dec	NEWA



AMLODIPINE BESYLATE; TELMISARTAN

## TABLET; ORAL

&gt;A&gt; TELMISARTAN AND AMLODIPINE

>A> AB	LUPIN LTD	EQ 5MG BASE;40MG	A201586	001	Jan 08, 2014	Dec	NEWA
>A> AB		EQ 5MG BASE;80MG	A201586	003	Jan 08, 2014	Dec	NEWA
>A> AB		EQ 10MG BASE;40MG	A201586	002	Jan 08, 2014	Dec	NEWA
>A> AB		EQ 10MG BASE;80MG	A201586	004	Jan 08, 2014	Dec	NEWA
>A> AB	TORRENT PHARMS LTD	EQ 5MG BASE;40MG	A202517	001	Jan 08, 2014	Dec	NEWA
>A> AB		EQ 5MG BASE;80MG	A202517	003	Jan 08, 2014	Dec	NEWA
>A> AB		EQ 10MG BASE;40MG	A202517	002	Jan 08, 2014	Dec	NEWA
>A> AB		EQ 10MG BASE;80MG	A202517	004	Jan 08, 2014	Dec	NEWA

## TWINSTA

>D>	BOEHRINGER INGELHEIM	EQ 5MG BASE;40MG	N022401	001	Oct 16, 2009	Dec	CFTG
>A> AB		EQ 5MG BASE;40MG	N022401	001	Oct 16, 2009	Dec	CFTG
>D>		EQ 5MG BASE;80MG	N022401	003	Oct 16, 2009	Dec	CFTG
>A> AB		EQ 5MG BASE;80MG	N022401	003	Oct 16, 2009	Dec	CFTG
>D>		EQ 10MG BASE;40MG	N022401	002	Oct 16, 2009	Dec	CFTG
>A> AB		EQ 10MG BASE;40MG	N022401	002	Oct 16, 2009	Dec	CFTG
>D>	+	EQ 10MG BASE;80MG	N022401	004	Oct 16, 2009	Dec	CFTG
>A> AB	+	EQ 10MG BASE;80MG	N022401	004	Oct 16, 2009	Dec	CFTG

AMLODIPINE BESYLATE; VALSARTAN

## TABLET; ORAL

## AMLODIPINE BESYLATE AND VALSARTAN

AB	PAR PHARM INC	EQ 5MG BASE;160MG	A090011	001	Mar 28, 2013	Mar	NEWA
AB		EQ 5MG BASE;320MG	A090144	001	Mar 28, 2013	Mar	NEWA
AB		EQ 10MG BASE;160MG	A090011	002	Mar 28, 2013	Mar	NEWA
AB		EQ 10MG BASE;320MG	A090011	004	Mar 28, 2013	Mar	NEWA
	EXFORGE						
AB	NOVARTIS	EQ 5MG BASE;160MG	N021990	002	Jun 20, 2007	Mar	CFTG
AB		EQ 5MG BASE;320MG	N021990	004	Jun 20, 2007	Mar	CFTG
AB	+	EQ 10MG BASE;160MG	N021990	003	Jun 20, 2007	Mar	CFTG
AB	+	EQ 10MG BASE;320MG	N021990	005	Jun 20, 2007	Mar	CFTG

AMMONIA N-13

## INJECTABLE; INTRAVENOUS

## AMMONIA N 13

AP	CARDINAL HEALTH 414	30MCI-300MCI/8ML (3.75-37.5MCI/ML)	A203700	001	Feb 25, 2013	Feb	NEWA	
AP	+	FEINSTEIN	30MCI-300MCI/8ML (3.75-37.5MCI/ML)	N022119	001	Aug 23, 2007	Feb	CFTG
AP	KREITCHMAN PET CTR	30MCI-300MCI/8ML (3.75-37.5MCI/ML)	A203938	001	Dec 09, 2013	Nov	NEWA	
AP	MCPRF	30MCI-300MCI/8ML (3.75-37.5MCI/ML)	A203321	001	Feb 25, 2013	Feb	NEWA	
AP	UCLA BIOMEDICAL	30MCI-300MCI/8ML (3.75-37.5MCI/ML)	A203812	001	Jun 27, 2013	Jun	NEWA	

AMOXICILLIN

## FOR SUSPENSION; ORAL

## AMOXICILLIN

@	RANBAXY	200MG/5ML	A065113	001	Nov 29, 2002	Feb	DISC
@		400MG/5ML	A065113	002	Nov 29, 2002	Feb	DISC

## TABLET; ORAL

## AMOXICILLIN

@	DAVA PHARMS INC	875MG	A065344	001	Jan 15, 2009	Jun	DISC
---	-----------------	-------	---------	-----	--------------	-----	------

## TABLET, CHEWABLE; ORAL

## AMOXICILLIN

@	DAVA PHARMS INC	125MG	A064139	001	Jan 29, 1996	Mar	DISC
@		250MG	A064139	002	Jan 29, 1996	Mar	DISC
@	RANBAXY	200MG	A065060	001	Nov 29, 2000	Feb	DISC
@		400MG	A065060	002	Nov 29, 2000	Feb	DISC

## AMOXIL

@	DR REDDYS LABS INC	200MG	N050761	001	Apr 15, 1999	Feb	DISC
@		400MG	N050761	002	Apr 15, 1999	Feb	DISC

## TABLET, FOR SUSPENSION; ORAL

## AMOXICILLIN

@	AUROBINDO PHARMA LTD	200MG	A065324	001	Jan 17, 2007	Jan	DISC
@		400MG	A065324	002	Jan 17, 2007	Jan	DISC

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

## CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET; ORAL

## LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

AB	TEVA PHARMS USA	500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, 30MG	A200218	001	Aug 30, 2013	Aug	NEWA
----	-----------------	--	---------	-----	--------------	-----	------

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET;ORAL  
PREVPAC

AB	+	TAKEDA PHARMS USA	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG	N050757	001	Dec 02, 1997	Aug CFTG
----	---	-------------------	--	---------	-----	--------------	----------

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB		WOCKHARDT EU OPERATN	600MG/5ML;EQ 42.9MG BASE/5ML	A065420	001	Dec 02, 2013	Nov NEWA
----	--	----------------------	------------------------------	---------	-----	--------------	----------

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

	@	APOTEX INC	250MG;EQ 125MG BASE	A065333	001	Feb 24, 2009	Apr DISC
	@		500MG;EQ 125MG BASE	A065333	002	Feb 24, 2009	Apr DISC
	@		875MG;EQ 125MG BASE	A065317	003	Oct 20, 2008	Apr DISC
	@	RANBAXY LABS	500MG;EQ 125MG BASE	A065109	001	Nov 04, 2002	Apr DISC
AB		TEVA PHARMS USA	875MG;EQ 125MG BASE	A065096	001	Oct 29, 2002	Apr CRLD

AUGMENTIN '250'

AB	+	DR REDDYS LABS INC	250MG;EQ 125MG BASE	N050564	001	Aug 06, 1984	Apr CRLD
----	---	--------------------	---------------------	---------	-----	--------------	----------

AUGMENTIN '500'

AB	+	DR REDDYS LABS INC	500MG;EQ 125MG BASE	N050564	002	Aug 06, 1984	Apr CRLD
----	---	--------------------	---------------------	---------	-----	--------------	----------

AUGMENTIN '875'

AB	+	DR REDDYS LABS INC	875MG;EQ 125MG BASE	N050720	001	Feb 13, 1996	Apr CRLD
----	---	--------------------	---------------------	---------	-----	--------------	----------

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

AMPHETAMINE ASP AMPHETAMINE SULF DEXTROAMPHET SACCHARATE & DEXTR SULF

AB		TEVA	1.25MG;1.25MG;1.25MG;1.25MG	A077488	001	Apr 29, 2013	Apr NEWA
AB			2.5MG;2.5MG;2.5MG;2.5MG	A077488	002	Apr 29, 2013	Apr NEWA
AB			3.75MG;3.75MG;3.75MG;3.75MG	A077488	003	Apr 29, 2013	Apr NEWA
AB			5MG;5MG;5MG;5MG	A077488	004	Apr 29, 2013	Apr NEWA
AB			6.25MG;6.25MG;6.25MG;6.25MG	A077488	005	Apr 29, 2013	Apr NEWA
AB			7.5MG;7.5MG;7.5MG;7.5MG	A077488	006	Apr 29, 2013	Apr NEWA

DEXTROAMP SACCHARATE,AMP ASPARTATE,DEXTROAMP SULFATE AND AMP SULFATE

AB		BARR LABS INC	1.25MG;1.25MG;1.25MG;1.25MG	A076536	001	Feb 12, 2013	Jan NEWA
AB			2.5MG;2.5MG;2.5MG;2.5MG	A076536	002	Feb 12, 2013	Jan NEWA
AB			3.75MG;3.75MG;3.75MG;3.75MG	A076536	003	Feb 12, 2013	Jan NEWA
AB			5MG;5MG;5MG;5MG	A076536	004	Feb 12, 2013	Jan NEWA
AB			6.25MG;6.25MG;6.25MG;6.25MG	A076536	005	Feb 12, 2013	Jan NEWA
AB			7.5MG;7.5MG;7.5MG;7.5MG	A076536	006	Feb 12, 2013	Jan NEWA

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		AUROLIFE PHARMA LLC	1.25MG;1.25MG;1.25MG;1.25MG	A202424	001	Nov 27, 2013	Nov NEWA
AB			1.875MG;1.875MG;1.875MG;1.875MG	A202424	002	Nov 27, 2013	Nov NEWA
AB			2.5MG;2.5MG;2.5MG;2.5MG	A202424	003	Nov 27, 2013	Nov NEWA
AB			3.125MG;3.125MG;3.125MG;3.125MG	A202424	004	Nov 27, 2013	Nov NEWA
AB			3.75MG;3.75MG;3.75MG;3.75MG	A202424	005	Nov 27, 2013	Nov NEWA
AB			5MG;5MG;5MG;5MG	A202424	006	Nov 27, 2013	Nov NEWA
AB			7.5MG;7.5MG;7.5MG;7.5MG	A202424	007	Nov 27, 2013	Nov NEWA
AB		MALLINCKRODT INC	1.25MG;1.25MG;1.25MG;1.25MG	A040440	001	Oct 07, 2003	Sep CMFD
AB			1.875MG;1.875MG;1.875MG;1.875MG	A040440	002	Oct 07, 2003	Sep CMFD
AB			2.5MG;2.5MG;2.5MG;2.5MG	A040440	003	Oct 07, 2003	Sep CMFD
AB			3.125MG;3.125MG;3.125MG;3.125MG	A040440	004	Oct 07, 2003	Sep CMFD
AB			3.75MG;3.75MG;3.75MG;3.75MG	A040440	005	Oct 07, 2003	Sep CMFD
AB			5MG;5MG;5MG;5MG	A040440	006	Oct 07, 2003	Sep CMFD
AB			7.5MG;7.5MG;7.5MG;7.5MG	A040440	007	Oct 07, 2003	Sep CMFD
AB		MUTUAL PHARM	1.25MG;1.25MG;1.25MG;1.25MG	A040480	001	Sep 09, 2003	Oct CMFD
AB			1.875MG;1.875MG;1.875MG;1.875MG	A040480	002	Sep 09, 2003	Oct CMFD
AB			2.5MG;2.5MG;2.5MG;2.5MG	A040480	003	Sep 09, 2003	Oct CMFD
AB			3.125MG;3.125MG;3.125MG;3.125MG	A040480	004	Sep 09, 2003	Oct CMFD
AB			3.75MG;3.75MG;3.75MG;3.75MG	A040480	005	Sep 09, 2003	Oct CMFD
AB			5MG;5MG;5MG;5MG	A040480	006	Sep 09, 2003	Oct CMFD
AB			7.5MG;7.5MG;7.5MG;7.5MG	A040480	007	Sep 09, 2003	Oct CMFD
	@	TEVA PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A040472	001	Sep 30, 2003	Jan DISC
	@		2.5MG;2.5MG;2.5MG;2.5MG	A040472	002	Sep 30, 2003	Jan DISC
	@		5MG;5MG;5MG;5MG	A040472	003	Sep 30, 2003	Jan DISC
	@		7.5MG;7.5MG;7.5MG;7.5MG	A040472	004	Sep 30, 2003	Jan DISC

AMPHOTERICIN B

INJECTABLE; INJECTION  
AMPHOTERICIN B

>D>	AP	+	X GEN PHARMS	50MG/VIAL	A 063206	001	Apr 29, 1992	Dec	CTEC
>A>		+		50MG/VIAL	A 063206	001	Apr 29, 1992	Dec	CTEC

AMPICILLIN SODIUM

INJECTABLE; INJECTION  
AMPICILLIN SODIUM

AP			ACS DOBFAR SPA	EQ 1GM BASE/VIAL	A 090884	002	Apr 03, 2013	Mar	NEWA
AP				EQ 2GM BASE/VIAL	A 090884	003	Apr 03, 2013	Mar	NEWA
AP				EQ 10GM BASE/VIAL	A 090889	001	Apr 03, 2013	Mar	NEWA
AP				EQ 500MG BASE/VIAL	A 090884	001	Apr 03, 2013	Mar	NEWA
		@	ANTIBIOTICE	EQ 1GM BASE/VIAL	A 090354	003	Dec 28, 2009	Jun	DISC
		@		EQ 2GM BASE/VIAL	A 090354	004	Dec 28, 2009	Jun	DISC
		@		EQ 250MG BASE/VIAL	A 090354	001	Dec 28, 2009	Jun	DISC
		@		EQ 500MG BASE/VIAL	A 090354	002	Dec 28, 2009	Jun	DISC
>A>	AP		ISTITUTO BIO ITA SPA	EQ 10MG BASE/VIAL	A 201404	001	Dec 20, 2013	Dec	NEWA

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION  
UNASYN

AP	+		PFIZER	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A 062901	002	Feb 27, 1992	Jul	NEWA
AP	+			EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A 062901	001	Nov 23, 1988	Jul	CRLD

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL  
ANAGRELIDE HYDROCHLORIDE

	@	WATSON LABS	EQ 0.5MG BASE	A 076417	001	Apr 18, 2005	Sep	DISC
	@		EQ 1MG BASE	A 076417	002	Apr 18, 2005	Sep	DISC

ANASTROZOLE

TABLET; ORAL  
ANASTROZOLE

AB			ACCORD HLTHCARE	1MG	A 090568	001	Jun 28, 2010	Apr	CAHN
	@		IMPAX LABS INC	1MG	A 091242	001	May 31, 2012	Oct	DISC
	@		KUDCO IRELAND	1MG	A 091331	001	Jan 05, 2011	Feb	DISC

ARIPIPRAZOLE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR  
ABILIFY MAINTENA KIT

			OTSUKA PHARM CO LTD	300MG/VIAL	N 202971	001	Feb 28, 2013	Feb	NEWA
+				400MG/VIAL	N 202971	002	Feb 28, 2013	Feb	NEWA

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION  
ORABLOC

			PIERREL	4%;EQ 0.009MG BASE/1.8ML (EQ 0.005MG BASE/ML)	N 022466	001	Feb 26, 2010	Oct	CTNA
+				4%;EQ 0.018MG BASE/1.8ML (EQ 0.01MG BASE/ML)	N 022466	002	Feb 26, 2010	Oct	CTNA

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL  
MOVIPREP

	@	NOVEL LABS INC	4.7GM;100GM;1.015GM;5.9GM;2.691GM; 7.5GM	A 090145	001	Jan 25, 2012	Aug	DISC
+		SALIX PHARMS	4.7GM;100GM;1.015GM;5.9GM;2.691GM; 7.5GM	N 021881	001	Aug 02, 2006	Aug	CTEC

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL  
ORPHENGESIC

	@	PRINSTON INC	385MG;30MG;25MG	A 075141	001	May 29, 1998	Apr	CAHN
	@	PRINSTON INC	770MG;60MG;50MG	A 075141	002	May 29, 1998	Apr	CAHN

ATENOLOL

TABLET;ORAL

ATENOLOL

@ MYLAN	25MG	A074126	003	Aug 26, 1998	Aug	DISC
@	50MG	A074126	001	Mar 23, 1994	Aug	DISC
@	100MG	A074126	002	Mar 23, 1994	Aug	DISC
@ WATSON LABS	50MG	A073352	001	Dec 27, 1991	Mar	DISC
@	100MG	A073353	001	Dec 27, 1991	Mar	DISC

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB	KUDCO IRELAND	EQ 10MG BASE	A091624	001	Apr 05, 2013	Mar	NEWA
AB		EQ 20MG BASE	A091624	002	Apr 05, 2013	Mar	NEWA
AB		EQ 40MG BASE	A091624	003	Apr 05, 2013	Mar	NEWA
AB		EQ 80MG BASE	A091624	004	Apr 05, 2013	Mar	NEWA

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL

LIPTRUZET

MERCK SHARP DOHME	EQ 10MG BASE;10MG	N200153	001	May 03, 2013	May	NEWA
	EQ 20MG BASE;10MG	N200153	002	May 03, 2013	May	NEWA
	EQ 40MG BASE;10MG	N200153	003	May 03, 2013	May	NEWA
+	EQ 80MG BASE;10MG	N200153	004	May 03, 2013	May	NEWA

AZACITIDINE

INJECTABLE;IV-SC

AZACITIDINE

AP	DR REDDYS LABS LTD	100MG/VIAL	A201537	001	Sep 16, 2013	Aug	NEWA
	VIDAZA						
AP	+ CELGENE	100MG/VIAL	N050794	001	May 19, 2004	Aug	CFTG

AZELAIC ACID

GEL;TOPICAL

FINACEA

+	BAYER HLTHCARE	15%	N021470	001	Dec 24, 2002	Jun	CAHN
---	----------------	-----	---------	-----	--------------	-----	------

AZILSARTAN KAMEDOXOMIL

TABLET;ORAL

EDARBI

	ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Sep	CAHN
+		EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Sep	CAHN

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET;ORAL

EDARBYCLOR

	ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL;12.5MG	N202331	001	Dec 20, 2011	Sep	CAHN
+		EQ 40MG MEDOXOMIL;25MG	N202331	002	Dec 20, 2011	Sep	CAHN

AZITHROMYCIN

FOR SUSPENSION, EXTENDED RELEASE;ORAL

ZMAX

+	PF PRISM CV	EQ 2GM BASE/BOT	N050797	001	Jun 10, 2005	Aug	CAHN
---	-------------	-----------------	---------	-----	--------------	-----	------

INJECTABLE;INJECTION

AZITHROMYCIN

AP	SUN PHARM INDS LTD	EQ 500MG BASE/VIAL	A090923	001	Apr 02, 2013	Mar	NEWA
----	--------------------	--------------------	---------	-----	--------------	-----	------

SOLUTION/DROPS;OPHTHALMIC

AZASITE

+	OAK PHARMS AKORN	1%	N050810	001	Apr 27, 2007	Nov	CAHN
---	------------------	----	---------	-----	--------------	-----	------

BACITRACIN

OINTMENT;OPHTHALMIC

BACITRACIN

>A>	AT	AKORN	500 UNITS/GM	A203257	001	Dec 13, 2013	Dec	NEWA
>D>	+	PERRIGO CO TENNESSEE	500 UNITS/GM	A061212	001		Dec	CTEC
>A>	AT		500 UNITS/GM	A061212	001		Dec	CTEC
	+		500 UNITS/GM	A061212	001		Jun	CAHN

POWDER;FOR RX COMPOUNDING

BACI-RX

@	X GEN PHARMS	5,000,000 UNITS/BOT	A061580	001		Mar	DISC
---	--------------	---------------------	---------	-----	--	-----	------

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC  
CORTISPORIN

@ CITRON PHARMA LLC 400 UNITS/GM;1%;EQ 3.5MG N050416 002 Nov CAHN  
BASE/GM;10,000 UNITS/GM

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC  
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

AT PERRIGO CO TENNESSEE 400 UNITS/GM;EQ 3.5MG BASE;10,000 A060764 002 Jun CAHN  
UNITS/GM

NEOSPORIN

@ CITRON PHARMA LLC 400 UNITS/GM;EQ 3.5MG N050417 001 Nov CAHN  
BASE/GM;10,000 UNITS/GM

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC  
BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT PERRIGO CO TENNESSEE 500 UNITS/GM;10,000 UNITS/GM A065022 001 Feb 27, 2002 Jun CAHN

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC  
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

+ PERRIGO CO TENNESSEE 400 UNITS/GM;1%;EQ 3.5MG A062166 002 Jun CAHN  
BASE;10,000 UNITS/GM

BACLOFEN

INJECTABLE;INTRATHECAL  
GABLOFEN

AP MALLINCKRODT INC 0.05MG/ML N022462 001 Nov 19, 2010 May CAHN  
AP 0.5MG/ML N022462 002 Nov 19, 2010 May CAHN

1MG/ML N022462 004 Jun 22, 2012 May CAHN

AP 2MG/ML N022462 003 Nov 19, 2010 May CAHN

LIORESAL

AP + MEDTRONIC NEURO 0.05MG/ML N020075 003 Nov 07, 1996 Nov CAHN

AP + 0.5MG/ML N020075 001 Jun 17, 1992 Nov CAHN

AP + 2MG/ML N020075 002 Jun 17, 1992 Nov CAHN

BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED

TABLET;ORAL  
DUAVEE

+ WYETH PHARMS PFIZER EQ 20MG BASE;0.45MG N022247 001 Oct 03, 2013 Oct NEWA

BENDAMUSTINE HYDROCHLORIDE

SOLUTION;IV (INFUSION)  
TREANDA

+ CEPHALON 45MG/0.5ML (90MG/ML) N022249 003 Sep 13, 2013 Oct CMS2

+ 45MG/0.5ML (90MG/ML) N022249 003 Oct 13, 2013 Sep NEWA

+ 180MG/2ML (90MG/ML) N022249 004 Sep 13, 2013 Oct CMS2

+ 180MG/2ML (90MG/ML) N022249 004 Oct 13, 2013 Sep NEWA

BENZONATATE

CAPSULE;ORAL  
BENZONATATE

AA CARACO 100MG A040587 001 Mar 19, 2008 May CAHN

AA 200MG A040587 002 Mar 19, 2008 May CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL  
ACANYA

+ DOW PHARM 2.5%;1.2% N050819 001 Oct 23, 2008 Apr CAHN

BENZAACLIN

AB VALEANT BERMUDA 5%;EQ 1% BASE N050756 001 Dec 21, 2000 Apr CAHN

BT + 5%;EQ 1% BASE N050756 002 Apr 20, 2007 Apr CAHN

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL;TOPICAL  
BENZAMYCIN PAK

+ VALEANT LUXEMBOURG 5%;3% N050769 001 Nov 27, 2000 Jun CAHN

<u>BENZPHETAMINE HYDROCHLORIDE</u>									
TABLET; ORAL									
BENZPHETAMINE HYDROCHLORIDE									
	@ COREPHARMA	50MG	A 040714	001	Oct 29, 2007	Feb	DISC		
<u>BENZTROPINE MESYLATE</u>									
INJECTABLE; INJECTION									
BENZTROPINE MESYLATE									
AP	NAVINTA LLC	1MG/ML	A 091525	001	Feb 05, 2013	Jan	NEWA		
TABLET; ORAL									
BENZTROPINE MESYLATE									
	@ PROSAM LABS	0.5MG	A 040699	001	Feb 14, 2008	Mar	DISC		
	@	1MG	A 040705	001	Feb 14, 2008	Mar	DISC		
	@	2MG	A 040706	001	Feb 14, 2008	Mar	DISC		
<u>BETAMETHASONE</u>									
SYRUP; ORAL									
CELESTONE									
	@ MERCK SHARP DOHME	0.6MG/5ML	N 014215	002		Apr	CAHN		
<u>BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE</u>									
INJECTABLE; INJECTION									
CELESTONE SOLUSPAN									
AB	+ MERCK SHARP DOHME	3MG/ML;EQ 3MG BASE/ML	N 014602	001		Apr	CAHN		
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE</u>									
SUSPENSION; TOPICAL									
TACLONEX									
	+ LEO PHARMA AS	0.064%;0.005%	N 022185	001	May 09, 2008	Sep	CAHN		
<u>BETAMETHASONE VALERATE</u>									
AEROSOL, FOAM; TOPICAL									
BETAMETHASONE VALERATE									
AB	PERRIGO	0.12%	A 078337	001	Nov 26, 2012	Apr	CPOT		
LUXIQ									
AB	+ DELCOR ASSET	0.12%	N 020934	001	Feb 28, 1999	Sep	CAHN		
AB	+ STIEFEL	0.12%	N 020934	001	Feb 28, 1999	Apr	CPOT		
<u>BETAXOLOL HYDROCHLORIDE</u>									
SOLUTION/DROPS; OPHTHALMIC									
BETAXOLOL HYDROCHLORIDE									
	@ APOTEX INC	EQ 0.5% BASE	A 075446	001	Sep 28, 2000	Apr	DISC		
<u>BETHANECHOL CHLORIDE</u>									
TABLET; ORAL									
BETHANECHOL CHLORIDE									
AA	CARACO	5MG	A 040897	001	Apr 22, 2009	Jun	CAHN		
AA		10MG	A 040897	002	Apr 22, 2009	Jun	CAHN		
AA		25MG	A 040897	003	Apr 22, 2009	Jun	CAHN		
AA		50MG	A 040897	004	Apr 22, 2009	Jun	CAHN		
	@ LANNETT HOLDINGS INC	5MG	A 040703	001	Mar 27, 2008	Jun	DISC		
	@	50MG	A 040677	001	Mar 27, 2008	Jun	DISC		
<u>BEXAROTENE</u>									
CAPSULE; ORAL									
TARGRETIN									
	+ VALEANT LUXEMBOURG	75MG	N 021055	001	Dec 29, 1999	Jun	CAHN		
GEL; TOPICAL									
TARGRETIN									
	+ VALEANT LUXEMBOURG	1%	N 021056	001	Jun 28, 2000	Jun	CAHN		
	+ VALEANT PHARMS INC	1%	N 021056	001	Jun 28, 2000	Feb	CAHN		
<u>BICALUTAMIDE</u>									
TABLET; ORAL									
BICALUTAMIDE									
AB	ACCORD HLTHCARE	50MG	A 078917	001	Jul 06, 2009	Apr	CAHN		
	@ KUDCO IRELAND	50MG	A 077995	001	Jul 06, 2009	Nov	DISC		
	@ SYNTHON PHARMS	50MG	A 077973	001	Jul 06, 2009	Sep	DISC		

BLEOMYCIN SULFATE

		INJECTABLE; INJECTION							
		BLEOMYCIN SULFATE							
	@	PHARMACHEMIE BV	EQ 15 UNITS BASE/VIAL	A 065201	001	Dec 13, 2007	Feb	DISC	
>D>	AP	TEVA PARENTERAL	EQ 15 UNITS BASE/VIAL	A 065033	001	Jun 27, 2000	Dec	CAHN	
>D>	AP		EQ 30 UNITS BASE/VIAL	A 065033	002	Jun 27, 2000	Dec	CAHN	
>A>	AP	TEVA PHARMS USA	EQ 15 UNITS BASE/VIAL	A 065033	001	Jun 27, 2000	Dec	CAHN	
>A>	AP		EQ 30 UNITS BASE/VIAL	A 065033	002	Jun 27, 2000	Dec	CAHN	

BRIMONIDINE TARTRATE

		GEL; TOPICAL							
		MIRVASO							
	+	GALDERMA LABS LP	EQ 0.33% BASE	N 204708	001	Aug 23, 2013	Oct	CPOT	
	+		0.33%	N 204708	001	Aug 23, 2013	Sep	CAHN	
	+	GALDERMA R AND D	0.33%	N 204708	001	Aug 23, 2013	Aug	NEWA	
		SOLUTION/DROPS; OPHTHALMIC							
		BRIMONIDINE TARTRATE							
>D>	AT	ALCON PHARMS LTD	0.15%	N 021764	001	May 22, 2006	Dec	CTNA	
		QOLIANA							
>A>	AT	ALCON PHARMS LTD	0.15%	N 021764	001	May 22, 2006	Dec	CTNA	

BRIMONIDINE TARTRATE; BRINZOLAMIDE

		SUSPENSION/DROPS; OPHTHALMIC							
		SIMBRINZA							
	+	ALCON RES LTD	0.2%; 1%	N 204251	001	Apr 19, 2013	Apr	NEWA	

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

		SOLUTION/DROPS; OPHTHALMIC							
		COMBIGAN							
	+	ALLERGAN	0.2%; EQ 0.5% BASE	N 021398	001	Oct 30, 2007	Oct	CPOT	

BROMFENAC SODIUM

		SOLUTION/DROPS; OPHTHALMIC							
		BROMDAY							
	+	ISTA PHARMS INC	EQ 0.09% ACID	N 021664	002	Oct 16, 2010	Apr	CPOT	
		BROMFENAC SODIUM							
AT		COASTAL PHARMS	EQ 0.09% ACID	A 201211	001	May 11, 2011	Apr	CPOT	
AT		LUITPOLD	EQ 0.09% ACID	A 202030	001	Jan 09, 2013	Apr	CPOT	
AT			0.09%	A 202030	001	Jan 09, 2013	Feb	CAHN	
		PROLENSA							
	+	BAUSCH AND LOMB	EQ 0.07% ACID	N 203168	001	Apr 05, 2013	Apr	NEWA	
		XIBROM							
	@	ISTA PHARMS INC	EQ 0.09% ACID	N 021664	001	Mar 24, 2005	Apr	CPOT	

BUDESONIDE

		SUSPENSION; INHALATION							
		BUDESONIDE							
	@	APOTEX INC	0.25MG/2ML	A 078202	001	Mar 30, 2009	Apr	DISC	
	@		0.5MG/2ML	A 078202	002	Mar 30, 2009	Apr	DISC	
AN		SANDOZ	0.25MG/2ML	A 201966	003	Sep 27, 2013	Sep	NEWA	
AN			0.5MG/2ML	A 201966	002	Sep 27, 2013	Sep	NEWA	
AN			1MG/2ML	A 201966	001	Sep 27, 2013	Sep	NEWA	
		PULMICORT RESPULES							
AN	+	ASTRAZENECA	1MG/2ML	N 020929	003	Aug 08, 2000	Sep	CTEC	
		TABLET, EXTENDED RELEASE; ORAL							
		UCERIS							
	+	SANTARUS	9MG	N 203634	001	Jan 14, 2013	Jan	NEWA	

BUPIVACAINE HYDROCHLORIDE

		INJECTABLE; INJECTION							
		BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE							
AP		AUROBINDO PHARMA LTD	0.25%	A 203895	001	Nov 05, 2013	Oct	NEWA	
AP			0.5%	A 203895	002	Nov 05, 2013	Oct	NEWA	
AP			0.75%	A 203895	003	Nov 05, 2013	Oct	NEWA	
	@	INTL MEDICATED	0.25%	A 076012	001	Jan 09, 2002	Jun	DISC	
	@		0.5%	A 076012	002	Jan 09, 2002	Jun	DISC	
	@		0.75%	A 076012	003	Jan 09, 2002	Jun	DISC	

BUPRENORPHINE

FILM, EXTENDED RELEASE;TRANSDERMAL  
BUTRANS

PURDUE PHARMA LP 15MCG/HR N021306 004 Jul 25, 2013 Aug NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;SUBLINGUAL  
SUBOXONE

RECKITT BENCKISER EQ 8MG BASE;EQ 2MG BASE N022410 002 Aug 30, 2010 Jul CRLD  
+ EQ 12MG BASE;EQ 3MG BASE N022410 004 Aug 10, 2012 Jul CRLD

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB ACTAVIS ELIZABETH EQ 2MG BASE;EQ 0.5MG BASE A091422 001 Feb 22, 2013 Jul CTNA  
AB + EQ 8MG BASE;EQ 2MG BASE A091422 002 Feb 22, 2013 Jul CTNA  
AB AMNEAL PHARMS EQ 8MG BASE;EQ 2MG BASE A203136 002 Feb 22, 2013 Aug CTNA  
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE  
AB AMNEAL PHARMS EQ 2MG BASE;EQ 0.5MG BASE A203136 001 Feb 22, 2013 Aug CTNA  
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE  
AB ACTAVIS ELIZABETH EQ 2MG BASE;EQ 0.5MG BASE A091422 001 Feb 22, 2013 Feb NEWA  
AB + EQ 8MG BASE;EQ 2MG BASE A091422 002 Feb 22, 2013 Apr CRLD  
AB EQ 8MG BASE;EQ 2MG BASE A091422 002 Feb 22, 2013 Feb NEWA  
AB AMNEAL PHARMS EQ 2MG BASE;EQ 0.5MG BASE A203136 001 Feb 22, 2013 Feb NEWA  
AB EQ 8MG BASE;EQ 2MG BASE A203136 002 Feb 22, 2013 Feb NEWA

ZUBSOLV

OREXO AB EQ 1.4MG BASE;EQ 0.36MG BASE N204242 001 Jul 03, 2013 Jul NEWA  
+ EQ 5.7MG BASE;EQ 1.4MG BASE N204242 002 Jul 03, 2013 Jul NEWA

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

APLENZIN

VALEANT BERMUDA 174MG N022108 001 Apr 23, 2008 Apr CAHN  
348MG N022108 002 Apr 23, 2008 Nov CRLD  
+ 348MG N022108 002 Apr 23, 2008 Apr CAHN  
+ 522MG N022108 003 Apr 23, 2008 Nov CRLD  
522MG N022108 003 Apr 23, 2008 Apr CAHN

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

@ TEVA 75MG A075310 001 Nov 29, 1999 Feb CDFR  
@ 100MG A075310 002 Nov 29, 1999 Feb DISC

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

@ IMPAX LABS 300MG A077415 002 Dec 15, 2006 Apr DISC  
AB1 JUBILANT LIFE 100MG A202774 001 Oct 11, 2013 Sep NEWA  
AB1 150MG A202774 002 Oct 11, 2013 Sep NEWA  
AB2 150MG A202775 001 Oct 11, 2013 Sep NEWA  
AB1 200MG A202774 003 Oct 11, 2013 Sep NEWA  
BX WATSON LABS 300MG A077715 002 Jun 13, 2007 Sep CTEC  
AB1 WATSON LABS INC 100MG A077455 001 Jul 19, 2010 Apr CAHN  
AB3 150MG A077285 001 Nov 26, 2008 Apr CAHN  
AB1 150MG A077455 002 Mar 12, 2008 Apr CAHN  
AB1 200MG A077455 003 Jul 19, 2010 Apr CAHN  
AB3 300MG A077285 002 Aug 15, 2008 Apr CAHN

BUTOCONAZOLE NITRATE

CREAM;VAGINAL

BUTOCONAZOLE NITRATE

+ PERRIGO ISRAEL 2% A200923 001 May 18, 2012 Mar CRLD  
GYNAZOLE-1  
@ KV PHARM 2% N019881 001 Feb 07, 1997 Mar DISC

BUTORPHANOL TARTRATE

INJECTABLE;INJECTION

BUTORPHANOL TARTRATE

@ APOTEX INC 2MG/ML A075697 001 Oct 23, 2001 Apr DISC  
BUTORPHANOL TARTRATE PRESERVATIVE FREE  
@ APOTEX INC 1MG/ML A075695 001 Oct 23, 2001 Apr DISC  
@ 2MG/ML A075695 002 Oct 23, 2001 Apr DISC



INJECTABLE; INJECTION

STADOL

@ APOTHECON	2MG/ML	N017857	004		Jun	DISC
STADOL PRESERVATIVE FREE						
@ APOTHECON	1MG/ML	N017857	001		Jun	DISC
@	2MG/ML	N017857	002		Jun	DISC

CABERGOLINE

TABLET; ORAL

CABERGOLINE

AB	APOTEX CORP	0.5MG	A201503	001	Mar 08, 2013	Feb	NEWA
AB	MYLAN PHARMS INC	0.5MG	A202947	001	Dec 02, 2013	Nov	NEWA

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL

MIGERGOT

>A>	+	CREALTA PHARMS LLC	100MG; 2MG	A086557	001	Oct 04, 1983	Dec	CAHN
>D>	+	G AND W LABS	100MG; 2MG	A086557	001	Oct 04, 1983	Dec	CAHN

TABLET; ORAL

ERGOTAMINE TARTRATE AND CAFFEINE

AA	MIKART	100MG; 1MG	A040590	001	Sep 16, 2005	Mar	CMFD
	@	100MG; 1MG	A040590	001	Sep 16, 2005	Jan	DISC

CALCIPOTRIENE

OINTMENT; TOPICAL

DOVONEX

@ LEO PHARMA AS	0.005%	N020273	001	Dec 29, 1993	Sep	CAHN
-----------------	--------	---------	-----	--------------	-----	------

CALCITRIOL

CAPSULE; ORAL

CALCITRIOL

AB	BANNER PHARMACAPS	0.25MCG	A091174	001	May 24, 2013	May	NEWA
AB		0.5MCG	A091174	002	May 24, 2013	May	NEWA

CALCIUM ACETATE

CAPSULE; ORAL

CALCIUM ACETATE

AB	INVAGEN PHARMS	EQ 169MG CALCIUM	A203135	001	Feb 07, 2013	Jan	NEWA
----	----------------	------------------	---------	-----	--------------	-----	------

TABLET; ORAL

CALCIUM ACETATE

AB	INVAGEN PHARMS	EQ 169MG CALCIUM	A202420	001	Feb 05, 2013	Jan	NEWA
----	----------------	------------------	---------	-----	--------------	-----	------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER

@ B BRAUN	35MG/100ML; 5GM/100ML; 30MG/100ML; 74 MG/100ML; 640MG/100ML; 500MG/100ML; 7 4MG/100ML	N019867	001	Dec 20, 1993	Mar	DISC
-----------	---	---------	-----	--------------	-----	------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

@ FRESENIUS	18.4MG/100ML; 1.5GM/100ML; 5.08MG/10 0ML; 538MG/100ML; 448MG/100ML	A020374	001	Jun 13, 1994	Nov	CMS2
-------------	---	---------	-----	--------------	-----	------

@	18.4MG/100ML; 1.5GM/100ML; 5.08MG/10 0ML; 538MG/100ML; 448MG/100ML	A020374	001	Jun 13, 1994	Feb	DISC
---	---	---------	-----	--------------	-----	------

INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

@ FRESENIUS	18.4MG/100ML; 2.5GM/100ML; 5.08MG/10 0ML; 538MG/100ML; 448MG/100ML	A020374	002	Jun 13, 1994	Nov	CMS2
-------------	---	---------	-----	--------------	-----	------

@	18.4MG/100ML; 2.5GM/100ML; 5.08MG/10 0ML; 538MG/100ML; 448MG/100ML	A020374	002	Jun 13, 1994	Feb	DISC
---	---	---------	-----	--------------	-----	------

INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

@ FRESENIUS	18.4MG/100ML; 3.5GM/100ML; 5.08MG/10 0ML; 538MG/100ML; 448MG/100ML	A020374	003	Jun 13, 1994	Nov	CMS2
-------------	---	---------	-----	--------------	-----	------

@	18.4MG/100ML; 3.5GM/100ML; 5.08MG/10 0ML; 538MG/100ML; 448MG/100ML	A020374	003	Jun 13, 1994	Feb	DISC
---	---	---------	-----	--------------	-----	------

INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

@ FRESENIUS	18.4MG/100ML; 4.25GM/100ML; 5.08MG/1 00ML; 538MG/100ML; 448MG/100ML	A020374	004	Jun 13, 1994	Nov	CMS2
-------------	--	---------	-----	--------------	-----	------

@	18.4MG/100ML; 4.25GM/100ML; 5.08MG/1 00ML; 538MG/100ML; 448MG/100ML	A020374	004	Jun 13, 1994	Feb	DISC
---	--	---------	-----	--------------	-----	------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATEINJECTABLE; INTRATHECAL  
ELLIOTTS B SOLUTION

+	LUKARE MEDICAL LLC	0.2MG/ML; 0.8MG/ML; 0.3MG/ML; 0.3MG/M L; 1.9MG/ML; 7.3MG/ML; 0.2MG/ML	N020577	001	Sep 27, 1996	Jun	CAHN
---	--------------------	---	---------	-----	--------------	-----	------

CANAGLIFLOZINTABLET; ORAL  
INVOKANA

	JANSSEN PHARMS	100MG	N204042	001	Mar 29, 2013	Apr	CAHN
+		300MG	N204042	002	Mar 29, 2013	Apr	CAHN
	JANSSEN RES AND DEV	100MG	N204042	001	Mar 29, 2013	Mar	NEWA
+		300MG	N204042	002	Mar 29, 2013	Mar	NEWA

CANDESARTAN CILEXETILTABLET; ORAL  
ATACAND

AB	ASTRAZENECA	4MG	N020838	001	Jun 04, 1998	Apr	CFTG	
AB		8MG	N020838	002	Jun 04, 1998	Apr	CFTG	
AB		16MG	N020838	003	Jun 04, 1998	Apr	CFTG	
AB	+	32MG	N020838	004	Jun 04, 1998	Apr	CFTG	
	CANDESARTAN CILEXETIL							
>A>	AB	APOTEX INC	4MG	A202079	001	Jan 10, 2014	Dec	NEWA
>A>	AB		8MG	A202079	002	Jan 10, 2014	Dec	NEWA
>A>	AB		16MG	A202079	003	Jan 10, 2014	Dec	NEWA
>A>	AB		32MG	A202079	004	Jan 10, 2014	Dec	NEWA
AB	SANDOZ	4MG	A078702	001	May 03, 2013	Apr	NEWA	
AB		8MG	A078702	002	May 03, 2013	Apr	NEWA	
AB		16MG	A078702	003	May 03, 2013	Apr	NEWA	
AB		32MG	A078702	004	May 03, 2013	Apr	NEWA	

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB	APOTEX INC	32MG; 25MG	A202884	003	Jun 03, 2013	May	NEWA
AB	DR REDDYS LABS LTD	16MG; 12.5MG	A202965	001	Jun 03, 2013	May	NEWA
AB		32MG; 12.5MG	A202965	002	Jun 03, 2013	May	NEWA
AB		32MG; 25MG	A202965	003	Jun 03, 2013	May	NEWA

CAPECITABINE

TABLET; ORAL

CAPECITABINE

AB	TEVA PHARMS USA	150MG	A091649	001	Sep 16, 2013	Aug	NEWA
AB		500MG	A091649	002	Sep 16, 2013	Aug	NEWA
	XELODA						
AB	HOFFMANN LA ROCHE	150MG	N020896	001	Apr 30, 1998	Aug	CFTG
AB	+	500MG	N020896	002	Apr 30, 1998	Aug	CFTG

CAPSAICIN

PATCH; TOPICAL

QUTENZA

+	ACORDA	8%	N022395	001	Nov 16, 2009	Jul	CAHN
---	--------	----	---------	-----	--------------	-----	------

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

@ PRINSTON INC

12.5MG

A074477 001 Feb 13, 1996 Jun DISC

@ 25MG

A074477 002 Feb 13, 1996 Jun DISC

@ 50MG

A074477 003 Feb 13, 1996 Jun DISC

@ 100MG

A074477 004 Feb 13, 1996 Jun DISC

@ TEVA 12.5MG

A074483 001 Feb 13, 1996 Jun DISC

@ 25MG

A074483 002 Feb 13, 1996 Jun DISC

@ 50MG

A074483 003 Feb 13, 1996 Jun DISC

@ 100MG

A074483 004 Feb 13, 1996 Jun DISC

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL  
CARBAMAZEPINE

AB	TARO	100MG	A201106	001	Jun 21, 2013	Jun	NEWA
AB		200MG	A201106	002	Jun 21, 2013	Jun	NEWA
AB		300MG	A201106	003	Jun 21, 2013	Jun	NEWA

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE;ORAL  
CARBIDOPA AND LEVODOPA

AB	ACCORD HLTHCARE	25MG;100MG	A202323	001	Feb 08, 2013	Jan	NEWA
AB		50MG;200MG	A202323	002	Feb 08, 2013	Jan	NEWA

CARBINOXAMINE MALEATE

SUSPENSION, EXTENDED RELEASE;ORAL  
KARBINAL ER

+	TRIS PHARMA INC	4MG/5ML	N022556	001	Mar 28, 2013	Mar	NEWA
---	-----------------	---------	---------	-----	--------------	-----	------

CARBOPLATIN

INJECTABLE;INJECTION  
CARBOPLATIN

@	PLIVA	50MG/VIAL	A076602	001	Nov 16, 2004	Feb	DISC
@		150MG/VIAL	A076602	002	Nov 16, 2004	Feb	DISC
@		450MG/VIAL	A076602	003	Nov 16, 2004	Feb	DISC

INJECTABLE;IV (INFUSION)  
CARBOPLATIN

@	FRESENIUS KABI USA	50MG/5ML (10MG/ML)	A077266	001	Feb 15, 2006	Mar	DISC
@		150MG/15ML (10MG/ML)	A077266	002	Feb 15, 2006	Mar	DISC
@	PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077679	001	Feb 25, 2009	Apr	DISC
@		150MG/15ML (10MG/ML)	A077679	002	Feb 25, 2009	Apr	DISC
@		450MG/45ML (10MG/ML)	A077679	003	Feb 25, 2009	Apr	DISC
AP	SAGENT PHARMS	50MG/5ML (10MG/ML)	A077096	001	Jun 14, 2005	Oct	CMFD
AP		150MG/15ML (10MG/ML)	A077096	002	Jun 14, 2005	Oct	CMFD
AP		450MG/45ML (10MG/ML)	A077096	003	Jun 14, 2005	Oct	CMFD
AP		600MG/60ML (10MG/ML)	A077096	004	Jun 03, 2013	Oct	NEWA
>D>	+	TEVA PARENTERAL	A077139	001	Sep 21, 2005	Dec	CAHN
>D>	+		A077139	002	Sep 21, 2005	Dec	CAHN
>D>	+		A077139	003	Sep 21, 2005	Dec	CAHN
>D>	+		A077139	004	Sep 21, 2005	Dec	CAHN
>A>	+	TEVA PHARMS USA	A077139	001	Sep 21, 2005	Dec	CAHN
>A>	+		A077139	002	Sep 21, 2005	Dec	CAHN
>A>	+		A077139	003	Sep 21, 2005	Dec	CAHN
>A>	+		A077139	004	Sep 21, 2005	Dec	CAHN
		PARAPLATIN					
@	CORDENPHARMA	50MG/5ML (10MG/ML)	N020452	001	Jul 14, 2003	Mar	CAHN
@		150MG/15ML (10MG/ML)	N020452	002	Jul 14, 2003	Mar	CAHN
@		450MG/45ML (10MG/ML)	N020452	003	Jul 14, 2003	Mar	CAHN
@		600MG/60ML (10MG/ML)	N020452	004	Jan 15, 2004	Mar	CAHN

CARISOPRODOL

TABLET;ORAL  
CARISOPRODOL

AA	ACCELRX LABS	350MG	A040576	001	Jun 07, 2005	May	CAHN
	@ COREPHARMA	350MG	A040397	001	Sep 21, 2000	Feb	DISC
	@ PROSAM LABS	350MG	A040188	001	Mar 07, 1997	Jun	DISC
>D>	AA	WEST WARD	A040124	001	Jan 24, 1996	Dec	DISC
>A>	@	350MG	A040124	001	Jan 24, 1996	Dec	DISC

CARMUSTINE

IMPLANT;INTRACRANIAL  
GLIADEL

+	ARBOR PHARMS LLC	7.7MG	N020637	001	Sep 23, 1996	Mar	CAHN
---	------------------	-------	---------	-----	--------------	-----	------

INJECTABLE;INJECTION  
BICNU

+	EMCURE PHARMS LTD	100MG/VIAL	N017422	001		Jan	CAHN
---	-------------------	------------	---------	-----	--	-----	------

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
 CARTEOLOL HYDROCHLORIDE  
 @ APOTEX INC 1%

A076097 001 Feb 06, 2002 Apr DISC

CARVEDILOL

TABLET;ORAL  
 CARVEDILOL

AB	CIPLA LTD	3.125MG	A077474	001	Sep 05, 2007	Aug	CAHN
AB		6.25MG	A077474	002	Sep 05, 2007	Aug	CAHN
AB		12.5MG	A077474	003	Sep 05, 2007	Aug	CAHN
AB		25MG	A077474	004	Sep 05, 2007	Aug	CAHN
	@ WOCKHARDT LTD	3.125MG	A078786	001	Dec 22, 2009	Feb	DISC
	@	6.25MG	A078786	002	Dec 22, 2009	Feb	DISC
	@	12.5MG	A078786	003	Dec 22, 2009	Feb	DISC
	@	25MG	A078786	004	Dec 22, 2009	Feb	DISC

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION;ORAL  
 CEFADROXIL

AB	AUROBINDO	EQ 250MG BASE/5ML	A065349	001	Apr 25, 2013	Apr	NEWA
AB		EQ 500MG BASE/5ML	A065349	002	Apr 25, 2013	Apr	NEWA
	@ TEVA PHARMS USA	EQ 250MG BASE/5ML	A065278	001	Jan 20, 2006	Mar	DISC
	@	EQ 500MG BASE/5ML	A065278	002	Jan 20, 2006	Mar	DISC

CEFAZOLIN SODIUM

INJECTABLE;INJECTION  
 CEFZAZOLIN SODIUM

	@ AUROBINDO PHARMA	EQ 1GM BASE/VIAL	A065395	002	Aug 08, 2008	Aug	DISC
	@	EQ 500MG BASE/VIAL	A065395	001	Aug 08, 2008	Aug	DISC
AP	+ HOSPIRA INC	EQ 1GM BASE/VIAL	A065226	002	Apr 21, 2005	Feb	CRLD
AP	+	EQ 1GM BASE/VIAL	A065244	001	Aug 12, 2005	Feb	CRLD
AP	+	EQ 10GM BASE/VIAL	A065247	001	Aug 12, 2005	Feb	CRLD
AP	+	EQ 500MG BASE/VIAL	A065226	001	Apr 21, 2005	Feb	CRLD
AP	+ STERI PHARMA	EQ 20GM BASE/VIAL	A063209	002	Apr 30, 1999	Jul	CRLD

CEFEPIME HYDROCHLORIDE

INJECTABLE;INJECTION  
 CEFEPIME HYDROCHLORIDE

	@ SANDOZ	EQ 1GM BASE/VIAL	A090291	002	Dec 21, 2010	Mar	DISC
	@	EQ 2GM BASE/VIAL	A090291	003	Dec 21, 2010	Mar	DISC
	@	EQ 500MG BASE/VIAL	A090291	001	Dec 21, 2010	Mar	DISC

CEFIXIME

FOR SUSPENSION;ORAL  
 SUPRAX

+	LUPIN LTD	500MG/5ML	N202091	001	Feb 20, 2013	Feb	CDFR
	LUPIN PHARMS	100MG/5ML	A065129	001	Feb 23, 2004	Feb	CDFR
		200MG/5ML	A065355	001	Apr 10, 2007	Feb	CDFR

CEFOTAXIME SODIUM

INJECTABLE;INJECTION  
 CEFOTAXIME SODIUM

	@ AUROBINDO PHARMA	EQ 1GM BASE/VIAL	A065517	002	Nov 06, 2009	Aug	DISC
	@	EQ 2GM BASE/VIAL	A065517	003	Nov 06, 2009	Aug	DISC
	@	EQ 500MG BASE/VIAL	A065517	001	Nov 06, 2009	Aug	DISC
	@ AUROBINDO PHARMA LTD	EQ 10GM BASE/VIAL	A065516	001	Nov 06, 2009	Jun	DISC

CEFOXITIN SODIUM

INJECTABLE;INJECTION  
 CEFOXITIN

AP	+ ACS DOBFAR	EQ 1GM BASE/VIAL	A065414	001	Jun 12, 2009	Oct	CRLD
AP	+	EQ 2GM BASE/VIAL	A065414	002	Jun 12, 2009	Oct	CRLD
AP	+	EQ 10GM BASE/VIAL	A065415	001	May 19, 2010	Oct	CRLD

CEFTAZIDIME

INJECTABLE;INJECTION  
 CEFTAZIDIME

	@ AUROBINDO PHARMA LTD	1GM/VIAL	A065481	002	May 28, 2010	Jun	DISC
	@	2GM/VIAL	A065481	003	May 28, 2010	Jun	DISC
	@	6GM/VIAL	A065482	001	May 28, 2010	Jun	DISC

INJECTABLE; INJECTION  
CEFTAZIDIME

@ 500MG/VIAL A065481 001 May 28, 2010 Jun DISC

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV  
CEFTRIAXONE

@ AUROBINDO PHARMA LTD EQ 1GM BASE/VIAL A065505 003 Jul 31, 2008 May DISC  
 @ EQ 2GM BASE/VIAL A065505 004 Jul 31, 2008 May DISC  
 @ EQ 250MG BASE/VIAL A065505 001 Jul 31, 2008 May DISC  
 @ EQ 500MG BASE/VIAL A065505 002 Jul 31, 2008 May DISC  
 @ STERI PHARMA EQ 1GM BASE/VIAL A065268 001 Feb 28, 2007 Sep DISC  
 @ EQ 2GM BASE/VIAL A065268 002 Feb 28, 2007 Sep DISC  
 @ TEVA EQ 1GM BASE/VIAL A065262 001 Jun 29, 2006 Jul DISC  
 @ EQ 2GM BASE/VIAL A065262 002 Jun 29, 2006 Jul DISC  
 AP TEVA PHARMS USA EQ 1GM BASE/VIAL A065227 003 Mar 15, 2007 May CAHN  
 AP EQ 2GM BASE/VIAL A065227 004 Mar 15, 2007 May CAHN  
 AP EQ 250MG BASE/VIAL A065227 001 Mar 15, 2007 May CAHN  
 AP EQ 500MG BASE/VIAL A065227 002 Mar 15, 2007 May CAHN

INJECTABLE; INJECTION  
CEFTRIAXONE

@ AUROBINDO PHARMA LTD EQ 10GM BASE/VIAL A065504 001 Jul 31, 2008 May DISC  
 @ TEVA EQ 10GM BASE/VIAL A065274 001 May 01, 2006 Oct DISC

CEFUROXIME SODIUM

INJECTABLE; IM-IV  
CEFUROXIME SODIUM

@ TEVA PHARMS EQ 1.5GM BASE/VIAL A064192 001 Apr 16, 1998 Jul DISC  
 @ EQ 750MG BASE/VIAL A064192 002 Apr 16, 1998 Jul DISC

INJECTABLE; INJECTION  
CEFUROXIME SODIUM IN PLASTIC CONTAINER

@ SAMSON MEDCL EQ 75GM BASE/VIAL A065251 001 Dec 30, 2009 Aug DISC  
 @ EQ 225GM BASE/VIAL A065251 002 Dec 30, 2009 Aug DISC

ZINACEF IN PLASTIC CONTAINER

@ COVIS PHARMA SARL EQ 15MG BASE/ML N050643 001 Apr 28, 1989 Jun DISC

CEPHALEXIN

CAPSULE; ORAL  
CEPHALEXIN

AB ALKEM LABS LTD EQ 333MG BASE A090836 003 Mar 29, 2013 Mar NEWA  
 EQ 750MG BASE A090836 004 Mar 29, 2013 Mar NEWA  
 AB + KEFLEX SHIONOGI INC EQ 750MG BASE N050405 005 May 12, 2006 Mar CTEC

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

@ APOTEX INC 5MG/5ML A078412 001 Jun 18, 2008 Apr DISC  
 @ AUROBINDO PHARMA LTD 5MG/5ML A090751 001 Dec 16, 2009 Feb DISC  
 AA BIO PHARM INC 5MG/5ML A078870 001 Apr 27, 2009 May CAHN  
 AA BRECKENRIDGE PHARM 5MG/5ML A078488 001 Oct 06, 2008 Sep CAHN  
 AA CARACO 5MG/5ML A090191 001 Nov 12, 2009 Jun CAHN

CETRORELIX

INJECTABLE; INJECTION  
CETROTIDE

@ EMD SERONO INC EQ 3MG BASE/ML N021197 002 Aug 11, 2000 Jun DISC

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL

CEVIMELINE HYDROCHLORIDE

AB ROXANE 30MG A091591 001 Jul 08, 2013 Jun NEWA  
 AB + EVOXAC DAIICHI SANKYO 30MG N020989 002 Jan 11, 2000 Sep CAHN

CHLORDIAZEPOXIDE HYDROCHLORIDE

INJECTABLE; INJECTION  
LIBRIUM

>D> @ VALEANT PHARM INTL 100MG/AMP N012301 001 Dec CAHN  
 >A> @ VALEANT PHARMS LLC 100MG/AMP N012301 001 Dec CAHN

CHLORHEXIDINE GLUCONATE

	SOLUTION; DENTAL						
	CHLORHEXIDINE GLUCONATE						
	@ APOTEX INC	0.12%	A075561	001	Nov 14, 2000	Apr	DISC
	PAROEX						
AT	SUNSTAR AMERICAS	0.12%	A076434	001	Nov 29, 2005	Apr	CTNA

CHLOROTHIAZIDE

	TABLET; ORAL						
	CHLOROTHIAZIDE						
	+ MYLAN	250MG	A084388	001		Jul	CTEC
		500MG	A084217	001		Jul	CTEC
	@ WEST WARD	250MG	A086028	001	Jul 14, 1982	Jul	DISC
	@ DIURIL	500MG	A087736	001	Jul 14, 1982	Jul	DISC
	@ OAK PHARMS AKORN	250MG	N011145	004		Jan	CAHN
	@	500MG	N011145	002		Jan	CAHN

CHLOROTHIAZIDE SODIUM

	INJECTABLE; INJECTION						
	CHLOROTHIAZIDE SODIUM						
AP	LUITPOLD	EQ 500MG BASE/VIAL	A202561	001	Apr 22, 2013	Jun	CAHN
AP	PHARMAFORCE	EQ 500MG BASE/VIAL	A202561	001	Apr 22, 2013	Apr	NEWA
	DIURIL						
AP	+ OAK PHARMS AKORN	EQ 500MG BASE/VIAL	N011145	005		Jan	CAHN

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

	SOLUTION; ORAL						
	VITUZ						
	+ CYPRESS PHARM	4MG/5ML; 5MG/5ML	N204307	001	Feb 20, 2013	Feb	NEWA

CHLORPROPAMIDE

	TABLET; ORAL						
	CHLORPROPAMIDE						
	@ WATSON LABS INC	100MG	A088852	001	Sep 26, 1984	Jan	DISC
	@	250MG	A088826	001	Sep 26, 1984	Jan	DISC

CHLORTHALIDONE

	TABLET; ORAL						
	CHLORTHALIDONE						
	@ BARR LABS INC	25MG	A088902	001	Sep 19, 1985	Sep	DISC
AB		25MG	A088902	001	Sep 19, 1985	Sep	CAHN
	@	50MG	A088903	001	Sep 19, 1985	Sep	DISC
AB		50MG	A088903	001	Sep 19, 1985	Sep	CAHN
	MYLAN	25MG	A086831	002		Sep	CTEC
	+ THALITONE	50MG	A086831	001		Sep	CTEC
	+ CITRON PHARMA LLC	15MG	N019574	001	Dec 20, 1988	Nov	CAHN
	@	25MG	N019574	002	Feb 12, 1992	Nov	CAHN

CHOLINE FENOFIBRATE

	CAPSULE, DELAYED RELEASE; ORAL						
	FENOFIBRIC ACID						
AB	ANCHEN PHARMS	EQ 45MG FENOFIBRIC ACID	A201573	002	Jul 18, 2013	Jul	NEWA
AB		EQ 135MG FENOFIBRIC ACID	A201573	001	Jul 18, 2013	Jul	NEWA
AB	LUPIN LTD	EQ 45MG FENOFIBRIC ACID	A200750	001	Dec 04, 2013	Nov	NEWA
AB		EQ 135MG FENOFIBRIC ACID	A200750	002	Dec 04, 2013	Nov	NEWA
AB	MYLAN PHARMS INC	EQ 45MG FENOFIBRIC ACID	A200913	001	Mar 25, 2013	Mar	NEWA
AB		EQ 135MG FENOFIBRIC ACID	A200913	002	Mar 25, 2013	Mar	NEWA
	TRILIPIX						
AB	ABBVIE	EQ 45MG FENOFIBRIC ACID	N022224	001	Dec 15, 2008	Mar	CFTG
AB	+	EQ 135MG FENOFIBRIC ACID	N022224	002	Dec 15, 2008	Mar	CFTG

CICLOPIROX

	CREAM; TOPICAL						
	LOPROX						
AB	+ MEDIMETRIKS PHARMS	0.77%	N018748	001	Dec 30, 1982	Sep	CAHN
	SOLUTION; TOPICAL						
	CICLOPIROX						
	@ APOTEX INC	8%	A078172	001	Sep 18, 2007	Apr	DISC
AT	CIPLA LTD	8%	A078124	001	Sep 18, 2007	Aug	CAHN

## SOLUTION;TOPICAL

## CICLOPIROX

>D>	AT	MYLAN PHARMS INC	8%	A078567	001	Sep 18, 2007	Dec	DISC
>A>		@	8%	A078567	001	Sep 18, 2007	Dec	DISC
		@ TEVA PHARMS	8%	A078079	001	Sep 18, 2007	Jan	DISC
		PENLAC						
	AT	+ VALEANT BERMUDA	8%	N021022	001	Dec 17, 1999	May	CAHN
	AT	+ VALEANT INTL	8%	N021022	001	Dec 17, 1999	Feb	CAHN

## SUSPENSION;TOPICAL

## LOPROX

	AB	+ MEDIMETRIKS PHARMS	0.77%	N019824	001	Dec 30, 1988	Oct	CAHN
--	----	----------------------	-------	---------	-----	--------------	-----	------

CILOSTAZOL

## TABLET;ORAL

## CILOSTAZOL

>D>	AB	COREPHARMA	50MG	A077150	001	Mar 11, 2005	Dec	DISC
>A>		@	50MG	A077150	001	Mar 11, 2005	Dec	DISC
>D>	AB		100MG	A077022	001	Nov 23, 2004	Dec	DISC
>A>		@	100MG	A077022	001	Nov 23, 2004	Dec	DISC

CIMETIDINE

## TABLET;ORAL

## CIMETIDINE

		@ WATSON LABS INC	200MG	A074349	001	Aug 30, 1996	May	DISC
		@	300MG	A074349	002	Aug 30, 1996	May	DISC
		@	400MG	A074349	003	Aug 30, 1996	May	DISC
		@	800MG	A074316	001	Feb 28, 1996	Jun	DISC

CIMETIDINE HYDROCHLORIDE

## SOLUTION;ORAL

## CIMETIDINE HYDROCHLORIDE

		@ APOTEX INC	EQ 300MG BASE/5ML	A075560	001	Mar 15, 2000	Apr	DISC
--	--	--------------	-------------------	---------	-----	--------------	-----	------

CIPROFLOXACIN

## INJECTABLE;INJECTION

## CIPROFLOXACIN

		@ TEVA PHARMS USA	200MG/20ML (10MG/ML)	A077782	001	Aug 28, 2006	Apr	CAHN
		@	400MG/40ML (10MG/ML)	A077782	002	Aug 28, 2006	Apr	CAHN

CIPROFLOXACIN HYDROCHLORIDE

## SOLUTION/DROPS;OPHTHALMIC

## CIPROFLOXACIN HYDROCHLORIDE

		@ APOTEX INC	EQ 0.3% BASE	A075928	001	Jun 09, 2004	Apr	DISC
--	--	--------------	--------------	---------	-----	--------------	-----	------

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

## TABLET, EXTENDED RELEASE;ORAL

## CIPRO XR

		@ BAYER HLTHCARE	212.6MG;EQ 287.5MG BASE	N021473	001	Dec 13, 2002	May	DISC
		@	425.2MG;EQ 574.9MG BASE	N021473	002	Aug 28, 2003	May	DISC
			CIPROFLOXACIN EXTENDED RELEASE					
		@ DR REDDYS LABS LTD	212.6MG;EQ 287.5MG BASE	A077701	002	Oct 31, 2007	Jun	DISC
AB	+	MYLAN PHARMS INC	212.6MG;EQ 287.5MG BASE	A078183	001	Mar 22, 2007	May	CRLD
AB	+		425.2MG;EQ 574.9MG BASE	A078183	002	Mar 22, 2007	May	CRLD

CISPLATIN

## INJECTABLE;INJECTION

## CISPLATIN

AP		HQ SPCLT PHARMA	1MG/ML	N018057	004	Nov 08, 1988	Oct	CMFD
		@ TEVA PHARMS USA	1MG/ML	A074814	001	May 16, 2000	Sep	CAHN
			PLATINOL					
		@ HQ SPCLT PHARMA	10MG/VIAL	N018057	001		Jan	CAHN
		@	50MG/VIAL	N018057	002		Jan	CAHN
			PLATINOL-AQ					
		@ HQ SPCLT PHARMA	0.5MG/ML	N018057	003	Jul 18, 1984	Jan	CAHN
		@	1MG/ML	N018057	004	Nov 08, 1988	Jan	CAHN

CITALOPRAM HYDROBROMIDE

		SOLUTION; ORAL			
>D>		CELEXA			
>D>	AA	+ FOREST LABS	EQ 10MG BASE/5ML	N021046 001	Dec 22, 1999 Dec DISC
>A>		@	EQ 10MG BASE/5ML	N021046 001	Dec 22, 1999 Dec DISC
		CITALOPRAM HYDROBROMIDE			
>D>	AA	@ APOTEX INC	EQ 10MG BASE/5ML	A077601 001	Nov 15, 2005 Apr DISC
>D>	AA	ROXANE	EQ 10MG BASE/5ML	A077043 001	Dec 13, 2004 Dec CRLD
>A>	AA	+	EQ 10MG BASE/5ML	A077043 001	Dec 13, 2004 Dec CRLD
		TABLET; ORAL			
		CITALOPRAM HYDROBROMIDE			
AB		CIPLA LTD	EQ 10MG BASE	A077044 001	Nov 05, 2004 Aug CAHN
AB			EQ 20MG BASE	A077044 002	Nov 05, 2004 Aug CAHN
AB			EQ 40MG BASE	A077044 003	Nov 05, 2004 Aug CAHN
		@ COREPHARMA	EQ 10MG BASE	A077036 001	Oct 28, 2004 Feb DISC
		@	EQ 20MG BASE	A077036 002	Oct 28, 2004 Feb DISC
		@	EQ 40MG BASE	A077036 003	Oct 28, 2004 Feb DISC
		@ NATCO PHARMA LTD	EQ 20MG BASE	A077141 002	Apr 10, 2008 Jun DISC
		@	EQ 40MG BASE	A077141 001	Apr 10, 2008 Jun DISC

CLADRIBINE

		INJECTABLE; INJECTION			
		CLADRIBINE			
>D>	AP	FRESENIUS KABI USA	1MG/ML	A076571 001	Apr 22, 2004 Dec CRLD
>A>	AP	+	1MG/ML	A076571 001	Apr 22, 2004 Dec CRLD
>D>		LEUSTATIN			
>D>	AP	+ JANSSEN PHARMS	1MG/ML	N020229 001	Feb 26, 1993 Dec DISC
>A>		@	1MG/ML	N020229 001	Feb 26, 1993 Dec DISC

CLARITHROMYCIN

		TABLET; ORAL			
		CLARITHROMYCIN			
AB		ALLIED PHARMA INC	250MG	A202710 001	Jun 10, 2013 May NEWA
AB			500MG	A202710 002	Jun 10, 2013 May NEWA

CLEMASTINE FUMARATE

		SYRUP; ORAL			
		CLEMASTINE FUMARATE			
		@ APOTEX INC	EQ 0.5MG BASE/5ML	A075703 001	Nov 27, 2000 Apr DISC
		@ SILARX	EQ 0.5MG BASE/5ML	A074884 001	Dec 17, 1997 Mar DISC

CLEVIDIPINE

		EMULSION; INTRAVENOUS			
		CLEVIPREX			
		+ MEDICINES CO	25MG/50ML (0.5MG/ML)	N022156 001	Aug 01, 2008 Feb CAIN
		+	50MG/100ML (0.5MG/ML)	N022156 002	Aug 01, 2008 Feb CAIN
>A>		+	125MG/250ML (0.5MG/ML)	N022156 003	Nov 08, 2013 Dec NEWA

CLINDAMYCIN PALMITATE HYDROCHLORIDE

		FOR SOLUTION; ORAL			
		CLINDAMYCIN PALMITATE HYDROCHLORIDE			
AA		AUROBINDO PHARMA LTD	EQ 75MG BASE/5ML	A202409 001	Apr 30, 2013 Apr NEWA

CLINDAMYCIN PHOSPHATE

		AEROSOL, FOAM; TOPICAL			
		EVOCLIN			
AT		+ DELCOR ASSET	1%	N050801 001	Oct 22, 2004 Sep CAHN
		GEL; TOPICAL			
		CLINDAGEL			
BT		+ PRECISION DERMAT	EQ 1% BASE	N050782 001	Nov 27, 2000 Oct CAHN
		INJECTABLE; INJECTION			
		CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER			
AP		AKORN INC	EQ 6MG BASE/ML	A203048 001	Apr 04, 2013 Mar NEWA
AP			EQ 12MG BASE/ML	A203048 002	Apr 04, 2013 Mar NEWA
AP			EQ 18MG BASE/ML	A203048 003	Apr 04, 2013 Mar NEWA
		SOLUTION; TOPICAL			
		CLINDAMYCIN PHOSPHATE			
		@ ACTAVIS MID ATLANTIC	EQ 1% BASE	A062811 001	Sep 01, 1988 May CAHN
AT		PERRIGO NEW YORK	EQ 1% BASE	A064050 001	Nov 30, 1995 Aug CMFD
		@	EQ 1% BASE	A064050 001	Nov 30, 1995 Feb DISC



CLOBAZAM

TABLET;ORAL

ONFI

@ LUNDBECK LLC

5MG

N202067 001 Oct 21, 2011 Jul DISC

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

OLUX E

AB2 + DELCOR ASSET 0.05%

N022013 001 Jan 12, 2007 Jun CAHN

CREAM;TOPICAL

CLOBETASOL PROPIONATE

@ TEVA PHARMS USA

0.05%

A074087 001 Feb 16, 1994 Jun DISC

SOLUTION;TOPICAL

EMBELINE

AT + HI TECH PHARMA 0.05%

A074222 001 Dec 06, 1995 Jul CRLD

TEMOVATE

@ FOUGERA PHARMS

0.05%

N019966 001 Feb 22, 1990 Jul DISC

CLONAZEPAM

TABLET;ORAL

CLONAZEPAM

AB ACCORD HLTHCARE 0.5MG

A077147 001 May 02, 2005 Apr CAHN

AB 1MG

A077147 002 May 02, 2005 Apr CAHN

AB 2MG

A077147 003 May 02, 2005 Apr CAHN

@ APOTEX INC

0.5MG

A075468 001 Oct 06, 2000 Feb DISC

@ 1MG

A075468 002 Oct 06, 2000 Feb DISC

@ 2MG

A075468 003 Oct 06, 2000 Feb DISC

CLONIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

CLONIDINE HYDROCHLORIDE

AP EXELA PHARMA SCS LLC 1MG/10ML (0.1MG/ML)

A203167 001 Oct 29, 2013 Oct NEWA

AP 5MG/10ML (0.5MG/ML)

A203167 002 Oct 29, 2013 Oct NEWA

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

&gt;D&gt; @ ALEMBIC PHARMS LTD 0.1MG

A091368 001 Dec 06, 2011 Dec CMFD

&gt;A&gt; AB 0.1MG

A091368 001 Dec 06, 2011 Dec CMFD

@ 0.1MG

A091368 001 Dec 06, 2011 Nov DISC

&gt;D&gt; @ 0.2MG

A091368 002 Dec 06, 2011 Dec CMFD

&gt;A&gt; AB 0.2MG

A091368 002 Dec 06, 2011 Dec CMFD

@ 0.2MG

A091368 002 Dec 06, 2011 Nov DISC

&gt;D&gt; @ 0.3MG

A091368 003 Dec 06, 2011 Dec CMFD

&gt;A&gt; AB 0.3MG

A091368 003 Dec 06, 2011 Dec CMFD

@ 0.3MG

A091368 003 Dec 06, 2011 Nov DISC

AB CARLSBAD 0.1MG

A202297 001 Jun 13, 2013 May NEWA

AB 0.2MG

A202297 002 Jun 13, 2013 May NEWA

AB 0.3MG

A202297 003 Jun 13, 2013 May NEWA

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

AB ANCHEN PHARMS 0.1MG

A202984 001 Sep 30, 2013 Sep NEWA

AB 0.2MG

A202984 002 Sep 30, 2013 Sep NEWA

JENLOGA

@ CONCORDIA PHARMS INC 0.1MG

N022331 001 Sep 30, 2009 May CAHN

@ 0.2MG

N022331 002 May 25, 2010 May CAHN

KAPVAY

AB + CONCORDIA PHARMS INC 0.1MG

N022331 003 Sep 28, 2010 Sep CFTG

+

0.1MG

N022331 003 Sep 28, 2010 May CAHN

AB 0.2MG

N022331 004 Sep 28, 2010 Sep CFTG

0.2MG

N022331 004 Sep 28, 2010 May CAHN

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

AB ACCORD HLTHCARE EQ 75MG BASE

A202925 001 Mar 27, 2013 Mar NEWA

AB EQ 300MG BASE

A202925 002 Mar 27, 2013 Mar NEWA

AB ACTAVIS TOTOWA EQ 75MG BASE

A090307 001 May 28, 2013 May NEWA

AB MUTUAL PHARM EQ 75MG BASE

A078133 001 Jun 10, 2013 May NEWA

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL						
TRANXENE						
	@ RECORDATI RARE	3.75MG	N017105	001		May CAHN
	@	7.5MG	N017105	002		May CAHN
	@	15MG	N017105	003		May CAHN
TABLET; ORAL						
TRANXENE						
AB	RECORDATI RARE	3.75MG	N017105	006		May CAHN
AB		7.5MG	N017105	007		May CAHN
AB	+	15MG	N017105	008		May CAHN
TRANXENE SD						
	@ RECORDATI RARE	11.25MG	N017105	005		May CAHN
	@	22.5MG	N017105	004		May CAHN

CLOTTRIMAZOLE

CREAM; TOPICAL						
MYCELEX						
	@ BAYER	1%	N018183	001		Sep CAHN
SOLUTION; TOPICAL						
CLOTTRIMAZOLE						
>D>	AT	TARO	1%	A074580	001	Jul 29, 1996 Dec CTEC
>A>	AT	+	1%	A074580	001	Jul 29, 1996 Dec CTEC
MYCELEX						
>D>	AT	+	BAYER HLTHCARE	1%	N018181	001 Dec DISC
>A>		@		1%	N018181	001 Dec DISC

CLOZAPINE

SUSPENSION; ORAL						
VERSACLOZ						
	+	DOUGLAS PHARMS	50MG/ML	N203479	001	Feb 06, 2013 Feb NEWA
	+	JAZZ PHARMS III	50MG/ML	N203479	001	Feb 06, 2013 Mar CAHN

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL						
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE						
AA	AMNEAL PHARMS	10MG/5ML; 6.25MG/5ML	A200894	001	Apr 24, 2013	Apr NEWA
AA	CARACO	10MG/5ML; 6.25MG/5ML	A090180	001	Mar 17, 2010	May CAHN
	@ PHARM ASSOC	10MG/5ML; 6.25MG/5ML	A089647	001	Dec 22, 1988	Aug DISC

CRIZOTINIB

CAPSULE; ORAL						
XALKORI						
	PF PRISM CV	200MG	N202570	001	Aug 26, 2011	Sep CAHN
	+	250MG	N202570	002	Aug 26, 2011	Sep CAHN

CROMOLYN SODIUM

CONCENTRATE; ORAL						
CROMOLYN SODIUM						
AA	MICRO LABS LTD INDIA	100MG/5ML	A202745	001	Apr 04, 2013	Mar NEWA
SOLUTION; INHALATION						
CROMOLYN SODIUM						
	@ APOTEX INC	10MG/ML	A075333	001	Apr 30, 2002	Apr DISC
SOLUTION/DROPS; OPHTHALMIC						
CROMOLYN SODIUM						
	@ APOTEX INC	4%	A075615	001	Jan 26, 2001	Apr DISC

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL						
AMRIX						
AB	IVAX INTL	15MG	N021777	001	Feb 01, 2007	Jan CAHN
AB	+	30MG	N021777	002	Feb 01, 2007	Jan CAHN
CYCLOBENZAPRINE HYDROCHLORIDE						
AB	TWI PHARMS INC	15MG	A091281	001	Jan 31, 2013	Jan NEWA
AB		30MG	A091281	002	Jan 31, 2013	Jan NEWA
TABLET; ORAL						
CYCLOBENZAPRINE HYDROCHLORIDE						
AB	MYLAN PHARMS INC	7.5MG	A073144	003	Mar 25, 2013	Mar NEWA
	@ PROSAM LABS	5MG	A077291	001	Feb 03, 2006	Mar DISC
	@ SANDOZ	5MG	A072854	002	Feb 03, 2006	Apr DISC

	TABLET;ORAL								
	CYCLOBENZAPRINE HYDROCHLORIDE								
	@	10MG	A072854	001	Nov 19, 1991			Apr	DISC
	<u>CYCLOPENTOLATE HYDROCHLORIDE</u>								
	SOLUTION/DROPS;OPHTHALMIC								
	AKPENTOLATE								
	@ AKORN	2%	A040165	001	Jan 13, 1997			Mar	DISC
	CYCLOGYL								
	+ ALCON LABS INC	2%	A084108	001				Mar	CTEC
	<u>CYCLOPHOSPHAMIDE</u>								
	CAPSULE;ORAL								
	CYCLOPHOSPHAMIDE								
	ROXANE	25MG	N203856	001	Sep 16, 2013			Sep	NEWA
	+	50MG	N203856	002	Sep 16, 2013			Sep	NEWA
	INJECTABLE;INJECTION								
	CYTOXAN (LYOPHILIZED)								
AP	+ BAXTER HLTHCARE	1GM/VIAL	N012142	004	Aug 30, 1982			Mar	CTNA
	@	1GM/VIAL	N012142	010	Sep 24, 1985			Jan	CTNA
AP	+	2GM/VIAL	N012142	005	Aug 30, 1982			Mar	CTNA
	@	2GM/VIAL	N012142	009	Dec 10, 1985			Jan	CTNA
AP	+	500MG/VIAL	N012142	003				Mar	CTNA
	@	500MG/VIAL	N012142	008	Jan 04, 1984			Jan	CTNA
	<u>CYCLOSPORINE</u>								
	SOLUTION;ORAL								
	CYCLOSPORINE								
	@ APOTEX INC	100MG/ML	A065167	001	Jan 05, 2005			Apr	DISC
	<u>CYPROHEPTADINE HYDROCHLORIDE</u>								
	SYRUP;ORAL								
	CYPROHEPTADINE HYDROCHLORIDE								
AA	PHARM ASSOC	2MG/5ML	A091295	001	Mar 28, 2013			Mar	NEWA
	<u>CYSTEAMINE BITARTRATE</u>								
	CAPSULE, DELAYED RELEASE;ORAL								
	PROCYSBI								
	RAPTOR PHARMS	EQ 25MG BASE	N203389	001	Apr 30, 2013			Apr	NEWA
	+	EQ 75MG BASE	N203389	002	Apr 30, 2013			Apr	NEWA
	<u>CYTARABINE</u>								
	INJECTABLE;INJECTION								
	CYTOSAR-U								
AP	+ TEVA PHARMS USA	1GM/VIAL	A075206	004	Dec 30, 1998			Jun	CAHN
AP	+	2GM/VIAL	A075206	003	Dec 30, 1998			Jun	CAHN
AP	+	100MG/VIAL	A075206	001	Dec 30, 1998			Jun	CAHN
AP	+	500MG/VIAL	A075206	002	Dec 30, 1998			Jun	CAHN
	<u>DABRAFENIB MESYLATE</u>								
	CAPSULE;ORAL								
	TAFINLAR								
	GLAXOSMITHKLINE	EQ 50MG BASE	N202806	001	May 29, 2013			May	NEWA
	+	EQ 75MG BASE	N202806	002	May 29, 2013			May	NEWA
	<u>DACARBAZINE</u>								
	INJECTABLE;INJECTION								
	DACARBAZINE								
AP	+ TEVA PHARMS USA	200MG/VIAL	A075259	002	Aug 27, 1998			Apr	CAHN
AP	+	500MG/VIAL	A075259	001	Sep 22, 2000			Apr	CAHN
	<u>DACTINOMYCIN</u>								
	INJECTABLE;INJECTION								
	COSMEGEN								
AP	+ RECORDATI RARE	0.5MG/VIAL	N050682	001				May	CAHN
	DACTINOMYCIN								
AP	+ LUITPOLD	0.5MG/VIAL	A202562	001	Aug 23, 2013			Nov	CAHN
AP	+ PHARMAFORCE	0.5MG/VIAL	A202562	001	Aug 23, 2013			Aug	NEWA

DALTEPARIN SODIUMINJECTABLE;SUBCUTANEOUS  
FRAGMIN

@	EISAI INC	10,000IU/0.4ML (25,000IU/ML)	N020287	002	May 01, 2007	Jun	DISC
@		95,000IU/9.5ML (10,000IU/ML)	N020287	007	Apr 04, 2002	Jun	DISC

DANTROLENE SODIUMCAPSULE;ORAL  
DANTROLENE SODIUM

AB	MIKAH PHARMA	25MG	A076686	001	Oct 24, 2005	Jul	CMFD
AB		50MG	A076686	002	Oct 24, 2005	Jul	CMFD
AB		100MG	A076686	003	Oct 24, 2005	Jul	CMFD

DARUNAVIR ETHANOLATETABLET;ORAL  
PREZISTA

>D>	JANSSEN PRODS	EQ 400MG BASE	N021976	003	Oct 21, 2008	Dec	DISC
>A>	@	EQ 400MG BASE	N021976	003	Oct 21, 2008	Dec	DISC

DAUNORUBICIN HYDROCHLORIDEINJECTABLE;INJECTION  
DAUNORUBICIN HYDROCHLORIDE

AP	TEVA PHARMS USA	EQ 5MG BASE/ML	A065035	001	Jan 24, 2000	Apr	CAHN
----	-----------------	----------------	---------	-----	--------------	-----	------

DECITABINEINJECTABLE;INTRAVENOUS  
DACOGEN

AP	+ EISAI INC	50MG/VIAL	N021790	001	May 02, 2006	Jul	CFTG
AP	DR REDDYS LABS LTD	50MG/VIAL	A203131	001	Jul 11, 2013	Jul	NEWA

DESIPRAMINE HYDROCHLORIDETABLET;ORAL  
DESIPRAMINE HYDROCHLORIDE

@	BARR LABS INC	150MG	A071804	001	May 29, 1997	Nov	CAHN
---	---------------	-------	---------	-----	--------------	-----	------

DESIRUDIN RECOMBINANTINJECTABLE;SUBCUTANEOUS  
IPRIVASK

>D>	+ CANYON	15MG/VIAL	N021271	001	Apr 04, 2003	Dec	CAHN
>A>	+ MARATHON PHARMS LLC	15MG/VIAL	N021271	001	Apr 04, 2003	Dec	CAHN

DESMOPRESSIN ACETATEINJECTABLE;INJECTION  
DESMOPRESSIN ACETATE

AP	SUN PHARM INDS LTD	0.004MG/ML	A091280	001	Jan 25, 2013	Jan	NEWA
AP	TEVA PHARMS USA	0.004MG/ML	A074888	001	Oct 15, 1997	Apr	CAHN

SOLUTION;NASAL  
DESMOPRESSIN ACETATE

>A>	AB SUN PHARMA GLOBAL	0.01%	A078271	001	Dec 23, 2013	Dec	NEWA
-----	----------------------	-------	---------	-----	--------------	-----	------

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-28

DESOGESTREL AND ETHINYL ESTRADIOL

AB	FAMY CARE LTD	0.15MG,N/A;0.02MG,0.01MG	A202296	001	Aug 30, 2013	Aug	NEWA
AB	NOVAST LABS LTD	0.15MG;0.03MG	A091234	001	Jul 12, 2013	Jul	NEWA
	ENSKYCE						
AB	LUPIN LTD	0.15MG;0.03MG	A201887	001	Mar 07, 2013	Feb	NEWA
	PIMTREA						
AB	NOVAST LABS LTD	0.15MG,N/A;0.02MG,0.01MG	A091247	001	Aug 01, 2013	Jul	NEWA

DESONIDEGEL;TOPICAL  
DESONATE

+	BAYER HLTHCARE	0.05%	N021844	001	Oct 20, 2006	Jun	CAHN
---	----------------	-------	---------	-----	--------------	-----	------

DESOXIMETASONE

	OINTMENT; TOPICAL							
	DESOXIMETASONE							
AB	GLENMARK GENERICS	0.25%	A202838	001	Sep 20, 2013	Sep	NEWA	
	SPRAY; TOPICAL							
	TOPICORT							
	+ TARO	0.25%	N204141	001	Apr 11, 2013	Apr	NEWA	

DESVENLAFAXINE

	TABLET, EXTENDED RELEASE; ORAL							
	DESVENLAFAXINE							
BC	+ ALEMBIC PHARMS LTD	50MG	N204150	001	Mar 04, 2013	Jul	CTEC	
		50MG	N204150	001	Mar 04, 2013	Apr	CRLD	
		50MG	N204150	001	Mar 04, 2013	Mar	NEWA	
BC	+	100MG	N204150	002	Mar 04, 2013	Jul	CTEC	
		100MG	N204150	002	Mar 04, 2013	Mar	NEWA	
	KHEDEZLA							
BC	OSMOTICA PHARM CORP	50MG	N204683	001	Jul 10, 2013	Jul	NEWA	
BC		100MG	N204683	002	Jul 10, 2013	Jul	NEWA	

DESVENLAFAXINE FUMARATE

	TABLET, EXTENDED RELEASE; ORAL							
	DESVENLAFAXINE FUMARATE							
	+ TEVA PHARMS USA	EQ 50MG BASE	N205208	001	Oct 11, 2013	Oct	NEWA	
		EQ 100MG BASE	N205208	002	Oct 11, 2013	Oct	NEWA	

DEXAMETHASONE

	ELIXIR; ORAL							
	DEXAMETHASONE							
AA	WOCKHARDT EU OPERATN	0.5MG/5ML	A088254	001	Jul 27, 1983	May	CRLD	

DEXAMETHASONE SODIUM PHOSPHATE

	INJECTABLE; INJECTION							
	DEXAMETHASONE SODIUM PHOSPHATE							
AP	AGILA SPECLTS	EQ 4MG PHOSPHATE/ML	A040803	001	Aug 29, 2008	Nov	CAHN	
AP		EQ 10MG PHOSPHATE/ML	A040802	001	Aug 29, 2008	Nov	CAHN	

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

	OINTMENT; OPHTHALMIC							
	NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE							
AT	PERRIGO CO TENNESSEE	0.1%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	A062938	001	Jul 31, 1989	Jun	CAHN	
	SUSPENSION/DROPS; OPHTHALMIC							
	NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE							
	@ ALCON PHARMS LTD	0.1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	A062721	001	Nov 17, 1986	Jan	DISC	

DEXMEDETOMIDINE HYDROCHLORIDE

	INJECTABLE; INJECTION							
	PRECEDEX							
	+ HOSPIRA	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	N021038	002	Mar 13, 2013	Mar	NEWA	
		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	N021038	003	Mar 13, 2013	Mar	NEWA	

DEXMETHYLPHENIDATE HYDROCHLORIDE

	CAPSULE, EXTENDED RELEASE; ORAL							
	DEXMETHYLPHENIDATE HYDROCHLORIDE							
AB	INTELLIPHARMACEUTICS	15MG	A078992	003	Nov 18, 2013	Nov	NEWA	
AB		30MG	A078992	004	Nov 18, 2013	Nov	NEWA	
AB	MYLAN PHARMS INC	30MG	A202580	001	Aug 28, 2013	Aug	NEWA	
AB	TEVA PHARMS USA	5MG	A078908	001	Nov 19, 2013	Nov	NEWA	
AB		10MG	A078908	002	Nov 19, 2013	Nov	NEWA	
AB		20MG	A078908	003	Nov 19, 2013	Nov	NEWA	
AB		40MG	A202731	002	Nov 19, 2013	Nov	NEWA	
AB	WATSON LABS INC	30MG	A079108	005	Nov 21, 2013	Nov	NEWA	
	FOCALIN XR							
AB	NOVARTIS	5MG	N021802	001	May 26, 2005	Nov	CTEC	
AB		10MG	N021802	002	May 26, 2005	Nov	CTEC	
AB		15MG	N021802	004	Aug 01, 2006	Nov	CTEC	
AB		20MG	N021802	003	May 26, 2005	Nov	CTEC	
AB		30MG	N021802	005	Oct 23, 2009	Aug	CFTG	

		CAPSULE, EXTENDED RELEASE;ORAL							
		FOCALIN XR							
AB	+		40MG		N021802	006	Aug 11, 2010	Nov	CTEC
		<u>DEXRAZOXANE HYDROCHLORIDE</u>							
		INJECTABLE;INJECTION							
		TOTECT							
	+	BIOCODEX INC	EQ 500MG BASE/VIAL		N022025	001	Sep 06, 2007	May	CAHN
		<u>DEXTROAMPHETAMINE SULFATE</u>							
		SOLUTION;ORAL							
		DEXTROAMPHETAMINE SULFATE							
AA	+	OUTLOOK PHARMS	5MG/5ML		A040776	001	Jan 29, 2008	May	CFTG
AA		TRIS PHARMA INC	5MG/5ML		A203644	001	May 29, 2013	May	NEWA
		TABLET;ORAL							
		DEXTROAMPHETAMINE SULFATE							
AA		AUROLIFE PHARMA LLC	5MG		A202893	001	Jul 31, 2013	Jul	NEWA
AA			10MG		A202893	002	Jul 31, 2013	Jul	NEWA
		<u>DEXTROSE; POTASSIUM CHLORIDE</u>							
		INJECTABLE;INJECTION							
		POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER							
		@ B BRAUN	5GM/100ML;220MG/100ML		N018744	003	Nov 09, 1982	Jan	DISC
		<u>DIAZEPAM</u>							
		INJECTABLE;INJECTION							
		DIAZEPAM							
		@ WATSON LABS	5MG/ML		A070296	001	Feb 12, 1986	Jun	DISC
		<u>DIAZOXIDE</u>							
		SUSPENSION;ORAL							
		PROGLYCEM							
	+	TEVA BRANDED PHARM	50MG/ML		N017453	001		Apr	CAHN
		<u>DICLOFENAC</u>							
		CAPSULE;ORAL							
		ZORVOLEX							
		IROKO PHARMS LLC	18MG		N204592	001	Oct 18, 2013	Oct	NEWA
	+		35MG		N204592	002	Oct 18, 2013	Oct	NEWA
		<u>DICLOFENAC SODIUM</u>							
		GEL;TOPICAL							
		DICLOFENAC SODIUM							
AB		TOLMAR	3%		A200936	001	Oct 28, 2013	Oct	NEWA
		SOLARAZE							
AB	+	FOUGERA PHARMS	3%		N021005	001	Oct 16, 2000	Oct	CFTG
		SOLUTION/DROPS;OPHTHALMIC							
		DICLOFENAC SODIUM							
		@ APOTEX INC	0.1%		A077600	001	Nov 13, 2008	Apr	DISC
		<u>DICLOFENAC SODIUM; MISOPROSTOL</u>							
		TABLET, DELAYED RELEASE;ORAL							
		DICLOFENAC SODIUM AND MISOPROSTOL							
AB		SANDOZ	50MG;0.2MG		A200158	001	May 09, 2013	Apr	NEWA
AB			75MG;0.2MG		A200158	002	May 09, 2013	Apr	NEWA
		<u>DICYCLOMINE HYDROCHLORIDE</u>							
		CAPSULE;ORAL							
		DICYCLOMINE HYDROCHLORIDE							
		@ WEST WARD	10MG		A040204	001	Feb 28, 1997	Jul	DISC
		TABLET;ORAL							
		DICYCLOMINE HYDROCHLORIDE							
>D>	AB	WEST WARD	20MG		A040161	001	Oct 01, 1996	Dec	DISC
>A>		@	20MG		A040161	001	Oct 01, 1996	Dec	DISC
		<u>DIDANOSINE</u>							
		TABLET, FOR SUSPENSION;ORAL							
		DIDANOSINE							
		AUROBINDO	100MG		A077275	001	Aug 14, 2012	Apr	CDFR
			150MG		A077275	002	Aug 14, 2012	Apr	CDFR
	+		200MG		A077275	003	Aug 14, 2012	Apr	CDFR

DIFLORASONE DIACETATE

CREAM; TOPICAL		DIFLORASONE DIACETATE							
	@ FOUGERA PHARMS	0.05%	A 075187	001	Mar 30, 1998	May	DISC		
BX	+ TARO	0.05%	A 075508	001	Apr 24, 2000	May	CRLD		
PSORCON		@ TARO PHARMS NORTH		0.05%	N 020205	001	Nov 20, 1992	Jun	CAHN

DIGOXIN

TABLET; ORAL		DIGOXIN					
	@ CARACO	0.125MG	A 076363	001	Jan 31, 2003	Jun	DISC
	@	0.25MG	A 076363	002	Jan 31, 2003	Jun	DISC
AB	HIKMA PHARMS	0.125MG	A 077002	002	Oct 30, 2007	Oct	CAHN
AB		0.25MG	A 077002	001	Oct 30, 2007	Oct	CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL		DILTIAZEM HYDROCHLORIDE					
AB3	PAR PHARM	120MG	A 074984	001	Dec 20, 1999	Jan	CAHN
AB3		180MG	A 074984	002	Dec 20, 1999	Jan	CAHN
AB3		240MG	A 074984	003	Dec 20, 1999	Jan	CAHN
AB3		300MG	A 074984	004	Dec 20, 1999	Jan	CAHN
AB4	SANDOZ	120MG	A 091022	001	Sep 28, 2012	Feb	CAHN
AB4		180MG	A 091022	002	Sep 28, 2012	Feb	CAHN
AB4		240MG	A 091022	003	Sep 28, 2012	Feb	CAHN
AB4		300MG	A 091022	004	Sep 28, 2012	Feb	CAHN
AB4		360MG	A 091022	005	Sep 28, 2012	Feb	CAHN
AB4		420MG	A 091022	006	Sep 28, 2012	Feb	CAHN
INJECTABLE; INJECTION		DILTIAZEM HYDROCHLORIDE					
AP	AKORN INC	5MG/ML	A 075086	001	Apr 09, 1998	Jul	CAHN
	@ APOTEX INC	5MG/ML	A 075375	001	Sep 30, 1999	Apr	DISC
	@ TEVA PHARMS USA	5MG/ML	A 074894	001	Aug 26, 1997	Apr	CAHN
	+	10MG/ML	A 074894	002	Apr 19, 2002	Apr	CAHN

## TABLET; ORAL

DILTIAZEM HYDROCHLORIDE							
@	DAVA PHARMS INC	30MG	A 074093	001	Nov 05, 1992	Jan	DISC
@		60MG	A 074093	002	Nov 05, 1992	Jan	DISC
@		90MG	A 074093	003	Nov 05, 1992	Jan	DISC
@		120MG	A 074093	004	Nov 05, 1992	Jan	DISC

DIMENHYDRINATE

## INJECTABLE; INJECTION

DIMENHYDRINATE							
+	FRESENIUS KABI USA	50MG/ML	A 040519	001	Jun 23, 2004	Apr	CRLD
	@ WATSON LABS	50MG/ML	A 080615	001		Apr	DISC

DIMETHYL FUMARATE

## CAPSULE, DELAYED RELEASE; ORAL

TECFIDERA							
	BIOGEN IDEC INC	120MG	N 204063	001	Mar 27, 2013	Mar	NEWA
+		240MG	N 204063	002	Mar 27, 2013	Mar	NEWA

DIPHENHYDRAMINE HYDROCHLORIDE

## INJECTABLE; INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE							
@	WATSON LABS INC	10MG/ML	A 080873	001		Mar	DISC
@		50MG/ML	A 080873	002		Mar	DISC
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE							
AP	BD RX	50MG/ML	A 091526	001	Mar 26, 2013	Mar	NEWA
	@ WATSON LABS INC	50MG/ML	A 080873	003		Mar	DISC

DIPYRIDAMOLE

## INJECTABLE; INJECTION

DIPYRIDAMOLE							
@	AGILA SPECLTS	5MG/ML	A 075769	001	Nov 27, 2002	Aug	CAHN
@	APOTEX INC	5MG/ML	A 075769	001	Nov 27, 2002	Apr	DISC
@	TEVA PHARMS USA	5MG/ML	A 074952	001	Nov 26, 1997	May	CAHN

## TABLET;ORAL

## DIPYRIDAMOLE

@	PROSAM LABS	25MG	A040542	001	Apr 21, 2006	Jun	DISC
@		50MG	A040542	002	Apr 21, 2006	Jun	DISC
@		75MG	A040542	003	Apr 21, 2006	Jun	DISC

DISULFIRAM

## TABLET;ORAL

## DISULFIRAM

AB	ALVOGEN PINE BROOK	250MG	A091681	001	Aug 08, 2013	Jul	NEWA
----	--------------------	-------	---------	-----	--------------	-----	------

DIVALPROEX SODIUM

## TABLET, DELAYED RELEASE;ORAL

## DIVALPROEX SODIUM

@	MYLAN	EQ 125MG VALPROIC ACID	A077254	001	Jul 29, 2008	Aug	DISC
@		EQ 250MG VALPROIC ACID	A077254	002	Jul 29, 2008	Aug	DISC
@		EQ 500MG VALPROIC ACID	A077254	003	Jul 29, 2008	Aug	DISC

## TABLET, EXTENDED RELEASE;ORAL

## DIVALPROEX SODIUM

@	TEVA PHARMS USA	EQ 500MG VALPROIC ACID	A078700	001	Aug 03, 2009	Mar	DISC
---	-----------------	------------------------	---------	-----	--------------	-----	------

DOCETAXEL

## INJECTABLE; INJECTION

## DOCETAXEL

AP	ACCORD HLTHCARE	160MG/8ML (20MG/ML)	N201195	005	Apr 20, 2012	Aug	CTEC
AP	ACTAVIS INC	20MG/ML (20MG/ML)	N203551	001	Apr 12, 2013	Apr	NEWA
AP		80MG/4ML (20MG/ML)	N203551	002	Apr 12, 2013	Apr	NEWA
		140MG/7ML (20MG/ML)	N203551	003	Apr 12, 2013	Apr	NEWA
@	APOTEX INC	20MG/0.5ML (40MG/ML)	N022312	001	Jan 11, 2012	May	DISC
@		80MG/2ML (40MG/ML)	N022312	002	Jan 11, 2012	May	DISC
AP	+ SANOFI AVENTIS US	160MG/8ML (20MG/ML)	N020449	005	Apr 13, 2012	Aug	NEWA

DOLUTEGRAVIR SODIUM

## TABLET;ORAL

## TIVICAY

+	VIIV HLTHCARE	EQ 50MG BASE	N204790	001	Aug 12, 2013	Aug	NEWA
---	---------------	--------------	---------	-----	--------------	-----	------

DONEPEZIL HYDROCHLORIDE

## TABLET;ORAL

## ARICEPT

AB	+ EISAI INC	23MG	N022568	001	Jul 23, 2010	Jul	CTEC
	DONEPEZIL HYDROCHLORIDE						
@	ACCORD HLTHCARE	5MG	A201335	001	Aug 29, 2011	Jan	DISC
@		10MG	A201335	002	Aug 29, 2011	Jan	DISC
>D>	AB ACTAVIS GRP PTC	5MG	A090551	001	May 31, 2011	Dec	CAHN
AB		5MG	A090551	001	May 31, 2011	Apr	CAHN
>D>	AB	10MG	A090551	002	May 31, 2011	Dec	CAHN
AB		10MG	A090551	002	May 31, 2011	Apr	CAHN
AB	ALEMBIC PHARMS LTD	5MG	A201724	001	Feb 25, 2013	Feb	NEWA
AB		10MG	A201724	002	Feb 25, 2013	Feb	NEWA
AB	DR REDDYS LABS LTD	23MG	A202723	001	Jul 24, 2013	Jul	NEWA
AB	PAR PHARM	23MG	A202542	001	Jul 24, 2013	Jul	NEWA
>A>	AB VIVIMED LABS	5MG	A090551	001	May 31, 2011	Dec	CAHN
>A>	AB	10MG	A090551	002	May 31, 2011	Dec	CAHN

DORIPENEM

## INJECTABLE;IV (INFUSION)

## DORIBAX

	SHIONOGI INC	250MG/VIAL	N022106	002	Oct 05, 2010	Oct	CAHN
+		500MG/VIAL	N022106	001	Oct 12, 2007	Oct	CAHN

DORZOLAMIDE HYDROCHLORIDE

## SOLUTION/DROPS;OPHTHALMIC

## DORZOLAMIDE HYDROCHLORIDE

@	APOTEX INC	EQ 2% BASE	A078395	001	Oct 28, 2008	Apr	DISC
AT	ZACH SYSTEMS	EQ 2% BASE	A091034	001	Dec 04, 2013	Nov	NEWA



DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

		COSOPT							
AT	+	OAK PHARMS AKORN	EQ 2% BASE;EQ 0.5% BASE	N020869	001	Apr 07, 1998	Nov	CAHN	
		COSOPT PF							
	+	OAK PHARMS AKORN	EQ 2% BASE;EQ 0.5% BASE	N202667	001	Feb 01, 2012	Nov	CAHN	
		DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE							
		@ APOTEX INC	EQ 2% BASE;EQ 0.5% BASE	A078201	001	Oct 28, 2008	Apr	DISC	
AT		ZACH SYSTEMS	EQ 2% BASE;EQ 0.5% BASE	A091180	001	Dec 04, 2013	Nov	NEWA	

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION

		DOPRAM							
AP	+	HIKMA MAPLE	20MG/ML	N014879	001		Jul	CAHN	

DOXAZOSIN MESYLATE

TABLET;ORAL

		DOXAZOSIN MESYLATE							
		@ WATSON LABS INC	EQ 1MG BASE	A075426	001	Oct 18, 2000	Jan	DISC	
		@	EQ 2MG BASE	A075426	002	Oct 18, 2000	Jan	DISC	
		@	EQ 4MG BASE	A075426	003	Oct 18, 2000	Jan	DISC	
		@	EQ 8MG BASE	A075426	004	Oct 18, 2000	Jan	DISC	

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

		DOXEPIN HYDROCHLORIDE							
AB		MYLAN PHARMS INC	EQ 10MG BASE	A070791	002	May 13, 1986	Jun	CRLD	
AB			EQ 10MG BASE	A070791	002	May 13, 1986	May	CRLD	
AB	+		EQ 25MG BASE	A070791	003	May 13, 1986	Jun	CRLD	
		@ PAR PHARM	EQ 10MG BASE	A071697	001	Nov 09, 1987	May	DISC	
		@	EQ 25MG BASE	A071437	001	Nov 09, 1987	May	DISC	
		@	EQ 50MG BASE	A071595	001	Nov 09, 1987	May	DISC	
		@	EQ 75MG BASE	A071608	001	Nov 09, 1987	May	DISC	
		@	EQ 100MG BASE	A071422	001	Nov 09, 1987	May	DISC	
		@ WATSON LABS	EQ 10MG BASE	A071485	001	Apr 30, 1987	May	DISC	
		@	EQ 25MG BASE	A071486	001	Apr 30, 1987	May	DISC	
		@	EQ 50MG BASE	A071238	001	Apr 30, 1987	May	DISC	
		@	EQ 75MG BASE	A071326	001	Apr 30, 1987	May	DISC	
		@	EQ 100MG BASE	A071239	001	Apr 30, 1987	May	DISC	

CONCENTRATE;ORAL

		DOXEPIN HYDROCHLORIDE							
		@ PHARM ASSOC	EQ 10MG BASE/ML	A075924	001	Jan 15, 2004	Mar	DISC	

TABLET;ORAL

		DOXEPIN HYDROCHLORIDE							
AB		ACTAVIS ELIZABETH	EQ 3MG BASE	A201951	001	Jul 26, 2013	Jul	NEWA	
AB			EQ 6MG BASE	A201951	002	Jul 26, 2013	Jul	NEWA	
		SILENOR							
AB		PERNIX THERAPS LLC	EQ 3MG BASE	N022036	001	Mar 17, 2010	Jul	CFTG	
			EQ 3MG BASE	N022036	001	Mar 17, 2010	Apr	CAHN	
AB	+		EQ 6MG BASE	N022036	002	Mar 17, 2010	Jul	CFTG	
	+		EQ 6MG BASE	N022036	002	Mar 17, 2010	Apr	CAHN	

DOXERCALCIFEROL

CAPSULE;ORAL

		DOXERCALCIFEROL							
>A>	AB	ROXANE	1MCG	A091433	002	Jan 14, 2014	Dec	NEWA	
>A>	AB		2.5MCG	A091433	003	Jan 14, 2014	Dec	NEWA	
		HECTOROL							
>D>		GENZYME CORP	1MCG	N020862	003	Jul 13, 2009	Dec	CTEC	
>A>	AB		1MCG	N020862	003	Jul 13, 2009	Dec	CTEC	
>D>	+		2.5MCG	N020862	001	Jun 09, 1999	Dec	CTEC	
>A>	AB	+	2.5MCG	N020862	001	Jun 09, 1999	Dec	CTEC	
		INJECTABLE;INJECTION							
		DOXERCALCIFEROL							
AP		HIKMA PHARMS LLC	4MCG/2ML (2MCG/ML)	A091101	001	Aug 30, 2013	Oct	CAHN	
AP		INNOPHARMA INC	4MCG/2ML (2MCG/ML)	A091101	001	Aug 30, 2013	Aug	NEWA	
		HECTOROL							
AP	+	GENZYME CORP	4MCG/2ML (2MCG/ML)	N021027	001	Apr 06, 2000	Aug	CFTG	

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

AP	SAGENT PHARMS	2MG/ML	A 091495	001	Mar 18, 2013	Mar	NEWA
AP	TEVA PHARMS USA	2MG/ML	A 064140	001	Jul 28, 1995	Jun	CAHN
AP		200MG/100ML	A 064140	002	Jul 28, 1995	Jun	CAHN

INJECTABLE, LIPOSOMAL; INJECTION

DOXIL

AB	+	JANSSEN RES AND DEV	20MG/10ML (2MG/ML)	N 050718	001	Nov 17, 1995	Jan	CFTG
AB	+		50MG/25ML (2MG/ML)	N 050718	002	Jun 13, 2000	Jan	CFTG

DOXIL (LIPOSOMAL)

AB		JANSSEN RES AND DEV	20MG/10ML (2MG/ML)	N 050718	001	Nov 17, 1995	Jun	CRLD
AB	+		20MG/10ML (2MG/ML)	N 050718	001	Nov 17, 1995	Apr	CTNA
AB			50MG/25ML (2MG/ML)	N 050718	002	Jun 13, 2000	Jun	CRLD
AB	+		50MG/25ML (2MG/ML)	N 050718	002	Jun 13, 2000	Apr	CTNA

DOXORUBICIN HYDROCHLORIDE

AB		SUN PHARMA GLOBAL	20MG/10ML (2MG/ML)	A 203263	001	Feb 04, 2013	Jan	NEWA
AB			50MG/25ML (2MG/ML)	A 203263	002	Feb 04, 2013	Jan	NEWA

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

AB	+	SUN PHARMA GLOBAL	20MG/10ML (2MG/ML)	A 203263	001	Feb 04, 2013	Jun	CRLD
AB	+		20MG/10ML (2MG/ML)	A 203263	001	Feb 04, 2013	Apr	CTNA
AB	+		50MG/25ML (2MG/ML)	A 203263	002	Feb 04, 2013	Jun	CRLD
AB	+		50MG/25ML (2MG/ML)	A 203263	002	Feb 04, 2013	Apr	CTNA

DOXYCYCLINE

FOR SUSPENSION; ORAL

DOXYCYCLINE

AB		CHARTWELL LIFE SCI	EQ 25MG BASE/5ML	A 065454	001	Jul 16, 2008	Sep	CAHN
AB		LUPIN LTD	EQ 25MG BASE/5ML	A 201678	001	Mar 18, 2013	Mar	NEWA

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

AB		CHARTWELL LIFE SCI	EQ 50MG BASE	A 062500	001	Sep 11, 1984	Sep	CAHN
AB			EQ 100MG BASE	A 062500	002	Sep 11, 1984	Sep	CAHN
AB		HIKMA PHARMS	EQ 50MG BASE	A 062396	002	Nov 07, 1984	May	CAHN
AB			EQ 100MG BASE	A 062396	001	May 07, 1984	May	CAHN

INJECTABLE; INJECTION

DOXYCYCLINE

AP		AGILA SPECLTS	EQ 100MG BASE/VIAL	A 091406	001	Aug 21, 2012	Nov	CAHN
----	--	---------------	--------------------	----------	-----	--------------	-----	------

TABLET; ORAL

DOXYCYCLINE HYCLATE

		@ BLU CARIBE INC	EQ 50MG BASE	A 062269	003		Mar	CAHN
AB			EQ 100MG BASE	A 062269	002	Nov 08, 1982	Nov	CMFD
		@	EQ 100MG BASE	A 062269	002	Nov 08, 1982	Mar	CAHN
AB		CHARTWELL LIFE SCI	EQ 100MG BASE	A 062505	001	Sep 11, 1984	Jul	CAHN
AB	+	HIKMA PHARMS	EQ 100MG BASE	A 065095	001	Jul 02, 2003	May	CAHN

TABLET, DELAYED RELEASE; ORAL

DORYX

		MAYNE PHARMA	EQ 80MG BASE	N 050795	004	Apr 11, 2013	Apr	NEWA
			EQ 200MG BASE	N 050795	005	Apr 11, 2013	Apr	NEWA

DOXYCYCLINE HYCLATE

AB		HERITAGE PHARMS INC	EQ 75MG BASE	A 200856	001	Apr 30, 2013	Apr	NEWA
AB			EQ 100MG BASE	A 200856	002	Apr 30, 2013	Apr	NEWA
AB			EQ 150MG BASE	A 200856	003	Apr 30, 2013	Apr	NEWA

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE; ORAL

DICLEGIS

+		DUCHESNAY	10MG; 10MG	N 021876	001	Apr 08, 2013	Apr	NEWA
---	--	-----------	------------	----------	-----	--------------	-----	------

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS; ORAL

CYMBALTA

AB		LILLY	EQ 20MG BASE	N 021427	001	Aug 03, 2004	Nov	CFTG
AB			EQ 30MG BASE	N 021427	002	Aug 03, 2004	Nov	CFTG
AB	+		EQ 60MG BASE	N 021427	004	Aug 03, 2004	Nov	CFTG

DULOXETINE HYDROCHLORIDE

>A>	AB	ACTAVIS ELIZABETH	EQ 20MG BASE	A 090776	001	Dec 17, 2013	Dec	NEWA
>A>	AB		EQ 30MG BASE	A 090776	002	Dec 17, 2013	Dec	NEWA
>A>	AB		EQ 60MG BASE	A 090776	003	Dec 17, 2013	Dec	NEWA

CAPSULE, DELAYED REL PELLETS;ORAL  
 DULOXETINE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 20MG BASE	A 090778	001	Dec 11, 2013	Nov	NEWA	
AB		EQ 30MG BASE	A 090778	002	Dec 11, 2013	Nov	NEWA	
AB		EQ 60MG BASE	A 090778	003	Dec 11, 2013	Nov	NEWA	
AB	DR REDDYS LABS LTD	EQ 20MG BASE	A 090723	001	Dec 11, 2013	Nov	NEWA	
AB		EQ 30MG BASE	A 090723	002	Dec 11, 2013	Nov	NEWA	
AB		EQ 60MG BASE	A 090723	003	Dec 11, 2013	Nov	NEWA	
AB	LUPIN LTD	EQ 20MG BASE	A 090694	001	Dec 11, 2013	Nov	NEWA	
AB		EQ 30MG BASE	A 090694	002	Dec 11, 2013	Nov	NEWA	
		EQ 40MG BASE	A 090694	003	Dec 11, 2013	Nov	NEWA	
AB		EQ 60MG BASE	A 090694	004	Dec 11, 2013	Nov	NEWA	
AB	SUN PHARMA GLOBAL	EQ 20MG BASE	A 090745	001	Dec 11, 2013	Nov	NEWA	
AB		EQ 30MG BASE	A 090745	002	Dec 11, 2013	Nov	NEWA	
AB		EQ 60MG BASE	A 090745	003	Dec 11, 2013	Nov	NEWA	
AB	TEVA PHARMS USA	EQ 20MG BASE	A 090783	001	Dec 11, 2013	Nov	NEWA	
AB		EQ 30MG BASE	A 090783	002	Dec 11, 2013	Nov	NEWA	
AB		EQ 60MG BASE	A 090783	003	Dec 11, 2013	Nov	NEWA	
AB	TORRENT PHARMS LTD	EQ 20MG BASE	A 090774	001	Dec 11, 2013	Nov	NEWA	
AB		EQ 30MG BASE	A 090774	002	Dec 11, 2013	Nov	NEWA	
AB		EQ 60MG BASE	A 090774	003	Dec 11, 2013	Nov	NEWA	
>A>	AB	ZYDUS PHARMS USA INC	EQ 20MG BASE	A 090728	001	Jan 08, 2014	Dec	NEWA
>A>	AB		EQ 20MG BASE	A 090739	001	Jan 08, 2014	Dec	NEWA
>A>	AB		EQ 30MG BASE	A 090728	002	Jan 08, 2014	Dec	NEWA
>A>	AB		EQ 30MG BASE	A 090739	002	Jan 08, 2014	Dec	NEWA
>A>	AB		EQ 60MG BASE	A 090728	003	Jan 08, 2014	Dec	NEWA
>A>	AB		EQ 60MG BASE	A 090739	003	Jan 08, 2014	Dec	NEWA

DUTASTERIDE

CAPSULE;ORAL  
 DUTASTERIDE

AB	BANNER PHARMACAPS	0.5MG	A 200899	001	May 30, 2013	May	NEWA
----	-------------------	-------	----------	-----	--------------	-----	------

ECONAZOLE NITRATE

AEROSOL, FOAM;TOPICAL  
 ECOZA  
 + AMDERMA PHARMS  
 CREAM;TOPICAL  
 ECONAZOLE NITRATE

		1%	N 205175	001	Oct 24, 2013	Oct	NEWA
AB	IGI LABS INC	1%	A 076574	001	Dec 17, 2004	Mar	CAHN

EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION  
 TENSILON

AP	+ VALEANT PHARMS	10MG/ML	N 007959	001		Jul	CAHN
		TENSILON PRESERVATIVE FREE					
AP	+ VALEANT PHARMS	10MG/ML	N 007959	002		Jul	CAHN

ENALAPRIL MALEATE

FOR SOLUTION;ORAL  
 EPANED KIT

+ SILVERGATE PHARMS

TABLET;ORAL

ENALAPRIL MALEATE

@ MYLAN

@

@

@

		1MG/ML	N 204308	001	Aug 13, 2013	Aug	NEWA
		2.5MG	A 075472	001	Aug 22, 2000	Aug	DISC
		5MG	A 075472	002	Aug 22, 2000	Aug	DISC
		10MG	A 075472	003	Aug 22, 2000	Aug	DISC
		20MG	A 075472	004	Aug 22, 2000	Aug	DISC

ENALAPRILAT

INJECTABLE;INJECTION  
 ENALAPRILAT

AP	TEVA PHARMS USA	1.25MG/ML	A 075578	001	Aug 22, 2000	May	CAHN
----	-----------------	-----------	----------	-----	--------------	-----	------

ENTACAPONE

TABLET;ORAL  
 ENTACAPONE

AB	MYLAN PHARMS INC	200MG	A 202394	001	May 13, 2013	Apr	NEWA
----	------------------	-------	----------	-----	--------------	-----	------

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
 EPINASTINE HYDROCHLORIDE  
 AT BRECKENRIDGE PHARM 0.05% A090870 001 Mar 14, 2011 Nov CAHN

EPINEPHRINE

>A> INJECTABLE;IM-SC  
 >A> ADRENALIN  
 >A> + JHP PHARMS LLC 30MG/30ML (1MG/ML) N204640 001 Dec 18, 2013 Dec NEWA  
 EPIPEN  
 BX + MERIDIAN MEDCL TECHN 0.3MG/DELIVERY N019430 001 Dec 22, 1987 Jul CDFR  
 BX + MYLAN SPECLT 0.3MG/DELIVERY N019430 001 Dec 22, 1987 Sep CAHN  
 EPIPEN JR.  
 BX + MERIDIAN MEDCL TECHN 0.15MG/DELIVERY N019430 002 Dec 22, 1987 Jul CDFR  
 BX + MYLAN SPECLT 0.15MG/DELIVERY N019430 002 Dec 22, 1987 Sep CAHN  
 INJECTABLE;INTRAMUSCULAR  
 EPI E Z PEN JR  
 @ MYLAN SPECLT 0.15MG/DELIVERY N019430 004 Aug 03, 1995 Sep CAHN  
 EPIPEN E Z PEN  
 @ MYLAN SPECLT 0.3MG/DELIVERY N019430 003 Aug 03, 1995 Sep CAHN

EPIRUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION  
 EPIRUBICIN HYDROCHLORIDE  
 AP TEVA PHARMS USA 50MG/25ML (2MG/ML) A065331 001 Aug 09, 2007 Apr CAHN  
 AP 200MG/100ML (2MG/ML) A065331 002 Aug 09, 2007 Apr CAHN

EPOPROSTENOL SODIUM

INJECTABLE;INJECTION  
 EPOPROSTENOL SODIUM  
 AP TEVA PHARMS USA EQ 0.5MG BASE/VIAL A078396 001 Apr 23, 2008 Apr CAHN  
 AP EQ 1.5MG BASE/VIAL A078396 002 Apr 23, 2008 Apr CAHN

ERTAPENEM SODIUM

INJECTABLE;INTRAMUSCULAR, IV (INFUSION)  
 INVANZ  
 + MERCK SHARP DOHME EQ 1GM BASE/VIAL N021337 001 Nov 21, 2001 Jun CAHN

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS;ORAL  
 ERYC  
 AB + MAYNE PHARMA 250MG N050536 001 Mar CAHN  
 @ WARNER CHILCOTT LLC 250MG A062338 001 Apr DISC  
 GEL;TOPICAL  
 ERYGEL  
 AT + DELCOR ASSET CORP 2% N050617 001 Oct 21, 1987 Jul CAHN  
 OINTMENT;OPHTHALMIC  
 ERYTHROMYCIN  
 AT + PERRIGO CO TENNESSEE 0.5% A062447 001 Sep 26, 1983 Jun CAHN  
 SOLUTION;TOPICAL  
 SANSAC  
 @ DOW PHARM 2% A062522 001 Jan 24, 1985 Apr CAHN

ESCITALOPRAM OXALATE

SOLUTION;ORAL  
 ESCITALOPRAM OXALATE  
 AA SILARX PHARMS INC EQ 5MG BASE/5ML A090477 001 Jun 12, 2013 May NEWA

ESLICARBAZEPINE ACETATE

TABLET;ORAL  
 APTIOM  
 SUNOVION PHARMS INC 200MG N022416 001 Nov 08, 2013 Nov NEWA  
 400MG N022416 002 Nov 08, 2013 Nov NEWA  
 600MG N022416 003 Nov 08, 2013 Nov NEWA  
 + 800MG N022416 004 Nov 08, 2013 Nov NEWA

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE;ORAL  
 NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

AB		DR REDDYS LABS LTD	EQ 20MG BASE;375MG	A202461	001	Sep 27, 2013	Sep	NEWA
AB			EQ 20MG BASE;500MG	A202461	002	Sep 27, 2013	Sep	NEWA
		VIMOVO						
>D>	AB	ASTRAZENECA LP	EQ 20MG BASE;375MG	N022511	002	Apr 30, 2010	Dec	CAHN
	AB		EQ 20MG BASE;375MG	N022511	002	Apr 30, 2010	Sep	CFTG
>D>	AB	+	EQ 20MG BASE;500MG	N022511	001	Apr 30, 2010	Dec	CAHN
	AB	+	EQ 20MG BASE;500MG	N022511	001	Apr 30, 2010	Sep	CFTG
>A>	AB	HORIZON PHARMA	EQ 20MG BASE;375MG	N022511	002	Apr 30, 2010	Dec	CAHN
>A>	AB	+	EQ 20MG BASE;500MG	N022511	001	Apr 30, 2010	Dec	CAHN

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS  
 ESOMEPRAZOLE SODIUM

AP		SUN PHARMA GLOBAL	EQ 20MG BASE/VIAL	A200882	001	Mar 18, 2013	Mar	NEWA
AP			EQ 40MG BASE/VIAL	A200882	002	Mar 18, 2013	Mar	NEWA
		NEXIUM IV						
AP	+	ASTRAZENECA	EQ 20MG BASE/VIAL	N021689	001	Mar 31, 2005	Mar	CFTG
AP	+		EQ 40MG BASE/VIAL	N021689	002	Mar 31, 2005	Mar	CFTG

ESOMEPRAZOLE STRONTIUM

CAPSULE, DELAYED RELEASE;ORAL  
 ESOMEPRAZOLE STRONTIUM

		HANMI PHARM CO LTD	EQ 20MG BASE	N202342	001	Aug 06, 2013	Sep	CAHN
	+		EQ 40MG BASE	N202342	002	Aug 06, 2013	Sep	CAHN
		HANMI USA	EQ 20MG BASE	N202342	001	Aug 06, 2013	Aug	NEWA
	+		EQ 40MG BASE	N202342	002	Aug 06, 2013	Aug	NEWA

ESTRADIOL VALERATE

INJECTABLE;INJECTION  
 ESTRADIOL VALERATE

	@	WATSON LABS	40MG/ML	A083714	001		Jun	DISC
	@	WATSON LABS INC	20MG/ML	A083547	001		Jun	DISC

ESTROGENS, CONJUGATED SYNTHETIC A

CREAM;VAGINAL  
 SYNTHETIC CONJUGATED ESTROGENS A

	@	TEVA WOMENS	0.625MG/GM	N021788	001	Nov 28, 2008	Sep	DISC
--	---	-------------	------------	---------	-----	--------------	-----	------

ESTRONE

INJECTABLE;INJECTION  
 ESTRONE

	@	WATSON LABS	5MG/ML	A085239	001		Jun	DISC
--	---	-------------	--------	---------	-----	--	-----	------

ESTROPIPATE

TABLET;ORAL  
 ORTHO-EST

	@	CARACO	0.75MG	A089567	001	Feb 27, 1991	Apr	DISC
	@		1.5MG	A089582	001	Jul 17, 1991	Apr	DISC

ESZOPICLONE

TABLET;ORAL  
 ESZOPICLONE

AB		MYLAN PHARMS INC	1MG	A091151	001	Mar 26, 2013	Mar	NEWA
AB			2MG	A091151	002	Mar 26, 2013	Mar	NEWA
AB			3MG	A091151	003	Mar 26, 2013	Mar	NEWA
AB		SUN PHARMA GLOBAL	1MG	A091103	001	Apr 03, 2013	Mar	NEWA
AB			2MG	A091103	002	Apr 03, 2013	Mar	NEWA
AB			3MG	A091103	003	Apr 03, 2013	Mar	NEWA
		LUNESTA						
AB		SUNOVION PHARMS INC	1MG	N021476	001	Dec 15, 2004	Mar	CTEC
AB			2MG	N021476	002	Dec 15, 2004	Mar	CTEC
AB	+		3MG	N021476	003	Dec 15, 2004	Mar	CTEC

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL		ETHAMBUTOL HYDROCHLORIDE					
	@ WEST WARD	100MG	A 075095	001	Nov 30, 1999	Jul	DISC
	@	400MG	A 075095	002	Nov 30, 1999	Jul	DISC
	MYAMBUTOL						
AB	+ STI PHARMA LLC	400MG	N 016320	003		Jul	CRLD

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL		DAYSEE					
AB	LUPIN LTD	0.03MG, 0.01MG; 0.15MG, N/A	A 091467	001	Apr 10, 2013	Mar	NEWA
	QUARTETTE						
	+ TEVA BRANDED PHARM	0.02MG, 0.15MG; 0.025MG, 0.15MG; 0.03MG, 0.15MG; 0.01MG, N/A	N 204061	001	Mar 28, 2013	Mar	NEWA
TABLET; ORAL-28		LEVONORGESTREL AND ETHINYL ESTRADIOL					
AB1	FAMY CARE LTD	0.02MG; 0.1MG	A 200245	001	Oct 09, 2013	Sep	NEWA
AB1	LUPIN LTD	0.02MG; 0.1MG	A 091425	001	Jan 18, 2013	Jan	NEWA

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28		NORETHINDRONE AND ETHINYL ESTRADIOL					
AB	+ FAMY CARE LTD	0.05MG; 1MG	A 203006	001	Aug 05, 2013	Oct	CRLD
AB		0.05MG; 1MG	A 203006	001	Aug 05, 2013	Jul	NEWA
	OVCON-50						
	@ WARNER CHILCOTT LLC	0.05MG; 1MG	N 017576	001		Oct	DISC
AB	+ PIRMELLA 1/35	0.05MG; 1MG	N 017576	001		Jul	CFTG
AB	LUPIN LTD	0.035MG; 1MG	A 201512	001	Apr 24, 2013	Apr	NEWA
	PIRMELLA 7/7/7						
AB	LUPIN LTD	0.035MG, 0.035MG, 0.035MG; 0.5MG, 0.75MG, 1MG	A 201510	001	Apr 24, 2013	Apr	NEWA
	VYFEMLA						
AB	LUPIN LTD	0.035MG; 0.4MG	A 201886	001	Sep 26, 2013	Sep	NEWA
TABLET, CHEWABLE; ORAL		NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
AB	AMNEAL PHARMS	0.035MG; 0.4MG	A 078892	001	Sep 26, 2011	Sep	CAHN
>A>	+ WARNER CHILCOTT	0.025MG; 0.8MG	N 022573	001	Dec 22, 2010	Dec	CAHN
>D>	+ WATSON LABS INC	0.025MG; 0.8MG	N 022573	001	Dec 22, 2010	Dec	CAHN

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE; ORAL		MINASTRIN 24 FE					
	+ WARNER CHILCOTT	0.02MG; 1MG	N 204426	001	Apr 19, 2013	Apr	NEWA
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
	@ WARNER CHILCOTT	0.02MG; 1MG	N 204426	001	Apr 19, 2013	May	DISC
TABLET; ORAL		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL					
	+ BARR LABS INC	0.005MG; 1MG	A 076221	001	Nov 06, 2009	Jan	CRLD
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
AB	AMNEAL PHARMS	0.02MG; 1MG	A 078267	001	Sep 01, 2009	Sep	CAHN
TABLET; ORAL-21		LARIN 1/20					
AB	NOVAST LABS LTD	0.02MG; 1MG	A 202995	001	Dec 04, 2013	Nov	NEWA
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL						
AB	FAMY CARE LTD	0.02MG; 1MG	A 202771	001	Nov 06, 2013	Oct	NEWA
TABLET; ORAL-28		LARIN FE 1.5/30					
AB	NOVAST LABS LTD	0.03MG; 1.5MG	A 091453	001	Aug 23, 2013	Aug	NEWA
	LARIN FE 1/20						
AB	NOVAST LABS LTD	0.02MG; 1MG	A 091454	001	Aug 26, 2013	Aug	NEWA
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL						
AB	FAMY CARE LTD	0.02MG; 1MG	A 202772	001	Nov 14, 2013	Oct	NEWA
TABLET, CHEWABLE; ORAL		MINASTRIN 24 FE					
	+ WARNER CHILCOTT LLC	0.02MG; 1MG	N 203667	001	May 08, 2013	Oct	CTNA
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
	+ WARNER CHILCOTT LLC	0.02MG; 1MG	N 203667	001	May 08, 2013	May	NEWA

TABLET, CHEWABLE, TABLET;ORAL  
LO MINASTRIN FE

+ WARNER CHILCOTT 0.01MG,0.01MG,N/A;1MG,N/A,N/A N204654 001 Jul 24, 2013 Jul NEWA

ETHINYL ESTRADIOL; NORGESTIMATE

## TABLET;ORAL-28

## ESTARYLLA

AB SANDOZ 0.035MG;0.25MG A090794 001 Jan 30, 2013 Jan NEWA

## TRI LO SPRINTEC

## @ BARR LABS INC

0.025MG,0.025MG,0.025MG;0.18MG,0.2  
15MG,0.25MG A076784 001 Jun 29, 2009 Apr DISC

## TRI-ESTARYLLA

AB SANDOZ 0.035MG,0.035MG,0.035MG;0.18MG,0.2  
15MG,0.25MG A090793 001 Jan 30, 2013 Jan NEWA

ETHOTOIN

## TABLET;ORAL

## PEGANONE

+ RECORDATI RARE 250MG N010841 001 May CAHN

ETODOLAC

## TABLET;ORAL

## ETODOLAC

## @ PROSAM LABS

400MG A074819 001 Feb 28, 1997 Mar DISC

## @

500MG A074819 002 Apr 28, 1998 Mar DISC

ETOMIDATE

## INJECTABLE;INJECTION

## ETOMIDATE

>A> AP JHP PHARMS LLC 2MG/ML A091297 001 Jun 20, 2012 Dec CAHN

>D> AP MYLAN INSTITUTIONAL 2MG/ML A091297 001 Jun 20, 2012 Dec CAHN

ETOPOSIDE

## INJECTABLE;INJECTION

## ETOPOSIDE

AP ACCORD HLTHCARE 20MG/ML A074513 001 Mar 14, 1996 Apr CAHN

## @ PHARMACHEMIE

20MG/ML A074227 001 Feb 22, 1996 Apr DISC

AP TEVA PHARMS USA 20MG/ML A074284 001 Feb 10, 1994 May CAHN

AP 20MG/ML A074529 001 Jul 24, 1996 Apr CAHN

FAMCICLOVIR

## TABLET;ORAL

## FAMCICLOVIR

AB CIPLA LTD 125MG A078278 001 Mar 21, 2011 Jul CAHN

AB 250MG A078278 002 Mar 21, 2011 Jul CAHN

AB 500MG A078278 003 Mar 21, 2011 Jul CAHN

FAMOTIDINE

## INJECTABLE;INJECTION

## FAMOTIDINE

AP AGILA SPECLTS 10MG/ML A078641 001 Jun 25, 2008 Nov CAHN

## @ APOTEX INC

10MG/ML A075942 001 Aug 02, 2002 Apr DISC

## @ HIKMA MAPLE

10MG/ML A075799 001 Apr 30, 2002 Oct DISC

## FAMOTIDINE PRESERVATIVE FREE

AP AGILA SPECLTS 10MG/ML A078642 001 Jun 25, 2008 Nov CAHN

AP AKORN INC 10MG/ML A076324 001 Nov 27, 2002 Mar CAHN

## @ APOTEX INC

10MG/ML A076324 001 Nov 27, 2002 Apr DISC

## @ HIKMA MAPLE

10MG/ML A075789 001 Apr 30, 2002 Oct DISC

## FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)

AP AKORN INC 10MG/ML A076322 001 Nov 27, 2002 Mar CAHN

## @ APOTEX INC

10MG/ML A076322 001 Nov 27, 2002 Apr DISC

## TABLET;ORAL

## FAMOTIDINE

## @ WATSON LABS

20MG A075062 002 Apr 16, 2001 Sep DISC

## @

40MG A075062 001 Apr 16, 2001 Sep DISC

FELODIPINE

## TABLET, EXTENDED RELEASE;ORAL

## FELODIPINE

AB HERITAGE PHARMS INC 2.5MG A201964 001 Nov 08, 2013 Oct NEWA

AB 5MG A201964 002 Nov 08, 2013 Oct NEWA

AB 10MG A201964 003 Nov 08, 2013 Oct NEWA

TABLET, EXTENDED RELEASE;ORAL  
FELODIPINE

>A>	AB	RANBAXY LABS LTD	2.5MG	A091200	001	Dec 13, 2013	Dec	NEWA
>A>	AB		5MG	A091200	002	Dec 13, 2013	Dec	NEWA
>A>	AB		10MG	A091200	003	Dec 13, 2013	Dec	NEWA

FENOFIBRATE

CAPSULE;ORAL

ANTARA (MICRONIZED)

		LUPIN ATLANTIS	30MG	N021695	004	Oct 18, 2013	Oct	NEWA
			90MG	N021695	005	Oct 18, 2013	Oct	NEWA

FENOFIBRATE (MICRONIZED)

AB		APOTEX INC	43MG	A202252	001	Jul 26, 2013	Jul	NEWA
AB			130MG	A202252	002	Jul 26, 2013	Jul	NEWA

TABLET;ORAL

FENOGLIDE

>A>		SALIX PHARMS INC	40MG	N022118	001	Aug 10, 2007	Dec	CAHN
>A>	+		120MG	N022118	002	Aug 10, 2007	Dec	CAHN
>D>		SANTARUS	40MG	N022118	001	Aug 10, 2007	Dec	CAHN
>D>	+		120MG	N022118	002	Aug 10, 2007	Dec	CAHN

FENOFIBRIC ACID

TABLET;ORAL

FIBRICOR

		MUTUAL PHARM CO INC	35MG	N022418	001	Aug 14, 2009	Feb	CAHN
	+		105MG	N022418	002	Aug 14, 2009	Feb	CAHN

FENOPROFEN CALCIUM

TABLET;ORAL

FENOPROFEN CALCIUM

		@ IVAX SUB TEVA PHARMS	EQ 600MG BASE	A072557	001	Aug 29, 1988	Mar	DISC
	+	MYLAN PHARMS INC	EQ 600MG BASE	A072267	001	Aug 17, 1988	Mar	CTEC

FENTANYL

SPRAY;SUBLINGUAL  
SUBSYS

		INSYS THERAP	1.2MG	N202788	006	Aug 30, 2012	Aug	NEWA
			1.6MG	N202788	007	Aug 30, 2012	Aug	NEWA

FENTANYL CITRATE

FILM;BUCCAL

ONSOLIS

		@ MEDA PHARMS	EQ 0.2MG BASE	N022266	001	Jul 16, 2009	May	DISC
		@	EQ 0.4MG BASE	N022266	002	Jul 16, 2009	May	DISC
		@	EQ 0.6MG BASE	N022266	003	Jul 16, 2009	May	DISC
		@	EQ 0.8MG BASE	N022266	004	Jul 16, 2009	May	DISC
		@	EQ 1.2MG BASE	N022266	005	Jul 16, 2009	May	DISC

INJECTABLE;INJECTION

FENTANYL CITRATE PRESERVATIVE FREE

AP	+	HIKMA MAPLE	EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Jul	CAHN
----	---	-------------	-------------------	---------	-----	--------------	-----	------

SPRAY, METERED;NASAL

LAZANDA

		DEPOMED INC	EQ 0.1MG BASE	N022569	001	Jun 30, 2011	Sep	CAHN
	+		EQ 0.4MG BASE	N022569	002	Jun 30, 2011	Sep	CAHN

TABLET;BUCCAL, SUBLINGUAL

FENTORA

AB		CEPHALON	EQ 0.1MG BASE	N021947	001	Sep 25, 2006	Feb	CDFR
AB			EQ 0.2MG BASE	N021947	002	Sep 25, 2006	Feb	CDFR
		@	EQ 0.3MG BASE	N021947	006	Mar 02, 2007	Feb	CDFR
AB	+		EQ 0.4MG BASE	N021947	003	Sep 25, 2006	Feb	CDFR
AB			EQ 0.6MG BASE	N021947	004	Sep 25, 2006	Feb	CDFR
AB			EQ 0.8MG BASE	N021947	005	Sep 25, 2006	Feb	CDFR

TABLET;SUBLINGUAL

ABSTRAL

		GALENA BIOPHARMA	EQ 0.1MG BASE	N022510	001	Jan 07, 2011	May	CAHN
			EQ 0.2MG BASE	N022510	002	Jan 07, 2011	May	CAHN
			EQ 0.3MG BASE	N022510	003	Jan 07, 2011	May	CAHN
	+		EQ 0.4MG BASE	N022510	004	Jan 07, 2011	May	CAHN
			EQ 0.6MG BASE	N022510	005	Jan 07, 2011	May	CAHN
			EQ 0.8MG BASE	N022510	006	Jan 07, 2011	May	CAHN



FERRIC CARBOXYMALTOSE

INJECTABLE; IV  
INJECTAFER

+ LUITPOLD 750MG IRON/15ML (50MG IRON/ML) N203565 001 Jul 25, 2013 Jul NEWA

FERUMOXSIIL

SUSPENSION; ORAL  
GASTROMARK

@ AMAG PHARMS INC EQ 0.175MG IRON/ML N020410 001 Dec 06, 1996 Feb DISC

FINASTERIDE

TABLET; ORAL  
FINASTERIDE

AB ACCORD HLTHCARE 5MG A090121 001 Feb 23, 2010 Apr CAHN  
 AB ACCORD HLTHCARE INC 1MG A091643 001 Nov 05, 2013 Oct NEWA  
 AB ACTAVIS TOTOWA 1MG A078371 001 Nov 05, 2013 Oct NEWA  
 AB AUROBINDO PHARMA LTD 1MG A203687 001 Nov 05, 2013 Oct NEWA  
 AB HETERO LABS LTD III 1MG A090060 001 Jul 01, 2013 Jun NEWA  
 AB 5MG A090061 001 Jun 07, 2010 Apr CAHN  
 AB MYLAN PHARMS INC 1MG A078161 001 Nov 05, 2013 Oct NEWA  
 AB SUN PHARMA GLOBAL 1MG A090508 001 Jul 01, 2013 Jun NEWA  
 AB TEVA 1MG A076905 001 Nov 05, 2013 Oct NEWA

FLECAINIDE ACETATE

TABLET; ORAL  
FLECAINIDE ACETATE

@ APOTEX INC 50MG A079164 001 Jul 09, 2009 Apr DISC  
 @ 100MG A079164 002 Jul 09, 2009 Apr DISC  
 @ 150MG A079164 003 Jul 09, 2009 Apr DISC  
 AB + ROXANE 150MG A076278 003 Jan 14, 2003 May CRLD

FLUCONAZOLE

FOR SUSPENSION; ORAL  
FLUCONAZOLE

@ TARO PHARM INDS 50MG/5ML A076918 001 Dec 18, 2006 Mar DISC  
 @ 200MG/5ML A076918 002 Dec 18, 2006 Mar DISC

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

@ AGILA SPECLTS 200MG/100ML (2MG/ML) A076888 001 Mar 25, 2005 Aug CAHN  
 @ 400MG/200ML (2MG/ML) A076888 002 Mar 25, 2005 Aug CAHN  
 @ APOTEX INC 200MG/100ML (2MG/ML) A076888 001 Mar 25, 2005 Apr DISC  
 @ 400MG/200ML (2MG/ML) A076888 002 Mar 25, 2005 Apr DISC  
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9%  
 AP TEVA PHARMS USA 200MG/100ML (2MG/ML) A076653 001 Jul 29, 2004 May CAHN  
 AP 400MG/200ML (2MG/ML) A076653 002 Jul 29, 2004 May CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@ AGILA SPECLTS 200MG/100ML (2MG/ML) A076889 001 Mar 25, 2005 Aug CAHN  
 @ 400MG/200ML (2MG/ML) A076889 002 Mar 25, 2005 Aug CAHN  
 @ APOTEX INC 200MG/100ML (2MG/ML) A076889 001 Mar 25, 2005 Apr DISC  
 @ 400MG/200ML (2MG/ML) A076889 002 Mar 25, 2005 Apr DISC

TABLET; ORAL

FLUCONAZOLE

@ HARRIS PHARM 50MG A078423 001 Mar 07, 2011 Sep DISC  
 @ 100MG A078423 002 Mar 07, 2011 Sep DISC  
 @ 150MG A078423 003 Mar 07, 2011 Sep DISC  
 @ 200MG A078423 004 Mar 07, 2011 Sep DISC

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION  
FLUDARABINE PHOSPHATE

AP + FRESENIUS KABI USA 50MG/2ML (25MG/ML) A078393 001 Oct 15, 2007 Jan CRLD  
 AP TEVA PARENTERAL 50MG/2ML (25MG/ML) A076661 001 Apr 28, 2004 Jan CRLD  
 AP TEVA PHARMS USA 50MG/VIAL A076349 001 Aug 28, 2003 Apr CAHN  
 AP 50MG/2ML (25MG/ML) A076661 001 Apr 28, 2004 Apr CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS  
FLUDEOXYGLUCOSE F-18

>A> AP WI MEDCL CYCLOTRON 20-500mCi/ML A203709 001 Oct 23, 2013 Dec NEWA  
 >D> + FEINSTEIN 20-300mCi/ML N021870 002 Nov 21, 2008 Dec CTEC

INJECTABLE; INTRAVENOUS  
FLUDEOXYGLUCOSE F18

>A>	AP	+		20-300mCi/ML	N021870	002	Nov 21, 2008	Dec	CTEC
>D>		+	HOUSTON CYCLOTRON	20-500mCi/ML	A203665	001	Feb 14, 2013	Dec	CTEC
>A>	AP	+		20-500mCi/ML	A203665	001	Feb 14, 2013	Dec	CTEC
		+		20-500mCi/ML	A203665	001	Feb 14, 2013	Jun	CRLD
		+		20-500mCi/ML	A203665	001	Feb 14, 2013	Jan	NEWA
			MCPRF	20-240mCi/ML	A203612	001	Aug 05, 2013	Jul	NEWA
		+	UCLA BIOMEDICAL	4-40mCi/ML	A203811	001	Jun 27, 2013	Jun	NEWA
>A>			UNIV TX MD ANDERSON	20-150mCi/ML	A203246	001	Jan 13, 2014	Dec	NEWA
>A>	AP			20-300mCi/ML	A203246	002	Jan 13, 2014	Dec	NEWA

FLUDROCORTISONE ACETATE

TABLET; ORAL  
FLORINEF

			@ CITRON PHARMA LLC	0.1MG	N010060	001		Nov	CAHN
--	--	--	---------------------	-------	---------	-----	--	-----	------

FLUMAZENIL

INJECTABLE; INJECTION  
FLUMAZENIL

AP			AGILA SPECLTS	0.5MG/5ML (0.1MG/ML)	A078595	001	May 13, 2008	Nov	CAHN
AP		+		1MG/10ML (0.1MG/ML)	A078595	002	May 13, 2008	Nov	CAHN
			@ APOTEX INC	0.5MG/5ML (0.1MG/ML)	A076755	002	Oct 12, 2004	Apr	DISC
			@	1MG/10ML (0.1MG/ML)	A076755	001	Oct 12, 2004	Apr	DISC
AP		+	PFIZER	1MG/10ML (0.1MG/ML)	A078595	002	May 13, 2008	Oct	CRLD
			@ TEVA PHARMS USA	0.5MG/5ML (0.1MG/ML)	A076589	002	Oct 12, 2004	Apr	CAHN
			@	1MG/10ML (0.1MG/ML)	A076589	001	Oct 12, 2004	Apr	CAHN
			ROMAZICON						
			@ HOFFMANN LA ROCHE	1MG/10ML (0.1MG/ML)	N020073	001	Dec 20, 1991	Sep	DISC
			@	0.5MG/5ML (0.1MG/ML)	N020073	002	Dec 20, 1991	Sep	DISC

FLUNISOLIDE

AEROSOL, METERED; INHALATION  
AEROBID

			@ ROCHE PALO	0.25MG/INH	N018340	001	Aug 17, 1984	Sep	DISC
--	--	--	--------------	------------	---------	-----	--------------	-----	------

FLUOCINOLONE ACETONIDE

OIL; TOPICAL  
FLUOCINOLONE ACETONIDE

AT			PERRIGO ISRAEL	0.01%	A202847	001	Aug 09, 2013	Jul	NEWA
AT				0.01%	A202848	001	Aug 09, 2013	Jul	NEWA

FLUOCINONIDE

CREAM; TOPICAL  
FLUOCINONIDE

>A>	AB		PERRIGO ISRAEL	0.1%	A090256	001	Jan 14, 2014	Dec	NEWA
			VANOS						
>D>		+	MEDICIS	0.1%	N021758	001	Feb 11, 2005	Dec	CTEC
>A>	AB	+		0.1%	N021758	001	Feb 11, 2005	Dec	CTEC
			GEL; TOPICAL						
			FLUOCINONIDE						
AB		+	TARO	0.05%	A074935	001	Jul 29, 1997	Jan	CRLD
			LIDEX						
			@ CNTY LINE PHARMS	0.05%	N017373	001		Jan	CAHN
			OINTMENT; TOPICAL						
			FLUOCINONIDE						
AB		+	TARO	0.05%	A075008	001	Jun 30, 1999	Jan	CRLD
			LIDEX						
			@ CNTY LINE PHARMS	0.05%	N016909	002		Jan	CAHN
			SOLUTION; TOPICAL						
			FLUOCINONIDE						
AT			ACTAVIS MID ATLANTIC	0.05%	A071535	001	Dec 02, 1988	May	CAHN
AT		+	TARO	0.05%	A074799	001	Dec 31, 1996	Jan	CRLD
			LIDEX						
			@ CNTY LINE PHARMS	0.05%	N018849	001	Apr 06, 1984	May	CAHN
			@ MEDICIS	0.05%	N018849	001	Apr 06, 1984	Jan	DISC

FLUORESCEIN SODIUM

INJECTABLE; INTRAVENOUS  
AK-FLUOR 25%

+	AKORN	EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	N022186	002	Aug 08, 2008	Oct	CRLD
---	-------	--------------------------------------	---------	-----	--------------	-----	------

FLUOROURACIL

INJECTABLE; INJECTION  
FLUOROURACIL

>A>	AP	+	ACCORD HLTHCARE	1GM/20ML (50MG/ML)	A 040743	001	Apr 26, 2007	Dec	CAHN
>A>	AP	+		2.5GM/50ML (50MG/ML)	A 040798	002	Apr 26, 2007	Dec	CAHN
>A>	AP	+		5GM/100ML (50MG/ML)	A 040798	001	Apr 26, 2007	Dec	CAHN
>A>	AP	+		500MG/10ML (50MG/ML)	A 040743	002	Apr 26, 2007	Dec	CAHN
>D>	AP	+	MYLAN INSTITUTIONAL	1GM/20ML (50MG/ML)	A 040743	001	Apr 26, 2007	Dec	CAHN
>D>	AP	+		2.5GM/50ML (50MG/ML)	A 040798	002	Apr 26, 2007	Dec	CAHN
>D>	AP	+		5GM/100ML (50MG/ML)	A 040798	001	Apr 26, 2007	Dec	CAHN
>D>	AP	+		500MG/10ML (50MG/ML)	A 040743	002	Apr 26, 2007	Dec	CAHN
	AP	+	MYLAN LLC	1GM/20ML (50MG/ML)	A 040743	001	Apr 26, 2007	Feb	CAHN
	AP	+		500MG/10ML (50MG/ML)	A 040743	002	Apr 26, 2007	Feb	CAHN
	AP	+	TEVA PHARMS USA	2.5GM/50ML (50MG/ML)	A 040334	001	Feb 25, 2000	May	CAHN
	AP	+		5GM/100ML (50MG/ML)	A 040334	002	Feb 25, 2000	May	CAHN
	AP	+		500MG/10ML (50MG/ML)	A 040333	001	Jan 27, 2000	May	CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL  
FLUOXETINE HYDROCHLORIDE

			@ CARLSBAD	EQ 10MG BASE	A 076022	001	Jan 30, 2002	Mar	DISC
			@	EQ 20MG BASE	A 076022	002	Jan 30, 2002	Mar	DISC
			@ CR DOUBLE CRANE	EQ 10MG BASE	A 076165	001	Feb 01, 2002	Apr	DISC
AB1			@	EQ 10MG BASE	A 076165	001	Feb 01, 2002	Mar	CAHN
			@	EQ 20MG BASE	A 076165	002	Feb 01, 2002	Apr	DISC
AB1				EQ 20MG BASE	A 076165	002	Feb 01, 2002	Mar	CAHN
AB1			DR REDDYS LABS LTD	EQ 10MG BASE	A 075465	001	Jan 29, 2002	Sep	CAHN
AB1				EQ 20MG BASE	A 075465	002	Jan 29, 2002	Sep	CAHN
AB				EQ 40MG BASE	A 075465	003	Aug 02, 2001	Sep	CAHN
AB1			TEVA PHARMS USA	EQ 10MG BASE	A 076001	001	Jan 29, 2002	Jul	CAHN
AB1				EQ 20MG BASE	A 076001	002	Jan 29, 2002	Jul	CAHN
			@ WOCKHARDT LTD	EQ 10MG BASE	A 078143	001	Jan 16, 2008	Feb	DISC
			@	EQ 20MG BASE	A 078143	002	Jan 16, 2008	Feb	DISC
			@	EQ 40MG BASE	A 078143	003	Jan 16, 2008	Feb	DISC

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

			@ APOTEX INC	EQ 20MG BASE/5ML	A 075292	001	Feb 07, 2002	Apr	DISC
--	--	--	--------------	------------------	----------	-----	--------------	-----	------

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

AB			TEVA PHARMS	EQ 25MG BASE; EQ 3MG BASE	A 202074	001	Mar 25, 2013	Mar	NEWA
----	--	--	-------------	---------------------------	----------	-----	--------------	-----	------

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

			@ AGILA SPECLTS	25MG/ML	A 075918	001	Aug 17, 2001	Aug	CAHN
			@ APOTEX INC	25MG/ML	A 075918	001	Aug 17, 2001	Apr	DISC

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HYDROCHLORIDE

			@ WEST WARD	15MG	A 071107	001	Dec 08, 1986	Jul	DISC
			@	30MG	A 071108	001	Dec 08, 1986	Jul	DISC

FLUTEMETAMOL F-18

INJECTABLE; INTRAVENOUS

VIZAMYL

+	GE HEALTHCARE	40.5mCi/10ML (4.05mCi/ML)	N203137	001	Oct 25, 2013	Oct	NEWA
+		121.5mCi/30ML (4.05mCi/ML)	N203137	002	Oct 25, 2013	Oct	NEWA

FLUTICASONE FUROATE; VILANTEROL TRIFENATATEPOWDER; INHALATION  
BREQ ELLIPTA

+ GLAXO GRP LTD 0.1MG/INH;EQ 0.025MG BASE/INH N204275 001 May 10, 2013 May NEWA

FLUTICASONE PROPIONATECREAM; TOPICAL  
CUTIVATE

@ FOUGERA PHARMS 0.05% N019958 001 Dec 18, 1990 Aug DISC

LOTION; TOPICAL

FLUTICASONE PROPIONATE

AB PERRIGO ISRAEL 0.05% A091553 001 Jul 30, 2013 Jul NEWA

POWDER; INHALATION

FLOVENT DISKUS 100

+ GLAXO GRP LTD 0.1MG/INH N020833 002 Sep 29, 2000 May CAHN

FLOVENT DISKUS 250

+ GLAXO GRP LTD 0.25MG/INH N020833 003 Sep 29, 2000 May CAHN

FLOVENT DISKUS 50

+ GLAXO GRP LTD 0.05MG/INH N020833 001 Sep 29, 2000 May CAHN

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

AEROSOL, METERED; INHALATION

ADVAIR HFA

+ GLAXO GRP LTD 0.045MG/INH;EQ 0.021MG BASE/INH N021254 001 Jun 08, 2006 May CAHN

+ 0.115MG/INH;EQ 0.021MG BASE/INH N021254 002 Jun 08, 2006 May CAHN

+ 0.23MG/INH;EQ 0.021MG BASE/INH N021254 003 Jun 08, 2006 May CAHN

POWDER; INHALATION

ADVAIR DISKUS 100/50

+ GLAXO GRP LTD 0.1MG/INH;EQ 0.05MG BASE/INH N021077 001 Aug 24, 2000 May CAHN

ADVAIR DISKUS 250/50

+ GLAXO GRP LTD 0.25MG/INH;EQ 0.05MG BASE/INH N021077 002 Aug 24, 2000 May CAHN

ADVAIR DISKUS 500/50

+ GLAXO GRP LTD 0.5MG/INH;EQ 0.05MG BASE/INH N021077 003 Aug 24, 2000 May CAHN

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

FLUVOXAMINE MALEATE

AB ACTAVIS ELIZABETH 100MG A091482 001 Apr 23, 2013 Apr NEWA

AB 150MG A091482 002 Nov 18, 2013 Nov NEWA

AB ANCHEN PHARMS 100MG A091476 001 Mar 13, 2013 Mar NEWA

AB 150MG A091476 002 Mar 13, 2013 Mar NEWA

LUVOX CR

AB JAZZ PHARMS 100MG N022033 001 Feb 28, 2008 Mar CFTG

AB + 150MG N022033 002 Feb 28, 2008 Mar CFTG

TABLET; ORAL

FLUVOXAMINE MALEATE

@ CARACO 25MG A075900 001 Feb 23, 2006 Jun DISC

@ 50MG A075900 002 Feb 23, 2006 Jun DISC

@ 100MG A075900 003 Feb 23, 2006 Jun DISC

FOLIC ACID

TABLET; ORAL

FOLIC ACID

AA BICON PHARM 1MG A091145 001 Jul 12, 2013 Jul NEWA

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

EMEND

@ MERCK AND CO INC EQ 115MG BASE/VIAL N022023 001 Jan 25, 2008 Sep DISC

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

@ WATSON LABS 10MG A076987 001 Dec 23, 2004 Mar DISC

@ 20MG A076987 002 Dec 23, 2004 Mar DISC

@ 40MG A076987 003 Dec 23, 2004 Mar DISC

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

@ MYLAN	10MG;12.5MG	A 077705	001	Aug 14, 2006	Aug DISC
@	20MG;12.5MG	A 077705	002	Aug 14, 2006	Aug DISC

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

AP	AMNEAL PHARMS	EQ 50MG PNEYTOIN NA/ML	A 078476	001	Mar 18, 2008	May CAHN
	@ APOTEX INC	EQ 50MG PHENYTOIN NA/ML	A 078126	001	Aug 06, 2007	Apr DISC
	@ TEVA PHARMS USA	EQ 50MG PHENYTOIN NA/ML	A 076886	001	Aug 06, 2007	May CAHN

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

@ INTL MEDICATION	10MG/ML	N 018025	001		Jan DISC
-------------------	---------	----------	-----	--	----------

TABLET; ORAL

FUROSEMIDE

@ DAVA PHARMS INC	20MG	N 018415	001	Jul 27, 1982	Feb DISC
@	40MG	N 018415	002	Jul 27, 1982	Feb DISC
@	80MG	N 018415	003	Nov 26, 1984	Feb DISC

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

AB	TARO	100MG	A 077261	001	Aug 02, 2013	Jul NEWA
AB		300MG	A 077261	002	Aug 02, 2013	Jul NEWA
AB		400MG	A 077261	003	Aug 02, 2013	Jul NEWA

SOLUTION; ORAL

GABAPENTIN

AA	TARO	250MG/5ML	A 076672	001	Jul 03, 2013	Jun NEWA
----	------	-----------	----------	-----	--------------	----------

TABLET; ORAL

GABAPENTIN

AB	ALLIED PHARMA INC	600MG	A 203244	002	Jul 12, 2013	Jul NEWA
AB		800MG	A 203244	001	Jul 12, 2013	Jul NEWA

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE; ORAL

HORIZANT

XENOPORT INC	300MG	N 022399	002	Dec 13, 2011	May CAHN
+	600MG	N 022399	001	Apr 06, 2011	May CAHN

GADOBUTROL

SOLUTION; INTRAVENOUS

GADAVIST

>A>	+	BAYER HLTHCARE	1.20944GM/2ML (604.72MG/ML)	N 201277	006	Dec 18, 2013	Dec NEWA
-----	---	----------------	-----------------------------	----------	-----	--------------	----------

GADOTERATE MEGLUMINE

SOLUTION; INTRAVENOUS

DOTAREM

+	GUERBET	3.769GM/10ML (376.9MG/ML)	N 204781	002	Mar 20, 2013	Mar NEWA
+		5.6535GM/15ML (376.9MG/ML)	N 204781	003	Mar 20, 2013	Mar NEWA
+		7.538GM/20ML (376.9MG/ML)	N 204781	004	Mar 20, 2013	Mar NEWA
+		37.69GM/100ML (376.9MG/ML)	N 204781	001	Mar 20, 2013	Mar NEWA

GADOXETATE DISODIUM

SOLUTION; INTRAVENOUS

EOVIST

BAYER HLTHCARE	2.72145GM/15ML (181.43MG/ML)	N 022090	002	Feb 04, 2013	Feb NEWA
----------------	------------------------------	----------	-----	--------------	----------

GALLIUM NITRATE

INJECTABLE; INJECTION

GANITE

@ CHAPTER 7 TRUSTEE	25MG/ML	N 019961	002	Jan 17, 1991	Jul CAHN
@ GENTA	25MG/ML	N 019961	002	Jan 17, 1991	Jul DISC

<u>GANCICLOVIR</u>							
IMPLANT; IMPLANTATION							
VITRASERT							
	@ BAUSCH AND LOMB	4.5MG		N020569	001	Mar 04, 1996	May DISC
<u>GANCICLOVIR SODIUM</u>							
INJECTABLE; INJECTION							
GANCICLOVIR							
AP	LUITPOLD	EQ 500MG BASE/VIAL		A202624	001	Sep 18, 2013	Oct CAHN
AP	PHARMAFORCE	EQ 500MG BASE/VIAL		A202624	001	Sep 18, 2013	Aug NEWA
<u>GANIRELIX ACETATE</u>							
INJECTABLE; INJECTION							
GANIRELIX ACETATE							
	+ ORGANON USA INC	EQ 250MCG BASE/0.5ML		N021057	001	Jul 29, 1999	Aug CTNA
<u>GATIFLOXACIN</u>							
SOLUTION/DROPS; OPHTHALMIC							
GATIFLOXACIN							
	@ APOTEX INC	0.3%		A079084	001	Aug 19, 2011	Apr DISC
AT	LUPIN LTD	0.5%		A202653	001	Aug 28, 2013	Aug NEWA
	ZYMAXID						
AT	+ ALLERGAN	0.5%		N022548	001	May 18, 2010	Aug CFTG
<u>GEMCITABINE HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
GEMCITABINE HYDROCHLORIDE							
AP	CIPLA LTD	EQ 1GM BASE/VIAL		A078759	002	Jul 25, 2011	Jul CAHN
AP		EQ 200MG BASE/VIAL		A078759	001	Jul 25, 2011	Jul CAHN
AP	DR REDDYS LABS LTD	EQ 2GM BASE/VIAL		A202997	001	May 07, 2013	Apr NEWA
AP	JIANGSU HANSON PHARM	EQ 1GM BASE/VIAL		A202485	002	May 07, 2013	Apr NEWA
AP		EQ 200MG BASE/VIAL		A202485	001	May 07, 2013	Apr NEWA
AP	LUITPOLD	EQ 1GM BASE/VIAL		A202031	002	May 07, 2013	Aug CAHN
AP		EQ 200MG BASE/VIAL		A202031	001	May 07, 2013	Aug CAHN
AP	PHARMAFORCE	EQ 1GM BASE/VIAL		A202031	002	May 07, 2013	Apr NEWA
AP		EQ 200MG BASE/VIAL		A202031	001	May 07, 2013	Apr NEWA
AP	SAGENT PHARMS	EQ 1GM BASE/VIAL		A091597	002	May 07, 2013	Apr NEWA
AP		EQ 200MG BASE/VIAL		A091597	001	May 07, 2013	Apr NEWA
<u>GEMFIBROZIL</u>							
TABLET; ORAL							
GEMFIBROZIL							
AB	CARACO	600MG		A079239	001	Dec 29, 2008	Jun CAHN
<u>GEMIFLOXACIN MESYLATE</u>							
TABLET; ORAL							
FACTIVE							
	+ LG LIFE SCIENCES	EQ 320MG BASE		N021158	001	Apr 04, 2003	Nov CAHN
<u>GENTAMICIN SULFATE</u>							
INJECTABLE; INJECTION							
GENTAMICIN SULFATE							
	@ FRESENIUS KABI USA	EQ 10MG BASE/ML		A062356	001	Mar 04, 1982	Aug DISC
AP		EQ 10MG BASE/ML		A062366	002	Feb 06, 1986	Aug NEWA
	@	EQ 40MG BASE/ML		A062356	002	Mar 04, 1982	Aug DISC
AP	+	EQ 40MG BASE/ML		A062366	001	Aug 04, 1983	Aug CRLD
OINTMENT; OPHTHALMIC							
GENTAMICIN SULFATE							
AT	PERRIGO CO TENNESSEE	EQ 0.3% BASE		A065024	001	Jul 30, 2004	Jun CAHN
SOLUTION/DROPS; OPHTHALMIC							
GENTAMICIN SULFATE							
AT	PERRIGO CO TENNESSEE	EQ 0.3% BASE		A065121	001	Jan 30, 2004	Jun CAHN
<u>GLATIRAMER ACETATE</u>							
FOR SOLUTION; SUBCUTANEOUS							
COPAXONE							
	@ TEVA PHARMS USA	20MG/VIAL		N020622	001	Dec 20, 1996	Apr CAHN
INJECTABLE; SUBCUTANEOUS							
COPAXONE							
	+ TEVA PHARMS USA	20MG/ML		N020622	002	Feb 12, 2002	Apr CAHN

GLIMEPIRIDE

TABLET; ORAL		GLIMEPIRIDE						
	@ COREPHARMA	1MG		A 077274	001	Oct 06, 2005	Feb	DISC
	@	2MG		A 077274	002	Oct 06, 2005	Feb	DISC
	@	4MG		A 077274	003	Oct 06, 2005	Feb	DISC
AB	HIKMA PHARMS	1MG		A 078952	001	Aug 01, 2013	Jul	NEWA
AB		2MG		A 078952	002	Aug 01, 2013	Jul	NEWA
AB		4MG		A 078952	003	Aug 01, 2013	Jul	NEWA
AB	INDOCO REMEDIES	1MG		A 202112	001	Apr 17, 2013	Apr	NEWA
AB		2MG		A 202112	002	Apr 17, 2013	Apr	NEWA
AB		4MG		A 202112	003	Apr 17, 2013	Apr	NEWA
AB	MICRO LABS LTD INDIA	1MG		A 091220	001	Jun 29, 2012	Jul	CAHN
AB		2MG		A 091220	002	Jun 29, 2012	Jul	CAHN
		3MG		A 091220	003	Jun 29, 2012	Jul	CAHN
AB		4MG		A 091220	004	Jun 29, 2012	Jul	CAHN
		6MG		A 091220	005	Jun 29, 2012	Jul	CAHN
AB		8MG		A 091220	006	Jun 29, 2012	Jul	CAHN
	@ MYLAN	1MG		A 077486	001	Feb 10, 2006	Aug	DISC
	@	2MG		A 077486	002	Feb 10, 2006	Aug	DISC
	@	4MG		A 077486	003	Feb 10, 2006	Aug	DISC

GLIPIZIDE

TABLET; ORAL		GLIPIZIDE						
AB	ACCORD HLTHCARE	5MG		A 074550	001	Sep 11, 1997	Apr	CAHN
AB		10MG		A 074550	002	Sep 11, 1997	Apr	CAHN
	@ BARR LABS INC	5MG		A 074619	001	Apr 04, 1997	May	CAHN
	@	10MG		A 074619	002	Apr 04, 1997	May	CAHN
TABLET, EXTENDED RELEASE; ORAL		GLIPIZIDE						
AB	PAR PHARM	5MG		A 076159	002	Sep 20, 2013	Sep	NEWA
AB		10MG		A 076159	001	Sep 20, 2013	Sep	NEWA

GLYCEROL PHENYLBUTYRATE

LIQUID; ORAL		RAVICTI						
	+ HYPERION THERAP INC	1.1GM/ML		N 203284	001	Feb 01, 2013	Feb	NEWA

GLYCOPYRROLATE

INJECTABLE; INJECTION		ROBINUL						
AP	+ HIKMA MAPLE	0.2MG/ML		N 017558	001		Apr	CAHN
TABLET; ORAL		GLYCOPYRROLATE						
AA	AUROLIFE PHARMA LLC	1MG		A 202675	001	Apr 15, 2013	Apr	NEWA
	@ COREPHARMA	1MG		A 040568	001	Dec 22, 2004	Mar	DISC
	@	2MG		A 040568	002	Dec 22, 2004	Mar	DISC
	@ WEST WARD	1MG		A 040836	001	Mar 05, 2009	Jul	DISC
	@	2MG		A 040836	002	Mar 05, 2009	Jul	DISC

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION		GRANISETRON HYDROCHLORIDE						
	@ APOTEX INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)		A 078197	001	Dec 31, 2007	Apr	DISC
	@	EQ 1MG BASE/ML (EQ 1MG BASE/ML)		A 078198	001	Jun 30, 2008	Apr	DISC
	@	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)		A 078198	002	Jun 30, 2008	Apr	DISC
AP	DSM PHARMS INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)		A 078863	001	Jun 30, 2008	Nov	CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)		A 078880	001	Jun 30, 2008	Nov	CAHN
	@ EBEWE PHARMA	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)		A 078808	001	Apr 29, 2008	Feb	DISC
AP	+ TEVA PHARMS USA	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)		A 078392	001	Dec 31, 2007	May	CAHN
AP	+	EQ 1MG BASE/ML (EQ 1MG BASE/ML)		A 077963	001	Jan 03, 2008	May	CAHN
AP	+	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)		A 077297	001	Jun 30, 2008	May	CAHN
		GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE						
AP	DSM PHARMS INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)		A 078863	002	Jun 30, 2008	Nov	CAHN
	@ TEVA PHARMS USA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)		A 077165	001	Dec 31, 2007	May	CAHN

GRISEOFULVIN, MICROSIZE

		SUSPENSION;ORAL							
		GRIFULVIN V							
AB	+	VALEANT LUXEMBOURG	125MG/5ML	A062483	001	Jan 26, 1984	Apr	CAHN	
		TABLET;ORAL							
		GRISEOFULVIN							
		SANDOZ	250MG	A091592	001	Aug 07, 2013	Jul	NEWA	
AB			500MG	A091592	002	Aug 07, 2013	Jul	NEWA	

GRISEOFULVIN, ULTRAMICROSIZE

		TABLET;ORAL							
		GRISEOFULVIN, ULTRAMICROSIZE							
>A>	AB	RICONPHARMA LLC	125MG	A204371	001	Jan 09, 2014	Dec	NEWA	
>A>	AB		250MG	A204371	002	Jan 09, 2014	Dec	NEWA	

GUANFACINE HYDROCHLORIDE

		TABLET;ORAL							
		GUANFACINE HYDROCHLORIDE							
>D>		@ EPIC PHARMA LLC	EQ 1MG BASE	A074673	001	Feb 28, 1997	Dec	CMFD	
>A>	AB		EQ 1MG BASE	A074673	001	Feb 28, 1997	Dec	CMFD	
		@	EQ 1MG BASE	A074673	001	Feb 28, 1997	Jun	DISC	
>D>		@	EQ 2MG BASE	A074673	002	Feb 28, 1997	Dec	CMFD	
>A>	AB		EQ 2MG BASE	A074673	002	Feb 28, 1997	Dec	CMFD	
		@	EQ 2MG BASE	A074673	002	Feb 28, 1997	Jun	DISC	

HALOBETASOL PROPIONATE

		OINTMENT;TOPICAL							
		HALOBETASOL PROPIONATE							
		@ FOUGERA PHARMS	0.05%	A076903	001	Dec 16, 2004	Apr	DISC	
		@ G AND W LABS INC	0.05%	A077109	001	Jun 14, 2005	Jun	CAHN	
		@ TARO	0.05%	A076994	001	Dec 16, 2004	Mar	DISC	

HALOPERIDOL DECANOATE

		INJECTABLE;INJECTION							
		HALOPERIDOL DECANOATE							
		@ AGILA SPECLTS	EQ 50MG BASE/ML	A075440	001	Feb 28, 2000	Aug	CAHN	
		@	EQ 100MG BASE/ML	A075440	002	Feb 28, 2000	Aug	CAHN	
		@ APOTEX INC	EQ 50MG BASE/ML	A075440	001	Feb 28, 2000	Apr	DISC	
		@	EQ 100MG BASE/ML	A075440	002	Feb 28, 2000	Apr	DISC	
AO		TEVA PHARMS USA	EQ 50MG BASE/ML	A075393	001	May 11, 1999	Jun	CAHN	
AO			EQ 100MG BASE/ML	A075393	002	May 11, 1999	Jun	CAHN	

HALOPERIDOL LACTATE

		INJECTABLE;INJECTION							
		HALOPERIDOL							
AP		AGILA SPECLTS	EQ 5MG BASE/ML	A078347	001	Sep 14, 2009	Nov	CAHN	
		@ APOTEX INC	EQ 5MG BASE/ML	A076791	001	Aug 25, 2004	Apr	DISC	
		@	EQ 5MG BASE/ML	A076828	001	Aug 25, 2004	Apr	DISC	
AP		TEVA PHARMS USA	EQ 5MG BASE/ML	A076035	001	Aug 29, 2001	Jun	CAHN	

HEPARIN SODIUM

		INJECTABLE;INJECTION							
		HEPARIN SODIUM							
AP	+	HIKMA MAPLE	1,000 UNITS/ML	N017037	001		Aug	CAHN	
AP	+		5,000 UNITS/ML	N017037	002		Aug	CAHN	
		@	5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Aug	CAHN	
AP	+		10,000 UNITS/ML	N017037	003		Aug	CAHN	

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

		TABLET;ORAL							
		HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE							
AA		NOVEL LABS INC	1.5MG;5MG	A091528	001	Apr 20, 2011	Sep	CTEC	
AA	+	KING PHARMS	1.5MG;5MG	A088508	001	Jul 30, 1985	Sep	CTEC	

HYALURONIDASE

		INJECTABLE;INJECTION							
		VITRASE							
	+	BAUSCH AND LOMB	200 UNITS/VIAL	N021640	002	Dec 02, 2004	May	CAHN	
		@	6,200 UNITS/VIAL	N021640	001	May 05, 2004	May	CAHN	



HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION  
HYDRALAZINE HYDROCHLORIDE

AP	NAVINTA LLC	20MG/ML	A202938	001	Mar 28, 2013	Mar	NEWA
TABLET; ORAL							
HYDRALAZINE HYDROCHLORIDE							
AA	ACTAVIS GRP PTC	10MG	A091679	001	Mar 04, 2013	Apr	CAHN
AA		25MG	A091679	002	Mar 04, 2013	Apr	CAHN
AA		50MG	A091679	003	Mar 04, 2013	Apr	CAHN
AA		100MG	A091679	004	Mar 04, 2013	Apr	CAHN
AA	ACTAVIS PHARMA	10MG	A091679	001	Mar 04, 2013	Feb	NEWA
AA		25MG	A091679	002	Mar 04, 2013	Feb	NEWA
AA		50MG	A091679	003	Mar 04, 2013	Feb	NEWA
AA		100MG	A091679	004	Mar 04, 2013	Feb	NEWA
AA	ALKEM LABS LTD	10MG	A200737	001	Dec 07, 2012	Apr	CTEC
AA		25MG	A200737	002	Dec 07, 2012	Apr	CTEC
AA		50MG	A200737	003	Dec 07, 2012	Apr	CTEC
AA		100MG	A200737	004	Dec 07, 2012	Apr	CTEC
AA	HETERO LABS LTD III	10MG	A040901	001	Sep 12, 2008	Apr	CAHN
AA		25MG	A040901	002	Sep 12, 2008	Apr	CAHN
AA		50MG	A040901	003	Sep 12, 2008	Apr	CAHN
AA		100MG	A040901	004	Sep 12, 2008	Apr	CAHN
AA	STRIDES ARCOLAB LTD	25MG	A200770	001	May 03, 2013	Apr	NEWA
AA		50MG	A200770	002	May 03, 2013	Apr	NEWA
AA		100MG	A200770	003	May 03, 2013	Apr	NEWA
	@ ZYDUS PHARMS USA	10MG	A040858	001	Feb 26, 2010	Jun	DISC
	@	25MG	A040858	002	Feb 26, 2010	Jun	DISC
	@	50MG	A040858	003	Feb 26, 2010	Jun	DISC
	@	100MG	A040858	004	Feb 26, 2010	Jun	DISC

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL  
HYDROCHLOROTHIAZIDE

>D>	AB	WEST WARD	12.5MG	A077885	001	Nov 26, 2007	Dec	DISC
>A>		@	12.5MG	A077885	001	Nov 26, 2007	Dec	DISC
TABLET; ORAL								
HYDROCHLOROTHIAZIDE								
		@ WATSON LABS	25MG	A081189	001	Jan 24, 1992	Mar	DISC
>D>	AB	WEST WARD	25MG	A084878	002	Jul 12, 2006	Dec	DISC
>A>		@	25MG	A084878	002	Jul 12, 2006	Dec	DISC

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL  
IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB	AUROBINDO PHARMA LTD	12.5MG; 150MG	A203630	001	Feb 22, 2013	Feb	NEWA
AB		12.5MG; 300MG	A203630	002	Feb 22, 2013	Feb	NEWA
AB	LUPIN LTD	12.5MG; 150MG	A201524	001	Feb 27, 2013	Feb	NEWA
AB		12.5MG; 300MG	A201524	002	Feb 27, 2013	Feb	NEWA

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL  
LISINAPRIL AND HYDROCHLOROTHIAZIDE

AB	HIKMA PHARMS LLC	12.5MG; 10MG	A076265	001	Jul 08, 2002	Oct	CAHN
AB		12.5MG; 20MG	A076265	002	Jul 08, 2002	Oct	CAHN
AB		25MG; 20MG	A076265	003	Jul 08, 2002	Oct	CAHN

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL  
HYZAAR

AB	MERCK SHARP DOHME	12.5MG; 50MG	N020387	001	Apr 28, 1995	Oct	CAHN
AB		12.5MG; 100MG	N020387	003	Oct 20, 2005	Oct	CAHN
AB	+	25MG; 100MG	N020387	002	Nov 10, 1998	Oct	CAHN
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE							
AB	IPCA LABS LTD	12.5MG; 50MG	A201682	001	Mar 01, 2013	Feb	NEWA
AB		12.5MG; 100MG	A201682	002	Mar 01, 2013	Feb	NEWA
AB		25MG; 100MG	A201682	003	Mar 01, 2013	Feb	NEWA

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC PHARMS LTD	25MG;50MG	A202870	001	Nov 06, 2013	Oct	NEWA
AB		25MG;100MG	A202870	002	Nov 06, 2013	Oct	NEWA
AB		50MG;100MG	A202870	003	Nov 06, 2013	Oct	NEWA

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

INDERIDE-40/25

AB	+ WYETH PHARMS INC	25MG;40MG	N018031	001		Jul	CAHN
	INDERIDE-80/25						
	@ WYETH PHARMS INC	25MG;80MG	N018031	002		Jul	CAHN
	PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE						
	@ WATSON LABS	25MG;40MG	A070301	001	Apr 18, 1986	Sep	DISC
	@	25MG;80MG	A070305	001	Apr 18, 1986	Sep	DISC

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	APOTEX CORP	12.5MG;EQ 10MG BASE	A091524	001	Mar 12, 2013	Mar	NEWA
AB		12.5MG;EQ 20MG BASE	A091524	002	Mar 12, 2013	Mar	NEWA
AB		25MG;EQ 20MG BASE	A091524	003	Mar 12, 2013	Mar	NEWA

HYDROCHLOROTHIAZIDE; TRIAMTERENE

TABLET; ORAL

MAXZIDE

AB	+ MYLAN PHARMS INC	50MG;75MG	N019129	001	Oct 22, 1984	May	CAHN
	MAXZIDE-25						
AB	MYLAN PHARMS INC	25MG;37.5MG	N019129	003	May 13, 1988	May	CAHN
	TRIAMTERENE AND HYDROCHLOROTHIAZIDE						
	@ WATSON LABS	50MG;75MG	A071969	001	Apr 17, 1988	Jan	DISC

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC LTD	12.5MG;80MG	A201662	001	Mar 21, 2013	Mar	NEWA
AB		12.5MG;160MG	A201662	002	Mar 21, 2013	Mar	NEWA
AB		12.5MG;320MG	A201662	003	Mar 21, 2013	Mar	NEWA
AB		25MG;160MG	A201662	004	Mar 21, 2013	Mar	NEWA
AB		25MG;320MG	A201662	005	Mar 21, 2013	Mar	NEWA
AB	APOTEX INC	12.5MG;80MG	A203026	001	Mar 21, 2013	Mar	NEWA
AB		12.5MG;160MG	A203026	002	Mar 21, 2013	Mar	NEWA
AB		12.5MG;320MG	A203026	003	Mar 21, 2013	Mar	NEWA
AB		25MG;160MG	A203026	004	Mar 21, 2013	Mar	NEWA
AB		25MG;320MG	A203026	005	Mar 21, 2013	Mar	NEWA
AB	AUROBINDO PHARMA LTD	12.5MG;80MG	A202519	001	Mar 21, 2013	Mar	NEWA
AB		12.5MG;160MG	A202519	002	Mar 21, 2013	Mar	NEWA
AB		12.5MG;320MG	A202519	003	Mar 21, 2013	Mar	NEWA
AB		25MG;160MG	A202519	004	Mar 21, 2013	Mar	NEWA
AB		25MG;320MG	A202519	005	Mar 21, 2013	Mar	NEWA
AB	LUPIN LTD	12.5MG;80MG	A078946	003	Mar 21, 2013	Mar	NEWA
AB		12.5MG;160MG	A078946	004	Mar 21, 2013	Mar	NEWA
AB		12.5MG;320MG	A078946	001	Mar 21, 2013	Mar	NEWA
AB		25MG;160MG	A078946	005	Mar 21, 2013	Mar	NEWA
AB		25MG;320MG	A078946	002	Mar 21, 2013	Mar	NEWA
AB	MACLEODS PHARMS LTD	12.5MG;80MG	A203145	001	Apr 19, 2013	Apr	NEWA
AB		12.5MG;160MG	A203145	002	Apr 19, 2013	Apr	NEWA
AB		12.5MG;320MG	A203145	003	Apr 19, 2013	Apr	NEWA
AB		25MG;160MG	A203145	004	Apr 19, 2013	Apr	NEWA
AB		25MG;320MG	A203145	005	Apr 19, 2013	Apr	NEWA
AB	WATSON LABS INC	12.5MG;80MG	A091519	001	Mar 21, 2013	Mar	NEWA
AB		12.5MG;160MG	A091519	002	Mar 21, 2013	Mar	NEWA
AB		12.5MG;320MG	A091519	003	Mar 21, 2013	Mar	NEWA
AB		25MG;160MG	A091519	004	Mar 21, 2013	Mar	NEWA
AB		25MG;320MG	A091519	005	Mar 21, 2013	Mar	NEWA

HYDROCODONE BITARTRATECAPSULE, EXTENDED RELEASE;ORAL  
ZOHYDRO ER

+	ZOGENIX INC	10MG	N202880	001	Oct 25, 2013	Oct	NEWA
		15MG	N202880	002	Oct 25, 2013	Oct	NEWA
		20MG	N202880	003	Oct 25, 2013	Oct	NEWA
		30MG	N202880	004	Oct 25, 2013	Oct	NEWA
		40MG	N202880	005	Oct 25, 2013	Oct	NEWA
		50MG	N202880	006	Oct 25, 2013	Oct	NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

AB	SUN PHARM INDS INC	2.5MG;200MG	A091633	001	May 28, 2013	May	NEWA
AB		5MG;200MG	A091633	002	May 28, 2013	May	NEWA
AB		7.5MG;200MG	A091633	003	May 28, 2013	May	NEWA
AB		10MG;200MG	A091633	004	May 28, 2013	May	NEWA
	REPRESXAIN						
AB	AMNEAL PHARMS NY	2.5MG;200MG	A076642	003	Oct 19, 2007	May	CFTG
AB		10MG;200MG	A076642	004	Oct 19, 2007	May	CFTG

HYDROCORTISONE

LOTION;TOPICAL

STIE-CORT

@ PERRIGO CO

1%

A089066 001 Nov 25, 1985 Feb DISC

OINTMENT;TOPICAL

HYDROCORTISONE

@ TARO

2.5%

A040310 001 Dec 29, 2000 Mar DISC

TABLET;ORAL

HYDROCORTISONE

&gt;D&gt; BP

WEST WARD

20MG

A083365 001 Dec DISC

&gt;A&gt;

@

20MG

A083365 001 Dec DISC

HYDROCORTISONE ACETATE

CREAM;TOPICAL

MICORT-HC

+ SEBELA IRELAND LTD

2%

A040398 001 Mar 29, 2002 Nov CAHN

2.5%

A040396 001 Feb 27, 2001 Nov CAHN

PASTE;TOPICAL

ORABASE HCA

@ COLGATE

0.5%

A083205 001 Mar DISC

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

CREAM;TOPICAL

PRAMOSONE

SEBELA IRELAND LTD

0.5%;1%

A083778 001 Nov CAHN

1%;1%

A085368 001 Nov CAHN

LOTION;TOPICAL

PRAMOSONE

SEBELA IRELAND LTD

1%;1%

A085980 001 Nov CAHN

2.5%;1%

A085979 001 Nov CAHN

HYDROCORTISONE ACETATE; UREA

CREAM;TOPICAL

CARMOL HC

@ FOUGERA PHARMS

1%;10%

A080505 001 Aug DISC

U-CORT

TARO

1%;10%

A089472 001 Jun 13, 1988 Aug CTEC

HYDROCORTISONE BUTYRATE

CREAM;TOPICAL

HYDROCORTISONE BUTYRATE

AB GLENMARK GENERICS

0.1%

A202145 001 Sep 27, 2013 Sep NEWA

LOCOID LIPOCREAM

AB + PRECISION DERMAT

0.1%

N020769 001 Sep 08, 1997 Sep CTEC

HYDROCORTISONE VALERATE

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

@	FOUGERA PHARMS	0.2%	A075085	001	Jul 31, 2001	Feb	DISC
+	TARO	0.2%	A075043	001	Aug 25, 1998	Feb	CRLD

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OTIC

CORTISPORIN

AT	+	CITRON PHARMA LLC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A060613	001		Nov	CAHN
----	---	-------------------	-------------------------------------	---------	-----	--	-----	------

HYDROMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

EXALGO

		MALLINCKRODT INC	16MG	N021217	003	Mar 01, 2010	Jan	CRLD
	+		32MG	N021217	004	Aug 24, 2012	Jan	CRLD

HYDROXYUREA

CAPSULE; ORAL

HYDROXYUREA

@	BARR LABS INC	250MG	A075020	002	Jun 26, 2000	Jun	CAHN
@		500MG	A075020	001	Jul 30, 1998	Jun	CAHN

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

AA		SILARX PHARMS INC	10MG/5ML	A201674	001	Aug 21, 2013	Jul	NEWA
----	--	-------------------	----------	---------	-----	--------------	-----	------

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

AB		CARACO	10MG	A040899	001	Jun 10, 2008	Jun	CAHN
AB			25MG	A040899	002	Jun 10, 2008	Jun	CAHN
AB			50MG	A040899	003	Jun 10, 2008	Jun	CAHN
AB		HETERO LABS LTD III	10MG	A040805	001	May 29, 2008	Apr	CAHN
AB			25MG	A040805	002	May 29, 2008	Apr	CAHN
AB			50MG	A040805	003	May 29, 2008	Apr	CAHN

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

AB		EMCURE PHARMS USA	25MG	A201507	001	Jun 03, 2013	May	NEWA
AB			50MG	A201507	002	Jun 03, 2013	May	NEWA

IBRUTINIB

CAPSULE; ORAL

IMBRUVICA

+	PHARMACYCLICS INC	140MG	N205552	001	Nov 13, 2013	Nov	NEWA
---	-------------------	-------	---------	-----	--------------	-----	------

IBUPROFEN

SOLUTION; INTRAVENOUS

CALDOLOR

@	CUMBERLAND PHARMS	400MG/4ML (100MG/ML)	N022348	001	Jun 11, 2009	May	DISC
---	-------------------	----------------------	---------	-----	--------------	-----	------

IBUPROFEN LYISINE

INJECTABLE; INTRAVENOUS

NEOPROFEN

+	RECORDATI RARE	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903	001	Apr 13, 2006	May	CAHN
---	----------------	------------------------------------	---------	-----	--------------	-----	------

ICOSAPENT ETHYL

CAPSULE; ORAL

VASCEPA

+	AMARIN PHARMS	1GM	N202057	001	Jul 26, 2012	Jun	NEWA
---	---------------	-----	---------	-----	--------------	-----	------

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE PFS

AP		TEVA PHARMS USA	1MG/ML	A065036	001	May 01, 2002	Apr	CAHN
----	--	-----------------	--------	---------	-----	--------------	-----	------

IFOSFAMIDEINJECTABLE; INJECTION  
IFOSFAMIDE

AP	+	TEVA PHARMS USA	1GM/20ML (50MG/ML)	A 076657	001	Apr 04, 2007	May	CAHN
AP	+		3GM/60ML (50MG/ML)	A 076657	002	Apr 04, 2007	May	CAHN

IFOSFAMIDE; MESNAINJECTABLE; INTRAVENOUS  
IFOSFAMIDE/MESNA KIT

+	TEVA PHARMS USA	1GM/20ML; 1GM/10ML (50MG/ML; 100MG/ML)	A 075874	001	Feb 26, 2002	May	CAHN
+		3GM/60ML; 1GM/10ML (50MG/ML; 100MG/ML)	A 075874	002	Feb 26, 2002	May	CAHN

IMIPRAMINE HYDROCHLORIDETABLET; ORAL  
IMIPRAMINE HYDROCHLORIDE

@	PROSAM LABS	10MG	A 040753	001	Feb 28, 2008	Mar	DISC
@		25MG	A 040752	001	Feb 28, 2008	Mar	DISC
@		50MG	A 040751	001	Feb 28, 2008	Mar	DISC

IMIPRAMINE PAMOATECAPSULE; ORAL  
IMIPRAMINE PAMOATE

AB	MYLAN PHARMS INC	EQ 75MG HCL	A 202338	001	Jun 28, 2013	Jun	NEWA
AB		EQ 100MG HCL	A 202338	002	Jun 28, 2013	Jun	NEWA
AB		EQ 125MG HCL	A 202338	003	Jun 28, 2013	Jun	NEWA
AB		EQ 150MG HCL	A 202338	004	Jun 28, 2013	Jun	NEWA

INDINAVIR SULFATECAPSULE; ORAL  
CRIXIVAN

@	MERCK SHARP DOHME	EQ 100MG BASE	N 020685	006	Apr 19, 2000	Jun	DISC
---	-------------------	---------------	----------	-----	--------------	-----	------

INDOMETHACINCAPSULE; ORAL  
INDOCIN

@	ICEUTICA OPERATIONS	25MG	N 016059	001		Mar	CAHN
@		50MG	N 016059	002		Mar	CAHN

INDOMETHACIN

AB	CARACO	25MG	A 091401	001	Mar 28, 2013	Jun	CAHN
AB		50MG	A 091401	002	Mar 28, 2013	Jun	CAHN
AB	HETERO LABS LTD III	25MG	A 091240	001	Apr 12, 2011	Apr	CAHN
AB		50MG	A 091240	002	Apr 12, 2011	Apr	CAHN
AB	SUN PHARM INDS INC	25MG	A 091401	001	Mar 28, 2013	Mar	NEWA
AB		50MG	A 091401	002	Mar 28, 2013	Mar	NEWA

CAPSULE, EXTENDED RELEASE; ORAL  
INDOMETHACIN

AB	WATSON LABS INC	75MG	A 202572	001	Dec 09, 2013	Nov	NEWA
----	-----------------	------	----------	-----	--------------	-----	------

INDOMETHACIN SODIUMINJECTABLE; INJECTION  
INDOCIN

AP	+	RECORDATI RARE	EQ 1MG BASE/VIAL	N 018878	001	Jan 30, 1985	May	CAHN
----	---	----------------	------------------	----------	-----	--------------	-----	------

INSULIN GLARGINE RECOMBINANTINJECTABLE; INJECTION  
LANTUS SOLOSTAR

+	SANOFI AVENTIS US	300 UNITS/3ML (100 UNITS/ML)	N 021081	002	Apr 27, 2007	Aug	NEWA
---	-------------------	------------------------------	----------	-----	--------------	-----	------

IPRATROPIUM BROMIDESOLUTION; INHALATION  
IPRATROPIUM BROMIDE

@	APOTEX INC	0.02%	A 075441	001	Mar 28, 2001	Apr	DISC
@	TEVA PHARMS USA	0.02%	A 075313	001	Feb 07, 2000	Mar	DISC

SPRAY, METERED; NASAL  
IPRATROPIUM BROMIDE

@	APOTEX INC	0.021MG/SPRAY	A 076156	001	Apr 18, 2003	Apr	DISC
@		0.042MG/SPRAY	A 076155	001	Apr 18, 2003	Apr	DISC

IRINOTECAN HYDROCHLORIDE

		INJECTABLE; INJECTION					
		IRINOTECAN HYDROCHLORIDE					
AP	TEVA PHARMS USA	40MG/2ML (20MG/ML)	A 090101	002	Feb 27, 2008	Sep	CAHN
AP		100MG/5ML (20MG/ML)	A 090101	003	Feb 27, 2008	Sep	CAHN
AP		500MG/25ML (20MG/ML)	A 090101	001	Nov 26, 2008	Sep	CAHN

IRON SUCROSE

		INJECTABLE; INTRAVENOUS					
		VENOFER					
		@ LUITPOLD					
		EQ 65MG BASE/3.25ML (EQ 20MG BASE/ML)	N 021135	005	Mar 29, 2013	Sep	DISC
		EQ 65MG BASE/3.25ML (EQ 20MG BASE/ML)	N 021135	005	Mar 29, 2013	Mar	NEWA

ISONIAZID

		TABLET; ORAL					
		ISONIAZID					
		@ MIKART					
		100MG	A 040090	001	Jun 26, 1997	Aug	DISC
		300MG	A 040090	002	Jun 26, 1997	Aug	DISC
		@ WATSON LABS					
		300MG	A 080521	001		Jun	DISC
>D>	AA	WEST WARD	A 080212	001		Dec	DISC
>A>		@	A 080212	001		Dec	DISC
>D>	AA		A 087425	001		Dec	DISC
>A>		@	A 087425	001		Dec	DISC
		LANIAZID					
AA	LANNETT	300MG	A 089776	001	Jun 13, 1988	Nov	CMFD

ISONIAZID; RIFAMPIN

		CAPSULE; ORAL					
		RIFAMATE					
	+	SANOFI AVENTIS US	150MG; 300MG	A 061884	001		Apr
		RIFAMPIN AND ISONIAZID					
		@ WEST WARD PHARM CORP	150MG; 300MG	A 065221	001	Jul 29, 2005	Apr
							DISC

ISOPROTERENOL HYDROCHLORIDE

		INJECTABLE; INJECTION					
		ISOPROTERENOL HYDROCHLORIDE					
		@ INTL MEDICATION					
		0.2MG/ML	A 083724	001		Mar	DISC
		ISUPREL					
	+	HOSPIRA	0.2MG/ML	N 010515	001		Mar
							CTEC

ISOSORBIDE DINITRATE

		CAPSULE, EXTENDED RELEASE; ORAL					
		DILATRATE-SR					
	+	ACTIENT PHARMS	40MG	N 019790	001	Sep 02, 1988	May
		TABLET; ORAL					
		ISORDIL					
AB		VALEANT BERMUDA	5MG	N 012093	007	Jul 29, 1988	Apr
AB			10MG	N 012093	002	Jul 29, 1988	Apr
AB			20MG	N 012093	006	Jul 29, 1988	Apr
AB	+		30MG	N 012093	005	Jul 29, 1988	Apr
AB	+		40MG	N 012093	001	Jul 29, 1988	Apr
AB		VALEANT PHARM NORTH	5MG	N 012093	007	Jul 29, 1988	Mar
AB			10MG	N 012093	002	Jul 29, 1988	Mar
AB			20MG	N 012093	006	Jul 29, 1988	Mar
AB	+		30MG	N 012093	005	Jul 29, 1988	Mar
AB	+		40MG	N 012093	001	Jul 29, 1988	Mar
		ISOSORBIDE DINITRATE					
AB		PAR PHARM	5MG	A 086923	001	Mar 12, 1987	Apr
		@	5MG	A 086923	001	Mar 12, 1987	Feb
		@ WATSON LABS	5MG	A 086034	001	Jan 06, 1988	Apr
		@	10MG	A 086032	001	Jan 07, 1988	Apr
		TABLET; SUBLINGUAL					
		ISOSORBIDE DINITRATE					
		@ WEST WARD	2.5MG	A 086054	001	Oct 29, 1987	Aug
		@ WEST WARD PHARM CORP	5MG	A 086055	001	Nov 02, 1987	Aug
AB	+		5MG	A 086055	001	Nov 02, 1987	Jun
							CRLD

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE;ORAL  
ISOSORBIDE MONONITRATE

AB	HIKMA PHARMS	30MG	A 076813	002	Mar 30, 2006	Oct	CAHN
AB		60MG	A 076813	001	Jan 07, 2005	Oct	CAHN

ISOTRETINOIN

CAPSULE;ORAL  
ABSORICA

BX	RANBAXY	10MG	N 021951	001	May 25, 2012	Feb	CAHN
BX		20MG	N 021951	002	May 25, 2012	Feb	CAHN
BX		30MG	N 021951	003	May 25, 2012	Feb	CAHN
BX	+	40MG	N 021951	004	May 25, 2012	Aug	CRLD
BX		40MG	N 021951	004	May 25, 2012	Feb	CAHN
AMNESTEEM							
AB	MYLAN PHARMS INC	20MG	A 075945	002	Nov 08, 2002	Apr	CRLD
CLARAVIS							
AB	TEVA PHARMS USA	10MG	A 076356	001	Apr 11, 2003	May	CAHN
AB		30MG	A 076135	003	May 11, 2006	Apr	CRLD
AB	+	40MG	A 076135	001	Apr 11, 2003	Apr	CRLD
ZENATANE							
AB	DR REDDYS LABS LTD	10MG	A 202099	001	Mar 25, 2013	Mar	NEWA
AB		20MG	A 202099	002	Mar 25, 2013	Mar	NEWA
AB		40MG	A 202099	003	Mar 25, 2013	Mar	NEWA

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION  
KETOROLAC TROMETHAMINE

AP	AGILA SPECLTS	15MG/ML	A 078299	001	Jul 16, 2007	Nov	CAHN
AP		30MG/ML	A 078299	002	Jul 16, 2007	Nov	CAHN
	@ APOTEX INC	15MG/ML	A 075631	002	Jun 29, 2001	Apr	DISC
	@	30MG/ML	A 075626	001	Jul 24, 2001	Apr	DISC
	@	30MG/ML	A 075631	001	Jun 29, 2001	Apr	DISC
	@	30MG/ML	A 077201	001	Oct 14, 2005	Apr	DISC
	@ LUITPOLD	15MG/ML	A 078145	001	Jan 14, 2008	Jun	DISC
	@	30MG/ML	A 078145	002	Jan 14, 2008	Jun	DISC
AP	SAGENT PHARMS	15MG/ML	A 091065	001	Nov 27, 2013	Nov	NEWA
AP		30MG/ML	A 091065	002	Nov 27, 2013	Nov	NEWA

SOLUTION/DROPS;OPHTHALMIC  
ACULAR PRESERVATIVE FREE

@ ALLERGAN	0.5%	N 020811	001	Nov 03, 1997	May	DISC
------------	------	----------	-----	--------------	-----	------

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION  
LABETALOL HYDROCHLORIDE

AP	AKORN INC	5MG/ML	A 075431	001	Nov 29, 1999	Jul	CAHN
AP		5MG/ML	A 075524	001	Nov 29, 1999	Jul	CAHN
	@ APOTEX INC	5MG/ML	A 076051	001	Jul 05, 2002	Apr	DISC

TABLET;ORAL  
LABETALOL HYDROCHLORIDE

AB	+	SANDOZ	200MG	A 075113	002	Aug 04, 1998	Jan	CRLD
TRANDATE								
	@	PROMETHEUS LABS	100MG	N 018716	001	May 24, 1985	Jan	DISC
	@		200MG	N 018716	002	Aug 01, 1984	Jan	DISC

LACTULOSE

SOLUTION;ORAL  
LACTULOSE

@ APOTEX INC	10GM/15ML	A 075911	001	Feb 21, 2002	Apr	DISC
--------------	-----------	----------	-----	--------------	-----	------

SOLUTION;ORAL, RECTAL  
LACTULOSE

@ APOTEX INC	10GM/15ML	A 076645	001	Jul 28, 2003	Apr	DISC
--------------	-----------	----------	-----	--------------	-----	------

LAMIVUDINE

TABLET;ORAL  
EPIVIR-HBV

>D>	+	GLAXOSMITHKLINE	100MG	N 021003	001	Dec 08, 1998	Dec	CFTG
>A>	AB	+	100MG	N 021003	001	Dec 08, 1998	Dec	CFTG
LAMIVUDINE								
>A>	AB	APOTEX INC	100MG	A 202941	001	Jan 02, 2014	Dec	NEWA
>A>	AB	HETERO LABS LTD V	100MG	A 203260	001	Jan 02, 2014	Dec	NEWA

TABLET;ORAL  
LAMIVUDINE

>A>	AB		150MG		A203277	001	Jan 06, 2014	Dec	NEWA
>A>	AB		300MG		A203277	002	Jan 06, 2014	Dec	NEWA

LAMOTRIGINE

TABLET;ORAL  
LAMICTAL

AB	+	GLAXOSMITHKLINE LLC	25MG		N020241	005	Dec 27, 1994	Mar	CAHN
		@	50MG		N020241	006	Dec 27, 1994	Mar	CAHN
AB			100MG		N020241	001	Dec 27, 1994	Mar	CAHN
AB			150MG		N020241	002	Dec 27, 1994	Mar	CAHN
AB			200MG		N020241	003	Dec 27, 1994	Mar	CAHN
		@	250MG		N020241	004	Dec 27, 1994	Mar	CAHN

LAMOTRIGINE

AB		ALKEM LABS LTD	25MG		A200694	001	Jun 14, 2013	Jun	NEWA
AB			100MG		A200694	002	Jun 14, 2013	Jun	NEWA
AB			150MG		A200694	003	Jun 14, 2013	Jun	NEWA
AB			200MG		A200694	004	Jun 14, 2013	Jun	NEWA
AB		CIPLA LTD	25MG		A077783	001	Nov 01, 2010	Aug	CAHN
AB			100MG		A077783	002	Nov 01, 2010	Aug	CAHN
AB			150MG		A077783	003	Nov 01, 2010	Aug	CAHN
AB			200MG		A077783	004	Nov 01, 2010	Aug	CAHN
>D>	AB	SANDOZ	25MG		A078645	001	Jan 27, 2009	Dec	DISC
>A>		@	25MG		A078645	001	Jan 27, 2009	Dec	DISC
>D>	AB		100MG		A078645	002	Jan 27, 2009	Dec	DISC
>A>		@	100MG		A078645	002	Jan 27, 2009	Dec	DISC
>D>	AB		150MG		A078645	003	Jan 27, 2009	Dec	DISC
>A>		@	150MG		A078645	003	Jan 27, 2009	Dec	DISC
>D>	AB		200MG		A078645	004	Jan 27, 2009	Dec	DISC
>A>		@	200MG		A078645	004	Jan 27, 2009	Dec	DISC

TABLET, CHEWABLE;ORAL  
LAMICTAL CD

AB		GLAXOSMITHKLINE LLC	2MG		N020764	004	Sep 08, 2000	Mar	CAHN
AB			5MG		N020764	001	Aug 24, 1998	Mar	CAHN
AB	+		25MG		N020764	002	Aug 24, 1998	Mar	CAHN
		@	100MG		N020764	003	Aug 24, 1998	Mar	CAHN

TABLET, EXTENDED RELEASE;ORAL  
LAMICTAL XR

AB		GLAXOSMITHKLINE LLC	25MG		N022115	001	May 29, 2009	Mar	CAHN
AB	+		50MG		N022115	002	May 29, 2009	Mar	CAHN
AB			100MG		N022115	003	May 29, 2009	Mar	CAHN
AB			200MG		N022115	004	May 29, 2009	Mar	CAHN
AB			250MG		N022115	006	Jun 21, 2011	Mar	CAHN
AB			300MG		N022115	005	Apr 14, 2010	Mar	CAHN

LAMOTRIGINE

AB		ACTAVIS ELIZABETH	100MG		A200672	003	Oct 17, 2013	Sep	NEWA
AB			200MG		A200672	004	Oct 17, 2013	Sep	NEWA
AB			25MG		A200672	001	Oct 17, 2013	Sep	NEWA
AB			50MG		A200672	002	Oct 17, 2013	Sep	NEWA
AB			250MG		A203733	001	Nov 13, 2013	Oct	NEWA
AB			300MG		A200672	005	Oct 17, 2013	Sep	NEWA
AB		DR REDDYS LABS LTD	25MG		A202383	001	Jun 19, 2013	Jun	NEWA
AB			50MG		A202383	002	Jun 19, 2013	Jun	NEWA
AB			100MG		A202383	003	Jun 19, 2013	Jun	NEWA
AB			200MG		A202383	004	Jun 19, 2013	Jun	NEWA
AB			300MG		A202383	005	Jun 19, 2013	Jun	NEWA
AB		PAR PHARM	25MG		A201791	001	Jan 18, 2013	Jan	NEWA
AB			50MG		A201791	002	Jan 18, 2013	Jan	NEWA
AB			100MG		A201791	003	Jan 18, 2013	Jan	NEWA
AB			200MG		A201791	004	Jan 18, 2013	Jan	NEWA
AB			250MG		A201791	005	Jan 18, 2013	Jan	NEWA
AB			300MG		A201791	006	Jan 18, 2013	Jan	NEWA
>A>	AB	TORRENT PHARMS LTD	25MG		A203370	001	Dec 23, 2013	Dec	NEWA
>A>	AB		50MG		A203370	002	Dec 23, 2013	Dec	NEWA
>A>	AB		100MG		A203370	003	Dec 23, 2013	Dec	NEWA
>A>	AB		200MG		A203370	004	Dec 23, 2013	Dec	NEWA
AB		WILSHIRE PHARMS INC	25MG		A202887	001	Jun 17, 2013	Jun	NEWA
AB			50MG		A202887	002	Jun 17, 2013	Jun	NEWA
AB			100MG		A202887	003	Jun 17, 2013	Jun	NEWA
AB			200MG		A202887	004	Jun 17, 2013	Jun	NEWA



TABLET, ORALLY DISINTEGRATING;ORAL							
LAMICTAL ODT							
AB	GLAXOSMITHKLINE LLC	25MG	N022251	001	May 08, 2009	Jul	CFTG
		25MG	N022251	001	May 08, 2009	Mar	CAHN
AB	+	50MG	N022251	002	May 08, 2009	Jul	CFTG
	+	50MG	N022251	002	May 08, 2009	Mar	CAHN
AB		100MG	N022251	003	May 08, 2009	Jul	CFTG
		100MG	N022251	003	May 08, 2009	Mar	CAHN
AB		200MG	N022251	004	May 08, 2009	Jul	CFTG
		200MG	N022251	004	May 08, 2009	Mar	CAHN
LAMOTRIGINE							
AB	WATSON LABS INC	25MG	A200828	001	Jul 15, 2013	Jul	NEWA
AB		50MG	A200828	002	Jul 15, 2013	Jul	NEWA
AB		100MG	A200828	003	Jul 15, 2013	Jul	NEWA
AB		200MG	A200828	004	Jul 15, 2013	Jul	NEWA
<u>LANSOPRAZOLE</u>							
CAPSULE, DELAYED REL PELLETS;ORAL							
LANSOPRAZOLE							
AB	SUN PHARMA GLOBAL	15MG	A202637	001	Sep 13, 2013	Aug	NEWA
AB		30MG	A091509	001	Sep 13, 2013	Aug	NEWA
AB	ZYDUS HLTHCARE	15MG	A202366	001	Aug 19, 2013	Jul	NEWA
AB		30MG	A202366	002	Aug 19, 2013	Jul	NEWA
LANSOPRAZOLE							
AB	KRKA TOVARNA ZDRAVIL	15MG	A091212	001	Sep 16, 2013	Aug	NEWA
AB		30MG	A091212	002	Sep 16, 2013	Aug	NEWA
<u>LATANOPROST</u>							
SOLUTION/DROPS;OPHTHALMIC							
LATANOPROST							
	@ APOTEX INC	0.005%	A077697	001	Mar 22, 2011	Apr	DISC
AT	DR REDDYS LABS LTD	0.005%	A202077	001	Feb 11, 2013	Jan	NEWA
<u>LENALIDOMIDE</u>							
CAPSULE;ORAL							
REVLIMID							
	CELGENE	20MG	N021880	006	Jun 05, 2013	Jun	NEWA
<u>LEPIRUDIN RECOMBINANT</u>							
INJECTABLE;INJECTION							
REFLUDAN							
	@ BAYER HLTHCARE	50MG/VIAL	N020807	001	Mar 06, 1998	Jun	DISC
<u>LETROZOLE</u>							
TABLET;ORAL							
LETROZOLE							
AB	JIANGSU HENGRUI MED	2.5MG	A202716	001	May 16, 2013	Apr	NEWA
<u>LEUCOVORIN CALCIUM</u>							
INJECTABLE;INJECTION							
LEUCOVORIN CALCIUM							
AP	TEVA PHARMS USA	EQ 100MG BASE/VIAL	A081277	001	Sep 28, 1993	Mar	CAHN
AP		EQ 350MG BASE/VIAL	A040174	001	Jun 12, 1997	Mar	CAHN
LEUCOVORIN CALCIUM PRESERVATIVE FREE							
	@ LUITPOLD	EQ 50MG BASE/VIAL	A040338	001	Jan 31, 2001	Jun	DISC
<u>LEUPROLIDE ACETATE</u>							
INJECTABLE;INJECTION							
LEUPROLIDE ACETATE							
AP	TEVA PHARMS USA	1MG/0.2ML	A075471	001	Oct 25, 2000	Mar	CAHN
LUPRON							
	@ ABBVIE ENDOCRINE INC	1MG/0.2ML	N019010	001	Apr 09, 1985	Jul	CAHN
LUPRON DEPOT							
+	ABBVIE ENDOCRINE INC	3.75MG/VIAL	N020011	001	Oct 22, 1990	Apr	CAHN
+		7.5MG/VIAL	N019732	001	Jan 26, 1989	Jul	CAHN
+		11.25MG/VIAL	N020708	001	Mar 07, 1997	Jul	CAHN
+		22.5MG/VIAL	N020517	001	Dec 22, 1995	Jul	CAHN
+		30MG/VIAL	N020517	002	May 30, 1997	Jul	CAHN
+		45MG/VIAL	N020517	003	Jun 17, 2011	Jul	CAHN
LUPRON DEPOT-PED							
	@ ABBVIE ENDOCRINE INC	3.75MG/VIAL, 7.5MG/VIAL	N020263	003	Apr 16, 1993	Jul	CAHN
	@	7.5MG/VIAL, 7.5MG/VIAL	N020263	004	Apr 16, 1993	Jul	CAHN

INJECTABLE; INJECTION

LUPRON DEPOT-PED

+		7.5MG/VIAL	N020263	002	Apr 16, 1993	Jul CAHN
+		11.25MG/VIAL	N020263	005	Jan 21, 1994	Jul CAHN
+		11.25MG/VIAL	N020263	007	Aug 15, 2011	Jul CAHN
+		15MG/VIAL	N020263	006	Jan 21, 1994	Jul CAHN
+		30MG/VIAL	N020263	008	Aug 15, 2011	Jul CAHN

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

>A>	AN	CIPLA LTD	EQ 0.021% BASE	A078171	002	Dec 13, 2013	Dec NEWA
>A>	AN		EQ 0.042% BASE	A078171	003	Dec 13, 2013	Dec NEWA
>A>	AN		EQ 0.0103% BASE	A078171	001	Dec 13, 2013	Dec NEWA
	AN	DEY	EQ 0.0103% BASE	A077800	001	Mar 15, 2013	Mar NEWA
	AN		EQ 0.021% BASE	A077800	002	Mar 15, 2013	Mar NEWA
	AN		EQ 0.042% BASE	A077800	003	Mar 15, 2013	Mar NEWA
>D>	AN		EQ 0.25% BASE	A078309	001	Mar 20, 2009	Dec CAHN
>A>	AN	MYLAN SPECLT	EQ 0.25% BASE	A078309	001	Mar 20, 2009	Dec CAHN
	AN	TEVA PHARMS USA	EQ 0.0103% BASE	A090297	001	Apr 26, 2013	Apr NEWA
	AN		EQ 0.021% BASE	A090297	002	Apr 26, 2013	Apr NEWA
	AN		EQ 0.042% BASE	A090297	003	Apr 26, 2013	Apr NEWA

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

AP		SAGENT PHARMS	500MG/5ML (100MG/ML)	A091627	001	Jun 26, 2013	Jun NEWA
----	--	---------------	----------------------	---------	-----	--------------	----------

SOLUTION; ORAL

LEVETIRACETAM

		@ APOTEX INC	100MG/ML	A090187	001	Aug 05, 2011	Apr DISC
AA		BRECKENRIDGE PHARM	100MG/ML	A079120	001	Jan 16, 2009	Sep CAHN
AA		HETERO DRUGS LTD	100MG/ML	A203052	001	Feb 28, 2013	Feb NEWA
AA		HETERO LABS LTD III	100MG/ML	A203052	001	Feb 28, 2013	Apr CAHN
AA		ORIT LABS LLC	100MG/ML	A203067	001	May 09, 2013	Apr NEWA

TABLET; ORAL

LEVETIRACETAM

AB		HETERO LABS LTD III	1GM	A090515	004	Oct 08, 2010	Apr CAHN
AB			250MG	A090515	001	Oct 08, 2010	Apr CAHN
AB			500MG	A090515	002	Oct 08, 2010	Apr CAHN
AB			750MG	A090515	003	Oct 08, 2010	Apr CAHN
AB		PRINSTON INC	1GM	A078106	004	Feb 10, 2009	Apr CAHN
AB			250MG	A078106	001	Feb 10, 2009	Apr CAHN
AB			500MG	A078106	002	Feb 10, 2009	Apr CAHN
AB			750MG	A078106	003	Feb 10, 2009	Apr CAHN

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

		@ SANDOZ	500MG	A091668	001	Nov 01, 2012	Mar DISC
		@	750MG	A091668	002	Nov 01, 2012	Mar DISC
AB		SUN PHARMA GLOBAL	500MG	A203059	001	Sep 09, 2013	Aug NEWA
AB			750MG	A203059	002	Sep 09, 2013	Aug NEWA
AB		VINTAGE PHARMS LLC	500MG	A202533	001	Jul 20, 2012	Jan NEWA
AB			750MG	A202533	002	Jul 20, 2012	Jan NEWA

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

LEVOBUNOLOL HYDROCHLORIDE

		@ APOTEX INC	0.25%	A075473	001	Aug 03, 2000	Apr DISC
		@	0.5%	A075475	001	Aug 03, 2000	Apr DISC

LEVOCARNITINE

INJECTABLE; INJECTION

LEVOCARNITINE

AP		TEVA PHARMS USA	200MG/ML	A075881	001	Mar 29, 2001	May CAHN
----	--	-----------------	----------	---------	-----	--------------	----------

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AA		TARO PHARM INDS	2.5MG/5ML	A202673	001	Jul 26, 2013	Jul NEWA
----	--	-----------------	-----------	---------	-----	--------------	----------

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB		MICRO LABS LTD INDIA	5MG	A202046	001	Sep 17, 2013	Aug NEWA
AB		SANDOZ	5MG	A090486	001	Mar 26, 2013	Mar NEWA

## TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE  
AB SUN PHARMA GLOBAL 5MG A090362 001 Jan 31, 2013 Jan NEWA

LEVOFLOXACIN

## INJECTABLE; INJECTION

>D> LEVOFLOXACIN  
>D> AP AKORN EQ 500MG/20ML (EQ 25MG/ML) A091644 001 Jun 20, 2011 Dec DISC  
>A> @ EQ 500MG/20ML (EQ 25MG/ML) A091644 001 Jun 20, 2011 Dec DISC  
>D> AP EQ 750MG/30ML (EQ 25MG/ML) A091644 002 Jun 20, 2011 Dec DISC  
>A> @ EQ 750MG/30ML (EQ 25MG/ML) A091644 002 Jun 20, 2011 Dec DISC  
AP AUROBINDO PHARMA LTD EQ 500MG/20ML (EQ 25MG/ML) A202328 001 Jan 24, 2013 Jan NEWA  
AP EQ 750MG/30ML (EQ 25MG/ML) A202328 002 Jan 24, 2013 Jan NEWA  
AP CLARIS LIFESCIENCES EQ 500MG/20ML (EQ 25MG/ML) A091436 001 Jun 05, 2013 May NEWA  
AP EMCURE PHARMS LTD EQ 500MG/20ML (EQ 25MG/ML) A202590 001 Jan 24, 2013 Jan NEWA  
AP EQ 750MG/30ML (EQ 25MG/ML) A202590 002 Jan 24, 2013 Jan NEWA

## LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP CLARIS LIFESCIENCES EQ 250MG/50ML (EQ 5MG/ML) A091397 001 Aug 08, 2013 Jul NEWA  
AP EQ 500MG/100ML (EQ 5MG/ML) A091397 002 Aug 08, 2013 Jul NEWA  
AP EQ 750MG/150ML (EQ 5MG/ML) A091397 003 Aug 08, 2013 Jul NEWA  
AP FRESENIUS KABI USA EQ 250MG/50ML (EQ 5MG/ML) A200674 001 Jun 19, 2013 Jun NEWA  
AP EQ 500MG/100ML (EQ 5MG/ML) A200674 002 Jun 19, 2013 Jun NEWA  
AP EQ 750MG/150ML (EQ 5MG/ML) A200674 003 Jun 19, 2013 Jun NEWA

## SOLUTION/DROPS;OPHTHALMIC

LEVOFLOXACIN  
@ APOTEX INC 0.5% A078282 001 Dec 20, 2010 Apr DISC

## TABLET;ORAL

LEVOFLOXACIN  
AB WATSON LABS INC 250MG A201484 001 Nov 22, 2013 Nov NEWA  
AB 500MG A201484 002 Nov 22, 2013 Nov NEWA  
AB 750MG A201484 003 Nov 22, 2013 Nov NEWA

LEVOMILNACIPRAN HYDROCHLORIDE

## CAPSULE, EXTENDED RELEASE;ORAL

## FETZIMA

FOREST LABS INC EQ 20MG BASE N204168 001 Jul 25, 2013 Jul NEWA  
EQ 40MG BASE N204168 002 Jul 25, 2013 Jul NEWA  
EQ 80MG BASE N204168 003 Jul 25, 2013 Jul NEWA  
+ EQ 120MG BASE N204168 004 Jul 25, 2013 Jul NEWA

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

## INJECTABLE; INJECTION

ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN  
@ NOVOCOL 0.05MG/ML;2% A084697 001 Jun DISC  
SCANDONEST L  
+ DEPROCO 0.05MG/ML;2% A088388 001 Oct 10, 1984 Jun CRLD

LEVONORGESTREL

## INTRAUTERINE DEVICE; INTRAUTERINE

SKYLA  
+ BAYER HLTHCARE 13.5MG N203159 001 Jan 09, 2013 Jan NEWA

## TABLET;ORAL

LEVONORGESTREL  
AB LUPIN LTD 0.75MG A091328 001 Jan 23, 2013 Jan NEWA  
AB NOVEL LABS INC 1.5MG A202508 001 Feb 22, 2013 Feb NEWA

LEVOTHYROXINE SODIUM \*\*

\*\*See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

## TABLET;ORAL

LEVOTHYROXINE SODIUM  
@ MERCK KGAA 0.025MG A076752 001 Jun 16, 2005 Jul DISC  
@ 0.05MG A076752 002 Jun 16, 2005 Jul DISC  
@ 0.075MG A076752 003 Jun 16, 2005 Jul DISC  
@ 0.088MG A076752 004 Jun 16, 2005 Jul DISC  
@ 0.1MG A076752 005 Jun 16, 2005 Jul DISC  
@ 0.112MG A076752 006 Jun 16, 2005 Jul DISC  
@ 0.125MG A076752 007 Jun 16, 2005 Jul DISC  
@ 0.15MG A076752 008 Jun 16, 2005 Jul DISC  
@ 0.175MG A076752 009 Jun 16, 2005 Jul DISC  
@ 0.2MG A076752 010 Jun 16, 2005 Jul DISC  
@ 0.3MG A076752 011 Jun 16, 2005 Jul DISC

TABLET; ORAL

LEVOXYL

AB1, AB3	KING PHARMS R AND D	0.025MG	N021301	001	May 25, 2001	Mar	CAHN
AB1, AB3		0.05MG	N021301	002	May 25, 2001	Mar	CAHN
AB1, AB3		0.075MG	N021301	003	May 25, 2001	Mar	CAHN
AB1, AB3		0.088MG	N021301	004	May 25, 2001	Mar	CAHN
AB1, AB3		0.1MG	N021301	005	May 25, 2001	Mar	CAHN
AB1, AB3		0.112MG	N021301	006	May 25, 2001	Mar	CAHN
AB1, AB3		0.125MG	N021301	007	May 25, 2001	Mar	CAHN
AB1, AB3		0.137MG	N021301	008	May 25, 2001	Mar	CAHN
AB1, AB3		0.15MG	N021301	009	May 25, 2001	Mar	CAHN
AB1, AB3		0.175MG	N021301	010	May 25, 2001	Mar	CAHN
AB1, AB3	+	0.2MG	N021301	011	May 25, 2001	Mar	CAHN
AB3	@	0.3MG	N021301	012	May 25, 2001	Mar	CAHN

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

AP	AGILA SPECLTS	0.5%	A091056	001	Dec 08, 2010	Nov	CAHN
AP		0.5%	A091058	001	Sep 30, 2010	Nov	CAHN
AP		1%	A091056	002	Dec 08, 2010	Nov	CAHN
AP		1%	A091058	002	Sep 30, 2010	Nov	CAHN
AP	INTL MEDICATION	1%	A083173	001		Sep	CMFD
AP		2%	A083173	002		Sep	CMFD
	@ LUITPOLD	2%	A083198	001		Mar	DISC
	LIDOCAINE HYDROCHLORIDE	PRESERVATIVE FREE					
AP	AGILA SPECLTS	2%	A090665	001	Sep 27, 2010	Nov	CAHN
AP	AUROBINDO PHARMA LTD	1%	A203040	001	Mar 14, 2013	Mar	NEWA
AP		1%	A203082	001	Mar 14, 2013	Mar	NEWA
AP		2%	A203040	002	Mar 14, 2013	Mar	NEWA
AP		2%	A203082	002	Mar 14, 2013	Mar	NEWA
	JELLY; TOPICAL						
	ANESTACON						
	@ POLYMEDICA	2%	A080429	001		May	DISC
	LIDOCAINE HYDROCHLORIDE						
	@ TEVA PHARMS USA	2%	A081318	001	Apr 29, 1993	Jun	DISC

LIDOCAINE; TETRACAINE

PATCH; TOPICAL

SYNERA

+	GALEN SPECIALTY	70MG; 70MG	N021623	001	Jun 23, 2005	Aug	CAHN
---	-----------------	------------	---------	-----	--------------	-----	------

LIOTHYRONINE SODIUM

TABLET; ORAL

CYTOMEL

AB	KING PHARMS R AND D	EQ 0.005MG BASE	N010379	001		Mar	CAHN
AB		EQ 0.025MG BASE	N010379	002		Mar	CAHN
AB	+	EQ 0.05MG BASE	N010379	003		Mar	CAHN

LISINAPRIL

TABLET; ORAL

LISINAPRIL

AB	ACCORD HLTHCARE	2.5MG	A202554	001	Jul 30, 2013	Jul	NEWA
AB		5MG	A202554	002	Jul 30, 2013	Jul	NEWA
AB		10MG	A202554	003	Jul 30, 2013	Jul	NEWA
AB		20MG	A202554	004	Jul 30, 2013	Jul	NEWA
AB		30MG	A202554	005	Jul 30, 2013	Jul	NEWA
AB		40MG	A202554	006	Jul 30, 2013	Jul	NEWA
AB	HIKMA PHARMS	2.5MG	A076063	001	Jul 01, 2002	Oct	CAHN
AB		5MG	A076063	002	Jul 01, 2002	Oct	CAHN
AB		10MG	A076063	003	Jul 01, 2002	Oct	CAHN
AB		20MG	A076063	004	Jul 01, 2002	Oct	CAHN
AB		30MG	A076063	006	Jun 27, 2003	Oct	CAHN
AB		40MG	A076063	005	Jul 01, 2002	Oct	CAHN

TABLET;ORAL

LISINOPRIL

AB	INVAGEN PHARMS	2.5MG	A203508 001	Oct 29, 2013	Oct NEWA
AB		5MG	A203508 002	Oct 29, 2013	Oct NEWA
AB		10MG	A203508 003	Oct 29, 2013	Oct NEWA
AB		20MG	A203508 004	Oct 29, 2013	Oct NEWA
AB		30MG	A203508 005	Oct 29, 2013	Oct NEWA
AB		40MG	A203508 006	Oct 29, 2013	Oct NEWA
	@ SANDOZ	2.5MG	A075903 001	Jul 01, 2002	Aug DISC
	@	2.5MG	A075999 001	Jul 01, 2002	Jan CAHN
	@	5MG	A075903 002	Jul 01, 2002	Aug DISC
	@	5MG	A075999 002	Jul 01, 2002	Jan CAHN
	@	10MG	A075903 003	Jul 01, 2002	Aug DISC
	@	10MG	A075999 003	Jul 01, 2002	Jan CAHN
	@	20MG	A075903 004	Jul 01, 2002	Aug DISC
	@	20MG	A075999 004	Jul 01, 2002	Jan CAHN
	@	30MG	A075903 005	Jul 01, 2002	Aug DISC
	@	30MG	A075999 005	Jul 01, 2002	Jan CAHN
	@	40MG	A075903 006	Jul 01, 2002	Aug DISC
	@	40MG	A075999 006	Jul 01, 2002	Jan CAHN

LITHIUM CARBONATE

CAPSULE;ORAL

LITHIUM CARBONATE

	@ APOTEX INC	300MG	A076795 001	Nov 22, 2004	Feb DISC
AB	HETERO LABS LTD III	150MG	A090702 001	Sep 25, 2009	Apr CAHN
AB		300MG	A090702 002	Sep 25, 2009	Apr CAHN
AB		600MG	A090702 003	Sep 25, 2009	Apr CAHN
>D>	AB WEST WARD	600MG	A078763 001	Apr 15, 2008	Dec DISC
>A>	@	600MG	A078763 001	Apr 15, 2008	Dec DISC

TABLET;ORAL

LITHIUM CARBONATE

@ WEST WARD

300MG

A078715 001 Dec 28, 2010 Aug DISC

LOMUSTINE

CAPSULE;ORAL

CEENU

CORDEN PHARMA

10MG

N017588 001

Apr CAHN

40MG

N017588 002

Apr CAHN

+

100MG

N017588 003

Apr CAHN

LOPERAMIDE HYDROCHLORIDE

SOLUTION;ORAL

IMODIUM

>D>	@ JANSSEN PHARMA	1MG/5ML	N019037 001	Jul 31, 1984	Dec CAHN
>A>	@ JANSSEN PHARMS	1MG/5ML	N019037 001	Jul 31, 1984	Dec CAHN

LORAZEPAM

CONCENTRATE;ORAL

LORAZEPAM

AA	LUPIN LTD	2MG/ML	A091407 001	Feb 19, 2013	Feb NEWA
----	-----------	--------	-------------	--------------	----------

INJECTABLE;INJECTION

LORAZEPAM

AP	AKORN	2MG/ML	A075025 001	Jul 23, 1998	Jul CAHN
	@ WATSON LABS	2MG/ML	A074276 001	Apr 15, 1994	Sep DISC
	@	4MG/ML	A074276 002	Apr 15, 1994	Sep DISC

TABLET;ORAL

LORAZEPAM

@ SANDOZ

0.5MG

A071193 001 Apr 15, 1988 Apr DISC

@

1MG

A071194 001 Apr 15, 1988 Apr DISC

@

2MG

A071195 001 Apr 15, 1988 Apr DISC

LOSARTAN POTASSIUM

TABLET;ORAL

COZAAR

AB	MERCK SHARP DOHME	25MG	N020386 001	Apr 14, 1995	Oct CAHN
AB		50MG	N020386 002	Apr 14, 1995	Oct CAHN
AB	+	100MG	N020386 003	Oct 13, 1998	Oct CAHN
	LOSARTAN POTASSIUM				
>D>	AB ACTAVIS GRP PTC	25MG	A090382 001	Oct 06, 2010	Dec CAHN
AB		25MG	A090382 001	Oct 06, 2010	Mar CAHN
>D>	AB	50MG	A090382 002	Oct 06, 2010	Dec CAHN

<u>TABLET;ORAL</u>							
<u>LOSARTAN POTASSIUM</u>							
AB		50MG		A090382	002	Oct 06, 2010	Mar CAHN
>D>	AB	100MG		A090382	003	Oct 06, 2010	Dec CAHN
	AB	100MG		A090382	003	Oct 06, 2010	Mar CAHN
	AB	IPCA LABS LTD	25MG	A200290	001	Aug 30, 2013	Aug NEWA
	AB		50MG	A200290	002	Aug 30, 2013	Aug NEWA
	AB		100MG	A200290	003	Aug 30, 2013	Aug NEWA
>A>	AB	VIVIMED LABS	25MG	A090382	001	Oct 06, 2010	Dec CAHN
>A>	AB		50MG	A090382	002	Oct 06, 2010	Dec CAHN
>A>	AB		100MG	A090382	003	Oct 06, 2010	Dec CAHN
<u>LOVASTATIN</u>							
<u>TABLET;ORAL</u>							
<u>LOVASTATIN</u>							
AB	+	CARLSBAD	40MG	A075991	003	Jun 05, 2002	Feb CRLD
		MEVACOR					
		@ MERCK	20MG	N019643	003	Aug 31, 1987	Feb DISC
		@	40MG	N019643	004	Dec 14, 1988	Feb DISC
<u>LOXAPINE</u>							
<u>POWDER; INHALATION</u>							
<u>ADASUVE</u>							
	+	TEVA PHARMS USA INC	10MG	N022549	001	Dec 21, 2012	Jul CAHN
<u>LOXAPINE SUCCINATE</u>							
<u>CAPSULE;ORAL</u>							
<u>LOXAPINE SUCCINATE</u>							
AB		MIKAH PHARMA	EQ 5MG BASE	A076868	001	Aug 04, 2005	May CMFD
AB			EQ 10MG BASE	A076868	002	Aug 04, 2005	May CMFD
AB			EQ 25MG BASE	A076868	003	Aug 04, 2005	May CMFD
AB			EQ 50MG BASE	A076868	004	Aug 04, 2005	May CMFD
<u>LULICONAZOLE</u>							
<u>CREAM; TOPICAL</u>							
<u>LUZU</u>							
		MEDICIS	1%	N204153	001	Nov 14, 2013	Nov NEWA
<u>LURASIDONE HYDROCHLORIDE</u>							
<u>TABLET;ORAL</u>							
<u>LATUDA</u>							
		SUNOVION PHARMS INC	60MG	N200603	005	Jul 12, 2013	Jul NEWA
<u>MACITENTAN</u>							
<u>TABLET;ORAL</u>							
<u>OPSUMIT</u>							
	+	ACTELION PHARMS LTD	10MG	N204410	001	Oct 18, 2013	Oct NEWA
<u>MAFENIDE ACETATE</u>							
<u>CREAM; TOPICAL</u>							
<u>SULFAMYLON</u>							
	+	MYLAN INSTITUTIONAL	EQ 85MG BASE/GM	N016763	001		May CAHN
		FOR SOLUTION; TOPICAL					
		MAFENIDE ACETATE					
AB		PAR FORM	5%	A201511	001	Feb 12, 2013	Jan NEWA
		SULFAMYLON					
AB	+	MYLAN INSTITUTIONAL	5%	N019832	003	Jun 05, 1998	May CAHN
AB	+	MYLAN LLC	5%	N019832	003	Jun 05, 1998	Jan CFTG
<u>MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE</u>							
<u>SOLUTION;ORAL</u>							
<u>SUCLEAR</u>							
	+	BRAINTREE LABS	1.6GM/BOT, 3.13GM/BOT, 17.5GM/BOT, N/A, N/A, N/A, N/A; N/A, N/A, N/A, 210GM, 0.74GM, 2.86GM, 5.6GM	N203595	001	Jan 18, 2013	Jan NEWA

MANNITOL

INJECTABLE; INJECTION  
MANNITOL 20%

@ B BRAUN 20GM/100ML N014738 001 Jan DISC

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL  
MECAMYLAMINE HYDROCHLORIDE

NEXGEN PHARMA 2.5MG A204054 001 Mar 19, 2013 Mar NEWA

MECHLORETHAMINE HYDROCHLORIDE

GEL; TOPICAL  
VALCHLOR

+ ACTELION PHARMS LTD 0.02% N202317 001 Aug 23, 2013 Sep CAHN  
+ CEPTARIS THERAP 0.02% N202317 001 Aug 23, 2013 Aug NEWA

INJECTABLE; INJECTION  
MUSTARGEN

+ RECORDATI RARE 10MG/VIAL N006695 001 May CAHN

MECLIZINE HYDROCHLORIDE

TABLET; ORAL  
ANTIVERT

AA + CITRON PHARMA LLC 12.5MG N010721 006 Nov CAHN  
AA + 25MG N010721 004 Nov CAHN  
AA + 50MG N010721 001 Jan 20, 1982 Nov CAHN

TABLET, CHEWABLE; ORAL  
ANTIVERT

@ CITRON PHARMA LLC 25MG N010721 005 Nov CAHN

MECLOFENAMATE SODIUM

CAPSULE; ORAL  
MECLOFENAMATE SODIUM

MYLAN EQ 50MG BASE A071081 002 Sep 03, 1986 Sep CTEC  
+ EQ 100MG BASE A071081 001 Sep 03, 1986 Sep CTEC  
@ WATSON LABS EQ 50MG BASE A071468 001 Apr 15, 1987 Sep DISC  
@ EQ 100MG BASE A071469 001 Apr 15, 1987 Sep DISC

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION  
MEDROXYPROGESTERONE ACETATE

@ TEVA PHARMS USA 150MG/ML A076552 001 Oct 27, 2004 May CAHN  
AB 150MG/ML A076553 001 Jul 28, 2004 May CAHN

MEFENAMIC ACID

CAPSULE; ORAL  
MEFENAMIC ACID

AB BRECKENRIDGE PHARM 250MG A090359 001 Feb 05, 2013 Sep CAHN  
AB CYPRESS PHARM 250MG A090359 001 Feb 05, 2013 Jan NEWA

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL  
MEFLOQUINE HYDROCHLORIDE

@ WEST WARD PHARM CORP 250MG A077699 001 Apr 21, 2010 Jun DISC

MEGESTROL ACETATE

SUSPENSION; ORAL  
MEGESTROL ACETATE

@ APOTEX INC 40MG/ML A077404 001 Feb 16, 2006 Apr DISC

MELOXICAM

TABLET; ORAL  
MELOXICAM

AB CIPLA LTD 7.5MG A077929 001 Jul 19, 2006 Aug CAHN  
AB 15MG A077929 002 Jul 19, 2006 Aug CAHN  
@ COREPHARMA 7.5MG A077930 001 Jul 19, 2006 Feb DISC  
@ 15MG A077930 002 Jul 19, 2006 Feb DISC  
@ CR DOUBLE CRANE 7.5MG A078039 001 Dec 14, 2006 Apr DISC  
AB 7.5MG A078039 001 Dec 14, 2006 Mar CAHN  
@ 15MG A078039 002 Dec 14, 2006 Apr DISC  
AB 15MG A078039 002 Dec 14, 2006 Mar CAHN  
@ MYLAN 7.5MG A077934 001 Jul 20, 2006 Aug DISC

TABLET;ORAL  
MELOXICAM

@ 15MG A 077934 002 Jul 20, 2006 Aug DISC

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION  
MELPHALAN HYDROCHLORIDE

@ MYLAN INSTITUTIONAL EQ 50MG BASE/VIAL A 090299 001 Oct 27, 2009 Nov DISC

MEPROBAMATE

TABLET;ORAL  
MEPROBAMATE

@ TARO 200MG A 200998 001 May 23, 2011 Jan DISC

@ 400MG A 200998 002 May 23, 2011 Jan DISC

MESALAMINE

CAPSULE, DELAYED RELEASE;ORAL  
DELZICOL

+ WARNER CHILCOTT LLC 400MG N 204412 001 Feb 01, 2013 Feb NEWA

SUPPOSITORY;RECTAL  
CANASA

+ APTALIS PHARMA US 1GM N 021252 002 Nov 05, 2004 Feb CRLD

MESNA

INJECTABLE; INTRAVENOUS  
MESNA

>D> AP SAGENT AGILA 100MG/ML A 090913 001 Apr 13, 2010 Dec CAHN

>A> AP SAGENT PHARMS 100MG/ML A 090913 001 Apr 13, 2010 Dec CAHN

AP TEVA PHARMS USA 100MG/ML A 075764 001 Apr 27, 2001 May CAHN

METAPROTERENOL SULFATE

SOLUTION; INHALATION  
METAPROTERENOL SULFATE

@ APOTEX INC 0.4% A 075402 001 Feb 28, 2001 Apr DISC

@ 0.6% A 075403 001 Feb 28, 2001 Apr DISC

SYRUP;ORAL

METAPROTERENOL SULFATE

@ APOTEX INC 10MG/5ML A 075235 001 Jan 27, 2000 Apr DISC

@ NOVEX 10MG/5ML A 075235 001 Jan 27, 2000 Feb DISC

+ SILARX 10MG/5ML A 073632 001 Jul 22, 1992 Feb CTEC

TABLET;ORAL

METAPROTERENOL SULFATE

PAR PHARM 10MG A 072024 001 Jun 28, 1988 Mar CTEC

+ 20MG A 072025 001 Jun 28, 1988 Mar CTEC

@ WATSON LABS 10MG A 073013 001 Jan 31, 1991 Mar DISC

@ 20MG A 072795 001 Jan 31, 1991 Mar DISC

METAXALONE

TABLET;ORAL  
METAXALONE

AB AMNEAL PHARMS 800MG A 203399 001 Jun 21, 2013 Jun NEWA

METFORMIN HYDROCHLORIDE

TABLET;ORAL  
METFORMIN HYDROCHLORIDE

AB CHARTWELL LIFE SCI 1GM A 075972 003 Jan 24, 2002 Aug CAHN

AB 500MG A 075972 001 Jan 24, 2002 Aug CAHN

625MG A 075972 005 Jan 24, 2002 Aug CAHN

750MG A 075972 004 Jan 24, 2002 Aug CAHN

AB 850MG A 075972 002 Jan 24, 2002 Aug CAHN

AB SANDOZ 1GM A 075965 003 Jan 25, 2002 May CMFD

@ 1GM A 075965 003 Jan 25, 2002 Mar DISC

AB 500MG A 075965 001 Jan 25, 2002 May CMFD

@ 500MG A 075965 001 Jan 25, 2002 Mar DISC

AB 850MG A 075965 002 Jan 25, 2002 May CMFD

@ 850MG A 075965 002 Jan 25, 2002 Mar DISC

AB SCIEGEN PHARMS INC 500MG A 203769 001 Sep 11, 2013 Aug NEWA

AB 850MG A 203769 002 Sep 11, 2013 Aug NEWA

AB 1GM A 203769 003 Sep 11, 2013 Aug NEWA





METHOTREXATESOLUTION; SUBCUTANEOUS  
OTREXUP

		ANTARES PHARMA INC	10MG/0.4ML	N204824	001	Oct 11, 2013	Oct NEWA
			15MG/0.4ML	N204824	002	Oct 11, 2013	Oct NEWA
			20MG/0.4ML	N204824	003	Oct 11, 2013	Oct NEWA
	+		25MG/0.4ML	N204824	004	Oct 11, 2013	Oct NEWA

METHOTREXATE SODIUMINJECTABLE; INJECTION  
METHOTREXATE SODIUM PRESERVATIVE FREE

>A>	AP	+	ACCORD HLTHCARE	EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A040716	001	Apr 30, 2007	Dec CAHN
>A>	AP	+		EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A040767	001	Apr 30, 2007	Dec CAHN
>A>	AP	+		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A040768	001	Apr 30, 2007	Dec CAHN
>D>	AP	+	MYLAN INSTITUTIONAL	EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A040716	001	Apr 30, 2007	Dec CAHN
>D>	AP	+		EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A040767	001	Apr 30, 2007	Dec CAHN
>D>	AP	+		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A040768	001	Apr 30, 2007	Dec CAHN

METHOXSALENCAPSULE; ORAL  
OXSORALEN-ULTRA

	+	DOW PHARM	10MG	N019600	001	Oct 30, 1986	Apr CAHN
--	---	-----------	------	---------	-----	--------------	----------

METHYLCLOTHIAZIDETABLET; ORAL  
METHYLCLOTHIAZIDE

	+	MYLAN PHARMS INC	5MG	A087672	001	Aug 17, 1982	Jan CTEC
		@ WATSON LABS	5MG	A088724	001	Sep 06, 1984	Jan DISC

METHYL AMINOLEVULINATE HYDROCHLORIDECREAM; TOPICAL  
METVIXIA

	@	GALDERMA LABS LP	EQ 16.8% BASE	N021415	001	Jul 27, 2004	Jun DISC
--	---	------------------	---------------	---------	-----	--------------	----------

METHYLDOPATABLET; ORAL  
METHYLDOPA

	@	ACCORD HLTHCARE	125MG	A070070	003	Oct 15, 1985	Apr CAHN
AB			250MG	A070084	001	Oct 15, 1985	Apr CAHN
AB			500MG	A070085	001	Oct 15, 1985	Apr CAHN

METHYLPHENIDATE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL  
METADATE CD

AB2		UCB INC	10MG	N021259	003	May 27, 2003	Sep CTEC
AB2			50MG	N021259	005	Feb 19, 2006	Sep CTEC
AB2	+		60MG	N021259	006	Feb 19, 2006	Sep CTEC
AB2		TEVA PHARMS	10MG	A077707	001	Jul 19, 2012	Sep CTEC
AB2			50MG	A078873	002	Jul 19, 2012	Sep CTEC
AB2			60MG	A078873	003	Jul 19, 2012	Sep CTEC
AB1		WATSON LABS INC	20MG	A078458	001	Dec 01, 2011	Apr CAHN
AB1			30MG	A078458	002	Dec 01, 2011	Apr CAHN
AB1			40MG	A078458	003	Dec 01, 2011	Apr CAHN

SOLUTION; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AA		CARACO	5MG/5ML	A201466	001	Nov 12, 2013	Oct NEWA
AA			10MG/5ML	A201466	002	Nov 12, 2013	Oct NEWA

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB		CARACO	5MG	A090710	001	Mar 15, 2012	May CAHN
AB			10MG	A090710	002	Mar 15, 2012	May CAHN
AB			20MG	A090710	003	Mar 15, 2012	May CAHN

TABLET, EXTENDED RELEASE; ORAL

CONCERTA

AB		JANSSEN PHARMS	18MG	N021121	001	Aug 01, 2000	Jun CTEC
		METHYLIN ER					
		MALLINCKRODT INC	10MG	A075629	001	May 09, 2000	Feb CTEC

<u>TABLET, EXTENDED RELEASE;ORAL</u>										
<u>METHYLPHENIDATE HYDROCHLORIDE</u>										
AB	KUDCO IRELAND	18MG	A091695	001	Jul 09, 2013	Jun	NEWA			
AB		27MG	A091695	002	Jul 09, 2013	Jun	NEWA			
AB		36MG	A091695	003	Sep 23, 2013	Sep	NEWA			
AB		54MG	A091695	004	Sep 23, 2013	Sep	NEWA			
<u>METHYLPREDNISOLONE</u>										
<u>TABLET;ORAL</u>										
<u>MEDROL</u>										
AB	PHARMACIA AND UPJOHN	2MG	N011153	002		Oct	CMFD			
<u>METHYLPREDNISOLONE ACETATE</u>										
<u>INJECTABLE;INJECTION</u>										
<u>METHYLPREDNISOLONE ACETATE</u>										
AB	TEVA PHARMS USA	40MG/ML	A040557	001	Feb 23, 2005	May	CAHN			
AB		40MG/ML	A040620	001	Oct 27, 2006	May	CAHN			
AB		80MG/ML	A040557	002	Feb 23, 2005	May	CAHN			
AB		80MG/ML	A040620	002	Oct 27, 2006	May	CAHN			
<u>METOCLOPRAMIDE HYDROCHLORIDE</u>										
<u>INJECTABLE;INJECTION</u>										
<u>METOCLOPRAMIDE</u>										
>A>	AP	EMCURE PHARMS LTD	EQ 5MG BASE/ML	A204756	001	Dec 20, 2013	Dec	NEWA		
<u>METOCLOPRAMIDE HYDROCHLORIDE</u>										
AP	BD RX	EQ 5MG BASE/ML	A091392	001	Apr 19, 2013	Apr	NEWA			
	@ TEVA PARENTERAL	EQ 5MG BASE/ML	A073135	001	Nov 27, 1991	Feb	DISC			
>D>	@ TEVA PHARMS USA	EQ 5MG BASE/ML	A073135	001	Nov 27, 1991	Dec	CMFD			
>A>	AP	EQ 5MG BASE/ML	A073135	001	Nov 27, 1991	Dec	CMFD			
	@	EQ 5MG BASE/ML	A073135	001	Nov 27, 1991	May	CAHN			
<u>TABLET, ORALLY DISINTEGRATING;ORAL</u>										
<u>METOZOLV ODT</u>										
+	SALIX PHARMS	EQ 5MG BASE	N022246	001	Sep 04, 2009	Jul	CRLD			
	@	EQ 10MG BASE	N022246	002	Sep 04, 2009	Jul	DISC			
<u>METOLAZONE</u>										
<u>TABLET;ORAL</u>										
<u>METOLAZONE</u>										
	@ TEVA	2.5MG	A076600	001	Jan 06, 2004	Mar	DISC			
	@	5MG	A076833	001	Mar 01, 2004	Jun	DISC			
	@	10MG	A075543	003	Dec 24, 2003	May	DISC			
<u>METOPROLOL SUCCINATE</u>										
<u>TABLET, EXTENDED RELEASE;ORAL</u>										
<u>METOPROLOL SUCCINATE</u>										
	@ NESHER PHARMS	EQ 25MG TARTRATE	A077779	001	Mar 20, 2008	Feb	DISC			
	@	EQ 50MG TARTRATE	A077176	001	May 14, 2008	May	DISC			
<u>METOPROLOL TARTRATE</u>										
<u>INJECTABLE;INJECTION</u>										
<u>METOPROLOL TARTRATE</u>										
AP	CLARIS LIFESCIENCES	1MG/ML	A078950	001	Apr 29, 2013	Apr	NEWA			
	@ WATSON LABS	1MG/ML	A074032	001	Dec 21, 1993	Mar	DISC			
<u>TABLET;ORAL</u>										
<u>METOPROLOL TARTRATE</u>										
AB	ALEMBIC PHARMS LTD	25MG	A202871	001	May 28, 2013	May	NEWA			
AB		50MG	A202871	002	May 28, 2013	May	NEWA			
AB		100MG	A202871	003	May 28, 2013	May	NEWA			
	@ PRINSTON INC	50MG	A074453	001	Apr 27, 1995	Mar	CAHN			
	@	100MG	A074453	002	Apr 27, 1995	Mar	CAHN			
<u>METRONIDAZOLE</u>										
<u>TABLET;ORAL</u>										
<u>METRONIDAZOLE</u>										
AB	TEVA PHARMS USA	250MG	A070027	001	Nov 06, 1984	Mar	CAHN			

METYROSINECAPSULE; ORAL  
DEMSEER

+ ATON PHARMA VPNA 250MG N017871 001 Jun CAHN

MEXILETINE HYDROCHLORIDECAPSULE; ORAL  
MEXILETINE HYDROCHLORIDE

	TEVA	150MG	A074377	001	May 16, 1995	Sep CTEC
		200MG	A074377	002	May 16, 1995	Sep CTEC
+		250MG	A074377	003	May 16, 1995	Sep CTEC
	@ WATSON LABS	150MG	A074711	001	Feb 26, 1997	Sep DISC
	@	150MG	A074865	001	Apr 13, 1998	Sep DISC
	@	200MG	A074711	002	Feb 26, 1997	Sep DISC
	@	200MG	A074865	002	Apr 13, 1998	Sep DISC
	@	250MG	A074711	003	Feb 26, 1997	Sep DISC
	@	250MG	A074865	003	Apr 13, 1998	Sep DISC

MIDAZOLAM HYDROCHLORIDEINJECTABLE; INJECTION  
MIDAZOLAM HYDROCHLORIDE

AP	AKORN INC	EQ 1MG BASE/ML	A075494	001	Jun 30, 2000	Jul CAHN
AP		EQ 5MG BASE/ML	A075481	001	Jun 30, 2000	Jul CAHN
AP		EQ 5MG BASE/ML	A075494	002	Jun 30, 2000	Jul CAHN
	@ APOTEX INC	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000	Apr DISC
	@	EQ 5MG BASE/ML	A075637	002	Oct 31, 2000	Apr DISC
	@ CLARIS LIFESCIENCES	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000	Jan DISC
	@	EQ 5MG BASE/ML	A075637	002	Oct 31, 2000	Jan DISC
	@ INTL MEDICATED	EQ 1MG BASE/ML	A076144	001	Jan 26, 2005	Jun DISC
	@	EQ 5MG BASE/ML	A076144	002	Jan 26, 2005	Jun DISC
	@ INTL MEDICATION	EQ 1MG BASE/ML	A076020	001	Jul 16, 2004	May DISC
	@	EQ 5MG BASE/ML	A076020	002	Jul 16, 2004	May DISC

SYRUP; ORAL  
MIDAZOLAM HYDROCHLORIDE

@ APOTEX INC EQ 2MG BASE/ML A077115 001 Sep 09, 2005 Apr DISC

MILRINONE LACTATEINJECTABLE; INJECTION  
MILRINONE LACTATE

	@ APOTEX INC	EQ 1MG BASE/ML	A076427	001	Sep 21, 2004	Apr DISC
		MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER				
	@ APOTEX INC	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151	001	Jul 20, 2005	Apr DISC

MINOCYCLINE HYDROCHLORIDECAPSULE; ORAL  
MINOCYCLINE HYDROCHLORIDE

AB	CARACO	EQ 50MG BASE	A090867	001	May 13, 2013	Apr NEWA
AB		EQ 75MG BASE	A090867	002	May 13, 2013	Apr NEWA
AB		EQ 100MG BASE	A090867	003	May 13, 2013	Apr NEWA

CAPSULE, EXTENDED RELEASE; ORAL  
XIMINO

	@ RANBAXY LABS LTD	EQ 45MG BASE	N201922	001	Jul 11, 2012	May DISC
	@	EQ 67.5MG BASE	N201922	002	Jul 11, 2012	May DISC
	@	EQ 90MG BASE	N201922	003	Jul 11, 2012	May DISC
	@	EQ 112.5MG BASE	N201922	004	Jul 11, 2012	May DISC
	@	EQ 135MG BASE	N201922	005	Jul 11, 2012	May DISC

TABLET, EXTENDED RELEASE; ORAL  
SOLODYN

+	MEDICIS	EQ 55MG BASE	N050808	008	Aug 27, 2010	Apr CRLD
+		EQ 80MG BASE	N050808	007	Aug 27, 2010	Apr CRLD

MIPOMERSEN SODIUMSOLUTION; SUBCUTANEOUS  
KYNAMRO

+ GENZYME CORP 200MG/ML (200MG/ML) N203568 001 Jan 29, 2013 Jan NEWA



MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
EMBEDA

	+	ALPHARMA KING	60MG;2.4MG	N022321	004	Aug 13, 2009	Jul	CRLD
			100MG;4MG	N022321	006	Aug 13, 2009	Jul	CRLD

MUPIROCIN CALCIUM

CREAM;TOPICAL  
BACTROBAN

AB	+	GLAXOSMITHKLINE	EQ 2% BASE	N050746	001	Dec 11, 1997	Jan	CFTG
AB		GLENMARK GENERICS	EQ 2% BASE	A201587	001	Jan 24, 2013	Jan	NEWA

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL  
MYCOPHENOLATE MOFETIL

AB		ACCORD HLTHCARE	250MG	A090253	001	May 04, 2009	Apr	CAHN
AB		ALKEM LABS LTD	250MG	A200197	001	Jun 13, 2013	Jun	NEWA

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE;ORAL  
MYCOPHENOLIC ACID

>A>	AB		180MG	A091248	002	Jan 08, 2014	Dec	NEWA
>A>	AB	MYLAN PHARMS INC	360MG	A091248	001	Jan 08, 2014	Dec	NEWA
		MYFORTIC						
>D>		+	NOVARTIS	N050791	002	Feb 27, 2004	Dec	CTEC
>A>	AB	+		N050791	002	Feb 27, 2004	Dec	CTEC

NABUMETONE

TABLET;ORAL  
NABUMETONE

	@	DR REDDYS LABS LTD	500MG	A078420	001	Sep 24, 2008	Apr	DISC
	@		750MG	A078420	002	Sep 24, 2008	Apr	DISC
	@	PROSAM LABS	500MG	A079093	001	Feb 27, 2009	Mar	DISC
	@		750MG	A079093	002	Feb 27, 2009	Mar	DISC

NAFTIFINE HYDROCHLORIDE

GEL;TOPICAL  
NAFTIN

	+	MERZ PHARMS	2%	N204286	001	Jun 27, 2013	Jun	NEWA
--	---	-------------	----	---------	-----	--------------	-----	------

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET;ORAL  
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

AB		GAVIS PHARMS	EQ 0.5MG BASE;EQ 50MG BASE	A075735	001	Jul 11, 2001	Aug	CTNA
AB		RANBAXY	EQ 0.5MG BASE;EQ 50MG BASE	A075523	001	Mar 17, 2000	Aug	CTNA
AB	+	WATSON LABS	EQ 0.5MG BASE;EQ 50MG BASE	A074736	001	Jan 21, 1997	Aug	CTNA

NALTREXONE HYDROCHLORIDE

TABLET;ORAL  
NALTREXONE HYDROCHLORIDE

	@	SANDOZ	50MG	A075434	001	Mar 08, 2000	Apr	DISC
AB	+	TEVA WOMENS	50MG	N018932	001	Nov 20, 1984	Jul	CAHN

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
NAPHAZOLINE HYDROCHLORIDE

AT		AKORN INC	0.1%	A083590	001		Jul	CAHN
----	--	-----------	------	---------	-----	--	-----	------

NAPROXEN

TABLET;ORAL  
NAPROXEN

AB		WEST WARD PHARM CORP	250MG	A076494	001	Jan 14, 2004	Apr	CAHN
AB			375MG	A076494	002	Jan 14, 2004	Apr	CAHN
AB			500MG	A076494	003	Jan 14, 2004	Apr	CAHN

<u>NAPROXEN SODIUM</u>									
TABLET, EXTENDED RELEASE;ORAL									
NAPRELAN									
	ALMATICA PHARMA INC	EQ 375MG BASE		N020353	001	Jan 05, 1996	Nov	CAHN	
		EQ 500MG BASE		N020353	002	Jan 05, 1996	Nov	CAHN	
+		EQ 750MG BASE		N020353	003	Jan 05, 1996	Nov	CAHN	
<u>NARATRIPTAN HYDROCHLORIDE</u>									
TABLET;ORAL									
AMERGE									
AB	GLAXOSMITHKLINE LLC	EQ 1MG BASE		N020763	002	Feb 10, 1998	Mar	CAHN	
AB	+	EQ 2.5MG BASE		N020763	001	Feb 10, 1998	Mar	CAHN	
<u>NELFINAVIR MESYLATE</u>									
POWDER;ORAL									
VIRACEPT									
	@ AGOURON	EQ 50MG BASE/SCOOPFUL		N020778	001	Mar 14, 1997	Jun	DISC	
<u>NEOMYCIN SULFATE</u>									
POWDER;FOR RX COMPOUNDING									
NEO-RX									
	@ X GEN PHARMS	100%		A061579	001		Mar	DISC	
<u>NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE</u>									
SUSPENSION/DROPS;OPHTHALMIC									
POLY-PRED									
	@ ALLERGAN	EQ 0.35% BASE;10,000 UNITS/ML;0.5%		N050081	002		May	DISC	
<u>NEOSTIGMINE METHYLSULFATE</u>									
SOLUTION;INTRAVENOUS									
BLOXIVERZ									
+	ECLAT PHARMS LLC	5MG/10ML (0.5MG/ML)		N204078	001	May 31, 2013	May	NEWA	
+		10MG/10ML (1MG/ML)		N204078	002	May 31, 2013	May	NEWA	
<u>NEPAFENAC</u>									
SUSPENSION/DROPS;OPHTHALMIC									
ILEVRO									
+	ALCON RES LTD	0.3%		N203491	001	Oct 16, 2012	Aug	CTNA	
<u>NESIRITIDE RECOMBINANT</u>									
FOR SOLUTION;INTRAVENOUS									
NATRECOR									
+	SCIOS LLC	1.5MG/VIAL		N020920	001	Aug 10, 2001	Nov	CAHN	
<u>NIACIN</u>									
TABLET, EXTENDED RELEASE;ORAL									
NIACIN									
AB	BARR	1GM		A076250	001	Apr 14, 2005	Aug	CMFD	
AB		500MG		A076378	001	Apr 26, 2005	Aug	CMFD	
AB		750MG		A076378	002	Apr 26, 2005	Aug	CMFD	
NIASPAN									
AB	+	ABBVIE	1GM	N020381	004	Jul 28, 1997	Oct	CTEC	
AB			500MG	N020381	002	Jul 28, 1997	Oct	CTEC	
AB	+		750MG	N020381	003	Jul 28, 1997	Oct	CTEC	
<u>NIFEDIPINE</u>									
CAPSULE;ORAL									
NIFEDIPINE									
AB	ACTAVIS ELIZABETH	20MG		A072556	001	Sep 20, 1990	Apr	CTEC	
	@ CATALENT	10MG		A073250	001	Oct 08, 1991	Apr	DISC	
AB	EMCURE PHARMS USA	10MG		A202644	001	Apr 25, 2013	Apr	NEWA	
AB		20MG		A202644	002	Apr 25, 2013	Apr	NEWA	
<u>NILUTAMIDE</u>									
TABLET;ORAL									
NILANDRON									
	@ COVIS PHARMA SARL	50MG		N020169	001	Sep 19, 1996	Apr	CAHN	
+		150MG		N020169	002	Apr 30, 1999	Apr	CAHN	

NIMODIPINE

CAPSULE;ORAL							
NIMODIPINE							
AB	+	BANNER PHARMACAPS	30MG	A076740	001	Jan 17, 2008	Jul CRLD
AB		SUN PHARM INDS INC	30MG	A077067	001	Apr 17, 2007	Jul CRLD
SOLUTION;ORAL							
NYMALIZE							
	+	ARBOR PHARMS INC	60MG/20ML	N203340	001	May 10, 2013	May NEWA

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL							
NISOLDIPINE							
		MYLAN	20MG	A079051	001	Jul 25, 2008	Jul CRLD
			25.5MG	A091001	003	Jan 26, 2011	Oct CTEC
		SULAR					
	@	SHIONOGI INC	25.5MG	N020356	006	Jan 02, 2008	Oct DISC

NITISINONE

CAPSULE;ORAL							
ORFADIN							
		SWEDISH ORPHAN	2MG	N021232	001	Jan 18, 2002	May CAHN
			5MG	N021232	002	Jan 18, 2002	May CAHN
	+		10MG	N021232	003	Jan 18, 2002	May CAHN

NITROFURANTOIN

SUSPENSION;ORAL							
NITROFURANTOIN							
AB		CARACO	25MG/5ML	A201355	001	Aug 14, 2013	Jul NEWA

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL							
MACRODANTIN							
		ALVOGEN INC	25MG	N016620	003		Mar CTEC
AB			25MG	N016620	003		Feb CAHN
AB			50MG	N016620	001		Feb CAHN
AB	+		100MG	N016620	002		Feb CAHN
NITROFURANTOIN							
	@	WATSON LABS	25MG	A073696	001	Dec 31, 1992	Mar DISC
	@		50MG	A073696	002	Dec 31, 1992	Mar DISC
	@		100MG	A073696	003	Dec 31, 1992	Mar DISC

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL							
MACROBID							
AB	+	ALVOGEN INC	75MG;25MG	N020064	001	Dec 24, 1991	Mar CAHN

NITROGLYCERIN

AEROSOL, METERED;SUBLINGUAL							
NITROMIST							
>A>	+	MIST PHARMS LLC	0.4MG/SPRAY	N021780	001	Nov 02, 2006	Dec CAHN
>D>	+	NOVADEL	0.4MG/SPRAY	N021780	001	Nov 02, 2006	Dec CAHN
FILM, EXTENDED RELEASE;TRANSDERMAL							
NITRO-DUR							
AB1	+	MERCK SHARP DOHME	0.1MG/HR	N020145	001	Apr 04, 1995	Mar CAHN
AB1	+		0.2MG/HR	N020145	002	Apr 04, 1995	Mar CAHN
	+		0.3MG/HR	N020145	003	Apr 04, 1995	Mar CAHN
AB1	+		0.4MG/HR	N020145	004	Apr 04, 1995	Mar CAHN
AB1	+		0.6MG/HR	N020145	005	Apr 04, 1995	Mar CAHN
	+		0.8MG/HR	N020145	006	Apr 04, 1995	Mar CAHN
INJECTABLE;INJECTION							
NITROGLYCERIN							
	+	LUITPOLD	5MG/ML	A072034	001	May 24, 1988	Jul CTEC
SPRAY, METERED;SUBLINGUAL							
NITROGLYCERIN							
AB		PERRIGO ISRAEL	0.4MG/SPRAY	A091496	001	Sep 20, 2013	Sep NEWA
AB	+	POHL BOSKAMP	0.4MG/SPRAY	N018705	002	Jan 10, 1997	Sep CFTG



NIZATIDINE

CAPSULE;ORAL

NIZATIDINE

@ APOTEX INC	150MG	A076383	001	Jan 23, 2003	Feb	DISC
@	300MG	A076383	002	Jan 23, 2003	Feb	DISC

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

NOREPINEPHRINE BITARTRATE

AP	TEVA PHARMS USA	EQ 1MG BASE/ML	A040455	001	Mar 03, 2003	May	CAHN
----	-----------------	----------------	---------	-----	--------------	-----	------

NORETHINDRONE

TABLET;ORAL

NORETHINDRONE

AB1	HAUPT PHARMA	0.35MG	A202260	001	Aug 01, 2013	Jul	NEWA
-----	--------------	--------	---------	-----	--------------	-----	------

TABLET;ORAL-28

JENCYCLA

AB2	LUPIN LTD	0.35MG	A091323	001	Mar 28, 2013	Apr	CTEC
AB		0.35MG	A091323	001	Mar 28, 2013	Mar	NEWA

NORETHINDRONE

AB2	FAMY CARE LTD	0.35MG	A200980	001	Jun 12, 2013	May	NEWA
AB1		0.35MG	A201483	001	Jun 24, 2013	Jun	NEWA
AB1	HAUPT PHARMA	0.35MG	A202260	001	Aug 01, 2013	Aug	CDFR
AB2	NOVAST LABS	0.35MG	A200961	001	Sep 13, 2013	Aug	NEWA
AB1	NOVAST LABS LTD	0.35MG	A202014	001	Sep 13, 2013	Aug	NEWA

NORETHINDRONE ACETATE

TABLET;ORAL

NORETHINDRONE ACETATE

AB	AMNEAL PHARMS	5MG	A200275	001	Jul 30, 2012	Sep	CTNA
----	---------------	-----	---------	-----	--------------	-----	------

NYSTATIN

SUSPENSION;ORAL

NILSTAT

@ GLENMARK GENERICS	100,000 UNITS/ML	N050299	001		Feb	DISC
---------------------	------------------	---------	-----	--	-----	------

OCTREOTIDE ACETATE

INJECTABLE;INJECTION

OCTREOTIDE ACETATE

AP	SAGENT PHARMS	EQ 0.2MG BASE/ML	A091041	001	Nov 12, 2013	Oct	NEWA
AP		EQ 1MG BASE/ML	A091041	002	Nov 12, 2013	Oct	NEWA
AP	TEVA PHARMS USA	EQ 0.05MG BASE/ML	A075957	001	Oct 03, 2005	May	CAHN
AP		EQ 0.1MG BASE/ML	A075957	002	Oct 03, 2005	May	CAHN
AP		EQ 0.2MG BASE/ML	A075959	001	Nov 21, 2005	May	CAHN
AP		EQ 0.5MG BASE/ML	A075957	003	Oct 03, 2005	May	CAHN
AP		EQ 1MG BASE/ML	A075959	002	Nov 21, 2005	May	CAHN
	OCTREOTIDE ACETATE (PRESERVATIVE FREE)						
AP	SAGENT PHARMS	EQ 0.05MG BASE/ML	A090834	001	Nov 12, 2013	Oct	NEWA
AP		EQ 0.1MG BASE/ML	A090834	002	Nov 12, 2013	Oct	NEWA
AP		EQ 0.5MG BASE/ML	A090834	003	Nov 12, 2013	Oct	NEWA

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

OFLOXACIN

AT	ALTAIRE PHARMS INC	0.3%	A202692	001	Apr 29, 2013	Apr	NEWA
	@ APOTEX INC	0.3%	A076513	001	May 14, 2004	Apr	DISC

OLIVE OIL; SOYBEAN OIL

INJECTABLE;INJECTION

CLINOLIPID 20%

+	BAXTER HLTHCARE	16% (160GM/1000ML); 4% (40GM/1000ML)	N204508	001	Oct 03, 2013	Oct	NEWA
---	-----------------	--------------------------------------	---------	-----	--------------	-----	------

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

ZEGERID

>A>	AB	SALIX PHARMS INC	20MG;1.1GM	N021849	001	Feb 27, 2006	Dec	CAHN
>A>	AB	+	40MG;1.1GM	N021849	002	Feb 27, 2006	Dec	CAHN
>D>	AB	SANTARUS	20MG;1.1GM	N021849	001	Feb 27, 2006	Dec	CAHN
>D>	AB	+	40MG;1.1GM	N021849	002	Feb 27, 2006	Dec	CAHN

## FOR SUSPENSION;ORAL

## OMEPRAZOLE AND SODIUM BICARBONATE

AB	PAR PHARM	20MG/PACKET;1.68GM/PACKET	A 079182	001	Apr 19, 2013	Apr	NEWA
AB		40MG/PACKET;1.68GM/PACKET	A 079182	002	Apr 19, 2013	Apr	NEWA
<u>ZEGERID</u>							
>A>	AB	SALIX PHARMS INC	20MG/PACKET;1.68GM/PACKET	N 021636	001	Jun 15, 2004	Dec CAHN
>A>	AB	+	40MG/PACKET;1.68GM/PACKET	N 021636	002	Dec 21, 2004	Dec CAHN
>D>	AB	SANTARUS	20MG/PACKET;1.68GM/PACKET	N 021636	001	Jun 15, 2004	Dec CAHN
	AB		20MG/PACKET;1.68GM/PACKET	N 021636	001	Jun 15, 2004	Apr CFTG
>D>	AB	+	40MG/PACKET;1.68GM/PACKET	N 021636	002	Dec 21, 2004	Dec CAHN
	AB	+	40MG/PACKET;1.68GM/PACKET	N 021636	002	Dec 21, 2004	Apr CFTG

ONDANSETRON HYDROCHLORIDE

## INJECTABLE;INJECTION

## ONDANSETRON HYDROCHLORIDE

AP	AGILA SPECLTS	EQ 2MG BASE/ML	A 078257	001	Apr 23, 2008	Nov	CAHN
	@ APOTEX INC	EQ 2MG BASE/ML	A 077368	001	Dec 26, 2006	Apr	DISC
AP	CLARIS LIFESCIENCES	EQ 2MG BASE/ML	A 078288	001	Feb 22, 2013	Jul	CPOT
AP		2MG/ML	A 078288	001	Feb 22, 2013	Feb	NEWA
	@ LUITPOLD	EQ 2MG BASE/ML	A 077582	001	Dec 26, 2006	Mar	DISC
	@ PLIVA HRVATSKA DOO	EQ 2MG BASE/ML	A 077544	001	Dec 26, 2006	Feb	DISC
<u>ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER</u>							
>D>	AP	BEDFORD LABS	EQ 0.64MG BASE/ML	A 078291	001	Apr 13, 2009	Dec DISC
>A>		@	EQ 0.64MG BASE/ML	A 078291	001	Apr 13, 2009	Dec DISC
		@ CLARIS LIFESCIENCES	EQ 0.64MG BASE/ML	A 078308	001	Mar 17, 2008	Jan DISC
		@ HOSPIRA	EQ 0.64MG BASE/ML	A 077348	001	Feb 01, 2007	Jan DISC
<u>ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE</u>							
AP	AGILA SPECLTS	EQ 2MG BASE/ML	A 078244	001	Apr 23, 2008	Nov	CAHN
	@ APOTEX INC	EQ 2MG BASE/ML	A 077343	001	Dec 26, 2006	Apr	DISC
AP	BD RX	EQ 2MG BASE/ML	A 202253	001	Jul 19, 2013	Jul	NEWA
AP	CLARIS LIFESCIENCES	EQ 2MG BASE/ML	A 078287	001	Feb 22, 2013	Jul	CPOT
AP		2MG/ML	A 078287	001	Feb 22, 2013	Feb	NEWA
	@ LUITPOLD	EQ 2MG BASE/ML	A 077387	001	Dec 26, 2006	Mar	DISC
<u>TABLET;ORAL</u>							
<u>ONDANSETRON HYDROCHLORIDE</u>							
	@ TARO	EQ 4MG BASE	A 077729	001	Mar 28, 2011	Sep	DISC
	@	EQ 8MG BASE	A 077729	002	Mar 28, 2011	Sep	DISC
	@	EQ 24MG BASE	A 077729	003	Mar 28, 2011	Sep	DISC

ORPHENADRINE CITRATE

## TABLET, EXTENDED RELEASE;ORAL

## ORPHENADRINE CITRATE

AB	TEDOR PHARMA INC	100MG	A 040249	001	Jan 29, 1999	Oct	CAHN
----	------------------	-------	----------	-----	--------------	-----	------

OSPEMIFENE

## TABLET;ORAL

## OSPHEA

+	SHIONOGI INC	60MG	N 203505	001	Feb 26, 2013	Feb	NEWA
---	--------------	------	----------	-----	--------------	-----	------

OXACILLIN SODIUM

## INJECTABLE;INJECTION

## OXACILLIN SODIUM

AP	AUROBINDO PHARMA LTD	EQ 1GM BASE/VIAL	A 201539	001	Jan 18, 2013	Jan	NEWA
AP		EQ 2GM BASE/VIAL	A 201539	002	Jan 18, 2013	Jan	NEWA
AP		EQ 10GM BASE/VIAL	A 201538	001	Jan 18, 2013	Jan	NEWA

OXAPROZIN

## TABLET;ORAL

## OXAPROZIN

AB	CARACO	600MG	A 075844	001	Jan 03, 2002	Nov	CMFD
	@	600MG	A 075844	001	Jan 03, 2002	Jan	DISC

OXAZEPAM

## CAPSULE;ORAL

## OXAZEPAM

AB	+	ACTAVIS ELIZABETH	30MG	A 072253	001	Apr 14, 1988	Jul CRLD
AB		IVAX SUB TEVA PHARMS	30MG	A 070945	001	Aug 03, 1987	Jul CRLD

OXCARBAZEPINE

TABLET;ORAL

OXCARBAZEPINE

@	TEVA PHARMS USA	150MG	A078005	001	Dec 11, 2007	Mar	DISC
@		300MG	A078005	002	Dec 11, 2007	Mar	DISC
@		600MG	A078005	003	Dec 11, 2007	Mar	DISC

OXYBUTYNIN

GEL, METERED;TRANSDERMAL

GELNIQUE 3%

+	WATSON LABS INC	3%	N202513	001	Dec 07, 2011	Jun	CTNA
---	-----------------	----	---------	-----	--------------	-----	------

OXYBUTYNIN CHLORIDE

SYRUP;ORAL

OXYBUTYNIN CHLORIDE

@	APOTEX INC	5MG/5ML	A074997	001	Oct 15, 1997	Apr	DISC
@	MIKART	5MG/5ML	A075039	001	Jan 29, 1999	Jun	DISC

TABLET;ORAL

OXYBUTYNIN CHLORIDE

AB	TEVA PHARMS USA	5MG	A071655	001	Nov 14, 1988	Mar	CAHN
----	-----------------	-----	---------	-----	--------------	-----	------

OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

AA	ROXANE	5MG/5ML	A204037	001	Jul 15, 2013	Jul	NEWA
AA		100MG/5ML	A203208	001	Jul 12, 2013	Jul	NEWA
AA	+ VISTAPHARM	5MG/5ML	N201194	001	Jan 12, 2012	Jul	CTEC

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

AB	NESHER PHARMS	5MG	A077290	001	Dec 08, 2005	Jun	CMFD
	@	5MG	A077290	001	Dec 08, 2005	Mar	DISC
AB		10MG	A077290	002	Dec 08, 2005	Jun	CMFD
	@	10MG	A077290	002	Dec 08, 2005	Mar	DISC
AB		15MG	A077290	003	Dec 08, 2005	Jun	CMFD
	@	15MG	A077290	003	Dec 08, 2005	Mar	DISC
AB		20MG	A077290	004	Dec 08, 2005	Jun	CMFD
	@	20MG	A077290	004	Dec 08, 2005	Mar	DISC
AB		30MG	A077290	005	Dec 08, 2005	Jun	CMFD
	@	30MG	A077290	005	Dec 08, 2005	Mar	DISC

OXYMORPHONE HYDROCHLORIDE

TABLET;ORAL

OXYMORPHONE HYDROCHLORIDE

AB	AVANTHI INC	5MG	A203601	001	Jan 30, 2013	Jan	NEWA
AB		10MG	A203601	002	Jan 30, 2013	Jan	NEWA
AB	MALLINCKRODT INC	5MG	A202321	001	Apr 25, 2013	Apr	NEWA
AB		10MG	A202321	002	Apr 25, 2013	Apr	NEWA

TABLET, EXTENDED RELEASE;ORAL

OXYMORPHONE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	5MG	A079046	003	Jul 11, 2013	Jul	NEWA
AB		7.5MG	A079046	001	Dec 13, 2010	Apr	CAHN
AB		10MG	A079046	004	Jul 11, 2013	Jul	NEWA
AB		15MG	A079046	002	Dec 13, 2010	Apr	CAHN
AB		20MG	A079046	005	Jul 11, 2013	Jul	NEWA
AB		30MG	A079046	006	Jul 11, 2013	Jul	NEWA
AB		40MG	A079046	007	Jul 11, 2013	Jul	NEWA
AB	IMPAX LABS	5MG	A079087	001	Jun 14, 2010	Jul	CTEC
AB		10MG	A079087	003	Jun 14, 2010	Jul	CTEC
AB		20MG	A079087	005	Jun 14, 2010	Jul	CTEC
AB		30MG	A079087	006	Jul 22, 2010	Jul	CTEC
AB		40MG	A079087	007	Jun 14, 2010	Jul	CTEC
AB	ROXANE	5MG	A200822	002	Jul 15, 2013	Jul	NEWA
AB		7.5MG	A200822	003	Jul 15, 2013	Jul	NEWA
AB		10MG	A200822	004	Jul 15, 2013	Jul	NEWA
AB		15MG	A200822	005	Jul 15, 2013	Jul	NEWA
AB		20MG	A200822	006	Jul 15, 2013	Jul	NEWA
AB		30MG	A200822	007	Jul 15, 2013	Jul	NEWA
AB		40MG	A200822	001	Jul 15, 2013	Jul	NEWA

OXYTOCININJECTABLE; INJECTION  
OXYTOCIN

AP	HIKMA FARMACEUTICA	10USP UNITS/ML (10USP UNITS/ML)	A200219	001	Feb 13, 2013	Jan	NEWA
	@ TEVA PHARMS USA	10USP UNITS/ML (10USP UNITS/ML)	A077453	001	Jan 24, 2008	May	CAHN
	@	100USP UNITS/10ML (10USP UNITS/ML)	A077453	002	Jan 24, 2008	May	CAHN

PACLITAXELINJECTABLE; INJECTION  
PACLITAXEL

	@ ACCORD HLTHCARE	6MG/ML	A075436	001	Nov 12, 2004	Apr	DISC
	@ TEVA PHARMS USA	6MG/ML	A075297	001	Jan 25, 2002	May	CAHN
	TAXOL						
AP	HQ SPCLT PHARMA	6MG/ML	N020262	001	Dec 29, 1992	Apr	CMFD
	@	6MG/ML	N020262	001	Dec 29, 1992	Jan	CAHN

PAMIDRONATE DISODIUMINJECTABLE; INJECTION  
PAMIDRONATE DISODIUM

AP	AGILA SPECLTS	30MG/10ML (3MG/ML)	A078520	001	Oct 31, 2008	Nov	CAHN
AP		90MG/10ML (9MG/ML)	A078520	002	Oct 31, 2008	Nov	CAHN
AP	TEVA PHARMS USA	30MG/10ML (3MG/ML)	A076153	001	Mar 27, 2002	Mar	CAHN
AP		90MG/10ML (9MG/ML)	A076153	002	Mar 27, 2002	Mar	CAHN

PANCRELIPASE (AMYLASE; LIPASE; PROTEASE)CAPSULE, DELAYED RELEASE; ORAL  
CREON

	ABBVIE	180,000USP UNITS; 36,000USP UNITS; 114,000USP UNITS	N020725	005	Mar 14, 2013	Mar	NEWA
--	--------	---	---------	-----	--------------	-----	------

PANCURONIUM BROMIDEINJECTABLE; INJECTION  
PANCURONIUM BROMIDE

AP	+ TEVA PHARMS USA	1MG/ML	A072759	001	Jul 31, 1990	May	CAHN
AP	+	2MG/ML	A072760	001	Jul 31, 1990	Mar	CAHN

PARICALCITOLCAPSULE; ORAL  
PARICALCITOL

AB	TEVA PHARMS USA	1MCG	A090829	001	Sep 27, 2013	Sep	NEWA
AB		2MCG	A090829	002	Sep 27, 2013	Sep	NEWA
AB		4MCG	A090829	003	Sep 27, 2013	Sep	NEWA
	ZEMPLAR						
AB	ABBVIE	1MCG	N021606	001	May 26, 2005	Sep	CFTG
AB		2MCG	N021606	002	May 26, 2005	Sep	CFTG
AB	+	4MCG	N021606	003	May 26, 2005	Sep	CFTG

PAROXETINE HYDROCHLORIDESUSPENSION; ORAL  
PAROXETINE HYDROCHLORIDE

	@ APOTEX INC	EQ 10MG BASE/5ML	A077395	001	Dec 05, 2006	Apr	DISC
--	--------------	------------------	---------	-----	--------------	-----	------

PAROXETINE MESYLATECAPSULE; ORAL  
BRISDELLE

	+ NOVEN THERAP	EQ 7.5MG BASE	N204516	001	Jun 28, 2013	Jun	NEWA
--	----------------	---------------	---------	-----	--------------	-----	------

PEGINESATIDE ACETATESOLUTION; INTRAVENOUS, SUBCUTANEOUS  
OMONTYS

	@ TAKEDA PHARMS USA	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799	007	Mar 27, 2012	May	DISC
	+	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799	007	Mar 27, 2012	Apr	CAHN
	@	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799	008	Mar 27, 2012	May	DISC
	+	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799	008	Mar 27, 2012	Apr	CAHN
	OMONTYS PRESERVATIVE FREE						
	@ TAKEDA PHARMS USA	EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799	001	Mar 27, 2012	May	DISC
	+	EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799	001	Mar 27, 2012	Apr	CAHN
	@	EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799	002	Mar 27, 2012	May	DISC
	+	EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799	002	Mar 27, 2012	Apr	CAHN

SOLUTION;INTRAVENOUS, SUBCUTANEOUS  
OMONTYS PRESERVATIVE FREE

		5ML)							
@		EQ 3MG BASE/0.5ML (EQ 3MG	N202799	003	Mar 27, 2012	May	DISC		
		BASE/0.5ML)							
+		EQ 3MG BASE/0.5ML (EQ 3MG	N202799	003	Mar 27, 2012	Apr	CAHN		
		BASE/0.5ML)							
@		EQ 4MG BASE/0.5ML (EQ 4MG	N202799	004	Mar 27, 2012	May	DISC		
		BASE/0.5ML)							
+		EQ 4MG BASE/0.5ML (EQ 4MG	N202799	004	Mar 27, 2012	Apr	CAHN		
		BASE/0.5ML)							
@		EQ 5MG BASE/0.5ML (EQ 5MG	N202799	005	Mar 27, 2012	May	DISC		
		BASE/0.5ML)							
+		EQ 5MG BASE/0.5ML (EQ 5MG	N202799	005	Mar 27, 2012	Apr	CAHN		
		BASE/0.5ML)							
@		EQ 6MG BASE/0.5ML (EQ 6MG	N202799	006	Mar 27, 2012	May	DISC		
		BASE/0.5ML)							
+		EQ 6MG BASE/0.5ML (EQ 6MG	N202799	006	Mar 27, 2012	Apr	CAHN		
		BASE/0.5ML)							

PENICILLIN V POTASSIUM

TABLET;ORAL

PENICILLIN V POTASSIUM

AB	HIKMA PHARMS	EQ 250MG BASE	A090549	001	Oct 11, 2013	Sep	NEWA		
AB		EQ 500MG BASE	A090549	002	Oct 11, 2013	Sep	NEWA		

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

	PARAGON BIOTECK	2.5%	N203510	001	Mar 21, 2013	Mar	NEWA		
+		10%	N203510	002	Mar 21, 2013	Mar	NEWA		

PHENYTOIN SODIUM

INJECTABLE;INJECTION

PHENYTOIN SODIUM

@	HOSPIRA	50MG/ML	A089744	001	Dec 18, 1987	Mar	DISC		
---	---------	---------	---------	-----	--------------	-----	------	--	--

PHYTONADIONE

TABLET;ORAL

MEPHYTON

+	VALEANT PHARMS	5MG	N010104	003		Jun	CAHN		
---	----------------	-----	---------	-----	--	-----	------	--	--

PINDOLOL

TABLET;ORAL

PINDOLOL

	MYLAN PHARMS INC	5MG	A074019	001	Sep 03, 1992	Jun	CTEC		
+		10MG	A074019	002	Sep 03, 1992	Jun	CTEC		
@	WATSON LABS	5MG	A074437	001	Feb 27, 1995	Jun	DISC		
@		10MG	A074437	002	Feb 27, 1995	Jun	DISC		

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE

AB	ACCORD HLTHCARE	EQ 15MG BASE	A200044	001	Feb 13, 2013	Jan	NEWA		
AB		EQ 30MG BASE	A200044	002	Feb 13, 2013	Jan	NEWA		
AB		EQ 45MG BASE	A200044	003	Feb 13, 2013	Jan	NEWA		
AB	AUROBINDO PHARMA LTD	EQ 15MG BASE	A200268	001	Feb 13, 2013	Jan	NEWA		
AB		EQ 30MG BASE	A200268	002	Feb 13, 2013	Jan	NEWA		
AB		EQ 45MG BASE	A200268	003	Feb 13, 2013	Jan	NEWA		
AB	DR REDDYS LABS LTD	EQ 15MG BASE	A078383	001	Mar 12, 2013	Mar	NEWA		
AB		EQ 30MG BASE	A078383	002	Mar 12, 2013	Mar	NEWA		
AB		EQ 45MG BASE	A078383	003	Mar 12, 2013	Mar	NEWA		
AB	MACLEODS PHARMS LTD	EQ 15MG BASE	A202467	001	Feb 06, 2013	Jan	NEWA		
AB		EQ 30MG BASE	A202467	002	Feb 06, 2013	Jan	NEWA		
AB		EQ 45MG BASE	A202467	003	Feb 06, 2013	Jan	NEWA		
AB	SANDOZ	EQ 15MG BASE	A078670	001	Feb 13, 2013	Jan	NEWA		
AB		EQ 30MG BASE	A078670	002	Feb 13, 2013	Jan	NEWA		
AB		EQ 45MG BASE	A078670	003	Feb 13, 2013	Jan	NEWA		
AB	SYNTHON PHARMS	EQ 15MG BASE	A078472	001	Feb 13, 2013	Jan	NEWA		
AB		EQ 30MG BASE	A078472	002	Feb 13, 2013	Jan	NEWA		
AB		EQ 45MG BASE	A078472	003	Feb 13, 2013	Jan	NEWA		
>A> AB	TEVA PHARMS USA	EQ 15MG BASE	A077210	001	Jan 10, 2014	Dec	NEWA		
>A> AB		EQ 30MG BASE	A077210	002	Jan 10, 2014	Dec	NEWA		
>A> AB		EQ 45MG BASE	A077210	003	Jan 10, 2014	Dec	NEWA		

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE

AB	TORRENT PHARMS LTD	EQ 15MG BASE	A091298	001	Feb 13, 2013	Jan NEWA
AB		EQ 30MG BASE	A091298	002	Feb 13, 2013	Jan NEWA
AB		EQ 45MG BASE	A091298	003	Feb 13, 2013	Jan NEWA
AB	ZYDUS PHARMS USA INC	EQ 15MG BASE	A202456	001	Feb 13, 2013	Jan NEWA
AB		EQ 30MG BASE	A202456	002	Feb 13, 2013	Jan NEWA
AB		EQ 45MG BASE	A202456	003	Feb 13, 2013	Jan NEWA

POLIDOCANOL

SOLUTION;INTRAVENOUS  
VARITHENA

+	PROVENSIS	180MG/18ML (10MG/ML)	N205098	001	Nov 25, 2013	Nov NEWA
---	-----------	----------------------	---------	-----	--------------	----------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL  
COLYTE

	MEDA PHARMS	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	Jul CTEC
@		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987	Jul DISC
	MEDA PHARMS	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Jul CTEC
	MEDA PHARMS	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Jul DISC
@		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991	Jul DISC

POLYMYXIN B SULFATE

INJECTABLE;INJECTION  
POLYMYXIN B SULFATE

>A>	AP	XELLIA PHARMS APS	EQ 500,000 U BASE/VIAL	A202766	001	Jan 15, 2014	Dec NEWA
		POLY-RX					
	@	X GEN PHARMS	100,000,000 UNITS/BOT	A061578	001		Mar DISC

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC  
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT	AKORN INC	10,000 UNITS/ML;EQ 1MG BASE/ML	A065006	001	Dec 17, 1998	Jul CAHN
----	-----------	--------------------------------	---------	-----	--------------	----------

POMALIDOMIDE

CAPSULE;ORAL  
POMALYST

	CELGENE	1MG	N204026	001	Feb 08, 2013	Feb NEWA
		2MG	N204026	002	Feb 08, 2013	Feb NEWA
		3MG	N204026	003	Feb 08, 2013	Feb NEWA
+		4MG	N204026	004	Feb 08, 2013	Feb NEWA

POSACONAZOLE

TABLET, DELAYED RELEASE;ORAL  
NOXAFIL

+	MERCK SHARP DOHME	100MG	N205053	001	Nov 25, 2013	Nov NEWA
---	-------------------	-------	---------	-----	--------------	----------

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
POTASSIUM CHLORIDE

AB	AMNEAL PHARMS	10MEQ	A202128	001	Feb 22, 2013	Feb NEWA
>A>	AB	ANCHEN PHARMS	A202886	001	Dec 26, 2013	Dec NEWA
>A>	AB		A202886	002	Dec 26, 2013	Dec NEWA

TABLET, EXTENDED RELEASE;ORAL  
K-TAB

BC	ABBVIE	20MEQ	N018279	003	Nov 25, 2013	Nov NEWA
	KLOR-CON					
	UPSHER-SMITH LABS	8MEQ	N019123	001	Apr 17, 1986	Nov CTEC
	POTASSIUM CHLORIDE					
	@ ABBVIE	8MEQ	N018279	002	Aug 01, 1988	Nov DISC

PRAMIPEXOLE DIHYDROCHLORIDE

## TABLET; ORAL

## PRAMIPEXOLE DIHYDROCHLORIDE

AB	ACTAVIS GRP PTC	0.125MG	A091254	001	Nov 30, 2010	Mar	CAHN
AB		0.25MG	A091254	002	Nov 30, 2010	Mar	CAHN
AB		0.5MG	A091254	003	Nov 30, 2010	Mar	CAHN
AB		0.75MG	A091254	004	Nov 30, 2010	Mar	CAHN
AB		1MG	A091254	005	Nov 30, 2010	Mar	CAHN
AB		1.5MG	A091254	006	Nov 30, 2010	Mar	CAHN
AB	SUN PHARM INDS INC	0.125MG	A091683	001	Mar 27, 2013	Mar	NEWA
AB		0.25MG	A091683	002	Mar 27, 2013	Mar	NEWA
AB		0.5MG	A091683	003	Mar 27, 2013	Mar	NEWA
AB		0.75MG	A091683	004	Mar 27, 2013	Mar	NEWA
AB		1MG	A091683	005	Mar 27, 2013	Mar	NEWA
AB		1.5MG	A091683	006	Mar 27, 2013	Mar	NEWA

PRAMLINTIDE ACETATE

## INJECTABLE; SUBCUTANEOUS

## SYMLIN

	AMYLIN PHARMS	EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007	Jan	CAHN
+		EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332	001	Mar 16, 2005	Jan	CAHN
+	AMYLIN PHARMS LLC	EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007	Jun	CRLD
@		EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332	001	Mar 16, 2005	Jun	DISC

PRAVASTATIN SODIUM

## TABLET; ORAL

## PRAVASTATIN SODIUM

AB	CIPLA LTD	10MG	A077904	001	Oct 23, 2006	Aug	CAHN
AB		20MG	A077904	002	Oct 23, 2006	Aug	CAHN
AB		40MG	A077904	003	Oct 23, 2006	Aug	CAHN

PRAZIOUANTEL

## TABLET; ORAL

## BILTRICIDE

+	BAYER HLTHCARE	600MG	N018714	001	Dec 29, 1982	Jun	CAHN
---	----------------	-------	---------	-----	--------------	-----	------

PREDNISOLONE

## SYRUP; ORAL

## PREDNISOLONE

@	APOTEX INC	5MG/5ML	A040570	001	Aug 25, 2005	Apr	DISC
@		15MG/5ML	A040571	001	Aug 25, 2005	Apr	DISC

PREDNISOLONE SODIUM PHOSPHATE

## SOLUTION; ORAL

## ORAPRED

AA	+	CONCORDIA PHARMS INC	EQ 15MG BASE/5ML	A075117	001	Dec 14, 2000	May	CAHN
		PREDNISOLONE SODIUM PHOSPHATE						
	@	NESHER PHARMS	EQ 15MG BASE/5ML	A076988	001	May 24, 2005	May	DISC
	@	PHARM ASSOC	EQ 5MG BASE/5ML	A076123	001	Dec 23, 2002	Mar	DISC
	@	WE PHARMS	EQ 15MG BASE/5ML	A075250	001	Jul 12, 2002	Mar	DISC

## TABLET, ORALLY DISINTEGRATING; ORAL

## ORAPRED ODT

AB		CONCORDIA PHARMS INC	EQ 10MG BASE	N021959	001	Jun 01, 2006	May	CAHN
AB			EQ 15MG BASE	N021959	002	Jun 01, 2006	May	CAHN
AB	+		EQ 30MG BASE	N021959	003	Jun 01, 2006	May	CAHN
AB		SHIONOGI INC	EQ 10MG BASE	N021959	001	Jun 01, 2006	Mar	CFTG
AB			EQ 15MG BASE	N021959	002	Jun 01, 2006	Mar	CFTG
AB	+		EQ 30MG BASE	N021959	003	Jun 01, 2006	Mar	CFTG
		PREDNISOLONE SODIUM PHOSPHATE						
AB		MYLAN PHARMS INC	EQ 10MG BASE	A202179	001	Apr 10, 2013	Mar	NEWA
AB			EQ 15MG BASE	A202179	002	Apr 10, 2013	Mar	NEWA
AB			EQ 30MG BASE	A202179	003	Apr 10, 2013	Mar	NEWA

PREDNISONETABLET; ORAL  
PREDNISONE

AB	HIKMA PHARMS	1MG	A 040890	001	Nov 01, 2010	May	CAHN
AB		2.5MG	A 040538	001	Jan 08, 2004	May	CAHN
AB		5MG	A 080292	001		May	CAHN
AB		10MG	A 088832	001	Dec 04, 1985	May	CAHN
AB		20MG	A 083677	001		May	CAHN
AB		50MG	A 088465	001	Jun 01, 1984	May	CAHN

PRIMIDONETABLET; ORAL  
PRIMIDONE

	@ DR REDDYS LABS LTD	50MG	A 040862	001	Oct 03, 2008	Apr	DISC
	@	250MG	A 040862	002	Oct 03, 2008	Apr	DISC
	@ WEST WARD	50MG	A 040667	001	Jul 27, 2006	Jul	DISC

PROBENECIDTABLET; ORAL  
PROBENECID

	@ IVAX SUB TEVA PHARMS	500MG	A 083740	001	May 09, 1984	May	DISC
--	------------------------	-------	----------	-----	--------------	-----	------

PROCHLORPERAZINE EDISYLATEINJECTABLE; INJECTION  
PROCHLORPERAZINE EDISYLATE

AP	EMCURE PHARMS LTD	EQ 5MG BASE/ML	A 204147	001	Oct 15, 2013	Sep	NEWA
----	-------------------	----------------	----------	-----	--------------	-----	------

PROGESTERONECAPSULE; ORAL  
PROGESTERONE

AB	BANNER PHARMACAPS	100MG	A 200900	001	Aug 16, 2013	Jul	NEWA
AB		200MG	A 200900	002	Aug 16, 2013	Jul	NEWA
	PROMETRIUM						
AB	ABBVIE INC	100MG	N 019781	001	May 14, 1998	May	CAHN
AB	+	200MG	N 019781	002	Oct 15, 1999	May	CAHN
	@	300MG	N 019781	003	Oct 15, 1999	May	CAHN

PROMETHAZINE HYDROCHLORIDEINJECTABLE; INJECTION  
PROMETHAZINE HYDROCHLORIDE

AP	+ TEVA PHARMS USA	25MG/ML	A 040454	001	Aug 22, 2002	Mar	CAHN
AP	+	50MG/ML	A 040454	002	Aug 22, 2002	Mar	CAHN

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

AA	CARACO	6.25MG/5ML	A 040891	001	Mar 13, 2009	May	CAHN
----	--------	------------	----------	-----	--------------	-----	------

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

AB	CARACO	12.5MG	A 040863	001	Dec 30, 2008	May	CAHN
AB		25MG	A 040863	002	Dec 30, 2008	May	CAHN
AB		50MG	A 040863	003	Dec 30, 2008	May	CAHN

PROPARACAINE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC  
PROPARACAINE HYDROCHLORIDE

AT	AKORN INC	0.5%	A 040277	001	Mar 16, 2000	Jul	CAHN
----	-----------	------	----------	-----	--------------	-----	------

PROPIOMAZINE HYDROCHLORIDEINJECTABLE; INJECTION  
LARGON

	@ HIKMA MAPLE	20MG/ML	N 012382	002		Nov	CAHN
--	---------------	---------	----------	-----	--	-----	------

PROPOFOLINJECTABLE; INJECTION  
PROPOFOL

AB	TEVA PHARMS USA	10MG/ML	A 075102	001	Jan 04, 1999	Mar	CAHN
----	-----------------	---------	----------	-----	--------------	-----	------



PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
PROPRANOLOL HYDROCHLORIDE

AB	GLATT AIR	60MG	A 078065	001	Jan 26, 2007	Feb	CAHN
AB		80MG	A 078065	002	Jan 26, 2007	Feb	CAHN
AB		120MG	A 078065	003	Jan 26, 2007	Feb	CAHN
AB		160MG	A 078065	004	Jan 26, 2007	Feb	CAHN

TABLET;ORAL  
INDERAL

	@ WYETH PHARMS INC	10MG	N 016418	001		Jul	CAHN
	@	20MG	N 016418	003		Jul	CAHN
AB		40MG	N 016418	002		Jul	CAHN
AB		60MG	N 016418	009	Oct 18, 1982	Jul	CAHN
AB	+	80MG	N 016418	004		Jul	CAHN
	@	90MG	N 016418	010	Oct 18, 1982	Jul	CAHN

PROPYLTHIOURACIL

TABLET;ORAL  
PROPYLTHIOURACIL

>D>	BD	WEST WARD	50MG	A 080154	001		Dec	DISC
>A>		@	50MG	A 080154	001		Dec	DISC

PROTRIPTYLINE HYDROCHLORIDE

TABLET;ORAL  
VIVACTIL

	@ TEVA WOMENS	5MG	N 016012	001		Mar	CAHN
	@	10MG	N 016012	002		Mar	CAHN

PYRIDOSTIGMINE BROMIDE

TABLET;ORAL  
PYRIDOSTIGMINE BROMIDE

	@ COREPHARMA	60MG	A 040457	001	Dec 26, 2002	Nov	DISC
--	--------------	------	----------	-----	--------------	-----	------

PYRIMETHAMINE

TABLET;ORAL  
DARAPRIM

+	AMEDRA PHARMS	25MG	N 008578	001		Apr	CAHN
---	---------------	------	----------	-----	--	-----	------

QUAZEPAM

TABLET;ORAL  
DORAL

	@ SCIECURE PHARMA INC	7.5MG	N 018708	003	Feb 26, 1987	Jun	CAHN
+		15MG	N 018708	001	Dec 27, 1985	Jun	CAHN

QUETIAPINE FUMARATE

TABLET;ORAL  
QUETIAPINE FUMARATE

AB	ACCORD HLTHCARE	EQ 25MG BASE	A 202152	001	Mar 27, 2012	Apr	CAHN
AB		EQ 50MG BASE	A 202152	002	Mar 27, 2012	Apr	CAHN
AB		EQ 100MG BASE	A 202152	003	Mar 27, 2012	Apr	CAHN
AB		EQ 200MG BASE	A 202152	004	Mar 27, 2012	Apr	CAHN
AB		EQ 300MG BASE	A 202152	005	Mar 27, 2012	Apr	CAHN
AB		EQ 400MG BASE	A 202152	006	Mar 27, 2012	Apr	CAHN
AB	ACTAVIS GRP PTC	EQ 25MG BASE	A 201762	001	Feb 27, 2013	May	CAHN
AB		EQ 50MG BASE	A 201762	002	Feb 27, 2013	May	CAHN
AB		EQ 100MG BASE	A 201762	003	Feb 27, 2013	May	CAHN
AB		EQ 150MG BASE	A 201762	004	Feb 27, 2013	May	CAHN
AB		EQ 200MG BASE	A 201762	005	Feb 27, 2013	May	CAHN
AB		EQ 300MG BASE	A 201762	006	Feb 27, 2013	May	CAHN
AB		EQ 400MG BASE	A 201762	007	Feb 27, 2013	May	CAHN
AB	ACTAVIS PHARMA	EQ 25MG BASE	A 201762	001	Feb 27, 2013	Feb	NEWA
AB		EQ 50MG BASE	A 201762	002	Feb 27, 2013	Feb	NEWA
AB		EQ 100MG BASE	A 201762	003	Feb 27, 2013	Feb	NEWA
AB		EQ 150MG BASE	A 201762	004	Feb 27, 2013	Feb	NEWA
AB		EQ 200MG BASE	A 201762	005	Feb 27, 2013	Feb	NEWA
AB		EQ 300MG BASE	A 201762	006	Feb 27, 2013	Feb	NEWA
AB		EQ 400MG BASE	A 201762	007	Feb 27, 2013	Feb	NEWA
AB	ALKEM LABS LTD	EQ 25MG BASE	A 201504	001	Feb 12, 2013	Jan	NEWA
AB		EQ 50MG BASE	A 201504	002	Feb 12, 2013	Jan	NEWA
AB		EQ 100MG BASE	A 201504	003	Feb 12, 2013	Jan	NEWA
AB		EQ 150MG BASE	A 201504	004	Feb 12, 2013	Jan	NEWA

## TABLET;ORAL

QUETIAPINE FUMARATE							
AB		EQ 200MG BASE	A201504	005	Feb 12, 2013	Jan	NEWA
AB		EQ 300MG BASE	A201504	006	Feb 12, 2013	Jan	NEWA
AB		EQ 400MG BASE	A201504	007	Feb 12, 2013	Jan	NEWA
AB	JUBILANT LIFE	EQ 25MG BASE	A203150	001	Nov 26, 2013	Nov	NEWA

QUINAPRIL HYDROCHLORIDE

## TABLET;ORAL

QUINAPRIL HYDROCHLORIDE							
	@ APOTEX INC	EQ 5MG BASE	A076240	001	Jan 26, 2006	Mar	DISC
	@	EQ 10MG BASE	A076240	002	Jan 26, 2006	Mar	DISC
	@	EQ 20MG BASE	A076240	003	Jan 26, 2006	Mar	DISC
	@	EQ 40MG BASE	A076240	004	Jan 26, 2006	Mar	DISC
AB	AUROBINDO PHARMA LTD	EQ 5MG BASE	A202725	001	Apr 29, 2013	Apr	NEWA
AB		EQ 10MG BASE	A202725	002	Apr 29, 2013	Apr	NEWA
AB		EQ 20MG BASE	A202725	003	Apr 29, 2013	Apr	NEWA
AB		EQ 40MG BASE	A202725	004	Apr 29, 2013	Apr	NEWA
	@ MYLAN	EQ 5MG BASE	A076036	001	Jan 28, 2005	Aug	DISC
	@	EQ 10MG BASE	A076036	002	Jan 28, 2005	Aug	DISC
	@	EQ 20MG BASE	A076036	003	Jan 28, 2005	Aug	DISC
	@	EQ 40MG BASE	A076036	004	Jan 28, 2005	Aug	DISC

RABEPRAZOLE SODIUM

## CAPSULE, DELAYED RELEASE;ORAL

ACIPHEX SPRINKLE							
	EISAI INC	5MG	N204736	001	Mar 26, 2013	Mar	NEWA
	+	10MG	N204736	002	Mar 26, 2013	Mar	NEWA
TABLET, DELAYED RELEASE;ORAL							
	ACIPHEX						
AB	+ EISAI INC	20MG	N020973	002	Aug 19, 1999	Oct	CFTG
	RABEPRAZOLE SODIUM						
AB	DR REDDYS LABS LTD	20MG	A076824	001	Nov 08, 2013	Oct	NEWA
AB	KREMERS URBAN DEV	20MG	A090678	001	Nov 08, 2013	Oct	NEWA
AB	LUPIN LTD	20MG	A078964	001	Nov 08, 2013	Oct	NEWA
AB	MYLAN PHARMS INC	20MG	A076885	001	Nov 08, 2013	Oct	NEWA
AB	TEVA PHARMS USA	20MG	A076822	001	Nov 08, 2013	Oct	NEWA
AB	TORRENT PHARMS LTD	20MG	A202376	001	Nov 08, 2013	Oct	NEWA

RADIUM RA-223 DICHLORIDE

## SOLUTION;INTRAVENOUS

XOFIGO							
	+ BAYER HLTHCARE	162MCI/6ML (27MCI/ML)	N203971	001	May 15, 2013	May	NEWA

RALTEGRAVIR POTASSIUM

POWDER;ORAL							
>A>	ISENTRESS						
>A>	+ MERCK SHARP DOHME	EQ 100MG BASE/PACKET	N205786	001	Dec 20, 2013	Dec	NEWA
SOLUTION;ORAL							
>A>	ISENTRESS						
>A>	+ MERCK SHARP DOHME	100MG	N205786	001	Dec 20, 2013	Dec	NEWA

RAMELTEON

## TABLET;ORAL

RAMELTEON							
AB	TEVA PHARMS USA	8MG	A091693	001	Jul 26, 2013	Jul	NEWA
	ROZEREM						
AB	+ TAKEDA PHARMS USA	8MG	N021782	001	Jul 22, 2005	Jul	CFTG

RAMIPRIL

## CAPSULE;ORAL

RAMIPRIL							
	@ CIPLA	1.25MG	A077004	001	Aug 07, 2008	Jul	DISC
	@	2.5MG	A077004	002	Aug 07, 2008	Jul	DISC
	@	5MG	A077004	003	Aug 07, 2008	Jul	DISC
	@	10MG	A077004	004	Aug 07, 2008	Jul	DISC

RANITIDINE HYDROCHLORIDE

	GRANULE, EFFERVESCENT;ORAL							
	ZANTAC 150							
	@ GLAXO GRP LTD	EQ 150MG BASE/PACKET	N020251	002	Mar 31, 1994	Jun	CAHN	
	INJECTABLE;INJECTION							
	RANITIDINE HYDROCHLORIDE							
AP	ZYDUS PHARMS USA INC	25MG/ML	A091534	001	Feb 22, 2013	Feb	NEWA	
	ZANTAC IN PLASTIC CONTAINER							
	@ COVIS PHARMA SARL	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991	Jun	DISC	
	SYRUP;ORAL							
	RANITIDINE HYDROCHLORIDE							
	@ APOTEX INC	EQ 15MG BASE/ML	A077602	001	Sep 17, 2007	Apr	DISC	
AA	BIO PHARM INC	EQ 15MG BASE/ML	A090102	001	May 26, 2009	Apr	CAHN	
AA	BRECKENRIDGE PHARM	EQ 15MG BASE/ML	A078684	001	Aug 27, 2009	Sep	CAHN	
AA	CARACO	EQ 15MG BASE/ML	A091091	001	Sep 20, 2011	Apr	CAHN	
	ZANTAC							
AA	+ GLAXO GRP LTD	EQ 15MG BASE/ML	N019675	001	Dec 30, 1988	Jun	CAHN	
	TABLET;ORAL							
	RANITIDINE HYDROCHLORIDE							
	@ WATSON LABS	EQ 150MG BASE	A074864	001	Oct 20, 1997	Jan	DISC	
	@	EQ 300MG BASE	A074864	002	Oct 20, 1997	Jan	DISC	
	@ WATSON LABS INC	EQ 150MG BASE	A077426	001	Dec 19, 2005	Mar	DISC	
	@	EQ 300MG BASE	A077426	002	Dec 19, 2005	Mar	DISC	
	ZANTAC 150							
AB	GLAXO GRP LTD	EQ 150MG BASE	N018703	001	Jun 09, 1983	Jun	CAHN	
	ZANTAC 300							
AB	+ GLAXO GRP LTD	EQ 300MG BASE	N018703	002	Dec 09, 1985	Jun	CAHN	
	TABLET, EFFERVESCENT;ORAL							
	ZANTAC 150							
	@ GLAXO GRP LTD	EQ 150MG BASE	N020251	001	Mar 31, 1994	Jun	CAHN	

RANOLAZINE

	TABLET, EXTENDED RELEASE;ORAL							
	RANEXA							
AB	+ GILEAD	1GM	N021526	001	Feb 12, 2007	Jul	CFTG	
AB		500MG	N021526	002	Jan 27, 2006	Jul	CFTG	
	RANOLAZINE							
AB	LUPIN LTD	500MG	A201046	001	Jul 29, 2013	Jul	NEWA	
AB		1GM	A201046	002	Jul 29, 2013	Jul	NEWA	

RASAGILINE MESYLATE

	TABLET;ORAL							
	AZILECT							
AB	TEVA	EQ 0.5MG BASE	N021641	001	May 16, 2006	Jun	CFTG	
AB	+	EQ 1MG BASE	N021641	002	May 16, 2006	Jun	CFTG	
	RASAGILINE MESYLATE							
AB	APOTEX INC	EQ 0.5MG BASE	A201950	001	Sep 12, 2013	Aug	NEWA	
AB		EQ 1MG BASE	A201950	002	Sep 12, 2013	Aug	NEWA	
AB	WATSON LABS INC	EQ 0.5MG BASE	A201823	001	Jul 01, 2013	Jun	NEWA	
AB		EQ 1MG BASE	A201823	002	Jul 01, 2013	Jun	NEWA	

REPAGLINIDE

	TABLET;ORAL							
	PRANDIN							
AB	NOVO NORDISK INC	0.5MG	N020741	001	Dec 22, 1997	Jul	CTEC	
AB		1MG	N020741	002	Dec 22, 1997	Jul	CFTG	
AB	+	2MG	N020741	003	Dec 22, 1997	Jul	CFTG	
	REPAGLINIDE							
AB	CARACO	1MG	A077571	002	Jul 11, 2013	Jul	NEWA	
AB		2MG	A077571	003	Jul 11, 2013	Jul	NEWA	
AB	MYLAN PHARMS INC	0.5MG	A090252	001	Aug 23, 2013	Aug	NEWA	
AB	PADDOCK LLC	0.5MG	A201189	001	Jul 17, 2013	Jul	NEWA	
AB	SANDOZ	0.5MG	A078555	001	Nov 22, 2013	Nov	NEWA	

RESERPINE

	TABLET;ORAL							
	SERPALAN							
	@ LANNETT	0.1MG	N010124	001		May	DISC	
	@	0.25MG	N010124	002		May	DISC	

RIFAMPIN

	CAPSULE;ORAL						
	RIFAMPIN						
AB	LUPIN PHARMS	150MG	A090034	001	Aug 21, 2013	Jul	NEWA
AB		300MG	A090034	002	Aug 21, 2013	Jul	NEWA
	INJECTABLE;INJECTION						
	RIFAMPIN						
AP	AGILA SPECLTS	600MG/VIAL	A065421	001	May 22, 2008	Nov	CAHN

RILUZOLE

	TABLET;ORAL						
	RILUTEK						
AB	+ COVIS PHARMA SARL	50MG	N020599	001	Dec 12, 1995	Apr	CAHN
	RILUZOLE						
AB	APOTEX CORP	50MG	A091300	001	Jun 18, 2013	Jun	NEWA
AB	GLENMARK GENERICS	50MG	A091394	001	Jun 18, 2013	Jun	NEWA
AB	MYLAN PHARMS INC	50MG	A203042	001	Jul 01, 2013	Jun	NEWA
AB	SUN PHARM INDS LTD	50MG	A091417	001	Jun 18, 2013	Jun	NEWA

RIMANTADINE HYDROCHLORIDE

	TABLET;ORAL						
	RIMANTADINE HYDROCHLORIDE						
	@ COREPHARMA	100MG	A075916	001	Nov 02, 2001	Feb	DISC

RIOCIGUAT

	TABLET;ORAL						
	ADEMPAS						
	BAYER HLTHCARE	0.5MG	N204819	001	Oct 08, 2013	Oct	NEWA
		1MG	N204819	002	Oct 08, 2013	Oct	NEWA
		1.5MG	N204819	003	Oct 08, 2013	Oct	NEWA
		2MG	N204819	004	Oct 08, 2013	Oct	NEWA
	+	2.5MG	N204819	005	Oct 08, 2013	Oct	NEWA

RISPERIDONE

	SOLUTION;ORAL						
	RISPERIDONE						
AA	BIO PHARM INC	1MG/ML	A078909	001	Jul 29, 2009	May	CAHN
	TABLET, ORALLY DISINTEGRATING;ORAL						
	RISPERIDONE						
AB	MYLAN PHARMS INC	0.25MG	A091537	006	Feb 12, 2013	Feb	NEWA
AB	PAR PHARM	0.25MG	A077494	001	Apr 30, 2009	Feb	CTEC
AB	SUN PHARM INDS LTD	0.5MG	A078464	001	Apr 08, 2013	Mar	NEWA
AB		1MG	A078464	002	Apr 08, 2013	Mar	NEWA
AB		2MG	A078464	003	Apr 08, 2013	Mar	NEWA
AB		3MG	A078464	004	Apr 08, 2013	Mar	NEWA
AB		4MG	A078464	005	Apr 08, 2013	Mar	NEWA

RIVASTIGMINE TARTRATE

	CAPSULE;ORAL						
	RIVASTIGMINE TARTRATE						
AB	APOTEX INC	EQ 1.5MG BASE	A091072	001	May 16, 2013	Apr	NEWA
AB		EQ 3MG BASE	A091072	002	May 16, 2013	Apr	NEWA
AB		EQ 4.5MG BASE	A091072	003	May 16, 2013	Apr	NEWA
AB		EQ 6MG BASE	A091072	004	May 16, 2013	Apr	NEWA

RIZATRIPTAN BENZOATE

	TABLET;ORAL						
	RIZATRIPTAN BENZOATE						
AB	CIPLA LTD	EQ 5MG BASE	A077526	001	Mar 26, 2013	Mar	NEWA
AB		EQ 10MG BASE	A077526	002	Mar 26, 2013	Mar	NEWA
AB	EMCURE PHARMS LTD	EQ 5MG BASE	A204090	001	Nov 26, 2013	Nov	NEWA
AB		EQ 10MG BASE	A204090	002	Nov 26, 2013	Nov	NEWA
AB	INVAGEN PHARMS	EQ 5MG BASE	A204339	001	Jul 01, 2013	Jun	NEWA
AB		EQ 10MG BASE	A204339	002	Jul 01, 2013	Jun	NEWA
	TABLET, ORALLY DISINTEGRATING;ORAL						
	RIZATRIPTAN BENZOATE						
AB	APOTEX INC	EQ 5MG BASE	A202477	001	Jul 01, 2013	Jun	NEWA
AB		EQ 10MG BASE	A202477	002	Jul 01, 2013	Jun	NEWA
AB	AUROBINDO PHARMA LTD	EQ 5MG BASE	A203062	001	Jul 01, 2013	Jun	NEWA
AB		EQ 10MG BASE	A203062	002	Jul 01, 2013	Jun	NEWA
AB	GLENMARK GENERICS	EQ 5MG BASE	A201914	001	Jul 01, 2013	Jun	NEWA

TABLET, ORALLY DISINTEGRATING;ORAL  
RIZATRIPTAN BENZOATE

AB		EQ 10MG BASE	A201914	002	Jul 01, 2013	Jun	NEWA
AB	NATCO PHARMA LTD	EQ 5MG BASE	A203478	001	Jul 01, 2013	Jun	NEWA
AB		EQ 10MG BASE	A203478	002	Jul 01, 2013	Jun	NEWA
AB	SANDOZ	EQ 5MG BASE	A078739	001	Jul 01, 2013	Jun	NEWA
AB		EQ 10MG BASE	A078739	002	Jul 01, 2013	Jun	NEWA

ROCURONIUM BROMIDE

INJECTABLE;INJECTION  
ZEMURON

AP	+ ORGANON USA INC	50MG/5ML (10MG/ML)	N020214	001	Mar 17, 1994	Jan	CAHN
	@	10MG/ML (10MG/ML)	N020214	002	Mar 17, 1994	Jan	CAHN
AP	+	100MG/10ML (10MG/ML)	N020214	003	Mar 17, 1994	Jan	CAHN

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL  
REQUIP

AB	+ GLAXOSMITHKLINE LLC	EQ 0.25MG BASE	N020658	001	Sep 19, 1997	Mar	CAHN
AB		EQ 0.5MG BASE	N020658	002	Sep 19, 1997	Mar	CAHN
AB		EQ 1MG BASE	N020658	003	Sep 19, 1997	Mar	CAHN
AB		EQ 2MG BASE	N020658	004	Sep 19, 1997	Mar	CAHN
AB		EQ 3MG BASE	N020658	006	Jan 27, 1999	Mar	CAHN
AB		EQ 4MG BASE	N020658	007	Jan 27, 1999	Mar	CAHN
AB		EQ 5MG BASE	N020658	005	Sep 19, 1997	Mar	CAHN

ROPINIROLE HYDROCHLORIDE

@	COREPHARMA	EQ 0.25MG BASE	A078230	001	May 20, 2008	Jul	DISC
@		EQ 0.5MG BASE	A078230	002	May 20, 2008	Jul	DISC
@		EQ 1MG BASE	A078230	003	May 20, 2008	Jul	DISC
@		EQ 2MG BASE	A078230	004	May 20, 2008	Jul	DISC
@		EQ 3MG BASE	A078230	005	May 20, 2008	Jul	DISC
@		EQ 4MG BASE	A078230	006	May 20, 2008	Jul	DISC
@		EQ 5MG BASE	A078230	007	May 20, 2008	Jul	DISC

TABLET, EXTENDED RELEASE;ORAL

REQUIP XL

AB	+ GLAXOSMITHKLINE LLC	EQ 2MG BASE	N022008	001	Jun 13, 2008	Mar	CAHN
	@	EQ 3MG BASE	N022008	002	Jun 13, 2008	Mar	CAHN
AB		EQ 4MG BASE	N022008	003	Jun 13, 2008	Mar	CAHN
AB		EQ 6MG BASE	N022008	006	Apr 10, 2009	Mar	CAHN
AB		EQ 8MG BASE	N022008	004	Jun 13, 2008	Mar	CAHN
AB		EQ 12MG BASE	N022008	005	Oct 31, 2008	Mar	CAHN

ROPINIROLE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	EQ 2MG BASE	A090869	001	May 17, 2012	Apr	CAHN
AB		EQ 4MG BASE	A090869	002	May 17, 2012	Apr	CAHN
AB		EQ 6MG BASE	A090869	003	May 17, 2012	Apr	CAHN
AB		EQ 8MG BASE	A090869	004	May 17, 2012	Apr	CAHN
AB		EQ 12MG BASE	A090869	005	May 17, 2012	Apr	CAHN
AB	ALEMBIC LTD	EQ 2MG BASE	A202786	001	Apr 22, 2013	Apr	NEWA
AB		EQ 4MG BASE	A202786	002	Apr 22, 2013	Apr	NEWA
AB		EQ 6MG BASE	A202786	003	Apr 22, 2013	Apr	NEWA
AB		EQ 8MG BASE	A202786	004	Apr 22, 2013	Apr	NEWA
AB		EQ 12MG BASE	A202786	005	Apr 22, 2013	Apr	NEWA

ROSIGLITAZONE MALEATE

TABLET;ORAL  
AVANDIA

AB	SB PHARMCO	EQ 2MG BASE	N021071	002	May 25, 1999	Jan	CFTG
AB		EQ 4MG BASE	N021071	003	May 25, 1999	Jan	CFTG
AB	+	EQ 8MG BASE	N021071	004	May 25, 1999	Jan	CFTG

ROSIGLITAZONE MALEATE

AB	TEVA	EQ 2MG BASE	A076747	001	Jan 25, 2013	Jan	NEWA
AB		EQ 4MG BASE	A076747	002	Jan 25, 2013	Jan	NEWA
AB		EQ 8MG BASE	A076747	003	Jan 25, 2013	Jan	NEWA

ROTIGOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL  
NEUPRO

+	UCB INC	2MG/24HR	N021829	001	May 09, 2007	May	CRLD
		8MG/24HR	N021829	006	Apr 02, 2012	May	CRLD

SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION  
QUADRAMET

>D>	+	JAZZ EUSA PHARMA	50mCi/ML	N020570	001	Mar 28, 1997	Dec CAHN
>A>	+	LANTHEUS MEDICAL	50mCi/ML	N020570	001	Mar 28, 1997	Dec CAHN

SAPROPTERIN DIHYDROCHLORIDE

FOR SOLUTION; ORAL  
KUVAN

>A>	+	BIOMARIN PHARM	100MG	N205065	001	Dec 19, 2013	Dec NEWA
>A>		POWDER; ORAL					
>A>		KUVAN					
>A>	+	BIOMARIN PHARM	100MG/PACKET	N205065	001	Dec 19, 2013	Dec NEWA

SAQUINAVIR MESYLATE

TABLET; ORAL  
INVIRASE

+	HOFFMAN LA ROCHE	EQ 500MG BASE	N021785	001	Dec 17, 2004	Feb CAHN
---	------------------	---------------	---------	-----	--------------	----------

SELEGILINE HYDROCHLORIDE

TABLET; ORAL  
SELEGILINE HYDROCHLORIDE  
@ DAVA PHARMS INC 5MG

A074641	001	Aug 02, 1996	Jan DISC
---------	-----	--------------	----------

SERTACONAZOLE NITRATE

CREAM; TOPICAL  
ERTACZO

+	VALEANT LUXEMBOURG	2%	N021385	001	Dec 10, 2003	Jun CAHN
---	--------------------	----	---------	-----	--------------	----------

SERTRALINE HYDROCHLORIDE

TABLET; ORAL  
SERTRALINE HYDROCHLORIDE

@	CIPLA LTD	EQ 25MG BASE	A077162	001	Feb 06, 2007	Aug CAHN
@		EQ 50MG BASE	A077162	002	Feb 06, 2007	Aug CAHN
@		EQ 100MG BASE	A077162	003	Feb 06, 2007	Aug CAHN
@	DR REDDYS LABS LTD	EQ 25MG BASE	A076442	001	Apr 30, 2007	Apr DISC
@		EQ 50MG BASE	A076442	002	Apr 30, 2007	Apr DISC
@		EQ 100MG BASE	A076442	003	Apr 30, 2007	Apr DISC

SILDENAFIL CITRATE

TABLET; ORAL  
SILDENAFIL CITRATE

AB	ACTAVIS GRP PTC	EQ 20MG BASE	A200149	001	Feb 25, 2013	Apr CAHN
AB	ACTAVIS PHARMA	EQ 20MG BASE	A200149	001	Feb 25, 2013	Feb NEWA
AB	AMNEAL PHARMS	EQ 20MG BASE	A202025	001	Feb 28, 2013	Feb NEWA
>A> AB	MACLEODS PHARMS LTD	EQ 20MG BASE	A203814	001	Dec 17, 2013	Dec NEWA

SIMEPREVIR

CAPSULE; ORAL  
OLYSIO

+	JANSSEN RES AND DEV	150MG	N205123	001	Nov 22, 2013	Nov NEWA
---	---------------------	-------	---------	-----	--------------	----------

SIMVASTATIN; SITAGLIPTIN PHOSPHATE

TABLET; ORAL  
JUVISYNC

@	MERCK SHARP DOHME	10MG; EQ 50MG BASE	N202343	004	Sep 18, 2012	Sep DISC
@		10MG; EQ 100MG BASE	N202343	001	Oct 07, 2011	Sep DISC
@		20MG; EQ 50MG BASE	N202343	005	Sep 18, 2012	Sep DISC
@		20MG; EQ 100MG BASE	N202343	002	Oct 07, 2011	Sep DISC
@		40MG; EQ 50MG BASE	N202343	006	Sep 18, 2012	Sep DISC
@		40MG; EQ 100MG BASE	N202343	003	Oct 07, 2011	Sep DISC

SIROLIMUS

SOLUTION; ORAL  
RAPAMUNE

+	PF PRISM CV	1MG/ML	N021083	001	Sep 15, 1999	Sep CAHN
---	-------------	--------	---------	-----	--------------	----------

TABLET; ORAL  
RAPAMUNE

>D>		PF PRISM CV	0.5MG	N021110	004	Jan 25, 2010	Dec CFTG
>A>	AB		0.5MG	N021110	004	Jan 25, 2010	Dec CFTG
			0.5MG	N021110	004	Jan 25, 2010	Sep CAHN

TABLET;ORAL  
RAPAMUNE

		1MG	N021110	001	Aug 25, 2000	Sep CAHN
+		2MG	N021110	002	Aug 22, 2002	Sep CAHN
	@	5MG	N021110	003	Feb 23, 2004	Sep CAHN
>A>	SIROLIMUS					
>A> AB	ZYDUS PHARMS USA INC	0.5MG	A201676	003	Jan 08, 2014	Dec NEWA

SODIUM CHLORIDE

INJECTABLE;INJECTION  
SODIUM CHLORIDE 0.9%

	MEDEFIL INC	18MG/2ML (9MG/ML)	N202832	002	Jan 06, 2012	Mar NEWA
		22.5MG/2.5ML (9MG/ML)	N202832	003	Jan 06, 2012	Mar NEWA
		27MG/3ML (9MG/ML)	N202832	004	Jan 06, 2012	Mar NEWA
		45MG/5ML (9MG/ML)	N202832	005	Jan 06, 2012	Mar NEWA
		90MG/10ML (9MG/ML)	N202832	006	Jan 06, 2012	Mar NEWA
	SODIUM CHLORIDE 0.9%					
	HIKMA MAPLE	9MG/ML	A201833	001	Sep 24, 2013	Sep NEWA
	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	MEDEFIL INC	9MG/ML (9MG/ML)	N202832	001	Jan 06, 2012	Mar CPOT

SOLUTION;IRRIGATION  
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	@ BAXTER HLTHCARE	450MG/100ML	N017864	001		Jan DISC
--	-------------------	-------------	---------	-----	--	----------

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS  
SODIUM FLUORIDE F-18

>D>	+	HOUSTON CYCLOTRON	10-200mCi/ML	A203544	001	Dec 26, 2012	Dec CTEC
>A> AP	+		10-200mCi/ML	A203544	001	Dec 26, 2012	Dec CTEC
	+	MCPRF	10-91.5MCI/ML	A203605	001	Jun 28, 2013	Jun NEWA
>A> AP		UNIV TX MD ANDERSON	10-200mCi/ML	A203247	001	Dec 23, 2013	Dec NEWA

SODIUM IODIDE I-123

CAPSULE;ORAL  
SODIUM IODIDE I 123

	@ CARDINAL HLTH 414	400uCi	N018671	003	May 27, 1982	Sep DISC
--	---------------------	--------	---------	-----	--------------	----------

SODIUM PHENYLBUTYRATE

POWDER;ORAL  
BUPHENYL

>A> AB	+	HYPERION THERAPS INC	3GM/TEASPOONFUL	N020573	001	Apr 30, 1996	Dec CAHN
>D> AB	+	MEDICIS	3GM/TEASPOONFUL	N020573	001	Apr 30, 1996	Dec CAHN
AB	+		3GM/TEASPOONFUL	N020573	001	Apr 30, 1996	Mar CFTG
		SODIUM PHENYLBUTYRATE					
AB		SIGMAPHARM LABS LLC	3GM/TEASPOONFUL	A202819	001	Mar 22, 2013	Mar NEWA

TABLET;ORAL  
BUPHENYL

>A> AB	+	HYPERION THERAPS INC	500MG	N020572	001	May 13, 1996	Dec CAHN
>D> AB	+	MEDICIS	500MG	N020572	001	May 13, 1996	Dec CAHN

SODIUM PHOSPHATE, DIBASIC ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET;ORAL  
VISICOL

	@ SALIX PHARMS	0.398GM;1.102GM	N021097	001	Sep 21, 2000	Jul DISC
--	----------------	-----------------	---------	-----	--------------	----------

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET;ORAL  
MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE

	@ NOVEL LABS INC	0.398GM;1.102GM	A079247	001	Dec 30, 2011	Aug DISC
	OSMOPREP					
+	SALIX PHARMS	0.398GM;1.102GM	N021892	001	Mar 16, 2006	Aug CTEC

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE;INJECTION  
SODIUM PHOSPHATES IN PLASTIC CONTAINER

+	HOSPIRA	142MG/ML;276MG/ML	N018892	001	May 10, 1983	Jun CRLD
---	---------	-------------------	---------	-----	--------------	----------

SODIUM POLYSTYRENE SULFONATEPOWDER;ORAL, RECTAL  
KAYEXALATE

AA + COVIS PHARMA SARL 453.6GM/BOT N011287 001 Apr CAHN

SUSPENSION;ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

AA ROXANE 15GM/60ML A089049 001 Nov 17, 1986 Oct CMFD

@ 15GM/60ML A089049 001 Nov 17, 1986 Mar DISC

>A> SOFOSBUVIR

&gt;A&gt; TABLET;ORAL

&gt;A&gt; SOLVADI

&gt;A&gt; + GILEAD SCIENCES INC 400MG N204671 001 Dec 06, 2013 Dec NEWA

STAVUDINE

CAPSULE;ORAL

STAVUDINE

AB HETERO LABS LTD III 15MG A078957 001 Dec 29, 2008 Apr CAHN

AB 20MG A078957 002 Dec 29, 2008 Apr CAHN

AB 30MG A078957 003 Dec 29, 2008 Apr CAHN

AB 40MG A078957 004 Dec 29, 2008 Apr CAHN

STREPTOZOCIN

INJECTABLE;INJECTION

ZANOSAR

+ TEVA PHARMS USA 1GM/VIAL

N050577 001 May 07, 1982 Apr CAHN

SUCCIMER

CAPSULE;ORAL

CHEMET

+ RECORDATI RARE 100MG

N019998 002 Jan 30, 1991 May CAHN

SUCROFERRIC OXYHYDROXIDE

TABLET, CHEWABLE;ORAL

VELPHORO

+ VIFOR FRESENIUS 500MG

N205109 001 Nov 27, 2013 Nov NEWA

SULFACETAMIDE SODIUM

LOTION;TOPICAL

KLARON

AB + VALEANT BERMUDA 10% N019931 001 Dec 23, 1996 Feb CAHN

OINTMENT;OPHTHALMIC

SULFACETAMIDE SODIUM

AT PERRIGO CO TENNESSEE 10% A080029 001 Jun CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE;INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM

+ TEVA PHARMS USA 80MG/ML;16MG/ML

A073303 001 Oct 31, 1991 Mar CAHN

TABLET;ORAL

SULFAMETHOPRIM

@ NOVEL LABS INC 400MG;80MG

A070022 001 Feb 15, 1985 Mar DISC

SULFAMETHOPRIM-DS

@ NOVEL LABS INC 800MG;160MG

A070032 001 Feb 15, 1985 Mar DISC

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH

@ SANDOZ 800MG;160MG

N018598 004 May 19, 1982 Jun DISC

SULINDAC

TABLET;ORAL

SULINDAC

AB HERITAGE PHARMS INC 150MG A073262 002 Sep 06, 1991 Apr CMFD

AB 200MG A073262 001 Sep 06, 1991 Apr CMFD

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

AP AUROBINDO PHARMA LTD EQ 6MG BASE/0.5ML (EQ 12MG

BASE/ML) A202758 001 Apr 23, 2013 Apr NEWA

&gt;D&gt; AP FRESENIUS KABI USA EQ 6MG BASE/0.5ML (EQ 12MG

BASE/ML) A079240 002 Sep 18, 2009 Dec DISC

&gt;A&gt; @ EQ 6MG BASE/0.5ML (EQ 12MG A079240 002 Sep 18, 2009 Dec DISC



INJECTABLE; SUBCUTANEOUS  
SUMATRIPTAN SUCCINATE

			BASE/ML)						
>D>	AP		EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A 079240	001	Sep 18, 2009	Dec	DISC	
>A>	@		EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A 079240	001	Sep 18, 2009	Dec	DISC	
	AP	HIKMA FARMACEUTICA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A 200183	001	Sep 16, 2013	Aug	NEWA	
	AP	SAGENT AGILA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A 090641	001	Jul 28, 2010	Feb	CAHN	
>D>	AP	SANDOZ	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A 078067	002	Feb 06, 2009	Dec	DISC	
>A>	@		EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A 078067	002	Feb 06, 2009	Dec	DISC	
>D>	AP		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A 078067	001	Feb 06, 2009	Dec	DISC	
>A>	@		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A 078067	001	Feb 06, 2009	Dec	DISC	
	AP	TEVA PHARMS USA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A 077907	001	Feb 06, 2009	Mar	CAHN	

SYSTEM; IONTOPHORESIS  
ZECURITY

+ NUPATHE	EQ 6.5MG BASE/4HR	N 202278	001	Jan 17, 2013	Jan	NEWA
-----------	-------------------	----------	-----	--------------	-----	------

## TABLET; ORAL

## SUMATRIPTAN SUCCINATE

AB	HIKMA PHARMS	EQ 25MG BASE	A 078298	001	May 21, 2013	May	NEWA
AB		EQ 50MG BASE	A 078298	002	May 21, 2013	May	NEWA
AB		EQ 100MG BASE	A 078298	003	May 21, 2013	May	NEWA
	@ MYLAN	EQ 25MG BASE	A 077163	001	Nov 02, 2009	Aug	DISC
	@	EQ 50MG BASE	A 077163	002	Nov 02, 2009	Aug	DISC
	@	EQ 100MG BASE	A 077163	003	Nov 02, 2009	Aug	DISC
	@ TEVA	EQ 25MG BASE	A 076840	001	Feb 09, 2009	Nov	DISC
	@	EQ 50MG BASE	A 076840	002	Feb 09, 2009	Nov	DISC
	@	EQ 100MG BASE	A 076840	003	Feb 09, 2009	Nov	DISC

TACROLIMUS

## CAPSULE, EXTENDED RELEASE; ORAL

## ASTAGRAF XL

	ASTELLAS	EQ 0.5MG BASE	N 204096	001	Jul 19, 2013	Jul	NEWA
		EQ 1MG BASE	N 204096	002	Jul 19, 2013	Jul	NEWA
	+	EQ 5MG BASE	N 204096	003	Jul 19, 2013	Jul	NEWA

## OINTMENT; TOPICAL

## PROTOPIC

+	ASTELLAS	0.03%	N 050777	001	Dec 08, 2000	Jun	CRLD
---	----------	-------	----------	-----	--------------	-----	------

TAMSULOSIN HYDROCHLORIDE

## CAPSULE; ORAL

## TAMSULOSIN HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	0.4MG	A 202433	001	Apr 30, 2013	Apr	NEWA
----	----------------------	-------	----------	-----	--------------	-----	------

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

## INJECTABLE; INJECTION

## PULMOLITE

>A>	BS	JUBILANT DRAXIMAGE	N/A	N 017776	001		Dec	CAHN
>D>	BS	PHARMALUCENCE	N/A	N 017776	001		Dec	CAHN

TECHNETIUM TC-99M PENTETATE KIT

## INJECTABLE; INJECTION

## AN-DTPA

>A>	AP	JUBILANT DRAXIMAGE	N/A	N 017714	001		Dec	CAHN
>D>	AP	PHARMALUCENCE	N/A	N 017714	001		Dec	CAHN

TECHNETIUM TC-99M TILMANOCEPT

## INJECTABLE; INJECTION

## LYMPHOSEEK KIT

+	NAVIDEA BIOPHARMS	N/A	N 202207	001	Mar 13, 2013	Mar	NEWA
---	-------------------	-----	----------	-----	--------------	-----	------

TELMISARTAN

## TABLET; ORAL

## MICARDIS

>D>		BOEHRINGER INGELHEIM	20MG	N 020850	003	Apr 04, 2000	Dec	CFTG
>A>	AB		20MG	N 020850	003	Apr 04, 2000	Dec	CFTG
>D>			40MG	N 020850	001	Nov 10, 1998	Dec	CFTG
>A>	AB		40MG	N 020850	001	Nov 10, 1998	Dec	CFTG
>D>		+	80MG	N 020850	002	Nov 10, 1998	Dec	CFTG
>A>	AB	+	80MG	N 020850	002	Nov 10, 1998	Dec	CFTG

	TABLET;ORAL							
>A>	TELMISARTAN							
>A> AB	WATSON LABS	20MG	A078710	001	Jan 08, 2014	Dec	NEWA	
>A> AB		40MG	A078710	002	Jan 08, 2014	Dec	NEWA	
>A> AB		80MG	A078710	003	Jan 08, 2014	Dec	NEWA	
	<u>TEMSIROLIMUS</u>							
	SOLUTION;INTRAVENOUS							
	TORISEL							
>A>	+ PF PRISM CV	25MG/ML (25MG/ML)	N022088	001	May 30, 2007	Dec	CAHN	
>D>	+ WYETH PHARMS INC	25MG/ML (25MG/ML)	N022088	001	May 30, 2007	Dec	CAHN	
	<u>TENIPOSIDE</u>							
	INJECTABLE;INJECTION							
	VUMON							
	+ CORDEN PHARMA	10MG/ML	N020119	001	Jul 14, 1992	Apr	CAHN	
	+ HQ SPECLT PHARMA	10MG/ML	N020119	001	Jul 14, 1992	Jul	CAHN	
	<u>TERBINAFINE HYDROCHLORIDE</u>							
	TABLET;ORAL							
	TERBINAFINE HYDROCHLORIDE							
AB	CIPLA LTD	EQ 250MG BASE	A077137	001	Jul 02, 2007	Jul	CAHN	
	@ MYLAN	EQ 250MG BASE	A077136	001	Jul 02, 2007	Aug	DISC	
	<u>TERBUTALINE SULFATE</u>							
	INJECTABLE;INJECTION							
	TERBUTALINE SULFATE							
	@ TEVA PHARMS USA	1MG/ML	A076853	001	Jul 20, 2004	Mar	CAHN	
AP	UNITED BIOMEDCL	1MG/ML	A200122	001	Nov 08, 2013	Oct	NEWA	
	<u>TERCONAZOLE</u>							
	SUPPOSITORY;VAGINAL							
	TERCONAZOLE							
>D> AB	FOUGERA PHARMS	80MG	A076850	001	Jul 12, 2006	Dec	DISC	
>A>	@	80MG	A076850	001	Jul 12, 2006	Dec	DISC	
>D> AB	TARO	80MG	A077553	001	Mar 09, 2007	Dec	DISC	
>A>	@	80MG	A077553	001	Mar 09, 2007	Dec	DISC	
	<u>TESTOSTERONE</u>							
	GEL;TRANSDERMAL							
	TESTOSTERONE							
	PERRIGO ISRAEL	25MG/2.5GM PACKET	N203098	002	Jan 31, 2013	Jan	NEWA	
		50MG/5GM PACKET	N203098	003	Jan 31, 2013	Jan	NEWA	
	GEL, METERED;TRANSDERMAL							
	TESTOSTERONE							
	PERRIGO ISRAEL	12.5MG/1.25GM ACTUATION	N203098	001	Jan 31, 2013	Jan	NEWA	
	<u>TESTOSTERONE CYPIONATE</u>							
	INJECTABLE;INJECTION							
	TESTOSTERONE CYPIONATE							
AO	SUN PHARM INDS LTD	100MG/ML	A201720	001	Jun 03, 2013	May	NEWA	
AO		200MG/ML	A201720	002	Jun 03, 2013	May	NEWA	
	<u>TESTOSTERONE ENANTHATE</u>							
	INJECTABLE;INJECTION							
	DELATESTRYL							
	@ ENDO PHARMS	200MG/ML	N009165	001		Jan	CAHN	
AO	+	200MG/ML	N009165	003		Jan	CAHN	
	<u>TETRACYCLINE HYDROCHLORIDE</u>							
	CAPSULE;ORAL							
	ACHROMYCIN V							
>D>	@ HERITAGE PHARMS INC	250MG	N050278	003		Dec	CMFD	
>A> AB		250MG	N050278	003		Dec	CMFD	
>D>	@	500MG	N050278	001		Dec	CMFD	
>A> AB		500MG	N050278	001		Dec	CMFD	

THALLOUS CHLORIDE TL-201

INJECTABLE;INTRAVENOUS  
THALLOUS CHLORIDE TL 201  
@ MALLINCKRODT 2mCi/ML

A077698 001 Nov 09, 2006 Aug DISC

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL  
THEOPHYLLINE

>A>	AB	RHODES PHARMS	600MG	A040086	001	Apr 15, 1996	Dec	CMFD
	AB	+ TEVA PHARMS	450MG	A081236	001	Nov 09, 1992	Mar	CAHN
		UNIPHYL						
>D>		@ RHODES PHARMS	400MG	A087571	001	Sep 01, 1982	Dec	CMFD
>A>	AB		400MG	A087571	001	Sep 01, 1982	Dec	CMFD
>D>		@	600MG	A040086	001	Apr 15, 1996	Dec	CMFD

THIABENDAZOLE

SUSPENSION;ORAL  
MINTEZOL

@ MERCK SHARP DOHME 500MG/5ML

N016097 001 May CAHN

TABLET, CHEWABLE;ORAL  
MINTEZOL

@ MERCK SHARP DOHME 500MG

N016096 001 May CAHN

THIOGUANINE

TABLET;ORAL  
THIOGUANINE

+ ASPEN GLOBAL INC 40MG

N012429 001 Mar CAHN

TICLOPIDINE HYDROCHLORIDE

TABLET;ORAL

TICLOPIDINE HYDROCHLORIDE

@ MYLAN 250MG

A075161 001 Sep 13, 1999 Aug DISC

TIGECYCLINE

INJECTABLE;IV (INFUSION)  
TYGACIL

+ PF PRISM CV 50MG/VIAL

N021821 001 Jun 15, 2005 Aug CAHN

TILUDRONATE DISODIUM

TABLET;ORAL  
SKELID

@ SANOFI AVENTIS US EQ 200MG BASE

N020707 001 Mar 07, 1997 Jun DISC

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS;OPHTHALMIC  
TIMOPTIC-XE

AB + VALEANT PHARMS LLC EQ 0.25% BASE

N020330 001 Nov 04, 1993 Jan CAHN

AB + EQ 0.5% BASE

N020330 002 Nov 04, 1993 Jan CAHN

SOLUTION/DROPS;OPHTHALMIC  
ISTALOL

BT + BAUSCH AND LOMB EQ 0.5% BASE

N021516 001 Jun 04, 2004 May CAHN

TIMOLOL MALEATE

@ AKORN EQ 0.25% BASE

A074515 001 Mar 25, 1997 Jun DISC

@ APOTEX INC EQ 0.25% BASE

A075411 001 Sep 08, 2000 Apr DISC

@ EQ 0.5% BASE

A075412 001 Sep 08, 2000 Apr DISC

TINIDAZOLE

TABLET;ORAL  
TINIDAZOLE

AB UNIQUE PHARM LABS 250MG

A202489 001 Oct 09, 2013 Sep NEWA

AB 500MG

A202489 002 Oct 09, 2013 Sep NEWA

TIOPRONIN

TABLET;ORAL  
THIOLA

+ MISSION PHARMA 100MG

N019569 001 Aug 11, 1988 Aug CTNA

TIZANIDINE HYDROCHLORIDE

	CAPSULE; ORAL										
	TIZANIDINE HYDROCHLORIDE										
AB	MYLAN PHARMS INC	EQ 2MG BASE	A 091502	001	Nov 09, 2012	May	CAHN				
AB		EQ 4MG BASE	A 091502	002	Nov 09, 2012	May	CAHN				
AB		EQ 6MG BASE	A 091502	003	Nov 09, 2012	May	CAHN				
	TABLET; ORAL										
	TIZANIDINE HYDROCHLORIDE										
	@ MYLAN PHARMS INC	EQ 2MG BASE	A 076282	001	Dec 16, 2003	Feb	DISC				
	@	EQ 4MG BASE	A 076282	002	Dec 16, 2003	Feb	DISC				

TOBRAMYCIN

	POWDER; INHALATION										
	TOBI PODHALER										
	+	NOVARTIS	28MG	N 201688	001	Mar 22, 2013	Mar	NEWA			
	SOLUTION; INHALATION										
	TOBI										
AN	+	NOVARTIS PHARMS	300MG/5ML	N 050753	001	Dec 22, 1997	Sep	CFTG			
	TOBRAMYCIN										
AN		TEVA PHARMS USA	300MG/5ML	A 091589	001	Oct 10, 2013	Sep	NEWA			
	SOLUTION/DROPS; OPHTHALMIC										
	TOBRAMYCIN										
	@ APOTEX INC	0.3%	A 065087	001	Feb 25, 2002	Apr	DISC				

TOBRAMYCIN SULFATE

	INJECTABLE; INJECTION										
	TOBRAMYCIN SULFATE										
AP	AGILA SPECLTS	EQ 40MG BASE/ML	A 065407	001	Mar 11, 2008	Nov	CAHN				
AP	TEVA PHARMS USA	EQ 40MG BASE/ML	A 063100	001	Jan 30, 1992	Sep	CAHN				

TOFACITINIB CITRATE

	TABLET; ORAL										
	XELJANZ										
	+	PF PRISM CV	EQ 5MG BASE	N 203214	001	Nov 06, 2012	Sep	CAHN			

TOLAZAMIDE

	TABLET; ORAL										
	TOLAZAMIDE										
	MYLAN PHARMS INC	250MG	A 070259	001	Jan 02, 1986	Mar	CTEC				
	+	500MG	A 070259	003	Mar 17, 1986	Mar	CTEC				
	@ WATSON LABS	250MG	A 070514	001	Jan 09, 1986	Mar	DISC				
	@	500MG	A 070515	001	Jan 09, 1986	Mar	DISC				

TOLTERODINE TARTRATE

	CAPSULE, EXTENDED RELEASE; ORAL										
	DETROL LA										
AB	PHARMACIA AND UPJOHN	2MG	N 021228	001	Dec 22, 2000	Oct	CFTG				
AB	+	4MG	N 021228	002	Dec 22, 2000	Oct	CFTG				
	TOLTERODINE TARTRATE										
AB	MYLAN PHARMS INC	2MG	A 201486	001	Oct 31, 2013	Oct	NEWA				
AB		4MG	A 201486	002	Oct 31, 2013	Oct	NEWA				

TOPIRAMATE

	CAPSULE; ORAL										
	TOPIRAMATE										
>D>	AB	SANDOZ	15MG	A 079206	001	Oct 14, 2009	Dec	DISC			
>A>	@	15MG	A 079206	001	Oct 14, 2009	Dec	DISC				
>D>	AB	25MG	A 079206	002	Oct 14, 2009	Dec	DISC				
>A>	@	25MG	A 079206	002	Oct 14, 2009	Dec	DISC				
	CAPSULE, EXTENDED RELEASE; ORAL										
	TROKENDI XR										
		SUPERNUS PHARMS	25MG	N 201635	001	Aug 16, 2013	Aug	NEWA			
		50MG	N 201635	002	Aug 16, 2013	Aug	NEWA				
		100MG	N 201635	003	Aug 16, 2013	Aug	NEWA				
	+	200MG	N 201635	004	Aug 16, 2013	Aug	NEWA				
	TABLET; ORAL										
	TOPAMAX										
AB	JANSSEN PHARMS	25MG	N 020505	004	Dec 24, 1996	Apr	CRLD				
AB	+	100MG	N 020505	001	Dec 24, 1996	Apr	CRLD				

TABLET;ORAL							
TOPIRAMATE							
AB	ACTIVIS TOTOWA LLC	25MG	A078637	001	Feb 27, 2013	Feb	NEWA
AB		50MG	A078637	002	Feb 27, 2013	Feb	NEWA
AB		100MG	A078637	003	Feb 27, 2013	Feb	NEWA
AB		200MG	A078637	004	Feb 27, 2013	Feb	NEWA
AB	LUPIN	25MG	A078410	001	Sep 11, 2013	Aug	NEWA
AB		50MG	A078410	002	Sep 11, 2013	Aug	NEWA
AB		100MG	A078410	003	Sep 11, 2013	Aug	NEWA
AB		200MG	A078410	004	Sep 11, 2013	Aug	NEWA
AB	UNICHEM LABS LTD	200MG	A090162	004	Feb 19, 2013	Feb	NEWA
>D>	@ UPSHER SMITH	25MG	A078499	001	Jan 07, 2010	Dec	CMFD
>A>	AB	25MG	A078499	001	Jan 07, 2010	Dec	CMFD
	@	25MG	A078499	001	Jan 07, 2010	Jun	DISC
>D>	@	50MG	A078499	002	Jan 07, 2010	Dec	CMFD
>A>	AB	50MG	A078499	002	Jan 07, 2010	Dec	CMFD
	@	50MG	A078499	002	Jan 07, 2010	Jun	DISC
>D>	@	100MG	A078499	003	Jan 07, 2010	Dec	CMFD
>A>	AB	100MG	A078499	003	Jan 07, 2010	Dec	CMFD
	@	100MG	A078499	003	Jan 07, 2010	Jun	DISC
>D>	@	200MG	A078499	004	Jan 07, 2010	Dec	CMFD
>A>	AB	200MG	A078499	004	Jan 07, 2010	Dec	CMFD
	@	200MG	A078499	004	Jan 07, 2010	Jun	DISC
TOPIRAMATE							
AB	HIKMA PHARMS	25MG	A091185	001	Nov 25, 2013	Nov	NEWA
AB		50MG	A091185	002	Nov 25, 2013	Nov	NEWA
AB		100MG	A091185	003	Nov 25, 2013	Nov	NEWA
AB		200MG	A091185	004	Nov 25, 2013	Nov	NEWA
<u>TOPOTECAN HYDROCHLORIDE</u>							
CAPSULE;ORAL							
HYCANTIN							
	GLAXO WELLCOME	EQ 0.25MG BASE	N020981	001	Oct 11, 2007	Sep	CAHN
+		EQ 1MG BASE	N020981	002	Oct 11, 2007	Sep	CAHN
INJECTABLE;INJECTION							
TOPOTECAN HYDROCHLORIDE							
AP	ACCORD HLTHCARE	EQ 4MG BASE/VIAL	A202351	001	Jun 26, 2013	Jun	NEWA
AP	SUN PHARM INDS LTD	EQ 4MG BASE/VIAL	A202203	001	Aug 29, 2013	Aug	NEWA
<u>TOREMIFENE CITRATE</u>							
TABLET;ORAL							
FARESTON							
+	PROSTRAKAN INC	EQ 60MG BASE	N020497	001	May 29, 1997	May	CAHN
<u>TORSEMIDE</u>							
TABLET;ORAL							
TORSEMIDE							
AB	HETERO LABS LTD III	5MG	A079234	001	Jan 27, 2009	Apr	CAHN
AB		10MG	A079234	002	Jan 27, 2009	Apr	CAHN
AB		20MG	A079234	003	Jan 27, 2009	Apr	CAHN
AB		100MG	A079234	004	Jan 27, 2009	Apr	CAHN
<u>TRAMADOL HYDROCHLORIDE</u>							
TABLET;ORAL							
TRAMADOL HYDROCHLORIDE							
AB	ACCORD HLTHCARE INC	50MG	A202390	001	May 16, 2013	Apr	NEWA
AB	CSPC OUYI PHARM CO	50MG	A091498	001	Mar 29, 2013	Mar	NEWA
TABLET, EXTENDED RELEASE;ORAL							
TRAMADOL HYDROCHLORIDE							
AB2	ACTAVIS ELIZABETH	100MG	A091609	001	Jun 27, 2012	Apr	CAHN
AB2		200MG	A091609	002	Jun 27, 2012	Apr	CAHN
AB2		300MG	A091609	003	Jun 27, 2012	Apr	CAHN
AB1	PAR PHARM INC	100MG	A078783	001	Nov 13, 2009	Feb	CRLD
AB2	+ SUN PHARMA GLOBAL	100MG	A091607	001	Dec 30, 2011	Feb	CRLD
TABLET, ORALLY DISINTEGRATING;ORAL							
RYBIX ODT							
	@ SHIONOGI INC	50MG	N021693	001	May 05, 2005	Aug	DISC

TRAMETINIB DIMETHYL SULFOXIDE

TABLET; ORAL  
MEKINIST

	GLAXOSMITHKLINE LLC	EQ 0.5MG NON-SOLVATED PARENT	N204114	001	May 29, 2013	May	NEWA
		EQ 1MG NON-SOLVATED PARENT	N204114	002	May 29, 2013	May	NEWA
+		EQ 2MG NON-SOLVATED PARENT	N204114	003	May 29, 2013	May	NEWA

TRANDOLAPRIL

TABLET; ORAL

TRANDOLAPRIL

@	CIPLA	1MG	A077307	002	Jun 12, 2007	Jul	DISC
@		2MG	A077307	001	Jun 12, 2007	Jul	DISC
@		4MG	A077307	003	Jun 12, 2007	Jul	DISC
@	DR REDDYS LABS LTD	1MG	A078493	001	Aug 25, 2008	Apr	DISC
@		2MG	A078493	002	Aug 25, 2008	Apr	DISC
@		4MG	A078493	003	Aug 25, 2008	Apr	DISC

TRANEXAMIC ACID

INJECTABLE; INJECTION

TRANEXAMIC ACID

AP	CUSTOPHARM INC	100MG/ML	A201580	001	Jun 14, 2013	Jun	NEWA
AP	X-GEN PHARMS INC	100MG/ML	A201580	001	Jun 14, 2013	Oct	CAHN

TRAVOPROST

SOLUTION/DROPS; OPTHALMIC

TRAVOPROST

	PAR PHARM	0.004%	A091340	001	Mar 01, 2013	Feb	NEWA
--	-----------	--------	---------	-----	--------------	-----	------

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

AB	TEVA PHARMS USA	50MG	A071523	001	Dec 11, 1987	Mar	CAHN
AB		100MG	A071524	001	Dec 11, 1987	Mar	CAHN
AB	TORRENT PHARMS LTD	50MG	A202180	001	Nov 27, 2013	Nov	NEWA
AB		100MG	A202180	002	Nov 27, 2013	Nov	NEWA
AB		150MG	A202180	003	Nov 27, 2013	Nov	NEWA
AB		300MG	A202180	004	Nov 27, 2013	Nov	NEWA

TABLET, EXTENDED RELEASE; ORAL

OLEPTRO

@	ANGELINI LLC	150MG	N022411	001	Feb 02, 2010	May	DISC
@		300MG	N022411	002	Feb 02, 2010	May	DISC
+	ANGELINI PHARMA	150MG	N022411	001	Feb 02, 2010	Jun	CMFD
		300MG	N022411	002	Feb 02, 2010	Jun	CMFD

TREPROSTINIL

INJECTABLE; IV (INFUSION) - SC

REMODULIN

	UNITED THERAP	1MG/ML	N021272	001	May 21, 2002	May	CAIN
		2.5MG/ML	N021272	002	May 21, 2002	May	CAIN
		5MG/ML	N021272	003	May 21, 2002	May	CAIN
+		10MG/ML	N021272	004	May 21, 2002	Jun	CAIN

SOLUTION; INHALATION

TYVASO

+	UNITED THERAP	EQ 0.6MG BASE/ML	N022387	001	Jul 30, 2009	May	CAIN
---	---------------	------------------	---------	-----	--------------	-----	------

>A>

TABLET, EXTENDED RELEASE; ORAL

>A>

ORENITRAM

>A>		UNITED THERAP	0.125MG	N203496	001	Dec 20, 2013	Dec	NEWA
>A>			0.25MG	N203496	002	Dec 20, 2013	Dec	NEWA
>A>			1MG	N203496	003	Dec 20, 2013	Dec	NEWA
>A>	+		2.5MG	N203496	004	Dec 20, 2013	Dec	NEWA

TRETINOIN

CREAM; TOPICAL

RETIN-A

AB	+	VALEANT BERMUDA	0.025%	N019049	001	Sep 16, 1988	Jun	CAHN
AB1	+		0.05%	N017522	001		Jun	CAHN
AB	+		0.1%	N017340	001		Jun	CAHN

GEL; TOPICAL

ATRALIN

+	DOW PHARM	0.05%	N022070	001	Jul 26, 2007	Apr	CAHN
---	-----------	-------	---------	-----	--------------	-----	------

GEL;TOPICAL

AB	+	VALEANT INTL	0.04%	N020475	002	May 10, 2002	Jul	CTEC
AB	+		0.1%	N020475	001	Feb 07, 1997	Jul	CTEC
TRETINOIN								
AB		SPEAR PHARMS INC	0.04%	A202567	001	Jul 17, 2013	Jul	NEWA
AB			0.1%	A202026	001	Jul 17, 2013	Jul	NEWA

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

TRIACET								
	@	TEVA	0.025%	A084908	001		Apr	DISC
	@		0.5%	A084908	003		Apr	DISC
TRIAMCINOLONE ACETONIDE								
AT	+	FOUGERA PHARMS	0.025%	A085692	001		Apr	CRLD
AT	+		0.1%	A085692	003		Apr	CRLD
	@	G AND W LABS	0.025%	A089797	001	May 31, 1991	May	DISC
	@	TARO	0.025%	A086277	001		Apr	DISC
	@		0.1%	A086276	001		Apr	DISC
	@		0.5%	A086275	001		Apr	DISC

INJECTABLE;INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL

TRIVARIS								
	@	ALLERGAN	8MG/0.1ML (8MG/0.1ML)	N022220	001	Jun 16, 2008	May	DISC
LOTION;TOPICAL								
TRIAMCINOLONE ACETONIDE								
AT		VERSAPHARM INC	0.025%	A202374	001	May 08, 2013	Apr	NEWA
AT			0.1%	A202374	002	May 08, 2013	Apr	NEWA
AT	+	WOCKHARDT EU OPERATN	0.025%	A088450	001	Apr 01, 1985	Apr	CAHN

OINTMENT;TOPICAL

KENALOG								
	@	APOTHECON	0.025%	N011600	003		Apr	DISC
	@		0.1%	N011600	001		Apr	DISC
TRIAMCINOLONE ACETONIDE								
	@	TARO	0.025%	A040040	001	Sep 30, 1994	May	DISC
	@		0.025%	A040374	001	Jun 05, 2001	May	DISC
	@		0.1%	A087902	001	Dec 27, 1982	May	DISC
	@		0.5%	A040386	001	Jun 05, 2001	May	DISC

SPRAY, METERED;NASAL

TRIAMCINOLONE ACETONIDE								
		TEVA PHARMS	0.055MG/SPRAY	A078104	001	Jul 30, 2009	Oct	CTEC

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET;ORAL

TRIHEXYPHENIDYL HYDROCHLORIDE								
	@	WEST WARD	2MG	A040337	002	Feb 16, 2000	Jul	DISC
	@		5MG	A040337	001	Feb 16, 2000	Jul	DISC

TRIMETHOPRIM

TABLET;ORAL

TRIMETHOPRIM								
AB	+	TEVA	100MG	N018679	001	Jul 30, 1982	Jul	CRLD
	@		200MG	A071259	001	Jun 18, 1987	Jun	DISC

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

TROSPIUM CHLORIDE								
AB		PADDOCK LLC	60MG	A201291	001	May 24, 2013	May	NEWA

>A> UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE

POWDER;INHALATION								
ANORO ELLIPTA								
>A>	+	GLAXO GRP LTD	EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	N203975	001	Dec 18, 2013	Dec	NEWA

URSODIOL

TABLET;ORAL

URSODIOL								
AB		PAR PHARM	250MG	A202540	001	Feb 14, 2013	Feb	NEWA
AB			500MG	A202540	002	Feb 14, 2013	Feb	NEWA
	@	TEVA PHARMS USA	250MG	A079184	001	May 13, 2009	Apr	DISC
	@		500MG	A079184	002	May 13, 2009	Apr	DISC

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL							
VALACYCLOVIR HYDROCHLORIDE							
AB	ACTAVIS GRP PTC	EQ 1GM BASE	A090370	002	Mar 16, 2011	Mar	CAHN
AB		EQ 500MG BASE	A090370	001	Mar 16, 2011	Mar	CAHN

VALPROIC ACID

CAPSULE; ORAL							
VALPROIC ACID							
AB	SUN PHARM INDS LTD	250MG	A091037	001	Feb 22, 2013	Feb	NEWA
CAPSULE, DELAYED RELEASE; ORAL							
STAVZOR							
	@ BANNER PHARMACAPS	125MG	N022152	001	Jul 29, 2008	Jun	DISC
	@	250MG	N022152	002	Jul 29, 2008	Jun	DISC
	@	500MG	N022152	003	Jul 29, 2008	Jun	DISC

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION							
VANCOMYCIN HYDROCHLORIDE							
AP	AGILA SPECLTS	EQ 1GM BASE/VIAL	A065397	002	Dec 30, 2008	Sep	CAHN
AP		EQ 5GM BASE/VIAL	A065432	001	Dec 30, 2008	Sep	CAHN
AP		EQ 10GM BASE/VIAL	A091469	001	Jul 01, 2011	Sep	CAHN
AP		EQ 500MG BASE/VIAL	A065397	001	Dec 30, 2008	Sep	CAHN
AP	EMCURE PHARMS LTD	EQ 1GM BASE/VIAL	A202275	002	Oct 31, 2013	Oct	NEWA
AP		EQ 10GM BASE/VIAL	A202464	001	Oct 09, 2013	Sep	NEWA
AP		EQ 5GM BASE/VIAL	A202274	001	Oct 31, 2013	Oct	NEWA
AP		EQ 500MG BASE/VIAL	A202275	001	Oct 31, 2013	Oct	NEWA

VECURONIUM BROMIDE

INJECTABLE; INJECTION							
VECURONIUM BROMIDE							
AP	AGILA SPECLTS	10MG/VIAL	A090243	001	May 11, 2010	Nov	CAHN
AP		20MG/VIAL	A090243	002	May 11, 2010	Nov	CAHN
AP	TEVA PHARMS USA	10MG/VIAL	A074688	001	Aug 25, 1999	Apr	CAHN
AP		20MG/VIAL	A074688	002	Aug 25, 1999	Apr	CAHN

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL							
VENLAFAXINE HYDROCHLORIDE							
AB	VALEANT BERMUDA	EQ 37.5MG BASE	A090071	001	Apr 15, 2011	Jul	CAHN
AB		EQ 75MG BASE	A090071	002	Apr 15, 2011	Jul	CAHN
AB		EQ 150MG BASE	A090071	003	Apr 15, 2011	Jul	CAHN

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL							
VERELAN PM							
AB	ALKERMES GAINESVILLE	100MG	N020943	001	Nov 25, 1998	Sep	CAHN
AB		200MG	N020943	002	Nov 25, 1998	Sep	CAHN
AB	+	300MG	N020943	003	Nov 25, 1998	Sep	CAHN
INJECTABLE; INJECTION							
VERAPAMIL HYDROCHLORIDE							
	@ INTL MEDICATION	2.5MG/ML	A070451	001	Dec 16, 1985	Mar	DISC
TABLET; ORAL							
VERAPAMIL HYDROCHLORIDE							
AB	HERITAGE PHARMS INC	80MG	A071880	001	Apr 05, 1988	Aug	CMFD
AB		120MG	A071881	001	Apr 05, 1988	Aug	CMFD
TABLET, EXTENDED RELEASE; ORAL							
VERAPAMIL HYDROCHLORIDE							
AB	CARACO	120MG	A090529	001	Dec 30, 2011	May	CAHN
AB		180MG	A090529	002	Dec 30, 2011	May	CAHN
AB		240MG	A090529	003	Dec 30, 2011	May	CAHN

VERTEPORFIN

INJECTABLE; INJECTION							
VISUDYNE							
+	VALEANT PHARMS INC	15MG/VIAL	N021119	001	Apr 12, 2000	Jan	CAHN



VINCRISTINE SULFATE

INJECTABLE; INJECTION  
 VINCRISTINE SULFATE PFS  
 AP TEVA PHARMS USA 1MG/ML A075493 001 Sep 01, 1999 Apr CAHN

VINORELBINE TARTRATE

INJECTABLE; INJECTION  
 VINORELBINE TARTRATE  
 AP DR REDDYS LABS LTD EQ 10MG BASE/ML A202017 001 Sep 12, 2013 Aug NEWA  
 AP TEVA PHARMS USA EQ 10MG BASE/ML A076028 001 Feb 03, 2003 Apr CAHN

VORICONAZOLE

FOR SUSPENSION; ORAL  
 VFEND  
 AB + PFIZER 200MG/5ML N021630 001 Dec 19, 2003 May CFTG  
 VORICONAZOLE  
 AB MYLAN PHARMS INC 200MG/5ML A202361 001 May 28, 2013 May NEWA

VORTIOXETINE HYDROBROMIDE

TABLET; ORAL  
 BRINTELLIX  
 TAKEDA PHARMS USA EQ 5MG BASE N204447 001 Sep 30, 2013 Sep NEWA  
 EQ 10MG BASE N204447 002 Sep 30, 2013 Sep NEWA  
 EQ 15MG BASE N204447 003 Sep 30, 2013 Sep NEWA  
 + EQ 20MG BASE N204447 004 Sep 30, 2013 Sep NEWA

WARFARIN SODIUM

TABLET; ORAL  
 WARFARIN SODIUM  
 AB AMNEAL PHARMS 1MG A202202 001 Mar 04, 2013 Feb NEWA  
 AB 2MG A202202 002 Mar 04, 2013 Feb NEWA  
 AB 2.5MG A202202 003 Mar 04, 2013 Feb NEWA  
 AB 3MG A202202 004 Mar 04, 2013 Feb NEWA  
 AB 4MG A202202 005 Mar 04, 2013 Feb NEWA  
 AB 5MG A202202 006 Mar 04, 2013 Feb NEWA  
 AB 6MG A202202 007 Mar 04, 2013 Feb NEWA  
 AB 7.5MG A202202 008 Mar 04, 2013 Feb NEWA  
 AB 10MG A202202 009 Mar 04, 2013 Feb NEWA  
 AB IPCA LABS LTD 1MG A200104 001 Jun 27, 2013 Jun NEWA  
 AB 2MG A200104 002 Jun 27, 2013 Jun NEWA  
 AB 2.5MG A200104 003 Jun 27, 2013 Jun NEWA  
 AB 3MG A200104 004 Jun 27, 2013 Jun NEWA  
 AB 4MG A200104 005 Jun 27, 2013 Jun NEWA  
 AB 5MG A200104 006 Jun 27, 2013 Jun NEWA  
 AB 6MG A200104 007 Jun 27, 2013 Jun NEWA  
 AB 7.5MG A200104 008 Jun 27, 2013 Jun NEWA  
 AB 10MG A200104 009 Jun 27, 2013 Jun NEWA

ZALEPLON

CAPSULE; ORAL  
 SONATA  
 AB PFIZER 5MG N020859 001 Aug 13, 1999 Apr CAHN  
 AB + 10MG N020859 002 Aug 13, 1999 Apr CAHN

ZIDOVUDINE

INJECTABLE; INJECTION  
 ZIDOVUDINE  
 AP LIAONING CHENGDA 10MG/ML A204538 001 Nov 26, 2013 Nov NEWA  
 TABLET; ORAL  
 ZIDOVUDINE  
 AB HEC PHARM USA INC 300MG A202058 001 Oct 07, 2011 Feb CMFD  
 @ 300MG A202058 001 Oct 07, 2011 Jan DISC  
 AB + HETERO LABS LTD III 300MG A090092 001 Apr 25, 2008 Apr CRLD  
 AB SUNSHINE LAKE 300MG A202058 001 Oct 07, 2011 Oct CAHN

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL  
 ZIPRASIDONE HYDROCHLORIDE  
 AB MYLAN PHARMS INC EQ 20MG BASE A202395 001 Oct 10, 2013 Sep NEWA  
 AB EQ 40MG BASE A202395 002 Oct 10, 2013 Sep NEWA  
 AB EQ 60MG BASE A202395 003 Oct 10, 2013 Sep NEWA

CAPSULE;ORAL							
ZIPRASIDONE HYDROCHLORIDE							
AB		EQ 80MG BASE		A202395	004	Oct 10, 2013	Sep NEWA
<u>ZOLEDRONIC ACID</u>							
INJECTABLE;INJECTION							
ZOLEDRONIC ACID							
AP	DR REDDYS LABS LTD	EQ 5MG BASE/100ML		A091363	001	Mar 29, 2013	Mar NEWA
AP	EMCURE PHARMS LTD	EQ 5MG BASE/100ML		A201801	001	Mar 29, 2013	Mar NEWA
INJECTABLE;IV (INFUSION)							
RECLAST							
AP	+ NOVARTIS	EQ 5MG BASE/100ML		N021817	001	Apr 16, 2007	Mar CTEC
ZOLEDRONIC ACID							
AP	ACS DOBFAR INFO SA	EQ 4MG BASE/100ML		N203231	001	Aug 02, 2013	Aug NEWA
AP		EQ 5MG BASE/100ML		A202828	001	Sep 23, 2013	Sep NEWA
AP	ACTAVIS INC	EQ 4MG BASE/5ML		A202472	001	Mar 04, 2013	Feb NEWA
AP	AGILA SPECLTS	EQ 4MG BASE/5ML		A202650	001	Mar 04, 2013	Feb NEWA
AP	DR REDDYS LABS LTD	EQ 4MG BASE/5ML		A091186	001	Mar 04, 2013	Feb NEWA
AP		EQ 5MG BASE/100ML		A091363	001	Mar 29, 2013	Jul CFR
AP	EMCURE PHARMS LTD	EQ 4MG BASE/5ML		A201783	001	Mar 12, 2013	Mar NEWA
AP		EQ 5MG BASE/100ML		A201801	001	Mar 29, 2013	Jul CFR
AP	GLAND PHARMA LTD	EQ 4MG BASE/5ML		A202930	001	Aug 05, 2013	Jul NEWA
AP	HIKMA FARMACEUTICA	EQ 4MG BASE/5ML		A202182	001	Jun 03, 2013	May NEWA
AP	HOSPIRA INC	EQ 5MG BASE/100ML		A202837	001	Apr 05, 2013	Mar NEWA
AP	PHARMACEUTICS	EQ 4MG BASE/5ML		A091170	001	Mar 04, 2013	Feb NEWA
AP		EQ 5MG BASE/100ML		A202163	001	Aug 05, 2013	Jul NEWA
AP	PHARMS	EQ 4MG BASE/5ML		A202571	001	May 07, 2013	Apr NEWA
AP	+ SUN PHARMA GLOBAL	EQ 4MG BASE/VIAL		A090018	001	Mar 04, 2013	Feb NEWA
AP		EQ 4MG BASE/5ML		A202746	001	Mar 04, 2013	Feb NEWA
ZOMETA							
AP	+ NOVARTIS	EQ 4MG BASE/5ML		N021223	002	Mar 07, 2003	Feb CFTG
AP	+	EQ 4MG BASE/100ML		N021223	003	Jun 17, 2011	Aug CTEC
<u>ZOLMITRIPTAN</u>							
SPRAY;NASAL							
ZOMIG							
	ASTRAZENECA	2.5MG/SPRAY		N021450	003	Sep 16, 2013	Sep NEWA
TABLET;ORAL							
ZOLMITRIPTAN							
AB	APOTEX INC	2.5MG		A202078	001	May 14, 2013	Apr NEWA
AB		5MG		A202078	002	May 14, 2013	Apr NEWA
AB	GLENMARK GENERICS	2.5MG		A201779	001	May 14, 2013	Apr NEWA
AB		5MG		A201779	002	May 14, 2013	Apr NEWA
AB	MYLAN PHARMS INC	2.5MG		A203186	001	May 14, 2013	Apr NEWA
AB		5MG		A203186	002	May 14, 2013	Apr NEWA
ZOMIG							
AB	IPR	2.5MG		N020768	001	Nov 25, 1997	Apr CFTG
AB	+	5MG		N020768	002	Nov 25, 1997	Apr CFTG
TABLET, ORALLY DISINTEGRATING;ORAL							
ZOLMITRIPTAN							
AB	APOTEX INC	2.5MG		A202476	001	May 14, 2013	Apr NEWA
AB		5MG		A202476	002	May 14, 2013	Apr NEWA
AB	GLENMARK GENERICS	2.5MG		A202560	001	May 14, 2013	Apr NEWA
AB		5MG		A202560	002	May 14, 2013	Apr NEWA
AB	ZYDUS PHARMS USA INC	2.5MG		A202890	001	May 15, 2013	Apr NEWA
AB		5MG		A202890	002	May 15, 2013	Apr NEWA
ZOMIG-ZMT							
AB	ASTRAZENECA	2.5MG		N021231	001	Feb 13, 2001	Apr CFTG
AB	+	5MG		N021231	002	Sep 17, 2001	Apr CFTG
<u>ZOLPIDEM TARTRATE</u>							
TABLET;ORAL							
ZOLPIDEM TARTRATE							
	@ DR REDDYS LABS LTD	5MG		A077985	001	Apr 23, 2007	Apr DISC
	@	10MG		A077985	002	Apr 23, 2007	Apr DISC
TABLET, EXTENDED RELEASE;ORAL							
ZOLPIDEM TARTRATE							
AB	ACTAVIS ELIZABETH	6.25MG		A078179	002	Oct 13, 2010	Apr CAHN
AB		12.5MG		A078179	001	Jun 06, 2011	Apr CAHN
AB	APOTEX INC	6.25MG		A200266	001	Sep 10, 2013	Aug NEWA
AB		12.5MG		A200266	002	Sep 10, 2013	Aug NEWA
AB	LUPIN LTD	6.25MG		A078970	001	Sep 11, 2013	Aug NEWA

TABLET, EXTENDED RELEASE;ORAL  
ZOLPIDEM TARTRATE

AB		12.5MG	A078970	002	Sep 11, 2013	Aug NEWA
AB	WATSON LABS INC FL	6.25MG	A090153	001	Mar 25, 2013	Mar NEWA
AB		12.5MG	A090153	002	Mar 25, 2013	Mar NEWA

ZONISAMIDECAPSULE;ORAL  
ZONISAMIDE

@	COREPHARMA	25MG	A077876	001	Feb 21, 2007	Feb DISC
@		50MG	A077876	002	Feb 21, 2007	Feb DISC
@		100MG	A077876	003	Feb 21, 2007	Feb DISC
@	DR REDDYS LABS LTD	25MG	A077645	002	Sep 29, 2006	Mar DISC
@		50MG	A077645	003	Sep 29, 2006	Mar DISC
@		100MG	A077645	001	Dec 22, 2005	Mar DISC

ACETAMINOPHENSUPPOSITORY;RECTAL  
ACETAMINOPHEN

>D>	ACTAVIS MID ATLANTIC	120MG	N018337	003	Sep 12, 1983	Dec	CAHN
>D>		325MG	N018337	002		Dec	CAHN
>D>	+	650MG	N018337	001		Dec	CAHN
>A>	TARO PHARMS NORTH	120MG	N018337	003	Sep 12, 1983	Dec	CAHN
>A>		325MG	N018337	002		Dec	CAHN
>A>	+	650MG	N018337	001		Dec	CAHN
	INFANTS' FEVERALL						
>D>	ACTAVIS MID ATLANTIC	80MG	N018337	004	Aug 26, 1992	Dec	CAHN
>A>	TARO PHARMS NORTH	80MG	N018337	004	Aug 26, 1992	Dec	CAHN
	TABLET, EXTENDED RELEASE;ORAL						
	TYLENOL						
+	MCNEIL CONS	650MG	N019872	001	Jun 08, 1994	Jul	CTNA
+		650MG	N019872	002	Jan 11, 2001	Jul	CTNA

ASPIRINCAPSULE;ORAL  
ASPIRIN

+	PLX PHARMA	325MG	N203697	001	Jan 14, 2013	Jan	NEWA
---	------------	-------	---------	-----	--------------	-----	------

CETIRIZINE HYDROCHLORIDE

## SYRUP;ORAL

## CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

@	APOTEX INC	5MG/5ML	A090188	002	Apr 22, 2008	Apr	DISC
	BIO PHARM INC	5MG/5ML	A090474	002	Mar 30, 2009	May	CAHN
	CARACO	5MG/5ML	A091327	001	Oct 17, 2011	May	CAHN
	PERRIGO R AND D	5MG/5ML	A204226	001	Sep 09, 2013	Aug	NEWA

## CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@	APOTEX INC	5MG/5ML	A090188	001	Apr 22, 2008	Apr	DISC
	BIO PHARM INC	5MG/5ML	A090474	001	Mar 30, 2009	May	CAHN
	CARACO	5MG/5ML	A091327	002	Oct 17, 2011	May	CAHN

## TABLET;ORAL

## CETIRIZINE HYDROCHLORIDE ALLERGY

	CIPLA LTD	5MG	A077318	001	Jul 25, 2013	Jul	NEWA
		10MG	A077318	002	Jul 25, 2013	Jul	NEWA
	CONTRACT PHARMACAL	5MG	A076047	001	Dec 27, 2007	Oct	CAHN
		10MG	A076047	002	Dec 27, 2007	Oct	CAHN

## TABLET, CHEWABLE;ORAL

## CETIRIZINE HYDROCHLORIDE ALLERGY

+	SANDOZ	10MG	A078692	002	Feb 14, 2008	Apr	CRLD
	CHILDREN'S ZYRTEC ALLERGY						
@	MCNEIL CONS	5MG	N021621	003	Nov 16, 2007	Apr	DISC
+		5MG	N021621	003	Nov 16, 2007	Feb	CRLD
@		10MG	N021621	004	Nov 16, 2007	Feb	DISC
	CHILDREN'S ZYRTEC HIVES RELIEF						
@	MCNEIL CONS	5MG	N021621	005	Nov 16, 2007	Apr	DISC
+		5MG	N021621	005	Nov 16, 2007	Feb	CRLD
@		10MG	N021621	006	Nov 16, 2007	Feb	DISC

CHLORHEXIDINE GLUCONATE

## SOLUTION;TOPICAL

## DYNA-HEX

	BAJAJ MEDICAL LLC	0.75%	N020111	001	Sep 11, 1997	Apr	CAHN
--	-------------------	-------	---------	-----	--------------	-----	------

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

## SWAB;TOPICAL

## PREVANTICS MAXI SWABSTICK

+	PROF DSPLS	3.15%;70% (5.1ML)	N021524	003	Jun 03, 2005	Mar	CTNA
	PREVANTICS SWAB						
+	PROF DSPLS	3.15%;70% (1ML)	N021524	001	Jun 03, 2005	Mar	CTNA
	PREVANTICS SWABSTICK						
+	PROF DSPLS	3.15%;70% (1.6ML)	N021524	002	Jun 03, 2005	Mar	CTNA

CIMETIDINE

TABLET;ORAL							
TAGAMET HB							
@ MEDTECH PRODS	100MG		N020238	001	Jun 19, 1995	Aug	CAHN
+	200MG		N020238	002	Aug 21, 1996	Aug	CAHN

CLOTRIMAZOLE

CREAM;VAGINAL							
MYCELEX-7							
BAYER	1%		N018230	002	Dec 26, 1991	Sep	CAHN
CREAM, TABLET;TOPICAL, VAGINAL							
MYCELEX-7 COMBINATION PACK							
BAYER	1%,100MG		N020389	002	Jun 23, 1994	Sep	CAHN
TABLET;VAGINAL							
MYCELEX-7							
BAYER	100MG		N018182	002	Dec 26, 1991	Sep	CAHN

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL							
DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE							
AVANTHI INC	6MG;120MG		A078648	001	Feb 27, 2013	Feb	NEWA

FAMOTIDINE

TABLET;ORAL							
PEPCID AC							
MCNEIL CONS	10MG		N020902	001	Aug 05, 1999	Jul	CTNA

FEXOFENADINE HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING;ORAL							
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY							
DR REDDYS LABS LTD	30MG		A202978	001	Jan 18, 2013	Jan	NEWA
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES							
DR REDDYS LABS LTD	30MG		A202978	002	Jan 18, 2013	Jan	NEWA

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC							
KETOTIFEN FUMARATE							
@ APOTEX INC	EQ 0.025% BASE		A077354	001	May 09, 2006	Apr	DISC

LEVONORGESTREL

TABLET;ORAL							
LEVONORGESTREL							
LUPIN LTD	0.75MG		A091328	001	Jan 23, 2013	Jan	NEWA
NOVEL LABS INC	1.5MG		A202508	001	Feb 22, 2013	Feb	NEWA

LORATADINE

SYRUP;ORAL							
LORATADINE							
@ APOTEX INC	1MG/ML		A075565	001	Oct 05, 2004	Apr	DISC

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL							
LORATADINE AND PSEUDOEPHEDRINE SULFATE							
@ WATSON LABS INC FL	5MG;120MG		A076208	001	Jan 28, 2004	Feb	DISC

MICONAZOLE NITRATE

CREAM;VAGINAL							
MICONAZOLE NITRATE							
APHENA PHARMA MD	2%		A074366	001	Feb 22, 1996	Jan	CAHN
G AND W LABS INC	2%		A074366	001	Feb 22, 1996	Sep	CAHN

MINOXIDIL

SOLUTION;TOPICAL							
MINOXIDIL (FOR MEN)							
@ APOTEX INC	2%		A074924	001	Apr 29, 1998	Apr	DISC
MINOXIDIL (FOR WOMEN)							
@ APOTEX INC	2%		A074924	002	Apr 29, 1998	Apr	DISC
MINOXIDIL EXTRA STRENGTH (FOR MEN)							
@ APOTEX INC	5%		A075839	001	Oct 01, 2001	Apr	DISC

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS;OPHTHALMIC

NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE

AKORN INC

0.025%;0.3%

A202795 001 Jan 24, 2013 Jan NEWA

OMEPRAZOLE; SODIUM BICARBONATE

FOR SUSPENSION;ORAL

ZEGERID OTC

+ MSD CONSUMER

20MG/PACKET;1.68GM/PACKET

N022283 001 Jun 17, 2013 Jun NEWA

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYTROL FOR WOMEN

+ MSD CONSUMER

3.9MG/24HR

N202211 001 Jan 25, 2013 Jan NEWA

PIPERONYL BUTOXIDE; PYRETHRINS

AEROSOL;TOPICAL

RID MOUSSE

+ BAYER

4%;EQ 0.33% BASE

N021043 001 Mar 07, 2000 Sep CAHN

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

POLYETHYLENE GLYCOL 3350

PAR PHARM

17GM/SCOOPFUL

A079214 001 Jan 31, 2013 Jan NEWA

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

@ WATSON LABS

EQ 75MG BASE

A075212 001 Jan 14, 2000 Mar DISC

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL

NASACORT ALLERGY 24 HOUR

SANOFI AVENTIS US

0.055MG/SPRAY

N020468 002 Oct 11, 2013 Oct NEWA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

**CUMULATIVE SUPPLEMENT NUMBER 12 DECEMBER 2013**

NO DECEMBER 2013 APPROVALS

## ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>



**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY  
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO DECEMBER 2013 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE - ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE</u>						
A 202912	001				>A> PC	Jun 15, 2014
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379	001	5604213	Dec 13, 2016	DS DP U-1126		
		5604213	Dec 13, 2016	DS DP U-1314		
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539	001	8399445	Aug 24, 2025	U-1373		
<u>ACYCLOVIR - SITAVIR</u>						
N 203791	001	>A> 8592434	Dec 09, 2029	DP U-1460	NP	Apr 12, 2016
<u>ADAPALENE - DIFFERIN</u>						
N 022502	001	8435502	Sep 15, 2026	DP U-1078		
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N 022320	001	8445543	Jul 12, 2027	U-1078	NPP	Feb 01, 2016
<u>ADEFOVIR DIPIVOXIL - ADEFOVIR DIPIVOXIL</u>						
A 202051	001				PC	Mar 02, 2014
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292	001	6251912	Jul 29, 2018	DS DP U-1067	NCE	Jul 12, 2018
		8426586	Oct 10, 2029	DS DP	ODE	Jul 12, 2020
		8545884	Dec 19, 2029	DP		
		RE43431	Jan 22, 2022	DS DP		
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292	002	6251912	Jul 29, 2018	DS DP U-1067	NCE	Jul 12, 2018
		8426586	Oct 10, 2029	DS DP	ODE	Jul 12, 2020
		8545884	Dec 19, 2029	DP		
		RE43431	Jan 22, 2022	DS DP		
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292	003	6251912	Jul 29, 2018	DS DP U-1067	NCE	Jul 12, 2018
		8426586	Oct 10, 2029	DS DP	ODE	Jul 12, 2020
		8545884	Dec 19, 2029	DP		
		RE43431	Jan 22, 2022	DS DP		
<u>ALBUTEROL SULFATE - PROVENTIL-HFA</u>						
N 020503	001	5775321	Jul 07, 2015	DP		
		6006745	Dec 28, 2016	DP		
<u>ALCAFTADINE - LASTACFT</u>						
N 022134	001	5468743	Apr 20, 2016	DS DP		
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N 022217	001	8168616	Jul 03, 2026	DP		
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N 022217	002	8168616	Jul 03, 2026	DP		
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271	001	6150383	Jun 19, 2016	U-1330	NCE	Jan 25, 2018
		6211205	Jun 19, 2016	U-1331		
		6303640	Aug 09, 2016	U-1332		
		6303661	Apr 24, 2017	U-1333		
		6329404	Jun 19, 2016	DP U-1334		
		6890898	Feb 02, 2019	U-1335		
		7078381	Feb 02, 2019	U-1335		
		7459428	Feb 02, 2019	U-1336		
		7807689	Jun 27, 2028	DS DP U-1337		
		8173663	Mar 15, 2025	U-1338		
		8288539	Mar 15, 2025	DS		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 001	5965584	Jun 19, 2016	U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 002	5965584	Jun 19, 2016	U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 001	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 002	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 004	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALVIMOPAN - ENTEREG</u>						
N 021775 001	8112290	Jul 31, 2030	DP U-1443		M-128	Oct 18, 2016
<u>AMBRISANTAN - LETAIRIS</u>						
N 022081 001	8349843	Oct 07, 2015	DS DP			
<u>AMBRISANTAN - LETAIRIS</u>						
N 022081 002	8349843	Oct 07, 2015	DS DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 001	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 002	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 003	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 004	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 005	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMOXICILLIN - MOXATAG</u>						
N 050813 001	8357394	Dec 08, 2026	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	6413980	Dec 22, 2019	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1323			
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	6413980	Dec 22, 2019	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1323			
<u>ARFORMOTEROL TARTRATE - BROVANA</u>						
N 021912 001	6589508	Apr 03, 2014	U-793			
	7348362	Jun 22, 2021	DP U-793			
	7462645	Jun 22, 2021	U-793			
	7465756	Jun 22, 2021	DP			
	7473710	Jun 22, 2021	U-793			
	7541385	Jun 22, 2021	U-793			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 001	7053092	Jan 28, 2022	U-839			
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 002	7053092	Jan 28, 2022	U-839			
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 003	7053092	Jan 28, 2022	U-839			
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 004	7053092	Jan 28, 2022	U-839			
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 005	7053092	Jan 28, 2022	U-839			
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY</u>						
N 021436 006	7053092	Jan 28, 2022	U-839			
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021713 001 >A>	7053092	Jan 28, 2022	U-839			
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 002	7053092	Jan 28, 2022	U-839			
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 003	7053092	Jan 28, 2022	U-839			
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 004	7053092	Jan 28, 2022	U-839			
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 005	7053092	Jan 28, 2022	U-839			
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	5006528	Apr 20, 2015	DS DP U-543		NDF	Feb 28, 2016
	7807680	Oct 19, 2024	DP			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Dec 29, 2023	DS			
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	5006528	Apr 20, 2015	DS DP U-543		NDF	Feb 28, 2016
	7807680	Oct 19, 2024	DP			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Dec 29, 2023	DS			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	5763476	Jun 09, 2020	DP U-326			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	5763476	Jun 09, 2020	DP U-326			
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 001	5846966	Sep 21, 2013	DP U-1400		NC	May 03, 2016
	5846966*PED	Mar 21, 2014				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 002	5846966	Sep 21, 2013	DP U-1400		NC	May 03, 2016
	5846966*PED	Mar 21, 2014				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 003	5846966	Sep 21, 2013	DP U-1400		NC	May 03, 2016
	5846966*PED	Mar 21, 2014				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 004	5846966	Sep 21, 2013	DP U-1400		NC	May 03, 2016
	5846966*PED	Mar 21, 2014				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203 001	8518919	Nov 22, 2025	U-1430		M-129 NPP	Aug 30, 2016 Aug 30, 2016
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022371 001	8518919	Nov 22, 2025	U-1430			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 002					NC NCE	Dec 20, 2014 Feb 25, 2016
<u>AZTREONAM - CAYSTON</u>						
N 050814 001	8399496	Dec 20, 2021	DP U-1377			
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N 022205 001	8497256	Jun 23, 2031	U-1229			
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001	5998402	Apr 04, 2017	DS DP U-594			
	6479535	May 06, 2019	DP U-594			
	6479535	May 06, 2019	DP U-904			
	7138392	Apr 04, 2017	DS DP U-594			
	7683051	Mar 10, 2027	DS DP U-594			
	7683051	Mar 10, 2027	DS DP U-904			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001	7498343	Oct 02, 2024	DS DP U-1321		ODE	Dec 28, 2019
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001	8436190	Oct 26, 2030	DP		ODE	Oct 31, 2015
	8436190*PED	Apr 26, 2031			PED	May 01, 2016
	8445524	Mar 26, 2029	DS DP U-1402			
	8445524*PED	Sep 26, 2029				
	>A> 8609863	Jan 12, 2026	DP			
	>A> 8609863*PED	Jul 12, 2026				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002	8436190	Oct 26, 2030	DP		ODE	Oct 31, 2015
	8436190*PED	Apr 26, 2031			PED	May 01, 2016
	8445524	Mar 26, 2029	DS DP U-1402			
	8445524*PED	Sep 26, 2029				
	>A> 8609863	Jan 12, 2026	DP			
	>A> 8609863*PED	Jul 12, 2026				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 003	8344006	Sep 23, 2029	DP U-1402		ODE	Mar 20, 2015
	8344006*PED	Mar 23, 2030			ODE	Oct 31, 2015
	8445524	Mar 26, 2029	DS		PED	Sep 20, 2015
	8445524*PED	Sep 26, 2029			PED	May 01, 2016
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 004	8344006	Sep 23, 2029	DP U-1402		ODE	Oct 31, 2015
	8344006*PED	Mar 23, 2030			ODE	Mar 20, 2015
	8445524	Mar 26, 2029	DS		PED	May 01, 2016
	8445524*PED	Sep 26, 2029			PED	Sep 20, 2015
<u>BEPOTASTINE BESILATE - BEPREVE</u>						
N 022288 001	6780877	Sep 19, 2019	DS DP			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
N 022308 001	8415342	Nov 07, 2030	U-80			
	8481526	Jan 09, 2031	DS			
	>A> 8604020	Mar 12, 2030	DP			
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	8524777	Mar 16, 2025	U-1235			
	>A> 8586630	Mar 16, 2025	U-1458			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	8541466	Jan 21, 2022	U-1217			
<u>BOCEPREVIR - VICTRELIS</u>						
N 202258 001					M-126 NPP	Feb 27, 2016 Feb 13, 2016
<u>BRIMONIDINE TARTRATE - MIRVASO</u>						
N 204708 001	7439241	Aug 25, 2025	U-1428		NDF	Aug 23, 2016
	8053427	Jun 13, 2031	DP U-1428			
	8163725	Jun 13, 2031	DP			
	8231885	May 24, 2025	DP			
	8410102	May 24, 2025	U-1428			
	8426410	May 24, 2025	U-1428			
	8513247	Mar 25, 2031	DP U-1428			
	8513249	Mar 25, 2031	DP U-1428			
<u>BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA</u>						
N 204251 001	6316441	Dec 07, 2019	U-778		NC	Apr 19, 2016
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398 001	7323463	Jan 19, 2023	DP	Y		
	8354409	Apr 19, 2022	DP U-1371			
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168 001	8129431	Sep 11, 2025	DS DP		NP	Apr 05, 2016
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	7888310	Jul 25, 2023	U-1433			
	8137992	Jul 25, 2023	U-1433			
	8137993	Jul 25, 2023	U-1433			
	8137994	Jul 25, 2023	U-1433			
	8431155	Apr 30, 2032	DP U-976			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	7410651	Jun 09, 2020	DP U-1325		NDF	Jan 14, 2016
	7431943	Jun 09, 2020	DP			
	8293273	Jun 09, 2020	DP			
	RE43799	Jun 09, 2020	DP U-1325			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	8387615	Nov 10, 2024	DP			
	8528545	Oct 16, 2028	DP			
	8575137	Jan 29, 2023	DP U-1073			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	8387615	Nov 10, 2024	DP			
	8461211	Sep 09, 2018	U-1118			
	8528545	Oct 16, 2028	DP			
	8575137	Jan 29, 2023	DP U-1073			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	8475832	Mar 26, 2030	DP U-1411			
	>A> 8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	8475832	Mar 26, 2030	DP U-1411			
	>A> 8603514	Apr 03, 2024	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	8475832	Mar 26, 2030	DP U-1411			
	>A> 8603514	Apr 03, 2024	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	8475832	Mar 26, 2030	DP U-1411			
	>A> 8603514	Apr 03, 2024	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	8454996	Sep 24, 2019	U-1421			
	8470361	Oct 14, 2029	DP U-1425			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	8454996	Sep 24, 2019	U-1421			
	8470361	Oct 14, 2029	DP U-1425			
<u>CABOZANTINIB S-MALATE - COMETRIQ</u>						
N 203756 001					ODE	Nov 29, 2019
<u>CABOZANTINIB S-MALATE - COMETRIQ</u>						
N 203756 002					ODE	Nov 29, 2019
<u>CALCITONIN SALMON RECOMBINANT - FORTICAL</u>						
N 021406 001	RE43580	Feb 02, 2021	DP U-227			
<u>CALCIUM ACETATE - PHOSLYRA</u>						
N 022581 001	>A> 8591938	Feb 23, 2030	DP U-1469			
	>A> 8592480	Jul 20, 2027	U-1469			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001	7943582	Feb 26, 2029	DS DP U-493		NCE	Mar 29, 2018
	7943788	Jul 14, 2027	DS DP			
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002	7943582	Feb 26, 2029	DS DP U-493		NCE	Mar 29, 2018
	7943788	Jul 14, 2027	DS DP			
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANDESARTAN CILEXETIL - CANDESARTAN CILEXETIL</u>						
A 078702 001					PC	Jul 09, 2013
<u>CANDESARTAN CILEXETIL - CANDESARTAN CILEXETIL</u>						
A 078702 002					PC	Jul 09, 2013
<u>CANDESARTAN CILEXETIL - CANDESARTAN CILEXETIL</u>						
A 078702 003					PC	Jul 09, 2013
<u>CANDESARTAN CILEXETIL - CANDESARTAN CILEXETIL</u>						
A 078702 004					PC	Jul 09, 2013
<u>CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE - CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE</u>						
A 090704 003					PC	Jun 02, 2013
<u>CAPECITABINE - XELODA</u>						
N 020896 001	5472949	Dec 14, 2013	DS DP U-271		>A> M-131	Dec 10, 2016
	5472949*PED	Jun 14, 2014			>A> PED	Jun 10, 2017
<u>CAPECITABINE - XELODA</u>						
N 020896 002	5472949	Dec 14, 2013	DS DP U-271		>A> M-131	Dec 10, 2016
	5472949*PED	Jun 14, 2014			>A> PED	Jun 10, 2017
<u>CARBINOXAMINE MALEATE - KARBINAL ER</u>						
N 022556 001	8062667	Mar 29, 2029	DP			
<u>CELECOXIB - CELEBREX</u>						
N 020998 001	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1348			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1352			
	RE44048*PED	Dec 02, 2015				
<u>CELECOXIB - CELEBREX</u>						
N 020998 002	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1348			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1352			
	RE44048*PED	Dec 02, 2015				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CELECOXIB - CELEBREX</u>						
N 020998 003	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1348			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1352			
	RE44048*PED	Dec 02, 2015				
<u>CELECOXIB - CELEBREX</u>						
N 020998 004	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1348			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1352			
	RE44048*PED	Dec 02, 2015				
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832 002	7422388	Apr 25, 2027	DP U-1397			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832 005	7422388	Apr 25, 2027	DP U-1397			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832 007	7422388	Apr 25, 2027	DP U-1397			
<u>CICLESONIDE - ALVESCO</u>						
N 021658 002	8371292	Aug 25, 2027	U-1355		M-125	Dec 17, 2015
<u>CICLESONIDE - ALVESCO</u>						
N 021658 003	8371292	Aug 25, 2027	U-1355		M-125	Dec 17, 2015
<u>CICLESONIDE - OMNARIS</u>						
N 022004 001	8371292	Aug 25, 2027	U-1356			
	8383611	Oct 20, 2020	DP			
<u>CICLESONIDE - ZETONNA</u>						
N 202129 001	8371292	Aug 25, 2027	U-1357			
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N 021473 001	8187632	Jun 23, 2021	DP			
	8187632*PED	Dec 23, 2021				
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N 021473 002	8187632	Jun 23, 2021	DP			
	8187632*PED	Dec 23, 2021				
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - PREPOPIK</u>						
N 202535 001	8450338	Oct 10, 2028	DP			
	8481083	Oct 10, 2028	DP			
<u>CLOBAZAM - ONFI</u>						
N 203993 001					ODE	Oct 21, 2018
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A 201402 001					PC	Jul 31, 2013
<u>CLOBETASOL PROPIONATE - OLUX E</u>						
N 022013 001	8460641	Nov 05, 2028	DP U-1410			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	7635704	Oct 26, 2026	DS DP U-257			
	>A> 8592397	Jan 13, 2024	DP U-257			
<u>COLCHICINE - COLCRYS</u>						
N 022352 001	8415395	Oct 06, 2028	U-1007			
	8415396	Oct 06, 2028	U-1007			
	8440721	Feb 17, 2029	U-1007			
	8440722	Feb 17, 2029	U-1020			
<u>CROFELEMER - FULYZAQ</u>						
N 202292 001	8574634	Jan 11, 2018	U-1319			
<u>CYCLOSPORINE - RESTASIS</u>						
N 050790 001	>A> 8629111	Aug 27, 2024	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	8026284	Sep 22, 2027	U-1399		NDF	Apr 30, 2016
	8129433	Jan 26, 2027	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	8026284	Sep 22, 2027	U-1399		NDF	Apr 30, 2016
	8129433	Jan 26, 2027	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	7994185	Jan 20, 2030	DS DP U-1406		NCE	May 29, 2018
	8415345	Jan 20, 2030	DS DP U-1406		ODE	May 29, 2020
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	7994185	Jan 20, 2030	DS DP U-1406		NCE	May 29, 2018
	8415345	Jan 20, 2030	DS DP U-1406		ODE	May 29, 2020
<u>DALFAMPRIDINE - AMPYRA</u>						
N 022250 001	5540938	Jul 30, 2018	U-1030			
	8354437	Dec 22, 2026	U-1030			
	8440703	Apr 08, 2025	U-1030			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 001	8518987	Feb 16, 2024	DS DP		D-135	Feb 01, 2016
	8518987*PED	Aug 16, 2024			PED	Aug 01, 2016
	>A> 8597876	Jun 23, 2019	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 002	8518987	Feb 16, 2024	DS DP		D-135	Feb 01, 2016
	8518987*PED	Aug 16, 2024			PED	Aug 01, 2016
	>A> 8597876	Jun 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 003	8518987	Feb 16, 2024	DS DP		D-135	Feb 01, 2016
	8518987*PED	Aug 16, 2024			PED	Aug 01, 2016
	>A> 8597876	Jun 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 004	8518987	Feb 16, 2024	DS DP		D-135	Feb 01, 2016
	8518987*PED	Aug 16, 2024			PED	Aug 01, 2016
	>A> 8597876	Jun 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 005	8518987	Feb 16, 2024	DS DP		D-135	Feb 01, 2016
	8518987*PED	Aug 16, 2024			PED	Aug 01, 2016
	>A> 8597876	Jun 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 006	8518987	Feb 16, 2024	DS DP		D-135	Feb 01, 2016
	8518987*PED	Aug 16, 2024			PED	Aug 01, 2016
	>A> 8597876	Jun 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 202895 001	8518987	Feb 16, 2024	DS DP		D-135	Feb 01, 2016
	8518987*PED	Aug 16, 2024			PED	Aug 01, 2016
	>A> 8597876	Jun 23, 2019	U-1305			
<u>DEFERASIROX - EXJADE</u>						
N 021882 001					I-665	Jan 23, 2016
<u>DEFERASIROX - EXJADE</u>						
N 021882 002					I-665	Jan 23, 2016
<u>DEFERASIROX - EXJADE</u>						
N 021882 003					I-665	Jan 23, 2016
<u>DESONIDE - VERDESO</u>						
N 021978 001	8460641	Nov 05, 2028	DP U-1412			
<u>DESOXIMETASONE - TOPICORT</u>						
N 204141 001	5990100	Mar 24, 2018	DP U-1408		NDF	Apr 11, 2016
	8277780	Apr 23, 2028	DP U-1408			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 001	6673838	Feb 11, 2022	DS DP U-860		I-675	Feb 14, 2016
	6673838	Feb 11, 2022	DS DP U-1364			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 002	6673838	Feb 11, 2022	DS DP U-860		I-675	Feb 14, 2016
	6673838	Feb 11, 2022	DS DP U-1364			
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	8506987	Jan 09, 2023	U-1204			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 001	4910214	Jul 15, 2013	DS DP U-421			
	4910214*PED	Jan 15, 2014				
	6716867	Mar 31, 2019	U-1472			
	6716867*PED	Oct 01, 2019				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002	4910214	Jul 15, 2013	DS DP U-421			
	4910214*PED	Jan 15, 2014				
	6716867	Mar 31, 2019	U-1472			
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003	4910214	Jul 15, 2013	DS DP U-421			
	4910214*PED	Jan 15, 2014				
	6716867	Mar 31, 2019	U-1472			
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 202580 001					PC	May 17, 2014
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 001					NP	Oct 18, 2016
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 002					NP	Oct 18, 2016
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 020947 001	8546450	Aug 09, 2030	U-1435			
	8546450	Aug 09, 2030	U-1436			
	>A> 8618164	Jul 10, 2029	U-1477			
<u>DIFLUPREDNATE - DUREZOL</u>						
N 022212 001	6114319	May 18, 2019	DP		I-653	Jun 13, 2015
	6114319*PED	Nov 18, 2019			M-127	Mar 22, 2016
					ODE	Jun 13, 2019
					PED	Dec 13, 2015
					PED	Dec 13, 2019
					PED	Sep 22, 2016
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 001	6509376	Oct 29, 2019	DP		NCE	Mar 27, 2018
	7320999	May 18, 2020	U-1384			
	7619001	Apr 01, 2018	U-1384			
	7803840	Apr 01, 2018	U-1385			
	8399514	Feb 07, 2028	U-1384			
	8524773	Apr 01, 2018	U-1384			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 002	6509376	Oct 29, 2019	DP		NCE	Mar 27, 2018
	7320999	May 18, 2020	U-1384			
	7619001	Apr 01, 2018	U-1384			
	7803840	Apr 01, 2018	U-1385			
	8399514	Feb 07, 2028	U-1384			
	8524773	Apr 01, 2018	U-1384			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 001	8129385	Oct 05, 2027	DS DP		NCE	Aug 12, 2018
<u>DONEPEZIL HYDROCHLORIDE - DONEPEZIL HYDROCHLORIDE</u>						
A 202542 001					PC	Jan 22, 2014
<u>DONEPEZIL HYDROCHLORIDE - DONEPEZIL HYDROCHLORIDE</u>						
A 202723 001					PC	Jan 22, 2014
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT</u>						
N 022568 001	8481565	Oct 04, 2026	DP			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001	8513299	Apr 14, 2030	U-620			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002	8513299	Apr 14, 2030	U-620			
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	8394405	Apr 07, 2024	DP U-925			
	8394406	Apr 07, 2024	DP U-925			
	8470364	Apr 07, 2024	DP U-925			
	>A> 8603506	Apr 05, 2022	U-1063			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 004	6958161	Dec 15, 2022	DP U-918			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 005	6958161	Dec 15, 2022	DP U-918		D-136 NS	Apr 11, 2016 Apr 11, 2016
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - DICLEGIS</u>						
N 021876 001	6340695	Jun 21, 2021	DP U-1382		NP	Apr 08, 2016
	7560122	Jan 25, 2019	DP			
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N 022425 001	5223510	Jul 26, 2016	DS DP U-992			
	5223510	Jul 26, 2016	DS DP U-1261			
	8410167	Apr 16, 2029	U-1387			
	8410167	Apr 16, 2029	U-1388			
	>A> 8602215	Jun 30, 2031	U-1473			
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YAZ</u>						
N 021676 001	RE43916	Jun 30, 2014	U-1326			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ</u>						
N 022532 001	RE43916	Jun 30, 2014	U-1326			
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 001					M-61 PED	Oct 18, 2015 Apr 18, 2016
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 002					M-61 PED	Oct 18, 2015 Apr 18, 2016
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 004					M-61 PED	Oct 18, 2015 Apr 18, 2016
<u>ECONAZOLE NITRATE - ECOZA</u>						
N 205175 001	5993830	Jan 16, 2018	DP U-1449		NDF	Oct 24, 2016

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EFAVIRENZ - SUSTIVA</u>						
N 020972 001	5519021	May 21, 2013	DS DP		NPP	May 02, 2016
	5519021*PED	Nov 21, 2013			PED	Nov 02, 2016
	5663169	Sep 02, 2014	U-257			
	5663169*PED	Mar 02, 2015				
	6238695	Apr 06, 2019	DP			
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019	U-248			
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ - SUSTIVA</u>						
N 020972 002	5519021	May 21, 2013	DS DP			
	5519021*PED	Nov 21, 2013				
	5663169	Sep 02, 2014	U-257			
	5663169*PED	Mar 02, 2015				
	6238695	Apr 06, 2019	DP			
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019	U-248			
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ - SUSTIVA</u>						
N 020972 003	5519021	May 21, 2013	DS DP		NPP	May 02, 2016
	5519021*PED	Nov 21, 2013			PED	Nov 02, 2016
	5663169	Sep 02, 2014	U-257			
	5663169*PED	Mar 02, 2015				
	6238695	Apr 06, 2019	DP			
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019	U-248			
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ - SUSTIVA</u>						
N 021360 001	5519021	May 21, 2013				
	5519021*PED	Nov 21, 2013				
	5663169	Sep 02, 2014				
	5663169*PED	Mar 02, 2015				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ - SUSTIVA</u>						
N 021360 002	5519021	May 21, 2013	DS DP		NPP	May 02, 2016
	5519021*PED	Nov 21, 2013			PED	Nov 02, 2016
	5663169	Sep 02, 2014	U-248			
	5663169*PED	Mar 02, 2015				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	5519021	May 21, 2013	DS DP			
	5519021*PED	Nov 21, 2013				
	5663169	Sep 02, 2014		U-750		
	5663169	Sep 02, 2014		U-1170		
	5663169*PED	Mar 02, 2015				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
	>A> 8592397	Jan 13, 2024	DP U-750			
	>A> 8592397	Jan 13, 2024	DP U-1170			
	>A> 8598185	May 01, 2028	DP			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N 202123 001	>A> 8592397	Jan 13, 2024	DP U-257		>A> NPP	Dec 13, 2016
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 001	>A> 8592397	Jan 13, 2024	DP U-248			
	>A> 8592397	Jan 13, 2024	DP U-541			
	>A> 8592397	Jan 13, 2024	DP U-1170			
<u>ENALAPRIL MALEATE - EPANED KIT</u>						
N 204308 001	8568747	Nov 06, 2032	DP			
<u>ENTECAVIR - BARACLUDE</u>						
N 021797 001	5206244	Feb 21, 2015	DS		D-127	Oct 15, 2013
	5206244*PED	Aug 21, 2015			NPP	Oct 12, 2015
					NPP	Oct 12, 2015
					PED	Apr 12, 2016
					PED	Apr 15, 2014
					PED	Apr 12, 2016
<u>ENTECAVIR - BARACLUDE</u>						
N 021797 002	5206244	Feb 21, 2015	DS		D-127	Oct 15, 2013
	5206244*PED	Aug 21, 2015			NPP	Oct 12, 2015
					NPP	Oct 12, 2015
					PED	Apr 12, 2016
					PED	Apr 12, 2016
					PED	Apr 15, 2014
<u>ENTECAVIR - BARACLUDE</u>						
N 021798 001	5206244	Feb 21, 2015	DS		D-127	Oct 15, 2013
	5206244*PED	Aug 21, 2015			NPP	Oct 12, 2015
					NPP	Oct 12, 2015
					PED	Apr 12, 2016
					PED	Apr 12, 2016
					PED	Apr 15, 2014
<u>EPINEPHRINE - AUVI-O</u>						
N 201739 001	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
<u>EPINEPHRINE - AUVI-O</u>						
N 201739 002	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N 022260 001	8318802	Mar 15, 2027	DP			
	>A> 8598227	Feb 02, 2027				
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N 022260 002	8318802	Mar 15, 2027	DP			
	>A> 8598227	Feb 02, 2027				
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 001	6900221	Nov 09, 2020	DS DP U-659		I-671	May 14, 2016
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 002	6900221	Nov 09, 2020	DS DP U-659		I-671	May 14, 2016
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 003	6900221	Nov 09, 2020	DS DP U-659		I-671	May 14, 2016
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	5753646	Jun 27, 2016	DS DP U-1451		NCE	Nov 08, 2018
	8372431	Apr 17, 2030	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	5753646	Jun 27, 2016	DS DP U-1451		NCE	Nov 08, 2018
	8372431	Apr 17, 2030	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	5753646	Jun 27, 2016	DS DP U-1451		NCE	Nov 08, 2018
	8372431	Apr 17, 2030	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	5753646	Jun 27, 2016	DS DP U-1451		NCE	Nov 08, 2018
	8372431	Apr 17, 2030	DP			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021153 001	8466175	May 25, 2018	U-1417			
	8466175*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021153 002	8466175	May 25, 2018	U-1417			
	8466175*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957 001	8466175	May 25, 2018	U-1417			
	8466175*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957 002	8466175	May 25, 2018	U-1417			
	8466175*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	8557285	May 31, 2022	DP			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002	8557285	May 31, 2022	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 001	5656286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	8231906	Jul 04, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 002	5656286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	8231906	Jul 04, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 003	5656286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	8231906	Jul 04, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 004	5656286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	8231906	Jul 04, 2030	DS DP			
<u>ESZOPICLONE - LUNESTA</u>						
N 021476 001					M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ESZOPICLONE - LUNESTA</u>						
N 021476 002					M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ESZOPICLONE - LUNESTA</u>						
N 021476 003					M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - QUARTETTE</u>						
N 204061 001	8415332	Mar 11, 2029	DP		NP	Mar 28, 2016
	8450299	Oct 07, 2025	U-1			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MINASTRIN 24 FE</u>						
N 203667 001	5552394	Jul 22, 2014	U-1		NDF	May 08, 2016
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>						
N 204426 001	5552394	Jul 22, 2014	U-1			
	6652880	Mar 29, 2020	DP			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO MINASTRIN FE</u>						
N 204654 001	5552394	Jul 22, 2014	U-1			
	6667050	Apr 06, 2019	DP U-1			
	7704984	Feb 02, 2029	U-1			
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 001	5665772	Sep 09, 2019	DS DP U-1049		I-668	Feb 15, 2016
	5665772	Sep 09, 2019	DS DP U-1365			
	5665772*PED	Mar 09, 2020				
	6004973	Jul 12, 2016	DP U-1049			
	6004973	Jul 12, 2016	DP U-1365			
	6004973*PED	Jan 12, 2017				
	6440990	Sep 24, 2013	DP U-1049			
	6440990	Sep 24, 2013	DP U-1365			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518	Jul 29, 2017	U-1365			
	6455518*PED	Jan 29, 2018				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 002	5665772	Sep 09, 2019	DS DP U-1049		I-668	Feb 15, 2016
	5665772	Sep 09, 2019	DS DP U-1365			
	5665772*PED	Mar 09, 2020				
	6004973	Jul 12, 2016	DP U-1049			
	6004973	Jul 12, 2016	DP U-1365			
	6004973*PED	Jan 12, 2017				
	6440990	Sep 24, 2013	DP U-1049			
	6440990	Sep 24, 2013	DP U-1365			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518	Jul 29, 2017	U-1365			
	6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 003	5665772	Sep 09, 2019	DS DP U-1049		I-668	Feb 15, 2016
	5665772	Sep 09, 2019	DS DP U-1365			
	5665772*PED	Mar 09, 2020				
	6004973	Jul 12, 2016	DP U-1049			
	6004973	Jul 12, 2016	DP U-1365			
	6004973*PED	Jan 12, 2017				
	6440990	Sep 24, 2013	DP U-1049			
	6440990	Sep 24, 2013	DP U-1365			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518	Jul 29, 2017	U-1365			
	6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	8410131	May 22, 2025	DS DP U-1368			
	8410131*PED	Nov 22, 2025				
	8436010	Feb 22, 2022	DS DP U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	8410131	May 22, 2025	DS DP U-1368			
	8410131*PED	Nov 22, 2025				
	8436010	Feb 22, 2022	DS DP U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	8410131	May 22, 2025	DS DP U-1368			
	8410131*PED	Nov 22, 2025				
	8436010	Feb 22, 2022	DS DP U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	8410131	May 22, 2025	DS DP U-1368			
	8410131*PED	Nov 22, 2025				
	8436010	Feb 22, 2022	DS DP U-1396			
	8436010*PED	Aug 22, 2022				
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	8431685	Apr 13, 2025	DP U-412			
	8461105	Apr 13, 2025	DP U-412			
<u>FAMOTIDINE; IBUPROFEN - DUEXIS</u>						
N 022519 001	8449910	Jul 18, 2026	DP			
	8501228	Jul 18, 2026	U-1196			
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 001	5614520	Mar 25, 2019	DS DP U-954			
	8372872	Sep 08, 2031	U-1346			
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 002	5614520	Mar 25, 2019	DS DP U-954			
	8372872	Sep 08, 2031	U-1346			
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695 004	8026281	Apr 22, 2025	U-1447			
	8026281	Apr 22, 2025	U-1448			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695 005	8026281	Apr 22, 2025	U-1447			
	8026281	Apr 22, 2025	U-1448			
<u>FENOFIBRATE - FENOGLIDE</u>						
N 022118 001	8481078	Oct 01, 2024	DP U-1416			
<u>FENOFIBRATE - FENOGLIDE</u>						
N 022118 002	8481078	Oct 01, 2024	DP U-1416			
<u>FENTANYL - SUBSYS</u>						
N 202788 001	8486972	Apr 26, 2029	DP			
	8486973	Apr 26, 2029	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	8486972	Apr 26, 2029	DP			
	8486973	Apr 26, 2029	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	8486972	Apr 26, 2029	DP			
	8486973	Apr 26, 2029	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	8486972	Apr 26, 2029	DP			
	8486973	Apr 26, 2029	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	8486972	Apr 26, 2029	DP			
	8486973	Apr 26, 2029	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	8486972	Apr 26, 2029	DP		NP	Jan 04, 2015
	8486973	Apr 26, 2029	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	8486972	Apr 26, 2029	DP		NP	Jan 04, 2015
	8486973	Apr 26, 2029	U-55			
<u>FERRIC CARBOXYMALTOSIDE - INJECTAFER</u>						
N 203565 001	7612109	Feb 05, 2024	DS DP		NP	Jul 25, 2016
	7754702	Feb 13, 2027	DP U-1432			
<u>FERUMOXYTOL - FERAHEME</u>						
N 022180 001	8501158	Mar 08, 2020	U-1422			
	>A> 8591864	Mar 08, 2020	DP			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030 001	8338478	May 11, 2019	DS DP U-913			
	8501723	Jun 07, 2027	DP			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030 002	8338478	May 11, 2019	DS DP U-913			
	8501723	Jun 07, 2027	DP			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 021909 002	>A> 6037353	Mar 14, 2017	U-1158			
	>A> 6037353	Mar 14, 2017	U-1466			
	>A> 6723348	Nov 26, 2021	DP U-1466			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 021909 003	>A> 6037353	Mar 14, 2017				
	>A> 6723348	Nov 26, 2021	DP			
<u>FIDAXOMICIN - DIFICID</u>						
N 201699 001	8586551	Apr 12, 2024	DS DP			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008 001	8506929	Apr 30, 2027	DS DP U-1423			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008 002	8506929	Apr 30, 2027	DS DP U-1423			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008 003	8506929	Apr 30, 2027	DS DP U-1423			
<u>FLUNISOLIDE - AEROSPAN HFA</u>						
N 021247 001	5980867	Dec 20, 2013	DP		M-128	Aug 28, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936 001					NPP	Jul 26, 2016

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936	003				NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936	004				NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936	006				NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520	001				NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520	002				NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520	003				NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520	004				NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520	005				NPP	Jul 26, 2016
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137	001	8236282	May 21, 2024	DS DP		
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137	002	8236282	May 21, 2024	DS DP		
<u>FLUTICASON FUROATE - VERAMYST</u>						
N 022051	001	8347879	Apr 01, 2027	DP		
<u>FLUTICASON FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275	001	5873360	Feb 23, 2016	DP		
		6537983	Aug 03, 2021	DP U-1401		
		6759398	Aug 03, 2021	DP U-1401		
		6878698	Aug 03, 2021	U-1401		
		7101866	Aug 03, 2021	DS DP U-1401		
		7361787	Mar 23, 2023	DS DP U-1401		
		7439393	Sep 11, 2022	DS DP U-1401		
		7629335	Aug 03, 2021	DP		
		7776895	Sep 11, 2022	DP		
		8113199	Oct 23, 2027	DP		
		8161968	Feb 05, 2028	DP		
		8511304	Nov 11, 2025	DP U-1424		
		8534281	Aug 10, 2029	DP		
<u>FLUTICASON PROPIONATE - FLOVENT HFA</u>						
N 021433	001	7107986	Jun 08, 2018	DP		
		7107986*PED	Dec 08, 2018			
<u>FLUTICASON PROPIONATE - FLOVENT HFA</u>						
N 021433	002	7107986	Jun 08, 2018	DP		
		7107986*PED	Dec 08, 2018			
<u>FLUTICASON PROPIONATE - FLOVENT HFA</u>						
N 021433	003	7107986	Jun 08, 2018	DP		
		7107986*PED	Dec 08, 2018			
<u>FLUVOXAMINE MALEATE - FLUVOXAMINE MALEATE</u>						
A 091476	002				PC	Sep 09, 2013
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211	001	5929028	Jan 14, 2018	DP U-567		
		5929028	Jan 14, 2018	DP U-1366		
		7563763	Aug 23, 2019	U-993		
		7563763	Aug 23, 2019	U-1183		
		7563763	Aug 23, 2019	U-1367		
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211	002	5929028	Jan 14, 2018	DP U-567		
		5929028	Jan 14, 2018	DP U-1366		
		7563763	Aug 23, 2019	U-993		
		7563763	Aug 23, 2019	U-1183		
		7563763	Aug 23, 2019	U-1367		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 003	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			
	7563763	Aug 23, 2019	U-1367			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 004	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			
	7563763	Aug 23, 2019	U-1367			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021273 001	5767251	Jun 16, 2015	DS			
	5929028	Jan 14, 2018	DP U-1366			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021273 002	5767251	Jun 16, 2015	DS			
	5929028	Jan 14, 2018	DP U-1366			
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518 001	7566705	May 21, 2020	DP U-1068			
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518 002	7566705	May 21, 2020	DP U-1068			
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	8466139	Jan 09, 2021	U-596			
	8466139*PED	Jul 09, 2021				
<u>GABAPENTIN - GRALISE</u>						
N 022544 001	8333992	Oct 25, 2022	DP U-1114			
<u>GABAPENTIN - GRALISE</u>						
N 022544 002	8333992	Oct 25, 2022	DP U-1114			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N 021711 001	8394356	Feb 01, 2015	U-1112			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N 021711 002	8394356	Feb 01, 2015	U-1112			
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 001					NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 002					NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 003					NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 004					NCE	Mar 20, 2018
<u>GADOXETATE DISODIUM - EOVIIST</u>						
N 022090 002					NCE	Jul 03, 2013
<u>GANIRELIX ACETATE - GANIRELIX ACETATE</u>						
N 021057 001	6653286	Jun 16, 2018	U-1354			
<u>GATIFLOXACIN - GATIFLOXACIN</u>						
A 202653 001					PC	Mar 30, 2014
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 002	8367605	May 24, 2014	DS			
<u>GLIPIZIDE - GLUCOTROL XL</u>						
N 020329 001	RE44459	Mar 26, 2019	U-1431			
<u>GLIPIZIDE - GLUCOTROL XL</u>						
N 020329 002	RE44459	Mar 26, 2019	U-1431			
<u>GLIPIZIDE - GLUCOTROL XL</u>						
N 020329 003	RE44459	Mar 26, 2019	U-1431			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	5968979	Feb 07, 2015	DS DP U-1378		NE	Feb 01, 2016
	8404215	Mar 09, 2032	U-1383		ODE	Feb 01, 2020

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GLYCOPYRROLATE - ROBINUL</u>						
N 012827 001	7091236	Apr 24, 2024	U-877	Y		
<u>GLYCOPYRROLATE - ROBINUL FORTE</u>						
N 012827 002	7091236	Apr 24, 2024	U-877	Y		
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001 >A>	6902742	Nov 01, 2019	DP		NP	Oct 25, 2016
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002 >A>	6902742	Nov 01, 2019	DP		NP	Oct 25, 2016
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003 >A>	6902742	Nov 01, 2019	DP		NP	Oct 25, 2016
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004 >A>	6902742	Nov 01, 2019	DP		NP	Oct 25, 2016
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005 >A>	6902742	Nov 01, 2019	DP		NP	Oct 25, 2016
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006 >A>	6902742	Nov 01, 2019	DP		NP	Oct 25, 2016
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	7514444	Dec 28, 2026	DS DP		NCE	Nov 13, 2018
	8008309	Dec 28, 2026	DS DP		ODE	Nov 13, 2020
	8476284	Dec 28, 2026		U-1456		
	8497277	Dec 28, 2026		U-1456		
<u>IBUPROFEN LYSINE - NEOPROFEN</u>						
N 021903 001	8415337	Mar 02, 2032	DS DP			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	8357677	Feb 09, 2030		U-1287		
	8367652	Feb 09, 2030		U-1287		
	8377920	Feb 09, 2030		U-1287		
	8399446	Feb 09, 2030		U-1287		
	8415335	Feb 09, 2030		U-1287		
	8426399	Feb 09, 2030		U-1287		
	8431560	Feb 09, 2030		U-1287		
	8440650	Feb 09, 2030		U-1287		
	8445003	Apr 29, 2030		U-1287		
	8445013	Apr 29, 2030		U-1287		
	8501225	Apr 29, 2030		U-1287		
	8518929	Apr 29, 2030		U-1287		
	8524698	Apr 29, 2030		U-1287		
	8546372	Apr 29, 2030		U-1287		
	8551521	Apr 29, 2030		U-1287		
	8563608	Apr 29, 2030		U-1287		
>A> 8617593	Apr 29, 2030		U-1478			
>A> 8617594	Apr 29, 2030		U-1287			
>A> 8623406	Apr 29, 2030		U-1478			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 001	7544799	Jan 16, 2019	DS DP	Y	I-666	Jan 25, 2016
	7544799*PED	Jul 16, 2019			ODE	Jan 25, 2020
	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 002	7544799	Jan 16, 2019	DS DP	Y	I-666	Jan 25, 2016
	7544799*PED	Jul 16, 2019			ODE	Jan 25, 2020
	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>IMIQIUMOD - ZYCLARA</u>						
N 022483 001	8598196	Aug 18, 2029		U-172		
	8598196	Aug 18, 2029		U-1455		
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383 001	8067437	Jun 02, 2020		U-1168		
	8479730	Oct 11, 2028	DP			
<u>INDIUM IN-111 PENTETREOTIDE KIT - OCTREOSCAN</u>						
N 020314 001	6123916	Sep 26, 2017		U-1125		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	6844013	Dec 13, 2018	DS DP U-1221			
	8372827	Dec 18, 2026	DS DP			
	8372828	Dec 18, 2026	DS DP			
	8377919	Dec 18, 2026	DS DP			
	8536163	Dec 18, 2026	U-1440			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	6844013	Dec 13, 2018	DS DP U-1221			
	8372827	Dec 18, 2026	DS DP			
	8372828	Dec 18, 2026	DS DP			
	8377919	Dec 18, 2026	DS DP			
	8536163	Dec 18, 2026	U-1440			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	>A> 8603044	Mar 02, 2024	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	>A> 8603044	Mar 02, 2024	DP			
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 75/25 KWIKPEN</u>						
N 021017 002	7291132	Aug 09, 2024	DP			
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 50/50 KWIKPEN</u>						
N 021018 002	7291132	Aug 09, 2024	DP			
<u>INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN</u>						
N 020563 003	7291132	Aug 09, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN 70/30</u>						
N 019717 001	7291132	Aug 09, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN 70/30 PEN</u>						
N 019717 002	7291132	Aug 09, 2024	DP			
<u>INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN N</u>						
N 018781 001	7291132	Aug 09, 2024	DP			
<u>IOBENGUANE SULFATE I-123 - ADREVIEW</u>						
N 022290 001					I-669	Mar 20, 2016
<u>IRON SUCROSE - VENOFER</u>						
N 021135 005					NPP	Sep 21, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 001	8367102	Sep 21, 2021	U-1347			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 002	8367102	Sep 21, 2021	U-1347			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 003	8367102	Sep 21, 2021	U-1347			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 004	8367102	Sep 21, 2021	U-1347			
<u>ITRACONAZOLE - ONMEL</u>						
N 022484 001	8486456	Oct 03, 2028	DP U-1054			
	>A> 8591948	May 12, 2017	DP U-1054			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	8410274	Dec 28, 2026	DP			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	8377982	May 28, 2024	U-1363			
	8377982*PED	Nov 28, 2024				
	8541463	May 28, 2024	U-1441			
	8541463*PED	Nov 28, 2024				
<u>KETOROLAC TROMETHAMINE - ACUVAIL</u>						
N 022427 001	8512717	Mar 07, 2028	DP			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAPATINIB DITOSYLATE - TYKERB</u>						
N 022059 001	6391874	Jul 11, 2017	DS DP U-800			
	6391874	Jul 11, 2017	DS DP U-1429			
	6713485	Sep 29, 2020	DS DP U-800			
	6713485	Sep 29, 2020	DS DP U-1429			
	6727256	Jan 08, 2019	DS DP U-800			
	6727256	Jan 08, 2019	DS DP U-1429			
	6828320	Jul 11, 2017	U-800			
	6828320	Jul 11, 2017	U-1429			
	7157466	Nov 19, 2021	DS DP			
	8513262	Jan 08, 2019	DS DP			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	6281230	Jul 24, 2016	U-1212		I-672	Jun 05, 2016
	6281230	Jul 24, 2016	U-1414		ODE	Jun 05, 2020
	7468363	Oct 07, 2023	U-1414			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
	>A> 8589188	Aug 28, 2018	U-1210			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	6281230	Jul 24, 2016	U-1212		I-672	Jun 05, 2016
	6281230	Jul 24, 2016	U-1414		ODE	Jun 05, 2020
	7468363	Oct 07, 2023	U-1414			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
	>A> 8589188	Aug 28, 2018	U-1210			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	6281230	Jul 24, 2016	U-1212		I-672	Jun 05, 2016
	6281230	Jul 24, 2016	U-1414		ODE	Jun 05, 2020
	7468363	Oct 07, 2023	U-1414			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
	>A> 8589188	Aug 28, 2018	U-1210			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	6281230	Jul 24, 2016	U-1212		I-672	Jun 05, 2016
	6281230	Jul 24, 2016	U-1414		ODE	Jun 05, 2020
	7468363	Oct 07, 2023	U-1414			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
	>A> 8589188	Aug 28, 2018	U-1210			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	6281230	Jul 24, 2016	U-1212		I-672	Jun 05, 2016
	6281230	Jul 24, 2016	U-1414		ODE	Jun 05, 2020
	7468363	Oct 07, 2023	U-1414			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
	>A> 8589188	Aug 28, 2018	U-1210			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	5635517	Oct 04, 2019	DS DP U-1211		I-672	Jun 05, 2016
	6045501	Aug 28, 2018	U-1210		NS	Jun 05, 2016
	6281230	Jul 24, 2016	U-1212		ODE	Jun 05, 2020
	6281230	Jul 24, 2016	U-1414			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023	U-1414			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
>A>	8589188	Aug 28, 2018	U-1210			
<u>LEVALBUTEROL HYDROCHLORIDE - LEVALBUTEROL HYDROCHLORIDE</u>						
A 077756 001					PC	Feb 16, 2013
<u>LEVALBUTEROL HYDROCHLORIDE - LEVALBUTEROL HYDROCHLORIDE</u>						
A 077756 002					PC	Feb 16, 2013
<u>LEVALBUTEROL HYDROCHLORIDE - LEVALBUTEROL HYDROCHLORIDE</u>						
A 077756 003					PC	Feb 16, 2013
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140 001	6500829	Mar 07, 2022	DS DP			
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140 002	6500829	Mar 07, 2022	DS DP			
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140 003	6500829	Mar 07, 2022	DS DP			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 001	8481598	Mar 02, 2031	U-839		NCE*	Jul 25, 2018
	RE43879	Jun 03, 2023	U-839			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 002	8481598	Mar 02, 2031	U-839		NCE*	Jul 25, 2018
	RE43879	Jun 03, 2023	U-839			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 003	8481598	Mar 02, 2031	U-839		NCE*	Jul 25, 2018
	RE43879	Jun 03, 2023	U-839			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 004	8481598	Mar 02, 2031	U-839		NCE*	Jul 25, 2018
	RE43879	Jun 03, 2023	U-839			
<u>LEVONORGESTREL - PLAN B ONE-STEP</u>						
N 021998 001					RTO*	Apr 30, 2016
					RTO**	Apr 30, 2016
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	5785053	Dec 05, 2015	DP		NP	Jan 09, 2016
	7252839	Nov 13, 2023	DP			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 001	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 002	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 003	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 004	7101569	Oct 02, 2023	U-759			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 005	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 006	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 007	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 008	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 009	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 010	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 011	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 012	7101569	Oct 02, 2023	U-759			
<u>LIDOCAINE HYDROCHLORIDE - ZINGO</u>						
N 022114 001	8540665	Oct 22, 2029	U-1438			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	6268343	Aug 22, 2022	DS DP U-968			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	5712279	Feb 21, 2015	DS U-1317		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	5712279	Feb 21, 2015	DS U-1317		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	5712279	Feb 21, 2015	DS U-1317		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021251 001	8501219	Nov 28, 2021	DP			
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906 001	8025899	Dec 14, 2027	DP			
	8025899*PED	Jun 14, 2028				
	8377952	Oct 22, 2027	U-1372			
	8377952*PED	Apr 22, 2028				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8470347	Sep 17, 2026	DP			
	8470347*PED	Mar 17, 2027				
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906 002	8025899	Dec 14, 2027	DP			
	8025899*PED	Jun 14, 2028				
	8377952	Oct 22, 2027	U-1372			
	8377952*PED	Apr 22, 2028				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8470347	Sep 17, 2026	DP			
	8470347*PED	Mar 17, 2027				
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001	8367657	Apr 10, 2023	DS DP U-1252			
	8367657	Apr 10, 2023	DS DP U-1253			
	8367657	Apr 10, 2023	DS DP U-1254			
	8367657	Apr 10, 2023	DS DP U-1255			
	8546379	Apr 10, 2023	DS DP U-1252			
	8546379	Apr 10, 2023	DS DP U-1253			
	8546379	Apr 10, 2023	DS DP U-1254			
	8546379	Apr 10, 2023	DS DP U-1255			
	8575149	Apr 10, 2023	U-1452			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N 202872 001	5800807	Jan 29, 2017	DP			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	6716416	May 20, 2022	DP'			
	7052679	Mar 20, 2022	DP'			
	7078020	Oct 26, 2021	DP U-1375'			
	7090830	Oct 26, 2021	DP'			
	7458374	Aug 18, 2024	DP'			
	7537009	Oct 26, 2021	DP'			
	7585493	Oct 26, 2021	DP'			
	7601337	Oct 26, 2021	DP'			
	8074644	Oct 26, 2021	DP'			
	8173107	Oct 26, 2021	DP'			
	8235037	Oct 26, 2021	DP'			
	8387612	Oct 23, 2026	DP'			
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 001	6414016	Sep 05, 2020	U-717		I-670	Apr 19, 2016
	6414016	Sep 05, 2020	U-1392			
	6982283	Dec 04, 2022	U-1391			
	7064148	Aug 30, 2022	U-739			
	7064148	Aug 30, 2022	U-1404			
	8026393	Oct 25, 2027	DP			
	8071613	Sep 05, 2020	U-1203			
	8071613	Sep 05, 2020	U-1393			
	8097653	Nov 14, 2022	U-1214			
	8097653	Nov 14, 2022	U-1394			
	8389542	Nov 14, 2022	DP U-1345			
	8389542	Nov 14, 2022	DP U-1395			
<u>LUCINACTANT - SURFAXIN</u>						
N 021746 001 >A>	5407914	Nov 17, 2014	DS DP U-1242			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	5900488	Jul 05, 2016	DS DP U-540		NCE	Nov 14, 2018
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	5532372	Jul 02, 2018	DS		I-674	Jun 28, 2016
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	5532372	Jul 02, 2018	DS		I-674	Jun 28, 2016
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	5532372	Jul 02, 2018	DS		I-674	Jun 28, 2016
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	5532372	Jul 02, 2018	DS		I-674	Jun 28, 2016
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005					D-134 I-674 NCE	Apr 26, 2015 Jun 28, 2016 Oct 28, 2015
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001	7094781	Oct 12, 2022	DS DP		NCE	Oct 18, 2018
	8268847	Apr 18, 2029	U-1446		ODE	Oct 18, 2020
	8367685	Oct 04, 2028	DP U-1445			
<u>MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE - SUCLEAR</u>						
N 203595 001					NC	Jan 18, 2016
<u>MECHLORETHAMINE HYDROCHLORIDE - VALCHLOR</u>						
N 202317 001	7838564	Mar 07, 2026	DP		NDF	Aug 23, 2016
	7872050	Jul 08, 2029	U-1427		ODE	Aug 23, 2020
	8450375	Mar 07, 2026	DP			
	8501818	Mar 07, 2026	DP			
	8501819	Mar 07, 2026	U-1427			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 001	8168209	Nov 22, 2025	DP			
	8173708	Nov 22, 2025	U-539			
	8283379	Nov 22, 2025	U-539			
	8329752	Nov 22, 2025	DP			
	8362085	Nov 22, 2025	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 002	8168209	Nov 22, 2025	DP			
	8173708	Nov 22, 2025	U-539			
	8283379	Nov 22, 2025	U-539			
	8329752	Nov 22, 2025	DP			
	8362085	Nov 22, 2025	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 003	8168209	Nov 22, 2025	DP			
	8173708	Nov 22, 2025	U-539			
	8283379	Nov 22, 2025	U-539			
	8329752	Nov 22, 2025	DP			
	8362085	Nov 22, 2025	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 004	8168209	Nov 22, 2025	DP			
	8173708	Nov 22, 2025	U-539			
	8283379	Nov 22, 2025	U-539			
	8329752	Nov 22, 2025	DP			
	8362085	Nov 22, 2025	U-539			
>A>	8598233	Nov 22, 2025	DP			
<u>MESALAMINE - CANASA</u>						
N 021252 002	8217083	Jun 06, 2028	DP			
	8436051	Jun 06, 2028	DP			
<u>MESALAMINE - ASACOL HD</u>						
N 021830 001	8580302	Nov 15, 2021	DP			
<u>MESALAMINE - APRISO</u>						
N 022301 001	8496965	Apr 20, 2018	DP			
<u>MESALAMINE - DELZICOL</u>						
N 204412 001	5541170	Jul 30, 2013	DP	U-141		
	5541171	Jul 30, 2013	DP	U-141		
	6649180	Apr 13, 2020	DP			
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N 021574 001	8475841	Mar 20, 2018	U-604			
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N 021574 002	8475841	Mar 20, 2018	U-604			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 001	8470368	Sep 19, 2023	DP			
	8475841	Mar 20, 2018	U-973			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 002	8470368	Sep 19, 2023	DP			
	8475841	Mar 20, 2018	U-973			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001	RE44186	Jul 31, 2023	DS DP	U-1097		
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002	RE44186	Jul 31, 2023	DS DP	U-1097		
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003	RE44186	Jul 31, 2023	DS DP	U-1097		
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001	7459428	Feb 02, 2019	U-1036			
	8414921	Jul 21, 2028	DP	U-1036		
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002	7459428	Feb 02, 2019	U-1036			
	8414921	Jul 21, 2028	DP	U-1036		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	6746429	Apr 12, 2020	DP			
	7744582	Aug 10, 2019	DP U-1442			
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	6746429	Apr 12, 2020	DP			
	7744582	Aug 10, 2019	DP U-1442			
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	6746429	Apr 12, 2020	DP			
	7744582	Aug 10, 2019	DP U-1442			
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	6746429	Apr 12, 2020	DP			
	7744582	Aug 10, 2019	DP U-1442			
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 001	8420663	Sep 30, 2029			U-1185	
	8552025	Apr 08, 2024	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 002	8420663	Sep 30, 2029			U-1185	
	8552025	Apr 08, 2024	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 003	8420663	Sep 30, 2029			U-1185	
	8552025	Apr 08, 2024	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N 202100 001	8062667	Mar 29, 2029	DP			
	8287903	Feb 15, 2031	DP			
	8465765	Feb 15, 2031	DP U-1415			
	8563033	Feb 15, 2031	DP U-1415			
<u>METRONIDAZOLE - METRONIDAZOLE</u>						
A 090903 001					PC	Dec 28, 2013
<u>MICONAZOLE - ORAVIG</u>						
N 022404 001	8518442	Sep 11, 2022	DP			
<u>MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE - VUSION</u>						
N 021026 001	8147852	Mar 30, 2028			U-1426	
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922 001	5908838	Feb 19, 2018			U-1376	
	7541347	Apr 02, 2027			U-917	
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025			U-124	
	7919483	Mar 07, 2027			U-124	
	8252776	Jun 24, 2025			U-124	
	8268804	Jun 24, 2025			U-124	

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922 003	5908838	Feb 19, 2018	U-1376			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922 005	5908838	Feb 19, 2018	U-1376			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
<u>MIPOMERSEN SODIUM - KYNAMRO</u>						
N 203568 001	5914396	Jun 22, 2016	DS		NCE	Jan 29, 2018
	6166197	Dec 26, 2017	DS		ODE	Jan 29, 2020
	6222025	Mar 06, 2015	DS			
	6451991	Feb 11, 2017	DS			
	7015315	Mar 21, 2023	DS			
	7101993	Sep 05, 2023	DS			
	7407943	Aug 01, 2021	U-1353			
	7511131	Dec 13, 2025	DS			
<u>MOMETASONE FUROATE - FLOCON</u>						
N 019625 002					NP	Apr 19, 2016
<u>MOXIFLOXACIN HYDROCHLORIDE - MOXEZA</u>						
N 022428 001	8450311	May 29, 2029	DP			
<u>MUPIROCIN CALCIUM - BACTROBAN</u>						
N 050703 001	5569672	Oct 29, 2013	U-1358			
<u>MUPIROCIN CALCIUM - BACTROBAN</u>						
N 050746 001	5569672	Oct 29, 2013	U-1358			
<u>MYCOPHENOLIC ACID - MYFORTIC</u>						
N 050791 001	6306900	Feb 27, 2018	DP			
<u>MYCOPHENOLIC ACID - MYFORTIC</u>						
N 050791 002	6306900	Feb 27, 2018	DP			
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 204286 001					NP	Jun 27, 2016
<u>NEPAFENAC - ILEVRO</u>						
N 203491 001	5475034	Jun 06, 2014	U-100			
	6403609	Jul 17, 2018	DP			
	7947295	Jun 08, 2024	DP			
<u>NEVIRAPINE - VIRAMUNE XR</u>						
N 201152 001	8460704	Mar 12, 2029	U-1409			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 002	8455524	Apr 18, 2027	U-1029			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 003	8455524	Apr 18, 2027	U-1029			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 004	8455524	Apr 18, 2027	U-1029			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 005	8455524	Apr 18, 2027	U-1029			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360 001	8501164	Jun 14, 2029	DP			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360 002	8501164	Jun 14, 2029	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 001	8389537	Jul 18, 2026	DS DP U-1374			
	8415363	Jul 18, 2026	DS DP U-1407			
	8501760	Jul 18, 2026	DS DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 002	8389537	Jul 18, 2026	DS DP U-1374			
	8415363	Jul 18, 2026	DS DP U-1407			
	8501760	Jul 18, 2026	DS DP			
<u>NIMODIPINE - NYMALIZE</u>						
N 203340 001					ODE	May 10, 2020
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 002 >A>	6125846	May 16, 2017	DP U-1457			
	8431163	Jun 30, 2029	U-1286			
	8431163*PED	Dec 30, 2029				
	8573209	Jan 06, 2031	DP			
	8573209*PED	Jul 06, 2031				
	8573210	Jan 06, 2031	DP U-1453			
	8573210*PED	Jul 06, 2031				
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003 >A>	6125846	May 16, 2017	DP U-1457			
	8431163	Jun 30, 2029	U-1286			
	8431163*PED	Dec 30, 2029				
	8573209	Jan 06, 2031	DP			
	8573209*PED	Jul 06, 2031				
	8573210	Jan 06, 2031	DP U-1453			
	8573210*PED	Jul 06, 2031				
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 001					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 002					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 003					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 004					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 005					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 006					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086 001					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086 002					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086 003					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086 004					NPP	Jul 26, 2016
<u>OLOPATADINE HYDROCHLORIDE - PATANASE</u>						
N 021861 001	8399508	Sep 17, 2022	U-726			
	8399508*PED	Mar 17, 2023				
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 001	6489346	Jul 16, 2016	DS DP U-588		Y	
	6645988	Jul 16, 2016	DS DP		Y	
	6699885	Jul 16, 2016	U-588		Y	
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 002	6489346	Jul 16, 2016	DS DP U-623		Y	
	6489346	Jul 16, 2016	DS DP U-624		Y	
	6645988	Jul 16, 2016	DS DP		Y	
	6699885	Jul 16, 2016	U-623		Y	
	6699885	Jul 16, 2016	U-624		Y	



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID OTC</u>						
N 022281 001	6489346	Jul 15, 2016	DP U-1025	Y		
	6645988	Jul 15, 2016	DP	Y		
	6699885	Jul 15, 2016	DP	Y		
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID OTC</u>						
N 022283 001	5840737	Jul 16, 2016	U-1025			
	6780882	Jul 16, 2016	DP			
	7399772	Jul 16, 2016	U-1025			
<u>ONDANSETRON - ZUPLENZ</u>						
N 022524 001	8580830	Nov 23, 2029	DP			
<u>ONDANSETRON - ZUPLENZ</u>						
N 022524 002	8580830	Nov 23, 2029	DP			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 001					NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 002					NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 003					NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246 001					NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246 002					NPP	Dec 21, 2015
<u>OSPEMIFENE - OSPHENA</u>						
N 203505 001	6245819	Jul 21, 2020	U-1369		NCE	Feb 26, 2018
	8236861	Aug 11, 2026	U-1369			
	8236861	Aug 11, 2026	U-1370			
	8470890	Feb 13, 2024	U-1369			
	8470890	Feb 13, 2024	U-1370			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	>A> 8617600	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	>A> 8617600	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	>A> 8617600	Apr 13, 2027	DP			
<u>OXYBUTYNIN - OXYTROL FOR WOMEN</u>						
N 202211 001	5601839	Apr 26, 2015	DP U-1329		NP	Jan 25, 2016
	5834010	Apr 26, 2015	DP U-1329			
	6743441	Apr 26, 2020	DP U-1329			
	7081249	Apr 26, 2020	DP U-1329			
	7081250	Apr 26, 2020	DP U-1329			
	7081251	Apr 26, 2020	DP U-1329			
	7081252	Apr 26, 2020	DP U-1329			
	7179483	Apr 26, 2020	U-1329			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N 202080 001	8409616	Nov 26, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N 202080 002	8409616	Nov 26, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OXYMORPHONE HYDROCHLORIDE</u>						
A 079087 006					PC	Jul 07, 2013

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	7758891	Feb 21, 2026	U-1434		I-676	Sep 06, 2016
	7820788	Mar 03, 2024	DP U-1092		ODE	Sep 06, 2020
	7820788	Mar 03, 2024	DP U-1290			
	7820788	Mar 03, 2024	DP U-1434			
	7923536	Dec 09, 2023	U-1117			
	7923536	Dec 09, 2023	U-1290			
	7923536	Dec 09, 2023	U-1434			
	8138229	Dec 09, 2023	DP U-1092			
	8138229	Dec 09, 2023	DP U-1290			
	8138229	Dec 09, 2023	DP U-1434			
	8314156	Dec 09, 2023	U-1290			
	8314156	Dec 09, 2023	U-1434			
	RE41884	Aug 14, 2016	U-1117			
	RE41884	Aug 14, 2016	U-1290			
	RE41884	Aug 14, 2016	U-1434			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	8518981	Jan 30, 2024	DP			
	>A> 8598218	Jan 30, 2024	DP			
	>A> 8598219	Jan 30, 2024	DP			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	8518981	Jan 30, 2024	DP			
	>A> 8598218	Jan 30, 2024	DP			
	>A> 8598219	Jan 30, 2024	DP			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725 005					M-93 NCE	Jul 29, 2019 Apr 30, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 001	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP			
	8562980	Feb 20, 2028	DP			
	8562981	Feb 20, 2028				
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 002	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP			
	8562980	Feb 20, 2028	DP			
	8562981	Feb 20, 2028				
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 003	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP			
	8562980	Feb 20, 2028	DP			
	8562981	Feb 20, 2028				
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 004	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP			
	8562980	Feb 20, 2028	DP			
	8562981	Feb 20, 2028				
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 005	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP			
	8562980	Feb 20, 2028	DP			
	8562981	Feb 20, 2028				
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 006	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP			
	8562980	Feb 20, 2028	DP			
	8562981	Feb 20, 2028				
<u>PARICALCITOL - PARICALCITOL</u>						
A 090829 001					PC	Dec 24, 2013
<u>PARICALCITOL - PARICALCITOL</u>						
A 090829 002					PC	Dec 24, 2013

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PARICALCITOL - PARICALCITOL</u>						
A 090829	003				PC	Dec 24, 2013
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299	001	7598271	Feb 12, 2023	DS DP		
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299	002	7598271	Feb 12, 2023	DS DP		
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299	003	7598271	Feb 12, 2023	DS DP		
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299	004	7598271	Feb 12, 2023	DS DP		
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516	001	5874447	Jun 10, 2017	DS	NP	Jun 28, 2016
		7598271	Feb 12, 2023	DS		
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088	001	8440170	Mar 14, 2029	DP		
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088	002	8440170	Mar 14, 2029	DP		
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088	003	8440170	Mar 14, 2029	DP		
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYmia</u>						
N 022580	001	8580298	May 15, 2029	DP		
		8580299	Jun 14, 2029		U-1262	
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYmia</u>						
N 022580	002	8580298	May 15, 2029	DP		
		8580299	Jun 14, 2029		U-1262	
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYmia</u>						
N 022580	003	8580298	May 15, 2029	DP		
		8580299	Jun 14, 2029		U-1262	
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYmia</u>						
N 022580	004	8580298	May 15, 2029	DP		
		8580299	Jun 14, 2029		U-1262	
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363	001	5856336	Dec 25, 2020	DS	U-998	
		8557993	Feb 02, 2024		DP	
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363	002	5856336	Dec 25, 2020	DS	U-998	
		8557993	Feb 02, 2024		DP	
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363	003	5856336	Dec 25, 2020	DS	U-998	
		8557993	Feb 02, 2024		DS DP	
<u>PLERIXAFOR - MOZOBIL</u>						
N 022311	001	RE42152	Dec 10, 2018	DP		
<u>POLIDOCANOL - VARITHENA</u>						
N 205098	001	>A> 6572873	May 26, 2020		U-1461	
		>A> 6846412	Jul 19, 2022	DP		
		>A> 6942165	May 26, 2020	DP		
		>A> 7025290	May 26, 2020	DP	U-1461	
		>A> 7357336	May 26, 2020		U-1461	
		>A> 7604185	May 26, 2020	DS DP	U-1462	
		>A> 7731986	Nov 17, 2024	DS DP	U-1463	
		>A> 7814943	Nov 19, 2027	DP	U-1461	
		>A> 7842282	May 26, 2020		U-1461	
		>A> 7842283	May 26, 2020	DP		
		>A> 8122917	Sep 09, 2024	DP		
		>A> 8323677	May 26, 2020	DS		
		>A> RE38919	Oct 14, 2014	DS DP		
		>A> RE40640	Oct 14, 2014	DS DP	U-1462	

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	5635517	Jul 24, 2016	U-1359		NCE'	Feb 08, 2018
	6045501	Aug 28, 2018	U-1361		ODE'	Feb 08, 2020
	6315720	Oct 23, 2020	U-1361			
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
>A>	8589188	Aug 28, 2018	U-1361			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	6315720	Oct 23, 2020	U-1361			
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
>A>	8589188	Aug 28, 2018	U-1361			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	6315720	Oct 23, 2020	U-1361			
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
>A>	8589188	Aug 28, 2018	U-1361			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	6315720	Oct 23, 2020	U-1361			
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
>A>	8589188	Aug 28, 2018	U-1361			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001					ODE	Dec 14, 2019
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002					ODE	Dec 14, 2019

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>POSACONAZOLE - NOXAFIL</u>						
N 205053 001	5661151	Jul 19, 2019	DS DP U-1454			
	5703079	Aug 26, 2014	DS DP U-1454			
<u>PRALATREXATE - FOLOTYN</u>						
N 022468 001	6028071	Jul 16, 2022	DS DP U-1004			
<u>PRALATREXATE - FOLOTYN</u>						
N 022468 002	6028071	Jul 16, 2022	DS DP U-1004			
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 001	8404703	Nov 12, 2022				
	8569325	Nov 12, 2022	U-1381			
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 002	8404703	Nov 12, 2022				
	8569325	Nov 12, 2022	U-1381			
<u>PREDNISONE - RAYOS</u>						
N 202020 001	8394407	Apr 23, 2024	DP U-1362		M-128	Jul 26, 2015
<u>PREDNISONE - RAYOS</u>						
N 202020 002	8394407	Apr 23, 2024	DP U-1362		M-128	Jul 26, 2015
<u>PREDNISONE - RAYOS</u>						
N 202020 003	8394407	Apr 23, 2024	DP U-1362		M-128	Jul 26, 2015
<u>PREGABALIN - LYRICA</u>						
N 022488 001					I-651	Jun 20, 2015
<u>PROPOFOL - DIPRIVAN</u>						
N 019627 002	8476010	Dec 01, 2024	DS DP			
	8476010*PED	Jun 01, 2025				
<u>RABEPRAZOLE SODIUM - ACIPHEX SPRINKLE</u>						
N 204736 001	5045552	May 08, 2013	DS DP U-385		NDF	Mar 26, 2016
	5045552*PED	Nov 08, 2013			PED	Sep 26, 2016
<u>RABEPRAZOLE SODIUM - ACIPHEX SPRINKLE</u>						
N 204736 002	5045552	May 08, 2013	DS DP U-385		NDF	Mar 26, 2016
	5045552*PED	Nov 08, 2013			PED	Sep 26, 2016
<u>RADIUM RA-223 DICHLORIDE - XOFIGO</u>						
N 203971 001	6635234	Jan 03, 2020	U-1405		NCE	May 15, 2018
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 205786 001					>A> NDF	Dec 20, 2016
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001	8470801	Jun 22, 2019	U-116			
	8536150	Jun 22, 2019	U-116			
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001					I-667 ODE	Feb 25, 2016 Feb 25, 2020
<u>REPAGLINIDE - REPAGLINIDE</u>						
A 077571 002					PC	Jan 20, 2014
<u>REPAGLINIDE - REPAGLINIDE</u>						
A 077571 003					PC	Jan 20, 2014
<u>REPAGLINIDE - PRANDIN</u>						
N 020741 002	6677358	Jun 12, 2018	DS DP U-1265	Y		
<u>REPAGLINIDE - PRANDIN</u>						
N 020741 003	6677358	Jun 12, 2018	DP U-1265	Y		
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 001	8518949	Mar 27, 2026	DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	8518949	Mar 27, 2026	DP			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 001	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE	Oct 08, 2020
					ODE	Oct 08, 2020

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 002	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE	Oct 08, 2020
					ODE	Oct 08, 2020
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 003	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE	Oct 08, 2020
					ODE	Oct 08, 2020
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 004	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE	Oct 08, 2020
					ODE	Oct 08, 2020
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 005	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE	Oct 08, 2020
					ODE	Oct 08, 2020
<u>RITONAVIR - NORVIR</u>						
N 022417 001	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8470347	Sep 17, 2026	DP			
	8470347*PED	Mar 17, 2027				
<u>RIVASTIGMINE - EXELON</u>						
N 022083 005					NPP	Jun 27, 2016
<u>RIZATRIPTAN BENZOATE - RIZATRIPTAN BENZOATE</u>						
A 078173 001					PC	Jun 29, 2013
<u>RIZATRIPTAN BENZOATE - RIZATRIPTAN BENZOATE</u>						
A 078173 002					PC	Jun 29, 2013
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001	8431154	Feb 19, 2023	DP			
	8536206	Mar 08, 2024		U-1115		
	>A> 8604064	Mar 08, 2024		U-1115		
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 001	5670524	Sep 23, 2014	DS DP U-833			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 003	5670524	Sep 23, 2014	DS DP U-833			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 004	5670524	Sep 23, 2014	DS DP U-833			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 005	5670524	Sep 23, 2014	DS DP U-833			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 001 >A>	8617591	Jul 22, 2023	DP U-1474			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 002 >A>	8617591	Jul 22, 2023	DP U-1474			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 003 >A>	8617591	Jul 22, 2023	DP U-1474			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 004 >A>	8617591	Jul 22, 2023	DP U-1474			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 005 >A>	8617591	Jul 22, 2023	DP U-1474			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 006 >A>	8617591	Jul 22, 2023	DP U-1474			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	8415362	Dec 24, 2027	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	8415362	Dec 24, 2027	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	8415362	Dec 24, 2027	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	8415362	Dec 24, 2027	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	8415362	Dec 24, 2027	DS DP			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 022181 001	8318745	Nov 17, 2024	DP			
<u>SAQUINAVIR MESYLATE - INVIRASE</u>						
N 020628 001					M-61 PED	Nov 30, 2015 May 30, 2016
<u>SAQUINAVIR MESYLATE - INVIRASE</u>						
N 021785 001					M-61 PED	Nov 30, 2015 May 30, 2016
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001	RE44186	Jul 31, 2023	DS DP U-995			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002	RE44186	Jul 31, 2023	DS DP U-995			
<u>SERTRALINE HYDROCHLORIDE - ZOLOFT</u>						
N 020990 001	7067555	Oct 11, 2019	DP			
	7067555*PED	Apr 11, 2020				
<u>SIMEPREVIR - OLYSIO</u>						
N 205123 001	>A> 7671032	May 19, 2025	DS DP		NCE	Nov 22, 2018
	>A> 8148399	Sep 05, 2029	DS DP U-1467			
	>A> 8349869	Jul 28, 2026	DS DP U-1467			
<u>SODIUM NITRITE - SODIUM NITRITE</u>						
N 203922 001	8568793	Dec 24, 2031	DS DP			
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE</u>						
N 201444 001	8496973	Mar 29, 2031	DS DP U-1419			
	8568793	Dec 24, 2031	DS DP			
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	8457988	Dec 17, 2022	U-1110			
	>A> 8589182	Dec 17, 2022	U-1110			
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N 203923 001	8496973	Mar 29, 2031	DS DP U-1419			
<u>SOFOSBUVIR - SOLVADI</u>						
N 204671 001	>A> 7964580	Mar 26, 2029	DS DP U-1470		>A> NCE	Dec 06, 2018
	>A> 8334270	Mar 21, 2028	DS DP U-1470			
	>A> 8580765	Mar 21, 2028	DS DP U-1470			
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923 001	>A> 8124630	Jul 13, 2022	U-1459		I-677 >A> ODE	Nov 22, 2016 Nov 22, 2020
<u>SUCROFERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	>A> 6174442	Dec 19, 2016	DS U-1468		>A> NP	Nov 27, 2016
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N 022239 001	8343130	Oct 18, 2022	DP			
<u>SUMATRIPTAN SUCCINATE - ZECURITY</u>						
N 202278 001	6745071	Feb 21, 2023	DP		NDF	Jan 17, 2016
	7973058	Apr 12, 2027	U-1328			
	8155737	Apr 12, 2027	U-1328			
	8366600	Apr 21, 2029	U-1327			
	8470853	Apr 12, 2027	U-1328			
	8597272	Apr 12, 2027	DP			
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 001	6440458	Mar 25, 2019	DP		NDF	Jul 19, 2016
	6576259	Mar 25, 2019	DP U-1420			
	6884433	Mar 25, 2019	DP U-1420			
	8551522	Mar 25, 2019	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 002	6440458	Mar 25, 2019	DP		NDF	Jul 19, 2016
	6576259	Mar 25, 2019	DP U-1420			
	6884433	Mar 25, 2019	DP U-1420			
	8551522	Mar 25, 2019	DP			
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 003	6440458	Mar 25, 2019	DP		NDF	Jul 19, 2016
	6576259	Mar 25, 2019	DP U-1420			
	6884433	Mar 25, 2019	DP U-1420			
	8551522	Mar 25, 2019	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 001	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 002	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 003	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 004	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 005	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207 001 >A>	6409990	May 12, 2020	DS		NCE	Mar 13, 2018
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2015	DS DP U-1320		ODE	Dec 21, 2019
	7056886	Sep 18, 2022	DP U-1320			
	7847061	Nov 01, 2025	U-1320			
<u>TELAPREVIR - INCIVEK</u>						
N 201917 001	8431615	May 30, 2028	U-1398			
	8529882	Aug 31, 2021	U-1398			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N 022110 001	6635618	Sep 11, 2023	DS DP U-728		I-673	Jun 21, 2016
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N 022110 002	6635618	Sep 11, 2023	DS DP U-728		I-673	Jun 21, 2016
<u>TELBIVUDINE - TYZEKA</u>						
N 022011 001					M-124	Jan 28, 2016
<u>TELBIVUDINE - TYZEKA</u>						
N 022154 001					M-124	Jan 28, 2016
<u>TEMSIROLIMUS - TORISEL</u>						
N 022088 001	8455539	Jul 25, 2023	DP			
	8455539*PED	Jan 25, 2024				
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 001					M-128	Jul 24, 2016
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 002					M-128	Jul 24, 2016
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 003					M-128	Jul 24, 2016
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 004					M-128	Jul 24, 2016
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 022577 001					M-128	Jul 24, 2016



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 001	6794410	Apr 15, 2022	U-1285			
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 002	6794410	Apr 15, 2022	U-1285			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	8419307	Feb 26, 2027	U-1386			
	8435944	Jul 05, 2027	U-1390			
<u>TESTOSTERONE - TESTOSTERONE</u>						
N 203098 001					NP	Jan 31, 2016
<u>TESTOSTERONE - TESTOSTERONE</u>						
N 203098 002					NP	Jan 31, 2016
<u>TESTOSTERONE - TESTOSTERONE</u>						
N 203098 003					NP	Jan 31, 2016
<u>THALIDOMIDE - THALOMID</u>						
N 020785 001 >A>	8589188	Aug 28, 2018	U-1465			
<u>THALIDOMIDE - THALOMID</u>						
N 020785 002 >A>	8589188	Aug 28, 2018	U-1465			
<u>THALIDOMIDE - THALOMID</u>						
N 020785 003 >A>	8589188	Aug 28, 2018	U-1465			
<u>THALIDOMIDE - THALOMID</u>						
N 020785 004 >A>	8589188	Aug 28, 2018	U-1465			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	8425934	Dec 18, 2029	DP			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	8372995	Oct 08, 2030	DP			
<u>TIMOLOL MALEATE - ISTALOL</u>						
N 021516 001	6645963	Nov 02, 2018	DP			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020912 001	6770660	May 01, 2023				
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 001	6770660	Jun 01, 2023				
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 002	6770660	Jun 01, 2023				
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 003	6770660	Jun 01, 2023				
<u>TOBRAMYCIN - TOBI PODHALER</u>						
N 201688 001	7097827	Apr 16, 2016	DP		NP	Mar 22, 2016
	7368102	Dec 19, 2022	DP U-909			
	7442388	May 10, 2020	DP			
	7516741	Jan 11, 2024	DP			
	7559325	Oct 27, 2025	DP			
	8069851	Sep 24, 2024	DP			
	8349294	May 10, 2020	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOBRAMYCIN - BETHKIS</u>						
N 201820 001	6987094	Sep 22, 2022	DP			
	7696178	Mar 17, 2023	DP			
	7939502	Jun 14, 2022	U-1324			
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N 021228 001	6911217	Nov 11, 2019	DP U-544			
	6911217*PED	May 11, 2020				
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N 021228 002	6911217	Nov 11, 2019	DP U-544			
	6911217*PED	May 11, 2020				
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 001	5258510	Nov 02, 2013	DS DP			
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 002	5258510	Nov 02, 2013	DS DP			
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 003	5258510	Nov 02, 2013	DS DP			
	8501730	Sep 01, 2026	DS			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	8298576	Mar 18, 2029	DP U-106			
	8298580	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	8298576	Mar 18, 2029	DP U-106			
	8298580	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	8298576	Mar 18, 2029	DP U-106			
	8298580	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	8298576	Mar 18, 2029	DP U-106			
	8298580	Nov 16, 2027	DP U-106			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	7378423	Sep 13, 2025	DS DP		NCE	May 29, 2018
	8580304	Jan 28, 2032	DP		ODE	May 29, 2020
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	7378423	Sep 13, 2025	DS DP		NCE	May 29, 2018
	8580304	Jan 28, 2032	DP		ODE	May 29, 2020
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	7378423	Sep 13, 2025	DS DP		NCE	May 29, 2018
	8580304	Jan 28, 2032	DP		ODE	May 29, 2020
<u>TRANEXAMIC ACID - TRANEXAMIC ACID</u>						
A 202093 001					PC	Jul 02, 2013
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N 022430 001	8487005	Mar 04, 2025	DP U-1182			
<u>TRAVOPROST - TRAVATAN Z</u>						
N 021994 001	8388941	Sep 20, 2027	DP			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	7999007	Mar 29, 2029	DP U-1437			
	8497393	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	7999007	Mar 29, 2029	DP U-1437			
	8497393	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	7999007	Mar 29, 2029	DP U-1437			
	8497393	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	7999007	Mar 29, 2029	DP U-1437			
	8497393	Dec 15, 2028	DS			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	8497393	Dec 15, 2028	DS			
<u>TREPROSTINIL - ORENITRAM</u>						
N 203496 001	>A> 5153222	Oct 16, 2014		U-1475	>A> NDF	Dec 20, 2016
	>A> 6765117	Oct 24, 2017	DS			
	>A> 7417070	Aug 30, 2026	DS			
	>A> 7544713	Jul 14, 2024		U-1475		
	>A> 8252839	May 24, 2024	DP			
	>A> 8349892	Jan 22, 2031	DP			
	>A> 8410169	Feb 13, 2030	DP			
	>A> 8497393	Dec 15, 2028	DS			
<u>TREPROSTINIL - ORENITRAM</u>						
N 203496 002	>A> 5153222	Oct 16, 2014		U-1475	>A> NDF	Dec 20, 2016
	>A> 6765117	Oct 24, 2017	DS			
	>A> 7417070	Aug 30, 2026	DS			
	>A> 7544713	Jul 14, 2024		U-1475		
	>A> 8252839	May 24, 2024	DP			
	>A> 8349892	Jan 22, 2031	DP			
	>A> 8410169	Feb 13, 2030	DP			
	>A> 8497393	Dec 15, 2028	DS			
<u>TREPROSTINIL - ORENITRAM</u>						
N 203496 003	>A> 5153222	Oct 16, 2014		U-1475	>A> NDF	Dec 20, 2016
	>A> 6765117	Oct 24, 2017	DS			
	>A> 7417070	Aug 30, 2026	DS			
	>A> 7544713	Jul 14, 2024		U-1475		
	>A> 8252839	May 24, 2024	DP			
	>A> 8349892	Jan 22, 2031	DP			
	>A> 8410169	Feb 13, 2030	DP			
	>A> 8497393	Dec 15, 2028	DS			
<u>TREPROSTINIL - ORENITRAM</u>						
N 203496 004	>A> 5153222	Oct 16, 2014		U-1475	>A> NDF	Dec 20, 2016
	>A> 6765117	Oct 24, 2017	DS			
	>A> 7417070	Aug 30, 2026	DS			
	>A> 7544713	Jul 14, 2024		U-1475		
	>A> 8252839	May 24, 2024	DP			
	>A> 8349892	Jan 22, 2031	DP			
	>A> 8410169	Feb 13, 2030	DP			
	>A> 8497393	Dec 15, 2028	DS			
<u>TRIAMCINOLONE ACETONIDE - NASACORT ALLERGY 24 HOUR</u>						
N 020468 002	5976573	Jul 03, 2016	DP			
	6143329	Jul 03, 2016	DP			
	7977045	Jul 03, 2016	DP			
<u>TROSPIUM CHLORIDE - TROSPIUM CHLORIDE</u>						
A 091289 001					PC	Apr 10, 2013
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	8426392	Jun 12, 2030		U-1389		
	8512745	Feb 14, 2030	DP			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	>A> 5873360	Feb 23, 2016	DP			
	>A> 7361787	Mar 23, 2023	DS DP	U-1476		
	>A> 7439393	Sep 11, 2022	DS DP	U-1476		
	>A> 7488827	Apr 27, 2025	DS DP			
	>A> 7498440	Apr 27, 2025	DS DP			
	>A> 7776895	Sep 11, 2022	DP			
	>A> 8113199	Oct 23, 2027	DP			
	>A> 8161968	Feb 05, 2028	DP			
	>A> 8183257	Jul 27, 2025		U-1476		
	>A> 8309572	Apr 27, 2025		U-1476		
	>A> 8511304	Nov 11, 2025	DP	U-1476		
	>A> 8534281	Aug 10, 2029	DP			
<u>UNOPROSTONE ISOPROPYL - RESCULA'</u>						
N 021214 001	6770675	Nov 24, 2018	DP	U-1322'		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VELAGLUCERASE ALFA - VPRIV</u>						
N 022575 001					M-130	Nov 21, 2016
<u>VELAGLUCERASE ALFA - VPRIV</u>						
N 022575 002					M-130	Nov 21, 2016
<u>VMURAFENIB - ZELBORAF</u>						
N 202429 001	8470818	Aug 02, 2026	U-1418			
<u>VIGABATRIN - SABRIL</u>						
N 020427 001					NCE NPP PED PED	Aug 21, 2014 Oct 26, 2016 Feb 21, 2015 Apr 26, 2017
<u>VIGABATRIN - SABRIL</u>						
N 022006 001					NCE NPP ODE PED PED PED	Aug 21, 2014 Oct 26, 2016 Aug 21, 2016 Feb 21, 2015 Feb 21, 2017 Apr 26, 2017
<u>VORICONAZOLE - VORICONAZOLE</u>						
A 202361 001					PC	Mar 24, 2014
<u>VORINOSTAT - ZOLINZA</u>						
N 021991 001	RE38506	Jul 07, 2015	DS DP			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 001	7144884 8476279	Jan 09, 2023 Oct 02, 2022	DS DP U-1439 DP U-1439		NCE	Sep 30, 2018
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 002	7144884 8476279	Jan 09, 2023 Oct 02, 2022	DS DP U-1439 DP U-1439		NCE	Sep 30, 2018
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 003	7144884 8476279	Jan 09, 2023 Oct 02, 2022	DS DP U-1439 DP U-1439		NCE	Sep 30, 2018
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 004	7144884 8476279	Jan 09, 2023 Oct 02, 2022	DS DP U-1439 DP U-1439		NCE	Sep 30, 2018
<u>ZOLEDRONIC ACID - RECLAST</u>						
N 021817 001	8052987	Oct 27, 2023	U-1199			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 001	8512747	Sep 24, 2019	U-674			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 002	8512747	Sep 24, 2019	U-674			

## Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

## PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 33<sup>rd</sup> Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>